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Abstract 
 
The Kv1.3 channel increases cellular proliferation and migration in multiple cell types. 
Various mechanisms have been proposed to explain how the channel stimulates 
proliferation, but the topic remains controversial. Previously thought to be localised 
only to the plasma membrane, the channel has been found in the inner mitochondrial 
membrane. In cancer, mitochondrial Kv1.3 may regulate apoptosis, yet the role of 
mitochondrial Kv1.3 in non-pathophysiological states remains less well defined. 
Cellular proliferation has a high energy demand, requiring ATP for processes like signal 
transduction to DNA, RNA and protein synthesis. The distinct energy requirements of 
cellular proliferation coupled with the known mitochondrial localization of Kv1.3 may 
mean that the Kv1.3 channel links cellular energy metabolism to proliferation. This 
thesis investigates whether the mitochondrial Kv1.3 channel is an anti-proliferative 
target in HEK293/Kv1.3 cells. Overexpression of Kv1.3 in HEK293 cells increased 
glycolysis, mitochondrial membrane potential, oxidative phosphorylation, reactive 
oxygen species, non-mitochondrial respiration and proliferation. Inhibition of 
mitochondrial Kv1.3 channels with 100nM PAPTP reduced respiration and 
proliferation. Inhibition of ROS with 5µM MitoQ reduced proliferation. Kv1.3 pore 
mutants determined that the voltage sensor, as well as the tyrosine 447 residue on the 
C-terminal of the Kv1.3 channel, are needed to stimulate respiration in HEK293 cells. 
Mitochondrial Kv1.3 channels were also found in primary human saphenous vein 
smooth muscle cells. Upregulation of Kv1.3 drives pathological proliferation of vascular 
smooth muscle cells in conditions like atherosclerosis and hypertension, and these 
cells also have altered metabolism. This data shows that the mitochondrial Kv1.3 
channel directly increases oxidative phosphorylation, non-mitochondrial respiration 
and proliferation in HEK293 cells, providing a novel link between mitochondrial Kv1.3 
and cellular energy homeostasis. Although the exact mechanisms are unclear, these 
data suggest that mitochondrial Kv1.3, especially it’s ion conduction independent 
properties, is a valid target for future research into Kv1.3 induced proliferation in 
VSMCs.  
 
 
 
V 
 
Table of Contents 
 
Declaration………………….……………………………………………………………………………………………….II 
Acknowledgements…………………………………………………………………………………………………….III 
Abstract …………………………………………………………..…………………………………………………………IV 
Table of Contents…………………………………………………………………………………………………………V 
List of Figures…………………………………………………………………….…………………………….……….XIII 
List of Tables………………………………………………………….……………………………………….……….XVII 
List of Abbreviations……………………………………………….………………………………………………XVIII 
 
Chapter 1 
Introduction…………………………………………………………………………………………………………..…1 
1.1 Cardiovascular Disease………………………………………………………………………………….……1 
1.1.1 Overview……………………………………………………………………………………………………..…..1 
1.1.2 Cost of CVD………………………………………………………………………………………………………1 
1.1.3 Aetiology………………………………………………………………………………………………..………..2 
1.1.4 Treatments………………………………………………………………………………………..…………….3 
1.2 Vascular Remodelling in CVD……………………………………………………..……………………….5 
1.2.1 VSMCs……………………………………………………………………………………………………………..5 
1.2.2 Mechanisms…………………………………………………………………………………………………….6 
1.3 K+ Channels ………………………………………………………………………………………………………..8 
1.3.1 Overview………………….………………………………………………………………………………………8 
1.3.2 Voltage Gated K+ Channels…………….…………………………………………………………………9 
1.3.2.1 Structure………………………………………………………..……………………………..…10 
1.3.2.2 Location and Function…………………………………………………..……………….…11 
1.4 Kv1.3…………………………………………………………………………………………………………………13 
1.4.1 Overview………………………………………………………………………………………………………..13 
1.4.2 Location and function…………………………………………………………………………………..…14 
1.4.3 Biophysical phenotype…………………………………………………………………………………...14 
1.4.4 Regulation………………………………………………………………………………………………………15 
1.4.5 Pharmacology….…………………………………………………………………………………………….15 
1.5 Pharmacological targeting of Kv1.3 in disease………………………………………………..…16 
1.5.1 Oncology……………………………………………..…………………………………………………………16 
VI 
 
1.5.2 Immunology……………………………………………………………………………………………………16 
1.5.3 Neurology………………………………………………………………………………………………………17 
1.5.4 Vascular Biology……………………………………………………………………………………………..17 
1.6 Mechanisms of Kv1.3 induced proliferation………………………………………………………18 
1.6.1 Membrane potential………………………………………………………………………………………18 
1.6.2 Voltage Sensing………………………………………………………………………………………………19 
1.6.3 Association with other proteins………………………………………………………………………19 
1.7 Mitochondria………………………………………………………………………………………………..….21 
1.7.1 Structure……………………..…………………………………………………………………………………21 
1.7.2 Primary Function – Oxidative Phosphorylation…………………………………………………22 
1.8 Associated Bioenergetic pathways……………………………………………………………………24 
1.8.1 NAD+……………………………………………………………………………………………………………..24 
1.8.2 Glycolysis ………………………………………………………………………………………………………25 
1.8.3 Link Reaction………………………………………………………………………………………………….27 
1.8.4 The Citric Acid Cycle (TCA cycle) / Krebs Cycle…………………………………………………28 
1.8.5 Fatty acid β-oxidation…………………………………………………………………………………….30 
1.8.6 Amino Acid Metabolism………………………………………………………………………………….31 
1.8.7 Integration of Bioenergetic pathways………………………………………………………………33 
1.9 Additional Mitochondrial Functions………………………………………………………………….34 
1.10 Mitochondrial Ion Channels………………………………………………………………………….…34 
1.10.1 Overview………………………………………………………………………………………………………34 
1.10.2 Limitations to mitochondrial ion channel research………………………….…………….36 
1.11 Mitochondrial K+ Cycle……………………………………………………………………………………36 
1.11.1 Overview……………………………………………………………………………………………………..36 
1.11.2 Mitochondrial K+ channels……………………………………………………………………………37 
1.11.2.1 Mitochondrial Kv1.3……………………………………………………………………….37 
1.11.3 Mitochondrial K+ Flow and Respiration………………………………………………………….38 
1.11.4 Mitochondrial K+ Flow and Cytoprotection………………………………………………….…39 
1.12 Metabolism and Proliferation…………………………………………………………………………40 
1.12.1 Role of Kv1.3 in Metabolism……………………………………………………………………….…40 
1.12.2 Proliferation linked to metabolism…………………………………………………………..……41 
1.12.3 Proliferation and metabolism of VSMCs…………………………………………………………43 
VII 
 
1.13 Aims and Objectives ………………………………………………………………………………………45 
1.13.1 Aims…………………………………………………………………………………………………………….45 
1.13.2 Objectives………………………………………………………………………………………………….…45 
Chapter 2 Methods and Materials……………………………………………………………………….…46 
2.1 Cell Culture……………………………………………………………………………………………………….46 
2.1.1 WT HEK293 cells………………………………………………………………………………………….…46 
2.1.2 HEK293/Kv1.3 cells…………………………………………………………………………………………47 
2.1.3 HEK293/Kv1.3-P118 cells……………………………………………………………………………..…47 
2.1.4 HEK293/Kv1.3 mutant cells (P89, P93 and P121) ………………………………………….…47 
2.1.5 HEK293/Kv1.5 cells…………………………………………………………………………………………47 
2.1.6 Human Saphenous Vein Smooth Muscle Cells (HSVSMCs)……………………………..…47 
2.2 Generation of the HEK293/Kv1.3 mutant clones ………………………………………………49 
2.2.1 Generation of Luria-Bertani (LB) agar plates………………………………………………….…49 
2.2.2 DNA retrieval………………………………………………………………………………………………….49 
2.2.3 Generation of Kv1.3 mutant plasmids…………………………………………………………..…50 
2.2.3.1 Plasmids generation…………………………………………………………………………50 
2.2.3.2 Kv1.3 channel mutations…………………………………………………………….…….51 
2.2.3.2.1 Kv1.3-P89 channels…………………………………………………………….51 
2.2.3.2.2 Kv1.3-P93 channels…………………………………………………………….52 
2.2.3.2.1 Kv1.3-P121 channels…………………………………………………………..52 
2.2.4 DNA amplification…………………………………………………………………………………………..54 
2.2.5 Harvesting of DNA – Mini Prep…………………………………………………………………..……54 
2.2.6 Restriction analysis of DNA sequences…………………………………………………………….55 
2.2.7 Gel electrophoresis…………………………………………………………………………………………55 
2.2.8 Harvesting of DNA – Maxi Prep……………………………………………………………………….56 
2.2.9 Cell Transfection ……………………………………………………………………………………………58 
2.3 Proliferation Assays………………………………………………………………………………………….59 
2.4 High Resolution Respirometry…………………………………………………………………………..60 
2.4.1 O2K Oxygraph and DatLab Software………………………………………………………………..61 
2.4.2 Chemicals and Medium…………………………………………………………………………………..61 
2.4.3 Cell Preparation………………………………………………………………………………………………61 
2.4.4 Whole-cell respirometry protocol……………………..………………………………………….…61 
VIII 
 
2.4.5 Assessing Kv1.3 effect on respiration…………..……………………………………………….…64 
2.4.6 Assessing activity of the malate/aspartate shuttle………………………………..………...64 
2.4.7 Assessing contribution of glycolysis to respiration…………………………………………...64 
2.4.8 Complex IV activity…………….…………………………………………………………………………..65 
2.4.9 Data analysis………………………………………………………………………………………………….65 
2.5 Immunocytochemistry…………………………………………………………………………………..…66 
2.5.1 Cell preparation……….…………………………………………………………………………………….66 
2.5.2 Detection of Kv1.3 channels….……………………………………………………………………..…66 
 2.5.2.1 HEK293/Kv1.3 mutant and HEK293/Kv1.3-P118 cells…………………………66 
 2.5.2.2 WT HEK293 and HEK293/Kv1.3 cells……………………………………………….…67 
 2.5.2.3 HSVSMCs……………………………………………………………………………………….…67 
2.5.3 Detection of the mitochondrial network…….……………………………………………………67 
2.5.3.1 MitoTracker…………………………………………………………………………………..…67 
2.5.3.2 Anti-Cox IV labelling……………………………………………………………………….…68 
2.5.4 Detection of cellular ROS……………………………………………………………………………..…68 
2.6 Electrophysiology…………………………………………………………………………………………..…70 
2.6.1 Solutions………….…………………………………………………………………………………………….70 
2.6.2 Cell preparation………………………………………………………………………………………………70 
2.6.3 Electrophysiology rig set-up………………………….…………………………………………………70 
2.6.4 Protocols……….……………………………………………………………………………………………….71 
2.6.4.1 Inhibition of Kv1.3 channels……………………………………………………………..71 
2.7 Western Blotting.…….……………………………………………………………………………………….73 
2.7.1 Buffers………………………………………………………………………………………………………..…73 
2.7.2 Cell culture, lysis and protein extraction…….……………………………………………………73 
2.7.3 BCA protein assay……….………………………………………………………………………………….73 
2.7.4 SDS-PAGE………….……………………………………………………………………………………………74 
2.7.5 Electrophoretic Transfer……….………………………………………………………………………..74 
2.7.6 Immunodetection…….…………………………………………………………………………………….75 
2.8 Cairn Photometry……………………………………………………………………………………………..77 
2.8.1 Perfusion medias……………………………………………………………………………………………77 
2.8.2 Cell culture……..……………………………………………………………………………………………77 
2.8.3 TMRM treatment……….…………………………………………………………………………………..77 
IX 
 
2.8.4 Cairn photometry rig set up…….………………………………………………………………………77 
2.8.5 TMRM detection……….……………………………………………………………………………………78 
2.9 Citrate Synthase Assay………….………………………………………………………………………….79 
2.9.1 Stocks prepared monthly……….……………………………………………………………………….79 
2.9.2 Stocks prepared on day of experiment…….……………………………………………………..79 
2.9.3 Cell lysis and protein extraction………………………………………………………………………79 
2.9.4 BCA assay…….…………………………………………………………………………………………………80 
2.9.5 CS assay principle….…………………………………………………………………………………..……80 
2.9.6 CS assay…………….……………………………………………………………………………………………80 
2.9.6.1 Equipment set up………………………………………………………………………..……80 
2.9.6.2 Protocol……………………………………………………………………………………………80 
2.10 Flow Cytometry……….…………………………………………………………………………..…………81 
2.10.1 Cell preparation…….…………………………………………………………………………………..…81 
2.10.2 Protocols……………………………………………………………………………………………………...81 
2.10.2.1 Mitochondrial membrane potential………………..……………………………...81 
2.10.2.2 Mitochondrial Ca2+ ……………………………………………..………….……………..82 
2.10.2.3 NADH autofluorescence……………………………………….………………….…….82 
2.10.3 Data recording………………………………………………………………………………………………82 
2.11 Kv1.3 inhibitors…………………………………………………………………………………….…………83 
2.11.1 PAP-1………………………………………………………………………………………………….……….83 
2.11.2 ShK-Dap22………………………………………………………………………………………….……….83 
2.11.3  PAPTP…………………………………………………………………………………………….…………..83 
 2.11.3.1 Synthesis of PAPTP………………………………………………………………….…….83 
2.12 Data Analysis and Statistics…………………………………………………………………….………84 
 
Chapter 3 Kv1.3 expressing HEK293 cells have an increased rate of proliferation and 
respiration……………………………………………………………………………………………………………..85 
3.1 Introduction……………………………………………………………………………………………………..85 
3.2 Aims and Objectives………………………………………………………………………………………….85 
3.3 Results……………………………………………………………………………………………………………..87 
3.3.1 Confirmation of the HEK293/Kv1.3 cell line as a stably transfected overexpression 
system of functional Kv1.3 channels……………………………………………………………………..…86 
X 
 
3.3.2 HEK293/Kv1.3 cells have increased proliferation and respiration compared to WT 
HEK293 cells……………………………………………………………………………………………………………92 
3.3.3 Overexpression of Kv1.5 in HEK293 cells decreases mitochondrial respiration….98 
3.3.4 Kv1.3 channels co-localise with the mitochondrial network in HEK293/Kv1.3 
cells………………………………………………………………………………………….………………………….101 
3.3.5 Kv1.3 channels co-localise with the mitochondrial network in Primary Human 
Saphenous Vein Smooth Muscle Cells……………………………………………………………………106 
3.3.6 HEK293 and HEK293/Kv1.3 cells have comparable amounts of 
mitochondria………………………………………………………………………………………………………..108 
3.4 Discussion…………………………………………………………………………………………………….…112 
 
Chapter 4 Mitochondrial Kv1.3 channels regulate proliferation and respiration in 
HEK293 cells…………………………………………………………………………….……………………….….117 
4.1 Introduction……………………………………………………………………………………………………117 
4.2 Aims and Objectives……………………………………………………………………………………….119 
4.3 Results……………………………………………………………………………………………………………120 
4.3.1 Inhibition of intracellular Kv1.3 channels with PAP-1 reduces proliferation of 
HEK293/Kv1.3 cells at low concentrations………………………………………………………………120 
4.3.2 PAP-1 can reduce proliferation of HSVSMCs………………………………………………….124 
4.3.3 PAP-1 decreases mitochondrial respiration in HEK293 cells……………………………126 
4.3.4 WT HEK293 respiration was decreased by PAP-1…….…………………………………….130 
4.3.5 ShK-Dap22 inhibits plasma membrane potassium currents but does not decrease 
proliferation in HEK293/Kv1.3 cells………………………………………………………………….….…134 
4.3.6 ShK-Dap22 has no effect on the respiration of HEK293/Kv1.3 cells……………...…138 
4.3.7 A mitochondrially targeted Kv1.3 channel inhibitor decreasesHEK293/Kv1.3 cell 
proliferation………………………………………………………………………………………………………….139 
4.3.8 100nM PAPTP can reduce respiration in HEK293/Kv1.3 cells…….……………………142 
4.4 Discussion…….…………………………………………………………………………………………………145 
 
Chapter 5 Probing the mechanisms through which mitochondrial Kv1.3 regulates 
respiration and proliferation…………………………………………………………………………………153 
5.1 Introduction……………………………………………………………………………………………………153 
5.2 Aims and Objectives…………………………………………………………………………………….…156 
XI 
 
5.3 Results……………………………………………………………………………………………………………157 
5.3.1 Kv1.3 increases cellular NADH in HEK293 cells…………………………………………….…157 
5.3.2 Manipulation of the malate/aspartate shuttle with Dimethyl-2-Oxoglutarate and 
Phenylsuccinate did not affect respiration in HEK293 cells…………………………………..…159 
5.3.3 HEK293/Kv1.3 cells have an increased oxygen consumption compared to WT 
HEK293 cells when glycolysis is knocked down by 2-Deoxy-D-Glucose…………………….161 
5.3.4 HEK293/Kv1.3 cells have a hyperpolarised mitochondrial membrane potential 
compared with WT HEK293 cells…………………………………………………………………………...163 
5.3.5 Mitochondrial calcium is not increased by Kv1.3 expression HEK293 cells……...167 
5.3.6 HEK293/Kv1.3 cells have a greater concentration of cellular reactive oxygen 
species than WT HEK293 cells………………………………………………………………………….…...169 
5.3.7 The ROS scavenger MitoQ, trended to reduce proliferation of HEK293/Kv1.3 
cells………………………………………………………………………………………………………………………172 
5.4 Discussion………………………………………………………………….……………………………………175 
 
Chapter 6 Kv1.3 channels have non-conducting properties which increase respiration 
and proliferation in HEK293 cells……………………………………………………………………….…183 
6.1 Introduction……………………………………………………………………………………………………183 
6.2 Aims and Objectives…………………………………………………………………………………….…185 
6.3 Results…………………………………………………………………………………………………………...186 
6.3.1 The Kv1.3-P89, Kv1.3-P93 and Kv1.3-P121 mutant channels co-localise with 
mitochondria in HEK293 cells………………………………………………………………………………..186 
6.3.2 HEK293/Kv1.3-P89, HEK293/Kv1.3-P93 and HEK293/Kv1.3-P121 had reduced K+ 
currents compared to HEK293/Kv1.3 cells………………………………………………..……………190 
6.3.3 HEK293/Kv1.3-P89 cells have increased proliferation compared to WT HEK293 
cells………………………………………………………………………………………………………………………192 
6.3.4 Disruption of the Kv1.3 channel pore in the Kv1.3-P89 mutation did not abrogate 
Kv1.3-stimulated respiration in HEK293 cells……………………………………………………….…193 
6.3.5 Disruption of both the Kv1.3 voltage sensor and ion pore in HEK293/Kv1.3-P93 
cells reduces respiration compared to HEK293/Kv1.3 cells……………………….………….…195 
6.3.6 Mutation of tyrosine 447 to alanine in the Kv1.3-P121 mutant prevents Kv1.3 
induced respiration in HEK293 cells………………………….…………………………..…………….…197 
XII 
 
6.3.7 Disruption of the Kv1.3 channel pore in the Kv1.3-P89 mutation did not abrogate 
Kv1.3-stimulated residual oxygen consumption in HEK293 cells………………………….….199 
6.3.8 Mutation of the Kv1.3 pore independent of the voltage sensor did not affect 
Kv1.3 channel-stimulated ATP turnover in HEK293/Kv1.3-P89……………………………..…200 
6.3.9 HEK293/Kv1.3-P121 cells had reduced spare respiratory capacity compared to 
WT HEK293 cells……………………….………………………………………………………..…………………201 
6.4 Discussion……………………………………………………………………………………………………….203 
 
Chapter 7 General Discussion and Future Directions………………………………………….…210 
7.1 Summary………………………………………………………………………………………………………..210 
7.2 Principle Findings……………………………………………………………………………………………211 
7.3 Future Work………………………………………………………………………………………………..….214 
7.4 Conclusions…………………………………………………………………………………………………….216 
 
References……………………………………………………………………………………………….………..…218 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XIII 
 
List of Figures 
 
Figure 1.1 Vascular smooth muscle cell remodelling in arteries………………………….………3 
Figure 1.2 Vascular smooth muscle cell phenotypic switching…………………………….………6 
Figure 1.3 Summary of potassium ion channels………………………………………………….….….9 
Figure 1.4 Structural components of the Kv1.3 potassium channel…………………..………13 
Figure 1.5 Simple structure of the mitochondria………………………………………………………22 
Figure 1.6 Proteins of the electron transport chain in the inner mitochondrial 
membrane………………………………………………………………………………………………………………23 
Figure 1.7 Glycolysis pathway………………………………………………..………………………………..26 
Figure 1.8 Link Reaction pathway…………………………………………..………………………………..27 
Figure 1.9 The TCA Cycle………………………………………………………..……………………………….29 
Figure 1.10 The Beta Oxidation pathway………………………………………….………………………30 
Figure 1.11 Integration of Amino Acids into Energy Metabolism……………………………...….31 
Figure 1.12 Integration of Metabolic Pathways…………………………..……………………………33 
Figure 1.13 Ion channels of the mitochondrial membranes……..……………………………….35 
 
Figure 2.1 Plasmid maps for mutant Kv1.3 channels…………………………………………………51 
Figure 2.2 Schematic showing the location of the mutations in the Kv1.3 channels.…..53 
Figure 2.3 Analysis of an O2k Oxygraph respiratory trace…………………………………….……66 
Figure 2.4 Synthesis of PAPTP………………………………………………………………………….………84 
 
Figure 3.1 Increased Kv1.3 channel and protein expression in HEK293/Kv1.3 cell 
line…………………………………………………………………………………………………………………………88 
Figure 3.2 Alexa Fluor 488 provides a specific secondary antibody in HEK293/Kv1.3 or 
WT HEK293 cells…………………………………………………………………………………………………..…89 
Figure 3.3 The HEK293/Kv1.3 cells have a larger potassium ion current than WT HEK293 
cells…………………..……………………………………………………………………………………………………91 
Figure 3.4 HEK293/Kv1.3 cells have an increased proliferation rate compared to WT 
HEK293 cells……………………………………………………………………………………………………………92 
Figure 3.5 HEK293/Kv1.3 cells have increased OXPHOS compared to WT HEK293 
cells………………………………………………………………………………………………………………….….…95 
XIV 
 
Figure 3.6 Residual oxygen consumption-corrected respiration in WT HEK293 and 
HEK293/Kv1.3 cells……………………………………………………………………………………….…………97 
Figure 3.7 HEK293/Kv1.5 cells have decreased proliferation to WT HEK293 and 
HEK293/Kv1.3 cells………………………………………………………………………………………………….99 
Figure 3.8 HEK293/Kv1.5 cells have reduced OXPHOS compared to WT HEK293 and 
HEK293/Kv1.3 cells………………………………………………………………………………………….…..100 
Figure 3.9 Mitochondrial and Kv1.3 co-localisation in HEK293/Kv1.3 cells…………….…102 
Figure 3.10 MitoTracker controls in WT HEK293 and HEK293/Kv1.3 cells….…………..…103 
Figure 3.11 Mitochondrial and Kv1.3 co-localisation in HEK293/Kv1.3-P118 cells….…105 
Figure 3.12 Kv1.3 channels co-localise with mitochondria in primary human vascular 
smooth muscle cells………………………………………………………………………………………………107 
Figure 3.13 Kv1.3 expression does not alter mitochondrial content in HEK293 
cells……………………………………………………………………………………………………………………...109 
Figure 3.14 Kv1.3 expression does not alter mitochondrial networks in HEK293 
cells…………………………………………………………………………………………………………………..….110 
Figure 3.15 Kv1.3 expression does not alter mitochondrial complex IV protein content 
or affect the structure of the mitochondrial network in HEK293 cells………………..……111 
 
Figure 4.1 Proliferation of WT HEK293 cells is unaffected by PAP-1…….………………….121 
Figure 4.2 Proliferation of HEK293/Kv1.3 cells trends towards a reduction at low 
nanomolar concentrations of PAP-1………………………………………………………………………122 
Figure 4.3 PAP-1 inhibits the potassium ion current in HEK293/Kv1.3 cells……………..123 
Figure 4.4 PAP-1 inhibits HSVSMC proliferation……………………………………………………..125 
Figure 4.5 PAP-1 can reduce oxygen consumption in HEK293/Kv1.3 cells……………..…127 
Figure 4.6 PAP-1 reduces oxidative phosphorylation in HEK293/Kv1.3 cells……….……128 
Figure 4.7 Effect of PAP-1 on ATP Turnover Rate of HEK293/Kv1.3 cells. ……………..…129 
Figure 4.8 Effect of PAP-1 on Spare Respiratory Capacity of HEK293/Kv1.3 cells………129 
Figure 4.9 PAP-1 can reduce oxygen flow in WT HEK293 cells…………………………………130 
Figure 4.10 PAP-1 can reduce routine respiration in WT HEK293 cells………………….…132 
Figure 4.11 PAP-1 reduces ATP turnover in WT HEK293 cells……………………………….…133 
Figure 4.12 PAP-1 reduces spare respiratory capacity of WT HEK293 cells………………133 
Figure 4.13 SHK-dap 22 does not affect the proliferation of WT HEK293 cells………….135 
Figure 4.14 SHK-dap 22 does not affect the proliferation of HEK293/Kv1.3 cells………136 
XV 
 
Figure 4.15 SHK-dap 22 inhibits the potassium ion current in HEK293/Kv1.3 cells……137 
Figure 4.16 ShK-Dap22 has no effect on the respiration of HEK293/Kv1.3 cells……..…138 
Figure 4.17 PAPTP reduces proliferation in HEK293/Kv1.3 cells………………………………140 
Figure 4.18 100nM PAPTP can reduce HEK293/Kv1.3 proliferation despite losing 
potency…………………………………………………………………………………………………………………141 
Figure 4.19 The effect of 100nM PAPTP on HEK293/Kv1.3 respiration…………………….142 
Figure 4.20 100nM PAPTP reduced ATP turnover in both HEK293/Kv1.3 cells and 
HEK293 WT cells……………………………………………………………………………………………………143 
Figure 4.21 100nM PAPTP reduced spare respiratory capacity in HEK293/Kv1.3 
cells………………………………………………………………………………………………………………………144 
 
Figure 5.1 HEK293/Kv1.3 cells have increased NADH autofluorescence to WT HEK293 
cells………………………………………………………………………………………………………………………158 
Figure 5.2 Dimethyl-2-Oxoglutarate has no effect on WT HEK293 cell 
respiration………………………………………………………………………………………………………….…160 
Figure 5.3 Phenylsuccinate has no effect on HEK293/Kv1.3 cell respiration…….………160 
Figure 5.4 Respiration of HEK293/Kv1.3 is higher than WT HEK293 cells when glycolysis 
is inhibited with 2-Deoxy-D-Glucose……………………………………………………………………...162 
Figure 5.5 HEK293/Kv1.3 cells have a more hyperpolarised mitochondrial membrane 
potential than WT HEK293 cells…………………………………………………………………………….164 
Figure 5.6 100nM PAPTP has no significant effect on the mitochondrial membrane 
potential of HEK293 cells………………………………………………………………………………….……166 
Figure 5.7 Mean mitochondrial calcium is not significantly different in HEK293/Kv1.3 
cells compared to WT HEK293 cells…………………………………………………………………….…168 
Figure 5.8 HEK293/Kv1.3 cells have a higher level of reactive oxygen species than WT 
HEK293 cells…..………………………………………………………………………………………………….…169 
Figure 5.9 Representative images showing HEK293/Kv1.3 cells have a higher level of 
reactive oxygen species than WT HEK293 cells…………………………………………….………..170 
Figure 5.10 HEK293/Kv1.3 cells have a greater increase in cell reactive oxygen species 
in response to 100µM menadione than WT HEK293 cells……………………………………….171 
Figure 5.11 MitoQ had no significant effect on proliferation of HEK293/Kv1.3 
cells……………………………………………………………………………………………………………………...173 
Figure 5.12 MitoQ had no significant effect on proliferation of WT HEK293 cells…….174 
XVI 
 
 
Figure 6.1 Mitochondrial and Kv1.3 co-localisation in HEK293/Kv1.3-P89 and 
HEK293/Kv1.3-P99 cells…………………………………………………………………………………………187 
Figure 6.2 Mitochondrial and Kv1.3 co-localisation in HEK293/Kv1.3-P121 cells………188 
Figure 6.3 Mitochondrial Kv1.3 co-localisation analysis of HEK293/Kv1.3 and 
HEK293/Kv1.3 mutant cells……………………………………………………………………………………189 
Figure 6.4 Potassium ion currents in Kv1.3 mutant cells………………………………………….191 
Figure 6.5 HEK293/Kv1.3-P89 cells have increased proliferation compared to WT 
HEK293 cells………………………………………………………………………………………………………….192 
Figure 6.6 HEK293/Kv1.3-P89 cells have increased routine respiration compared to WT 
HEK293 cells..…………………………………………………………………………………………………….…194 
Figure 6.7 Loss of the functioning ion channel pore and voltage sensor in Kv1.3 
channels abrogates Kv1.3 induced respiration in HEK293 cells……………………………….196 
Figure 6.8 Mutation of tyrosine 447 to alanine on the C terminus of the Kv1.3-P121 
channel abolishes Kv1.3 stimulated respiration in HEK293 cells………………………………198 
Figure 6.9 Comparison of Residual Oxygen Consumption in WT HEK293, HEK293/Kv1.3 
and HEK293/Kv1.3 mutant cells…………………………………………………………………………….199 
Figure 6.10 HEK293/Kv1.3-P89 cells have ATP turnover increased to WT HEK293 cells 
and no different to HEK293/Kv1.3 cells…………………………………………………………….……200 
Figure 6.11 HEK293/Kv1.3-P121 cells have a reduced spare respiratory capacity 
compared to WT HEK293 and HEK293/Kv1.3 cells…………………………………………………202 
 
 
 
 
 
 
 
 
 
 
 
 
XVII 
 
List of Tables 
 
Table 2.1 Patient demographics for human SV cells………………………………………………….48 
Table 2.2 Plasmids for mutant Kv1.3 channels………………………………………………………….50 
Table 2.3 Primer pairs that were used for site directed mutagenesis of the Kv1.3 
channel....................................................................................................................52 
Table 2.4 Drugs added on Day 0 of proliferation assays……………………………………………60 
Table 2.5 Compounds and inhibitors used in respiratory experiments………………………63 
Table 2.6 Reagents used in immunocytochemistry experiments……………………………….69 
Table 2.7 Antibodies used in western blot experiments……………………………………………76 
Table 2.8 Fluorescent reagents used in flow cytometry experiments………………………..83 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XVIII 
 
List of Abbreviations 
 
2DDG    2 Deoxy-D-glucose 
ADP    Adenosine diphosphate 
AMP    Adenosine monophosphate 
AMPK    Adenosine monophosphate activated protein kinase 
ANOVA   Analysis of variance 
AS    Ascorbate 
ATP    Adenosine triphosphate     
BCA    Bicinchoninic acid 
BSA    Bovine serum albumin 
CCCP    Carbonyl cyanide m-chlorophenyl hydrazone 
CoA      Coenzyme A 
CREB protein   cAMP response element binding protein 
CS   Citrate synthase 
CVD    Cardiovascular disease 
DAPI    4′,6-diamidino-2-phenylindole 
dd   Double distilled 
DM2-OG   Dimethyl-2-oxoglutarate 
DNA    Deoxyribonucleic acid 
DPBS    Dulbecco’s phosphate buffered saline 
DTNB    5,5’-dithiobis-(2-nitrobenzoic acid) 
EAG    Ether-à-go-go potassium channel 
EB   Elution buffer 
ECM    Extracellular matrix 
EGTA  Ethylene glycol-bis (2-aminoethylether)-N,N,N′,N′-tetraacetic 
acid 
ER    Endoplasmic reticulum 
ERK    Extracellular signal regulated protein kinase 
ETS    Electron transport system 
FAD    Flavin adenine dinucleotide 
FADH2    Reduced flavin adenine dinucleotide 
FBS   Fetal bovine serum 
XIX 
 
FCCP     Carbonyl cyanide 4-(trifluoromethoxy)-phenylhydrazone 
FLIM    Fluorescence lifetime imaging microscopy 
GLUT    Glucose transporter 
HEK293 cell   Human embryonic kidney cell 293 
HEPES    4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HRP    Horseradish peroxidase 
HSVSMC   Human savenous vein smooth muscle cell 
IV    Current voltage relationship 
IMM    Inner mitochondrial membrane  
IMS    Intermembrane space 
KO    Knock-out 
MAPK    Mitogen activated protein kinase 
MCU    Mitochondrial calcium uniporter 
MEK    Mitogen activated protein kinase kinase 
MFI    Mean fluorescent intensity  
MgTx    Margatoxin 
MitoQ    10-(6′-ubiquinonyl) decyltriphenylphosphonium bromide 
MMP    Mitochondrial membrane potential 
MPTP    Mitochondrial permeability transition pore 
NAD    Nicotinamide adenine dinucleotide 
NADH     Reduced from of nicotinamide adenine dinucleotide 
NFAT    Nuclear factor of activated T cells 
NGS    Normal goat serum 
OXPHOS   Oxidative phosphorylation 
p     Statistical significance value 
PAGE   Polyacrylamide gel electrophoresis 
PAP-1    5-(4-Phenoxybutoxy) psoralen 
PAPTP    3-(4-(4-((7-oxo-7H-furo[3,2-g] benzopyran-4-yl) oxy) butoxy) 
phenyl) propyl) triphenyl phosphonium iodide   
PDZ    Post synaptic density protein 
pH     Acid/base scale 
PhS   Phenylsuccinic acid 
Pi     Inorganic phosphate 
XX 
 
PKA    Protein kinase A 
PKB    Protein kinase B 
PKG    Protein kinase G 
PM    Plasma membrane 
PVDF   Polyvinyl difluoride 
Rhod-2 AM   Cell-permeant acetoxymethyl (AM) ester form of rhodamine-2 
RNA    Ribonucleic acid 
ROS    Reactive oxygen species 
ROUT    Robust regression and outlier removal analysis 
ROX    Residual oxygen consumption 
RT    Room temperature 
SDS    Sodium dodecyl sulphate 
SEM    Standard error of the mean 
ShK-Dap22  Stichodactyla helianthus (ShK) with a non-natural amino acid 
diaminopropionic acid (Dap) replacing Lysine at position 22.  
SOD    Superoxide dismutase 
SDS   Sodium dodecyl sulphate 
SRC    Spare respiratory capacity 
TBS   Tris buffered saline 
TCA cycle   The citric acid cycle 
TMPD    N, N, N', N'-Tetramethyl-p-phenylenediamine dihydrochloride 
TMRM   Tetramethylrhodamine, methyl ester 
TNB    Thio-bis-[2-nitrobenzoic acid]) cysteine 
t-PMET  Trans-plasma membrane electron transport 
TPP+    Positively charged triphenyl phosphonium ion 
Tris   Tris(hydroxymethyl) aminomethane 
VDAC    Voltage dependent anion channel 
Vm   Plasma membrane voltage 
VSMCs   Vascular smooth muscle cells 
WT    Wild-type 
1 
 
Chapter One 
 
Introduction 
 
1.1 Cardiovascular Disease 
1.1.1 Overview 
Cardiovascular disease (CVD) is an umbrella term for disorders of the heart and 
circulatory system. CVD diseases include coronary heart disease, cerebrovascular 
disease, rheumatic heart disease, heart failure and other disorders (Nabel, 2003). The 
two main causes of death from CVD are myocardial infarctions and strokes, accounting 
for over 85% of CVD deaths (World Health Organisation, 2018). Myocardial infarctions 
and strokes are acute events which block the passage of oxygenated blood to areas of 
the heart and brain, respectively. These events occur when there is rupture of an 
atherosclerotic plaque in the inner wall of blood vessels 
1.1.2 Cost of CVD 
In the UK the National Health Service spends £7 billion a year on CVD (British Heart 
Foundation, 2018) and the annual cost of CVD to the EU economy is €210 billion 
(Wilkins et al., 2017). In 2008, a study calculated the one-year hospitalisation and 
medication costs for each patient with a history, or at risk of, atherothrombosis to be 
on average $7000 (Mahoney. et al., 2008). In the United States, the direct medical 
costs of CVD were $273 billion in 2010, and this number is predicted to triple by 2030 
(Heidenreich et al., 2011). In addition, the real indirect costs of CVD, due to a lack of 
productivity, are expected to rise to $276 billion by 2030 in the United States alone 
(Heidenreich et al., 2011). The prevalence of CVD is not only increasing in the United 
States (Khavjou, Phelps and Leib, 2016), but also elsewhere in the world (Wilkins et al., 
2017), especially in middle-low income countries (Gaziano et al., 2010). CVD is the 
World’s leading cause of death, with 17.9 million people dying as a result in 2016, an 
estimated 31% of deaths worldwide (World Health Organisation, 2018). In addition, 
worldwide, hypertension leads to 7.5 million deaths each year, which equates to 12.5% 
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of all deaths annually (World Health Organisation, 2013). In 2014, Public Health 
England revealed that hypertension was costing the NHS £2 billion per year (Public 
Health England, 2014).  
1.1.3 Aetiology 
VSMC proliferation is a prominent feature in the development, progression and 
treatment of CVD. Atherosclerosis is a progressive, chronic inflammatory disease of 
large arteries (Lusis, 2000). Atherosclerotic plaques develop from a build-up of lipids, 
immune cells, necrotic debris and VSMCs in the sub-endothelial layer of large blood 
vessel walls (Lusis, 2000). In addition, within the plaque exists inflammatory mediators, 
enzymes and extracellular matrix (ECM) secreted by VSMCs (Owens, Kumar and 
Wamhoff, 2004) (Figure 1.1 a, d and e). The accumulation of these cells and substances 
in the sub endothelial layer over time reduces the diameter of the vessel lumen, 
occluding blood flow (Rzucidlo, Martin and Powell, 2007). VSMCs can also migrate to 
the surface of the plaque to form a stabilising fibrotic cap (Lusis, 2000). However, 
activated macrophages within the plaque release inflammatory mediators and growth 
factors, stimulating VSMCs to proliferate more and to secrete matrix metalloproteases. 
Matrix metalloproteases  are involved in plaque instability (Galis et al., 1994) and 
neointimal hyperplasia (Porter et al., 1999), two preceding events to plaque rupture.  
Hypertension is a risk factor for multiple chronic diseases, including many 
cardiovascular disorders like heart failure, myocardial infarctions, stroke and vascular 
dementia (Touyz et al., 2018). Hypertension arises from high vascular resistance and 
causes remodelling of the vessel wall, which eventually reduces the diameter of the 
lumen (Sonoyama et al., 2007). The remodelling of the vessel wall is driven by VSMC 
proliferation (Owens, 1988; Mulvany, 1993) (Figure 1.1a, b and c),  and control of this 
proliferation produces antihypertensive effects (Hadrava et al., 1991). VSMC 
proliferation starts as an adaptive response to mechanical stress (the same 
advantageous response that would occur during vessel repair), but gradually becomes 
less controlled with an unchecked cell cycle leading to uncontrolled proliferation and 
de-differentiation of VSMCs (Owens, 1988). This results in media thickening, neointima 
hyperplasia and vessel stiffness  (Nemenoff et al., 2011).  
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1.1.4 Treatments 
People at risk, and those who already have CVD, are advised to make lifestyle changes 
to reduce their risk of disease progression. Stopping smoking, eating a healthy 
balanced diet, reducing stress, maintaining a healthy weight, reducing alcohol 
consumption and exercising regularly are all commonly prescribed (National Health 
Service, 2018). Medication, such as statins, can be prescribed to reduce blood lipids, 
but these are associated with significant side effects such as gastrointestinal problems 
(Piepoli et al., 2016). Other commonly prescribed drugs include bile acid sequestrants, 
fibrates and nicotinic acid, but they do not reduce the incidence of CVD events if 
Figure 1.1 Vascular smooth muscle cell remodelling in arteries. A. Healthy artery consisting 
of three layers; Tunica Adventitia (outer), Tunica Media (middle, containing VSMCs) and 
Tunica Intima (inner). B and C. VSMC remodelling in hypertension, showing proliferation of 
VSMCs in the Tunica Media leading to hyperplasia of the vessel wall. D and E. VSMC 
remodelling in atherosclerotic plaque formation. Proliferation of VSMCs in the Tunica Media, 
and migration of VSMCs into the atherosclerotic plaque that builds between the Tunica 
Media and the Tunica Intima. Servier Medical Art was used to generate images (Servier 
Medical Art, no date) 
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administered as a monotherapy, and again are associated with side effects (Piepoli et 
al., 2016). Future lipid lowering pharmacological therapies may focus on monoclonal 
antibody therapies, after the success of phase III clinical trials with alirocumab 
(Robinson et al., 2015) but further trials are needed. Anti-hypertensive treatments, 
glucose lowering drugs and anti-platelet therapy can also be used to reduce the risk of 
CVD events, but none are without side effects (Stewart, Manmathan and Wilkinson, 
2017). For established CVD, surgical interventions like coronary artery bypass grafting, 
balloon angioplasty and stent implantation are common procedures (Lacolley et al., 
2012). However, alongside the risks of surgical procedures, the effectiveness of these 
treatments are all limited by pathological VSMC proliferation. Percutaneous coronary 
intervention (PCI) with stent implantation is the most widely used treatment for 
coronary artery disease (Serruys and Rutherford, 2016). Proliferation of VSMCs occurs 
in response to damage to the vessel wall during stenting (Rzucidlo, Martin and Powell, 
2007).The vessel’s response to the stenting procedure is the same as it would be to an 
injury; proliferation and migration of VSMCs at the stenting site, and secretion of ECM. 
This causes hyperplastic lesions to form over and around the stent which re-narrow 
the blood vessel lumen. In-stent restenosis commonly leads to myocardial infarctions 
and severe angina which requires hospitalisation (Chen et al., 2006). However, while 
stents are becoming more advanced in their functional design, and drug eluting stents 
have reduced some problems associated with the devices (Liistro et al., 2002), the 
issue of delayed restenosis is still profound, as reviewed in (Brancati et al., 2017). Even 
heart transplantation can be affected by pathological proliferation of VSMCs, as 
cardiac allograft vasculopathy limits the long term success of the procedure (Maziar et 
al., 2006). Having more efficient treatments of CVD and reducing the reoccurrence of 
surgical complications by inhibiting VSMC proliferation is therefore of pressing need.  
 
 
 
 
 
 
5 
 
1.2 Vascular Remodelling in CVD 
1.2.1 VSMCs 
VSMCs in mature mammals are specialised cells that line the walls of blood vessels and 
arrange themselves in a circumferential manner within the vessel Tunica Media (Figure 
1.1). They control vascular tone, and so they have a direct role in regulating blood flow 
and distribution around the body (Matsumoto and Nagayama, 2012). Under normal 
conditions, these cells display a contractile phenotype, expressing vast numbers of ion 
channels, proteins and signalling molecules needed for contraction (Chamley-
Campbell, Campbell and Ross, 1979) (Figure 1.2a). However, in certain circumstances 
this phenotype switches to a proliferative one, known as ‘phenotypic modulation’ or 
the ‘phenotypic switch’ (Owens, Kumar and Wamhoff, 2004) (Figure 1.2b). Hallmarks 
of this proliferative state include the production and secretion of  extracellular matrix 
proteins and cytokines such as elastin, collagen and proteoglycans, that are necessary 
for the development of the blood vessel wall and mitosis and migration of the smooth 
muscle cells (Alexander and Owens, 2012). This irreversible proliferative phenotype is 
crucial in physiological processes such as vascular development and repair and has 
clearly developed as a protective mechanism in mammals over many years. Critically 
this phenomenon also occurs in response to environmental cues, including chemical, 
mechanical or inflammatory stimuli, causing neointimal hyperplasia of the blood vessel 
walls (Alexander and Owens, 2012). Inhibition of the VSMC switch to the proliferative, 
migratory and secretory phenotype may limit the progression of atherosclerosis, 
hypertension and CVD (Rzucidlo, Martin and Powell, 2007) 
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1.2.2 Mechanisms 
Several mechanisms have been proposed for aberrant VSMC proliferation, but a better 
understanding of the mechanisms controlling VSMC phenotypic switching is needed. 
Proliferative and contractile states of VSMCs are likely to respond to local 
environmental cues that regulate genetic programmes and thus determine cell 
phenotype (Owens, Kumar and Wamhoff, 2004). These cues can be hormonal (Cutini 
and Massheimer, 2010; Wang and Sun, 2010; Ueda et al., 2013), mechanical (Peter et 
al., 1996; Qiu et al., 2014) and traumatic (Marx, Totary-Jain and Marks, 2011), with 
damage to endothelial cells being a potent stimulator for VSMC proliferation (Hirschi, 
Rohovsky and D'Amore, 1998; Powell et al., 1998). These triggers can lead to the 
release of inflammatory mediators (Selzman et al., 1998) , growth factors (Lindner and 
Reidy, 1991) and gasotransmitters (Jeremy et al., 1999; Su et al., 2001) into the local 
environment that can act as mitogens by stimulating signalling pathways that lead to 
VSMC proliferation. In particular, platelet derived growth factor (PDGF) (Ross, 1981) 
and transforming growth factor beta1 (TGF-b) (Schulick et al., 1998) are key mitogens 
which stimulate proliferation of VSMCs. The signal for VSMCs to proliferate is driven by 
Figure 1.2 Vascular smooth muscle cell phenotypic switching.  A. Contractile VSMC with an 
elongated spindle shape, contractile protein fibres and no secretion of ECM. B. Proliferating 
VSMC with a rhomboid shape and secretion of ECM. ECM = Extracellular Matrix. Servier 
Medical Art was used to generate images (Servier Medical Art, no date) 
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various cell signalling pathways, such as Protein Kinase C (PKC) (Liu et al., 2007), 
Protein Kinase B (PKB) (Liu et al., 2010), Mitogen Activated Protein Kinases (MAPK) 
(Suwanabol et al., 2012; Cidad et al., 2015)  and Protein Kinase G (PKG) (Boerth et al., 
1997; Brophy et al., 2002), which activate transcription pathways. Some transcription 
pathways leads to protein synthesis which supports proliferation of VSMCs, whilst 
other transcription pathways lead to the downregulation of contractile proteins 
(Rzucidlo, Martin and Powell, 2007; Bennett, Sinha and Owens, 2016). Contractile 
genes are regulated by serum response factor (SRF) which binds to a DNA sequence 
known as the CArG box (a conserved DNA sequence [CC(A/T) 6 GG] ), and the SRF 
coactivator myocardin (Miano, 2003). In proliferating VSMCs, other transcription 
factors are more heavily involved, including  c-fos and c-jun (Sylvester et al., 1998; 
Zhao et al., 2002) and nuclear factor of activated T cells (NFAT) (Hill-Eubanks et al., 
2003). Regulation of transcription by splicing factors like  serine/arginine-rich splicing 
factor 1 (SRSF1) (Xie et al., 2017), DNA binding proteins like the GATA family of zinc 
finger DNA-binding domain proteins e.g. GATA-6 (Xie et al., 2015) and by epigenetics 
(Alexander and Owens, 2012) are additional mechanisms which regulate VSMC 
phenotype. The genes which are activated then regulate the expression and activity of 
a plethora of receptors, transporters and ion channels, which can support proliferation 
of VSMCs (Gomez and Owens, 2012). In particular interest for this work is the 
involvement of ion channels in VSMC proliferation, as they can be targeted 
pharmacologically to regulate their activity. Notable ion channels involved in VSMC 
proliferation include Ca2+ channels including T type (Duckles et al., 2015), transient 
receptor potential canonical (TRPC) channels (Alonso-Carbajo et al., 2017) and ORAI 
channels (Spinelli and Trebak, 2016), as well as K+ channels (Cidad et al., 2010; Lopez-
Lopez, Cidad and Perez-Garcia, 2018). From here on in, this thesis will focus on the role 
of K+ channels, in particular the Kv1.3 channel, in the phenotypic switching of VSMCs. 
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1.3 K+ Channels  
1.3.1 Overview 
K+ channels are proteins within cell membranes that allow K+ ions to pass through the 
membrane, down their electrochemical gradient. K+ channels are found in almost all 
species and play crucial roles in both excitable and non-excitable cells, regulating 
functions from cell volume, to hormone secretion and electrical impulse propagation 
(Hille, 2001). In mammals almost 80 genes encode K+ channels, making them the most 
widely distributed ion channel (Maljevic and Lerche, 2013). 
All K+ channels have transmembrane domains that sit in the lipid bilayer, and it is 
predominantly the structure of these transmembrane domains that allows K+ channels 
to be categorised. All K+ channels consist of two distinct regions; a pore forming region 
to allow K+ ions to pass through the channel and a regulatory region which allows for 
channel regulation. A selectivity filter in the pore ensures the channels are highly 
selective for K+ over other ions (Doyle et al., 1998). While the pore forming region is 
consistent in structure across all K+ channels, the regulatory region can vary widely 
between K+ channels and contributes to their classification (Kuang, Purhonen and 
Hebert, 2015). K+ channels can be divided into four groups based on their structure 
and mode of activation;  
- Inwardly rectifying potassium channels, Kir (2 transmembrane domains). 
- Two pore potassium channels, K2P (4 transmembrane domains). 
- Calcium activated potassium channels, KCa (6 or 7 transmembrane domains). 
- Voltage gated potassium channels, Kv (6 transmembrane domains). 
 
The structure of each of these types of K+ channel is shown in Figure 1.3, along with 
their associated genes. The Kv channels make up the largest group of K+ channels in 
mammals. With 40 genes encoding them in humans (Maljevic and Lerche, 2013), they 
are arguably the most structurally and functionally diverse members of all the voltage 
gated ion channels. 
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1.3.2 Voltage Gated K+ Channels 
The existence of these channels was first discovered over 60 years ago, through the 
pioneering work of Hodgkin and Huxley on the giant squid axon (Hodgkin and Huxley, 
1952). Kv channels open in response to changes in the transmembrane potential, 
which allows for K+ ions to flow through the channels to restore the resting membrane 
potential. Originally discovered in Drosophila, four groups of genes were found to code 
for Kv channels; shal, shaw, shab and shaker, and these have all been found to have 
human homologues. The Kv gene superfamily can be categorised into 12 families of 
channels, Kv1.x – Kv12.x (Gutman et al., 2005). In Figure 1.3, Kv5.x, Kv6.x, Kv8.x and 
Kv9.x are omitted due to them being modifiers of other potassium channels (Gutman 
et al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Summary of potassium ion channels. A. Cross 
section of the lipid bilayer of the plasma membrane 
containing the five members of potassium ion channels. 
For each example, one alpha subunit is shown, consisting 
of the transmembrane domains. Below the plasma 
membrane are the different genes associated with each 
example potassium channel. B. An above view of a 
potassium ion channel in the plasma membrane. Each 
potassium channel is made up of four alpha subunits, 
which create a tetramer around a central pore. Servier 
Medical Art was used to generate images (Servier Medical 
Art, no date).    
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1.3.2.1 Structure 
In 1998, the KcsA channel was the first K+ channel to have its structure characterised 
using x-ray crystallography (Doyle et al., 1998). This work paved the way for the 
molecular characterisation of other K+ channels, such as Kv1.2 in 2005 (Long, Campbell 
and MacKinnon, 2005). All mammalian Kv channels share a similar tetrameric structure 
(Figure 1.4), with each subunit consisting of two independently functioning domains; a 
voltage sensing domain and an ion conducting pore (Kuang, Purhonen and Hebert, 
2015). Each of the four subunits contains six transmembrane hydrophobic alpha 
helixes, S1-S6, and a P loop which re-enters the membrane. The ion conduction pore is 
made up by the four S5-P-S6 helixes which are arranged in a circumferential manner, 
while the four S1-S4 helixes sit on the periphery of the pore and make up the voltage 
sensing domain which controls channel gating. It is the S4 helix that is involved most 
heavily in the voltage sensing ability of the channel, as each S4 helix contains positively 
charged arginine residues. These charged residues are known as gating arginines, and 
four are found at every third position on this transmembrane helix. The two 
independently functioning parts of each subunit (the voltage sensor and the ion pore) 
are attached between S4 and S5 by what is known as the S4-S5 linker. 
Each gene encoding mammalian Kv channels codes for an individual subunit. As each 
functioning channel needs four subunits, the channels can exist as homotetramers or 
heterotetramers of different subunits within the same family (Gutman et al., 2005). 
This is one way in which the diversity of Kv channels is increased. The channels can also 
undergo post-translational modifications that further increase their structural and 
functional diversity. Kv channels can undergo post-translational phosphorylation 
(Jerng, Pfaffinger and Covarrubias, 2004), ubiquitinylation (Henke et al., 2004) and 
palmitoylation (Gubitosi-Klug, Mancuso and Gross, 2005). 
Movement of the gating arginines across the transmembrane electric field contributes 
to a gating charge. Every time the channel opens, around 12-13 charges are 
transferred across the electric field. These arginines are present in all voltage gated K+, 
Na+ and Ca2+ channels and are imperative for their gating. This charge transfer 
precedes channel opening. Gating occurs when a change in membrane potential is 
sensed in the S4 region which leads to a pulling action on the S4-S5 linker, resulting in 
a conformational change of the channel which allows for K+ to flow through the pore. 
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This mechanism is described as a ball and chain mode of action, with the chain (the linker) being able to pull the 
ball (the gate) out of the pore to allow for the passage of K+ only. 
Inactivation/activation can also occur due to conformational changes to the channel 
(Nekouzadeh and Rudy, 2016). 
The selectivity filter in these channels is positioned at the narrowest part of the pore. 
An amino acid sequence (Thr-Val-Gly-Tyr-Gly) or (Thr-Val-Gly-Phe-Gly) has been found 
to be essential for the potassium selectivity in Kv channels. As the K+ ions flow through 
the channel pore they interact with the carbonyl groups of the aforementioned 
sequences. This removes the hydration shell from the K+ ions and allows their diffusion 
through the channel. The size of the selectivity filter in the Kv channels allows for K+ 
ions to interact with the channel proteins, while it is too large to have the same effect 
on smaller cations such as Na+. The details of the Kv gating structure became clearer 
after the crystal structure of rat brain Kv1.2 (rat Kvα1.2/β2) was solved in 2005 (Long, 
Campbell, & MacKinnon, 2005). In addition to uncovering the mechanism of the gating, 
the structure of beta (β) subunits which associate with the alpha (α) subunits of the 
channel was also found (Figure 1.4b). For example, members of the Kv1.x family,  bind 
with Kvβ1-3 proteins through their N-terminal tetramerisation sites. This produces a 
symetrical tetramer which exists on the intracellular side of the channel. These 
auxillary subunits are able to modulate the gating of the channel. The binding of 
different β subunits to the channel adds to the diversity of biophysical and 
pharmacological properties within the Kv channel family.  
1.3.2.2 Location and Function 
Along with this large amount of structural diversity, Kv channels are also expressed in a 
wide range of human tissues, including the central and peripheral nervous systems 
(Shah and Aizenman, 2014), in non-excitable cells of the immune system (Wulff et al., 
2003) and smooth muscle (Cidad et al., 2010; Cheong et al., 2011). 
Kv channels allow propagation of electrical signals in the nervous system by 
determining the shape and size of action potentials, as the outward flow of K+ from the 
cells repolarises the membrane after an electrical stimulation (Shah and Aizenman, 
2014). Kv channels are subsequently key players in the role of neurotransmitter 
release. In addition, Kv channels regulate cell volume (Lang et al., 2007; Perez-Garcia, 
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Cidad and Lopez-Lopez, 2018), cellular proliferation and migration (Lopez-Lopez, Cidad 
and Perez-Garcia, 2018), and are also involved in metabolism and insulin signalling (Xu 
et al., 2003, 2004; Tucker et al., 2013).Kv channels are also highly expressed in immune 
cells and can activate T lymphocytes (Wulff et al., 2003). In all cells, the channels 
regulate the resting plasma membrane potential (Ouadid-Ahidouch and Ahidouch, 
2013). Therefore, Kv channels have been proposed as therapeutic targets for diseases 
ranging from cancer and autoimmune diseases to neurological, metabolic and 
cardiovascular disorders.  
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1.4 Kv1.3 
1.4.1 Overview 
Kv1.3 is a voltage-gated, shaker-related potassium channel of the delayed rectifier 
family that is encoded for by the KCNA3 gene. This channel was originally discovered in 
1984, when a study linked it to the proliferation of human T lymphocytes (DeCoursey 
et al., 1984). It was originally classified as an ‘n-type’ channel, for its prevalence in 
‘normal’ human T lymphocytes. This channel was found it to be a delayed rectifier Kv 
channel (Cahalan et al., 1985) and shares 60-70% identity with the channel encoded by 
the shaker gene in Drosophila (Kamb, Tseng-Crank and Tanouye, 1988). In 1991 this ‘n 
type’ channel was renamed mammalian shaker-related voltage gated K+ channel, 
Kv1.3, encoded by the KCNA3 gene (Chandy, 1991). The structure of Kv1.3 is shown in 
Figure 1.4. Readers are directed to (Chen et al., 2010) to see x-ray crystallography of 
the closely related Kv1.2 channel. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Structural components of the Kv1.3 potassium channel. A. The 6 
transmembrane domains of the alpha subunit of the Kv1.3 channel situated in the lipid 
bilayer. The voltage sensor is on S4, the fourth transmembrane domain. The pore region is 
situated between S5 and S6. The S4-S5 linker is associated with the channel gating. The KvB 
on the N Terminus is the beta subunit binding domain. B. Schematic of the Kv1.3 channel as 
it would be seen from above. The four beta subunits are shown (green squares), with one 
attached to each of the four alpha subunits. Servier Medical Art was used to generate 
images (Servier Medical Art, no date).    
A. 
B. 
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1.4.2 Location and function 
Kv1.3 channels have been found in brain tissue (Swanson et al., 1990; Veh et al., 1995; 
Bednarczyk et al., 2010; Bielanska et al., 2010) the olfactory bulb (Stuhmer et al., 
1989), epithelial cells (Grunnet et al., 2003), adipose tissue (Xu et al., 2004), 
macrophages (Kan et al., 2016), lymphocytes (Cahalan et al., 1985), and both skeletal 
(Hamilton et al., 2014) and smooth muscle cells (Villalonga et al., 2007; Cidad et al., 
2010; Bielanska et al., 2012). Originally thought to only be expressed in the plasma 
membrane of cells, they have now been located at other intracellular sites, such as the 
nucleus (Jang et al., 2015), the cis-Golgi (Zhu, Yan and Thornhill, 2014) and the inner 
mitochondrial membrane (Szabo et al., 2005).  
Kv1.3 channels have been found to contribute to cellular proliferation (Cidad et al., 
2010; Cheong et al., 2011), cell cycle progression (Deutsch and Lee, 1988), cell volume 
regulation (Deutsch and Lee, 1988), apoptosis (Leanza et al., 2012) and the control of 
the membrane potential (Blackiston, McLaughlin and Levin, 2009). Plasma membrane 
and intracellular Kv1.3 channels may have distinct roles. Mitochondrial Kv1.3 channels 
have been found to regulate apoptosis in cancer cells (Szabo et al., 2005). Kv1.3 
channels at the nucleus may regulate cellular proliferation via regulation of 
transcription factors like c-fos and CREB (Jang et al., 2015). 
1.4.3 Biophysical phenotype 
At voltages between -70 and -90mV Kv1.3 channels are typically closed, but open in 
response to a depolarisation of the membrane potential. Activation of Kv1.3 channel 
occurs between -60 and -50mV, where the channel displays a steep open probability 
with a midpoint of -40mV (Mahnke et al., 2013). The activation of these channels 
occurs quickly, over a few milliseconds, whereas the inactivation occurs over a much 
longer time course, and takes about 200ms (at +50mV) to occur (Panyi, 2005).  The 
inactivation midpoint of Kv1.3 channels is also very steep, occurring at around -45mV 
(McCormack et al., 1999) and displaying a c type pattern of inactivation (Rasmusson et 
al., 1998). This shows that Kv1.3 channels have a very small window current. 
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1.4.4 Regulation 
Other membrane proteins have been found to regulate Kv channels. KCNE peptides 
modulate the Kv1.3 channel in a way similar to β subunits, for example KCNE4 can 
supress Kv1.3 currents by altering channel trafficking to the membrane, surface 
expression at the membrane and channel gating (Sole et al., 2009). Cortactin can also 
regulate Kv1.3 trafficking to the membrane (Hajdu et al., 2015), as can post synaptic 
density (PDZ) proteins which additionally regulate clustering at the membrane and 
channel activity (Marks and Fadool, 2007; Szilagyi et al., 2013). Kv1.3 channels exhibit 
caveolin binding sites. Upon binding to the channel, caveolin inhibits channel activity 
(Perez-Verdaguer et al., 2016). Integrin receptors also interact and control Kv1.3 
channels (Levite et al., 2000). Post-translational modification of Kv1.3 can occur by 
glycosylation (Zhu, Yan and Thornhill, 2012), palmitoylation (Velez et al., 2016) and 
phosphorylation (Jimenez-Perez et al., 2016) which can regulate the channel’s 
interactions with other proteins. Phosphorylation of Kv1.3 is the most common post-
translational modification, with the channel being a substrate for many protein kinases 
(Chung and Schlichter, 1997b, 1997a). Of note, the Kv1.3 channel can also be 
modulated by ROS (Cayabyab et al., 2000). ROS can regulate cysteine, methionine, 
tyrosine, or histidine residues on ion channels (Cayabyab et al., 2000). Finally, Kv1.3 
may also be regulated by substrates and products of metabolism, such as glucose 
(Tucker et al., 2013) and ATP (Chung and Schlichter, 1997b).  
1.4.5 Pharmacology  
Inhibitors of Kv1.3 have been developed that either block the channel pore or prevent 
the channel from activating (Perez-Garcia, Cidad and Lopez-Lopez, 2018). Toxins 
derived from organisms such as scorpions (Bartok et al., 2014; Rashid et al., 2014), 
snakes (Yang et al., 2014) and sea anemones (Rashid et al., 2013; Chang et al., 2015) 
inhibit Kv1.3 by blocking the channel pore, whereas plant derived psoralens like PAP-1 
(Kundu-Raychaudhuri et al., 2014) and Psora-4 (Leanza et al., 2013) keep the channel 
in its inactive state. The ShK peptides derived from sea anemones are some of the 
most specific and potent Kv1.3 inhibitors, originating from toxins derived from sea 
anemones (Rashid et al., 2013). Most inhibitors, especially the toxin type, target only 
plasma membrane Kv1.3 channels, as they are impermeable to the lipid membrane. 
Recent advances in Kv1.3 pharmacology have chemically altered Kv1.3 inhibitors so 
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that they are able to target Kv1.3 channels at specific intracellular sites. Leanza and 
colleagues attached a delocalized cation, triphenyl phosphonium (TPP) moiety, onto a 
(5-(4-Phenoxybutoxy)psoralen) (PAP-1) derivative, targeting the Kv1.3 inhibitor to the 
negatively charged mitochondria, thus specifically inhibiting mitochondrial Kv1.3 
channels (Leanza et al., 2017; Mattarei et al., 2018). Intracellular and organelle 
targeting of compounds is key to specificity of a drug. It is important to note that not 
all compounds are specific for Kv1.3, e.g. Margatoxin (Bartok et al., 2014), as it also 
inhibits Kv1.2 with a similar affinity to Kv1.3 channels (Kd = 6.4pM) and has low affinity 
for Kv1.1 (Kd =4.2nM) (Bartok et al., 2014).  
 
1.5 Pharmacological targeting of Kv1.3 in disease 
1.5.1 Oncology 
Inhibition of Kv1.3 by pharmacological or genetic means inhibits the growth of cancer 
tumours, thus Kv1.3 inhibitors are fast becoming a promising  therapeutic avenue 
within oncology (Comes et al., 2013; Teisseyre, Gasiorowska and Michalak, 2015). 
Recent work has focused on the inhibition of mitochondrial Kv1.3 channels, using TPP 
bound psoralen inhibitors, to promote ROS-dependent apoptosis of tumour cells 
(Mattarei et al., 2018).  
1.5.2 Immunology 
The majority of the research into Kv1.3 channel characterisation and function has been 
carried out in T lymphocytes (T cells). T cells differentiate into effector memory T cells 
(TEM) upon repeated contact with a particular antigen. This process is characterised by 
increased expression and activity of Kv1.3 channels in TEM cells (Chandy et al., 2004).  
In autoimmune diseases, where there is increased differentiation and proliferation of 
TEM cells lead to attack of endogenous tissue, Kv1.3 inhibitors are promising 
therapeutic agents. Kv1.3 inhibitors are being researched to treat Multiple Sclerosis 
(Yuan et al., 2018), Sjogren’s Syndrome (Legany et al., 2016), Rheumatoid Arthritis 
(Tanner et al., 2017), Chronic Inflammatory Diseases such as Chronic Kidney Disease 
(Kazama et al., 2012), Inflammatory Bowel Disease (Kazama, 2015) and Ulcerative 
Colitis (Koch Hansen et al., 2014), as well as inflammatory conditions off the airways 
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such as asthma (Koshy et al., 2014) and COPD (Kazama and Tamada, 2016). Dalazatide, 
an analogue of ShK peptide has been successful in treating plaque psoriasis in a Phase 
1b clinical trial, and is currently ready for Phase 2 trials (Tarcha et al., 2017). In 
addition, Kv1.3 activity may be harnessed and modulated in B lymphocytes (Wulff et 
al., 2004), natural killer cells (Koshy et al., 2013) and macrophages (Vicente et al., 
2003; Kan et al., 2016) to prevent their activation, differentiation and proliferation for 
therapeutic benefit in inflammatory conditions.  
1.5.3 Neurology 
Astrocytes, oligodendrocytes and microglial cells are all glial cells of the central 
nervous system (CNS). Previously only thought to be the ‘housekeepers’ of the CNS, it 
is now widely accepted that glial cells can regulate the excitability of neurons by 
secreting chemical signalling molecules and displaying high levels of proliferation and 
migration (Stebbing, Cottee and Rana, 2015). These neuroinflammatory properties are 
thought to be a hallmark of many neurodegenerative diseases and this change in glial 
cell behaviour is partly regulated by Kv1.3 channels. In oligodendrites, Kv1.3 regulates 
the progression of the cell cycle of proliferating oligodendrite progenitor cells 
(Chittajallu et al., 2002), through a platelet derived growth factor driven mechanism 
(Vautier et al., 2004). Kv1.3 channel upregulation also occurs in microglial cell 
activation (Rangaraju et al., 2015). In healthy tissue in the CNS, astrocyte proliferation 
exists at a very low level. Upon injury, proliferation increases along with an 
upregulation of Kv1.3-like delayed rectifier potassium currents (MacFarlane and 
Sontheimer, 1997), however the exact identity of these delayed rectifier currents has 
not been elucidated to. Glial cell inflammation and secretion of factors involved in the 
pathogenesis of neurodegenerative disorders such as Alzheimer’s Disease (Lowinus et 
al., 2016) and  Parkinson’s Disease (Zhang et al., 2018). Kv1.3 inhibitors have shown 
promising results at reducing the severity of brain injuries from stroke by reducing 
microglial neuroinflammation (Chen et al., 2018).  
1.5.4 Vascular Biology 
In a gene expression analysis of 87 ion channels, only two genes were upregulated in 
proliferating VSMCs; the genes coding for the Kv1.3 channel and its associated β 
subunit, Kvβ2.1 (Cidad et al., 2010). Cultured proliferating VSMCs have increased 
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expression of Kv1.3 channels, and their sensitivity to the inhibitor PAP-1 increases 6-
fold compared to contractile VSMCs (Cidad et al., 2010). Kv1.3 inhibitors reduce VSMC 
proliferation and migration in in vitro and in vivo models (Cidad et al., 2010; Cheong et 
al., 2011). While the involvement of Kv1.3 in VSMC phenotypic switching is universally 
agreed, the mechanism that underlies it is controversial; three main themes have 
emerged. 
 
1.6 Mechanisms of Kv1.3 induced proliferation 
1.6.1 Membrane potential 
It has been proposed that Kv1.3 regulates phenotypic switching of VSMC via 
alterations in the plasma membrane potential. Activation of Kv1.3 channels causes 
efflux of K+ from the cytosol and hyperpolarisation of the plasma membrane potential 
(Vm). Activation of Kv1.3 is proposed to regulate the oscillations in Vm that occur 
throughout the cell cycle (Blackiston, McLaughlin and Levin, 2009). Hyperpolarisation 
of the Vm will lead to a more negatively charged cytosol compared to the extracellular 
milieu. This will increase the driving force for cation entry, which will cause water to 
follow and cell volume to increase. Cell volume will oscillate throughout the cell cycle 
in line with Vm, and there is an optimum volume for proliferation (Herrmann et al., 
2012). Alteration of the Vm and/or the cell volume by activation of Kv1.3 can alter 
other ion fluxes in the cell. An increase in intracellular Ca2+ can activate cell signalling 
pathways which drive proliferation. Some researchers propose that it is the 
downstream effects of Kv1.3 activation on Ca2+ fluxes which drive proliferation 
(Cheong et al., 2011). This mechanism may be more prevalent in the immune system, 
where cells, such as T lymphocytes are heavily reliant on Ca2+ signalling (Chandy et al., 
2004). Kv1.3 mediated hyperpolarisation of Vm has been proposed to be essential for 
proliferation of VSMCs (Neylon et al., 1999; Neylon, 2002). Cheong et al., also suggest 
that Kv1.3 induced changes to Vm are essential to drive Ca2+ induced proliferation 
(Cheong et al., 2011). However, in VSMCs, both Kv1.3 and Kv1.5 channels have similar 
effects on membrane potential but very different effects on proliferation (Cidad et al., 
2010, 2012). In addition, in femoral VSMCs, depolarisation induced by inhibition of 
other K+ channels or by a high extracellular K+ concentration did not affect 
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proliferation, suggesting the Vm is not the main determinant of proliferation in these 
cells (Cidad et al., 2010). Therefore, even though K+ flux through the Kv1.3 channel can 
contribute to proliferation, the final outcome of Kv1.3 proliferation must be triggered 
by an ion conduction-independent signalling pathway. 
1.6.2 Voltage Sensing 
Another proposed mechanism suggests that Kv1.3 channels have non-conducting roles 
which drive proliferation. Non-conducting Kv1.3 channels which have an intact voltage 
sensor are able to increase proliferation of HEK293 cells to the same extent as WT 
Kv1.3 channels (Cidad et al., 2012; Jimenez Perez et al., 2016). Kv1.3 may sense Vm 
and control progression of the cell cycle via a polyamine synthesis pathway (Pegg, 
2016).  Another explanation is that key signalling residues on the Kv1.3 channel 
participate in translating the pro-proliferative signal. The Kv1.3 channel has been 
found to contain 17 tyrosine residues, of which several are accessible to tyrosine 
phosphorylation (Fadool and Levitan, 1998; Fadool et al., 2000; Marks and Fadool, 
2007). Kv1.3/Kv1.5 chimeric channels indicate that there are putative docking sites on 
a YS segment of the C-terminus of the Kv1.3 channel. Upon sensing a change in Vm, 
there is a conformational change in the Kv1.3 channel from closed to open which 
exposes this YS segment to phosphorylation. Phosphorylation of the Kv1.3 channel 
then initiates MAPK signalling via extracellular signal-regulated kinase (ERK), which 
drives progression of the cell cycle (Jimenez-Perez et al., 2016). Non-conducting roles 
of other ion channels have been described (Urrego et al., 2014), such as the EAG 
channel (Hegle, Marble and Wilson, 2006) and the KCa channel (Millership et al., 
2011). Both the EAG and KCa channels require conformational changes which allow 
MAPKs, including ERK, c-jun N-terminal kinases (JNK) and p38 kinases to interact with 
the channels and stimulate proliferation via activating signalling pathways (Hegle, 
Marble and Wilson, 2006; Millership et al., 2011). Thus, Kv1.3 may be a kinase 
substrate and part of a voltage-initiated intracellular signalling network. 
1.6.3 Association with other proteins 
Kv1.3 channels interact with other proteins that can modulate channel activity and/or 
contribute to stabilising and to scaffolding the channel within the membrane. In knock-
out (KO) Kv1.3 mice, expression of channel-associated proteins, such as tyrosine 
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kinases, PDZ-containing proteins and adaptors is re-organised (Fadool et al., 1997). Re-
organisation of plasma membrane proteins may also occur if Kv1.3 is upregulated in 
the membrane, with alterations to proteins like integrins and PDZ proteins leading to 
altered regulation of Kv1.3 and potentially increased proliferation (Levite et al., 2000; 
Marks and Fadool, 2007). In addition, there is increasing evidence for the Kv1.3/Kv1.5 
ratio to be the determining factor driving cellular proliferation in oligodendrite 
progenitor cells (Attali et al., 1997), microglial cells (Kotecha and Schlichter, 1999) and 
VSMCs (Cidad et al., 2010). Cidad et al., proposed that it was the ratio of Kv1.5/Kv1.3 
which determined VSMC phenotype, with a high ratio (increased Kv1.5) reducing 
proliferation and a low ratio (increased Kv1.3) that increased proliferation (Cidad et al., 
2010). Increased Kv1.3 to decreased Kv1.5 channel expression would alter the balance 
of K+ in cells, as the channels have different voltage dependencies (Perez-Garcia, Cidad 
and Lopez-Lopez, 2018). In addition, if both of these channels have non-conducting 
functions (Cidad et al., 2012; Jimenez-Perez et al., 2016), they may alter cell signalling 
pathways which regulate the cell cycle and proliferation. Interestingly, intracellular 
organelles also have specific transmembrane potentials, and it may be that 
Kv1.3/Kv.1.5 ratio contributes to the potential in these organelles too. Mitochondrial 
Kv1.3 in the inner mitochondrial membrane regulates cell growth and apoptosis of 
cancer cells via its effect on the mitochondrial membrane potential (MMP) (Szabo et 
al., 2005; Teisseyre, Gasiorowska and Michalak, 2015; Leanza et al., 2017). A decrease 
in mitochondrial Kv1.5 has been found to promote proliferation in human cancer cell 
lines (lung, glioblastoma and breast cancer), whilst its reinstatement reduces 
proliferation and promotes apoptosis (Bonnet et al., 2007). The contribution of each of 
these channels to proliferation, apoptosis and cellular energy status in VSMCs and 
other non-cancerous cell types remains poorly defined. Therefore, in this thesis, we 
explored the role of mitochondrial Kv1.3 on the proliferation, bioenergetic status and 
the functional link between the two, in HEK293 cells. 
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1.7 Mitochondria 
1.7.1 Structure 
Mitochondria are organelles present in almost all eukaryotic cells. They are thought to 
have arisen from a proteobacterium being engulfed by a host archaebacterium and 
have evolved to become part of the eukaryotic cell. The general structure of a 
mitochondrion is shown in Figure 1.5. Mitochondria have two membranes; the outer 
mitochondrial membrane (OMM), which separates the mitochondrial contents from 
the cytosol, and an inner mitochondrial membrane (IMM), which encompasses the 
matrix. The matrix is the site of key metabolic processes including fatty acid β-
oxidation and the conversion of Acetyl-CoA to reducing equivalents needed for 
oxidative phosphorylation (OXPHOS) in the Krebs/TCA (the citric acid) cycle, essential 
for cellular energy status. The IMM has a large surface area due to multiple 
folds/invaginations termed cristae. Embedded in these cristae are the multiple protein 
complexes which participate in OXPHOS. There are 5 multi-subunit enzymatic 
complexes in the IMM, complexes I, II, III, IV and V, with the fifth being the adenosine 
triphosphate (ATP) synthase that resynthesises ATP from adenosine diphosphate (ADP) 
and inorganic phosphate (Pi). Respectively, complexes I-IV are called NADH: 
ubiquinone oxidoreductase, succinate dehydrogenase, cytochrome bc1 complex and 
cytochrome c oxidase. The two membranes are separated by the intermembrane 
space (IMS). Across the IMM exists an electrochemical gradient comprised of both a 
chemical component and an electrical component (Nicholls and Ferguson, 2013). The 
electrical component is the voltage difference between the IMS and the matrix, 
normally around 160-200mV (Szabo and Zoratti, 2014), while the chemical component 
is the pH of the matrix, determined by the concentration of H+ protons (Nicholls and 
Ferguson, 2013). 
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1.7.2 Primary Function – Oxidative Phosphorylation 
 
OXPHOS in the IMM involves the generation of ATP from chemical energy released 
when reducing equivalents donate electrons to the electron transport system (ETS), 
where they are transferred across the mitochondrial complexes to be accepted by the 
terminal electron acceptor, oxygen (O2), at complex IV (Figure 1.6). The reducing 
equivalents of nicotinamide adenine dinucleotide (NADH) and flavin adenine 
dinucleotide (FADH2) are donated to the complexes at the beginning of the ETS. NADH 
reduces complex I (complex I gains two electrons from one NADH molecule) and 
FADH2 reduces complex II (complex II gains two electrons from one FADH2 molecule), 
before electrons are transferred along the ETS via a series of redox reactions. The 
electron transporter ubiquinone/co-enzyme Q10 transports electrons from complexes 
I and II to complex III, whilst cytochrome c carrier transports electrons from complex III 
to complex IV. At complex IV O2 is reduced to water (H2O). These redox reactions 
release energy which is used to actively pump H+ ions across the IMM at complexes I, 
III and IV from the matrix to the IMS. For each pair of electrons donated, 4 protons are 
pumped at complexes I and III, while only 2 are pumped at complex IV. This process 
results in an electrochemical gradient generated across the IMM. This gradient drives 
Intermembrane Space Outer 
Mitochondrial 
 Membrane 
Mitochondrial 
 Matrix Inner Mitochondrial  
Membrane 
Figure 1.5  Simple structure of a mitochondrion. The outer mitochondrial membrane 
encases the organelle. The intermembrane space separates the outer mitochondrial 
membrane and the inner mitochondrial membrane. The inner mitochondrial 
membrane is folded into invaginations and encases the matrix. Servier Medical Art was 
used to generate images (Servier Medical Art, no date).    
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the flow of protons down their electrochemical gradient through the ATP synthase, by 
chemiosmotic coupling (Mitchell, 1961), and generates ATP.  NADH can be used as an 
indirect measure of the amount of ATP generated in the cell (Blacker and Duchen, 
2016). ATP is exported out of the matrix via the adenine nucleotide transporters 
(ANTs). As O2 is the terminal electron acceptor, its consumption reflects ATP 
resynthesis via OXPHOS and so O2 consumption can be measured to estimate the ATP 
production within cells. Often, electron transfer between complexes is not 100% 
efficient, and electrons ‘leak’ from the complexes. These free electrons are mopped up 
by O2 molecules, generating reactive oxygen species (ROS).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Proteins of the electron transport chain in the inner mitochondrial membrane. 
Complexes 1-4 (I, II, III, IV) of the electron transport chain, along with ATP synthase. 
Diagram shows how the electrochemical gradient is set up via proton pumping into the 
intermembrane space of the mitochondria. H+ = hydrogen protons, Q = ubiquinone/co-
enzyme Q10,  C = cytochrome c, NADH/NAD+ = reduced/oxidised nicotinamide adenine 
dinucleotide (respectively), FADH2/FAD+ = reduced/oxidised flavin adenine dinucleotide 
(respectively), O2 = oxygen, H2O = water, ATP = adenosine triphosphate, ADP = adenosine 
diphosphate, Pi = inorganic phosphate. Dashed line shows the passage of electrons 
between the protein complexes. Black vertical arrows show direction of H+ pumping. Black 
curved arrows show chemical reactions occurring. Servier Medical Art was used to 
generate images (Servier Medical Art, no date).    
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1.8 Associated Bioenergetic Pathways 
1.8.1 NAD+ 
NAD+ is a coenzyme found in all living cells (Verdin, 2015). It is made up of vitamin B3, 
or niacin, and ATP. The role of NAD+ was first elucidated to by Otto Warburg, who 
isolated NAD+ and discovered it to be vital for hydrogen transfer in biochemical 
pathways (Warburg, Posener and Negelein, 1924; Warburg, 1925). The niacin accepts 
and carries one hydrogen atom and two electrons. Once NAD+ has accepted the 
hydrogen and electrons, it becomes known as NADH, the reduced form of the 
coenzyme, thus NADH is often referred to as a ‘reducing equivalent’. NADH becomes a 
hydrogen and electron donor, capable of oxidising other NAD+ molecules and Complex 
I of the ETS. NADH diffuses through the OMM but needs IMM transporters, such as the 
malate/aspartate and glycerol 3 phosphate shuttles, to enter the matrix. Although the 
main function of NAD+/NADH is to participate in the redox reactions of metabolism, an 
emerging role for NAD+/NADH has been found in cell signalling (Canto, Menzies and 
Auwerx, 2015). NAD+/NADH can tightly regulate signalling molecules like sirtuins and 
poly ADP ribose polymerases (PARPs). In low O2 situations NAD+/NADH can contribute 
to the production of lactic acid. NAD+ and NADH can also be phosphorylated, and 
NADP/NADPH molecules are important for cellular antioxidant defences and have a 
role in biosynthesis of lipids such as cholesterol  (Yang et al., 2008; Blacker and 
Duchen, 2016). NAD+ and NAD(P)+ both participate in redox reactions in the cell and 
their pools are of similar size (Ronchi et al., 2013).  
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1.8.2 Glycolysis  
Glucose is a major source of energy for the production of new cell mass, and it is 
metabolised to pyruvate during glycolysis. Glycolysis is an anaerobic process which 
occurs in the cytosol once glucose has entered the cell. As glucose is a large polar 
molecule, transporters are needed to facilitate its entry into the cytosol. There are two 
main types of glucose transporter in the plasma membrane of cells, sodium-glucose 
linked transporters (SGLTs) which are localised to the intestinal mucosa and the 
proximal tubule of the nephron, and facilitated diffusion glucose transporters (GLUTs) 
(Navale and Paranjape, 2016). In VSMCs, GLUT1 and GLUT4 are involved in glucose 
uptake, with GLUT1 being the main facilitator of glucose entry and GLUT4 facilitating 
glucose uptake when stimulated by insulin (Park et al., 2005; Lin et al., 2013). 
Glycolysis involves a series of enzymatic reactions, summarised in Figure 1.7. Glycolysis 
oxidises glucose to release energy to generate ATP and reduces two molecules of NAD+ 
to NADH. For every molecule of glucose that is oxidised to pyruvate, 2 molecules of 
ADP and 2 molecules of Pi are re-synthesised to two molecules of ATP. If O2 is limited, 
fermentation of pyruvate occurs, and it is anaerobically metabolised to lactic acid. It 
has been suggested that glycolysis, especially pyruvate fermentation, synthesises the 
macromolecular building blocks needed to support cell proliferation (Vander Heiden, 
Cantley and Thompson, 2009; Sullivan et al., 2015). If O2 is not limited, pyruvate can 
undergo a series of reactions, specifically the link reaction and the Krebs cycle, which 
lead to large amounts of ATP being generated via OXPHOS. Glycolysis is regulated by 
three enzymes; hexokinase, phosphofructokinase and pyruvate kinase (Figure 1.7). 
Each of these enzymes are regulated by different molecules; hexokinase is inhibited by 
glucose 6 phosphate, phosphofructokinase is inhibited by high ATP, citrate and pH but 
is stimulated by adenine monophosphate (AMP) and fructose-2,6-biphosphate, and 
finally pyruvate kinase is allosterically regulated by fructose-1, 6-biphosphate (Naish, 
Syndercombe Court and Revest, 2009). 
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Figure 1.7 Glycolysis pathway. Schematic shows the metabolism of glucose to pyruvate. 
The process is regulated by three enzymes, hexokinase, phosphofructokinase and pyruvate 
kinase (blue boxes). The first stage of glycolysis is ATP consuming (red boxes). The second 
stage of glycolysis produces NADH (green box) and ATP (yellow boxes). Image adapted 
from Medical Science by Naish, Syndercombe Court and Revest, 2009. 
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1.8.3 Link Reaction 
Pyruvate is transferred into the mitochondrial matrix by mitochondrial pyruvate 
carriers (McCommis and Finck, 2015). In the matrix, pyruvate is oxidatively 
decarboxylated, and then combined with Co-enzyme A to form Acetyl-CoA. The link 
reaction is catalysed by pyruvate dehydrogenase (Figure 1.8), and the link reaction acts 
as the bridge between glycolysis and the Krebs Cycle. As one molecule of glucose is 
metabolised to two molecules of pyruvate during glycolysis, the link reaction occurs 
twice for every glucose molecule. Thus, for every molecule of glucose, 2 Acetyl-CoA 
molecules, 2 NADH molecules, 2 CO2 molecules and 2 H+ are produced. The Acetyl-CoA 
molecules can then enter the Krebs Cycle. The Link Reaction is regulated by pyruvate 
dehydrogenase and many factors can affect the activity of this enzyme. Whilst Ca2+ and 
insulin can stimulate pyruvate dehydrogenase activity, high Acetyl-CoA and high NADH 
can inhibit the activity of it (Naish, Syndercombe Court and Revest, 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Link Reaction pathway. Pyruvate is broken down into Acetyl-CoA. The process is 
regulated by one enzyme; pyruvate dehydrogenase (blue box). NADH is produced (green 
box). Image adapted from Medical Science by Naish, Syndercombe Court and Revest, 2009. 
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1.8.4 The Citric Acid Cycle (TCA cycle) / Krebs Cycle 
The TCA cycle is series of enzymatic reactions that occur in the mitochondrial matrix 
which break down Acetyl-CoA into CO2 and H2O and generate the reducing equivalents 
NADH and FADH2 (Figure 1.9). Citrate synthase first catalyses the reaction of Acetyl-
CoA and oxaloacetate, producing citrate. Citrate is then isomerised to isocitrate, which 
then undergoes dehydrogenation to oxalosuccinate. Oxalosuccinate is decarboxylated 
to alpha-ketoglutarate, which is oxidatively decarboxylated to Succinyl-CoA by alpha-
ketoglutarate dehydrogenase. Succinyl-CoA is converted to succinate, which generates 
ATP, before succinate dehydrogenase converts succinate to fumarate. Fumarase 
converts fumarase to malate before oxaloacetate is regenerated by malate 
dehydrogenase. During these enzymatic reactions, electrons and hydrogen are 
released to NAD+ and FAD+. For every molecule of Acetyl-CoA which enters the Krebs 
cycle, 2 CO2, 1 GTP, 3 NADH and 1 FADH2 molecules are formed. Thus, per glucose 
molecule, 4 CO2, 2 GTP, 6 NADH and 2 FADH2 are produced. The NADH and FADH2 then 
enter the ETS, whilst the GTP is converted to ATP. The Krebs Cycle is regulated by the 
enzymes citrate synthase, isocitrate dehydrogenase and dehydrogenase. Citrate 
synthase is sensitive to the availability of its substrates, oxaloacetate and Acetyl-CoA, 
but is also inhibited by ATP and activated by ADP, whilst isocitrate dehydrogenase and 
dehydrogenase are both sensitive to NAD+ levels (Naish, Syndercombe Court and 
Revest, 2009). 
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Figure 1.9 The TCA Cycle. Acetyl-CoA is fed into the TCA cycle. The process is regulated by 
three enzymes; citrate synthase, isocitrate dehydrogenase, and dehydrogenase (blue boxes). 
NADH (green boxes), GTP (grey box) and FADH (purple box) are produced. Image adapted 
from Medical Science by Naish, Syndercombe Court and Revest, 2009. 
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1.8.5 Fatty acid β-oxidation 
Fatty acids are highly efficient energy storage molecules and per gram, contain almost 
twice the amount of energy as carbohydrates. β-oxidation of fatty acids is an oxidative 
process that occurs in the mitochondrial matrix. It involves the metabolism of fatty 
acids into Acetyl-CoA (Figure 1.10). Before fatty acids enter the mitochondria, they are 
conjugated with CoA to form a long-chain fatty-acyl-CoA. This is then modified to 
acylcarnitine which can pass across the mitochondrial membrane. Before beta 
oxidation can occur in the matrix, this acylcarnitine is converted back to a long chain 
Acyl-CoA. Acyl-CoA is then oxidised in a 4-step process (Abcam, no date), as displayed 
in Figure 1.10. Briefly, this process involved dehydrogenation of Acyl-CoA to Trans-2-
Enoyl-CoA, hydration of this molecule to 3-Hydroxyacyl-CoA, dehydrogenation to Beta-
Ketoacyl-CoA before finally thiolytic cleavage of this molecule to produce an Acetyl 
CoA and an Acyl-CoA molecule that is two carbons shorter than the previous one. This 
Acyl-CoA can re-enter the beta oxidation pathway, and the Acetyl-CoA can then enter 
the Krebs cycle to provide energy from fats. During the process of β-oxidation, NADH 
and FADH2 are generated, which then can enter the ETS. The process is regulated by 
the activity of 4 enzymes; Acyl-CoA dehydrogenase, Enoyl-CoA hydratase, 3-
Hydroxyacyl-CoA dehydrogenase and Beta-Ketoacyl-CoA thiolase (Naish, Syndercombe 
Court and Revest, 2009). 
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1.8.6 Amino Acid Metabolism 
Under certain conditions, like fasting, amino acids can be used to provide energy. The 
first step is to remove the amine group from the amino acid, by a process called 
transamination. In transamination, the amine group is transferred to another amino 
acid, most commonly alpha ketoglutarate, which forms glutamate. Glutamate can 
either be used for protein synthesis or in other transamination reactions. Glutamate 
can also be converted to glutamine, which is transported to the liver to enable removal 
of ammonium. Ammonium is incorporated into urea in the liver, released into the 
blood and excreted via the kidneys. After the removal of the amine group from an 
amino acid the carbon backbone can be converted into different metabolic 
intermediates, depending on the type of amino acid. There are two main types of 
Figure 1.10 The beta oxidation pathway. Acyl-CoA is recycled by beta oxidation. The 
process is regulated by four enzymes; Acyl-CoA dehydrogenase, Enoyl-CoA hydratase, 3-
Hydroxyacyl-CoA dehydrogenase, Beta-Ketoacyl-CoA thiolase (blue boxes). FADH (purple 
box) and NADH (green box) is produced. Acetyl-CoA is produced at the final stage of beta 
oxidation. Image adapted from Medical Science by Naish, Syndercombe Court and Revest, 
2009. 
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amino acid; glucogenic and ketogenic. Glucogenic amino acids are the more abundant 
type and are converted to pyruvate or intermediates of the Krebs Cycle, where they 
serve as precursors to glucogenesis. Ketogenic amino acids are broken down into 
Acetyl CoA or Acetoacetyl CoA, both which give rise to ketone bodies or fatty acids. 
Therefore, it is these ketogenic amino acids that can be directly oxidised to release 
energy. In summary, amino acid catabolism can give rise to pyruvate, Acetyl-CoA or 
Acetoacetyl CoA and a number of TCA cycle intermediates, thus, amino acids are able 
to be integrated into energy metabolism (Figure 1.11).  
 
  
 
 
Figure 1.11 Integration of Amino Acids into Energy Metabolism. Diagram shows how 
both ketogenic (blue boxes) and glucogenic (pink boxes) amino acids are integrated into 
multiple different stages of energy metabolism. 
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1.8.7 Integration of Bioenergetic Pathways. 
The integration of bioenergetic pathways is summarised in Figure 1.12. Amino acids, 
glucose and fatty acids are transported across the plasma membrane and into the 
cytoplasm. Glucose and amino acids can both undergo metabolism to pyruvate, which 
can enter the Link Reaction and be converted to Acetyl-CoA, which can then enter the 
TCA cycle. Acetyl Co-A is also generated by amino acids, like leucine, being converted 
into Acetyl-CoA and also by β-oxidation of Acyl CoA. Some amino acids, like glutamine, 
can be converted directly into TCA cycle intermediates such as alpha-ketoglutaric acid. 
Acetyl-CoA and/or the amino acid TCA cycle intermediates then generate reducing 
equivalents for the ETS, the common ending for all of these metabolic pathways. 
 
 
 
 
 
 
 
 
 
 
Figure 1.12 Integration of Metabolic Pathways. Diagram showing the metabolism of 
amino acids, glucose and fatty acids. Amino acids, glucose and fatty acids cross the lipid 
bilayer and are metabolised, before they enter the mitochondria where they eventually 
converge in the TCA Cycle and enter the electron transport system. TCA Cycle = the citric 
acid cycle. ETS = electron transport system. Carbon dioxide (CO2) and water (H2O) are the 
metabolic waste products. 
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1.9 Additional Mitochondrial Functions 
Our canonical understanding of the function of mitochondria is that they are the 
‘powerhouses of the cell’ i.e. their main function is to resynthesise ATP using OXPHOS. 
However, within the last decade, a new role for mitochondria as key co-ordinators of 
intracellular signalling has emerged (Antico Arciuch et al., 2009; Chandel, 2015). 
Mitochondria can regulate biosynthetic, cell signalling, apoptosis, redox and anti-
oxidant defence pathways (Herst et al., 2017). These organelles have also been found 
to contain cell signalling  kinases, such as the MAPK ERK, which may maintain the MMP 
in times of cellular stress in neurons (Lee et al., 2004; Poderoso et al., 2008; Galli et al., 
2009), and may also maintain lung tumour cell phenotypes in a ROS dependent 
manner (Galli et al., 2008). Mitochondrial ERK activation causes nuclear translocation, 
where information about mitochondrial bioenergetics and redox status is passed to 
nuclear pathways that control proliferation and differentiation (Antico Arciuch et al., 
2009). Thus, these organelles are key metabolic sensors which mediate both cell 
survival and apoptosis (Chiong et al., 2014). 
1.10 Mitochondrial Ion Channels 
1.10.1 Overview 
Many ion channels are located in the mitochondrial membranes (Szabo and Zoratti, 
2014) (Figure 1.13). In the OMM there are channels that regulate apoptosis, such as 
Bcl-2 family proteins and ANT channels which allow adenine nucleotides to enter and 
exit the mitochondria. In addition, there are OMM channels that allow proteins to 
enter and exit the organelle, such as TOM40, and voltage dependent anion channels 
(VDACs) that allow passage of anions into and out of the mitochondria. These OMM 
channels all allow for optimal functioning of the mitochondria (Szabo and Zoratti, 
2014). In the IMM there are numerous channels selecting for K+ ions, like the TASK-3, 
Kv1.3 and calcium activated potassium channels BKCa, IKCa and SKCa, the roles of which 
will be discussed in more detail in the next section. There are also channels that select 
for Ca2+, such as the mitochondrial calcium uniporter (MCU) and the ryanodine 
receptor (RyR), which are thought to be involved in regulating calcium signalling, which 
has roles in proliferation to apoptosis (Rizzuto et al., 2012). Magnesium (Mg2+) is an 
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essential component of cells, and the mitochondria facilitate its storage in the matrix 
via Mg2+ selective channels (Mrs2) (Kolisek et al., 2003). In the IMM there are also non-
selective anion and cation channels, like the inner membrane anion channel (IMAC) 
and TIM22 and TIM23, respectively, and the nonselective mitochondrial permeability 
pore (MPTP), which control cell survival and apoptosis (Szabo and Zoratti, 2014) .There 
are other mitochondrial proteins which act as ion channels, such as acetylcholine 
receptors of the OMM, and uncoupling proteins (UCP) and the n-methyl-d-aspartate 
(NMDA) glutamate receptors of the IMM, which their functions remain a subject of 
debate (Szabo and Zoratti, 2014). These channels are tightly regulated to avoid 
disruption to the balance of ions in the mitochondria, and in addition to ion channels 
there exists a plethora of exchangers and transporters which maintain ionic balance of 
the mitochondria (Bernardi, 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13 Ion channels of the mitochondrial membranes. Outer membrane channels; 
voltage dependent anion channels (VDAC), inwardly rectifying potassium channels (Kir), 
protein import pores (TOM40 and SAM50) and Bcl-2 family members (Bcl-2 and Bax). Inner 
membrane channels; potassium channels (twin pore potassium channel, TASK-3, big, 
intermediate and small conductance calcium activated potassium channels, BKCa including 
SLO2, IKCa and SKCa (respectively), voltage gated potassium channels, Kv1.3 and Kv7.4, and 
ATP regulated potassium channel, KATP), magnesium channels (magnesium permeable 
channel, Mrs2), calcium channels (ryanodine receptor, RyR, and mitochondrial calcium 
uniporter, MCU), non-selective cation channels (TIM23 and TIM22), anion selective channels 
(inner membrane anion channel, IMAC, inner membrane chloride channel, CLIC4), non-
selective channels (permeability transition pore, PTP) and inner membrane carriers which act 
as ion channels (adenine nucleotide translocator, ANT). Image adapted from Szabo and 
Zoratti (2014). 
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1.10.2 Limitations to mitochondrial ion channel research 
It is important to note that mitochondrial ion channel research is limited by the current 
techniques on offer to accurately identify mitochondrial ion channels. Western blotting 
of the mitochondrial membranes for channel proteins is a common technique used to 
identify ion channels that reside here. However, this approach is often blighted by 
contamination of the blot by membranes from other organelles. A multifaceted 
approach also consisting of immunocytochemistry and electrophysiology would be 
advised for all mitochondrial ion channel research (Szabo and Zoratti, 2014). To 
confirm ion channels exist in the mitochondrial membranes, molecular identification is 
needed. Despite modern proteomic technologies, molecular identification is still a 
challenge as most mitochondrial ion channels are thought to be encoded by the 
nucleus and do not have an independent organelle specific identity. Proteomics is also 
hindered by the fact that most ion channels exist in low abundance in most cells 
making molecular identification even more challenging (Szabo and Zoratti, 2014).  
1.11 Mitochondrial K+ Cycle 
1.11.1 Overview 
Ion channels tightly regulate mitochondrial H2O and ion balance to control 
mitochondrial volume. A high matrix volume would risk rupturing the IMM and OMM, 
leading to cell death. Increased matrix volume can also alter biochemical pathways of 
the cell, for example, increase fatty acid oxidation in the matrix (Garlid and Paucek, 
2003). In the cytoplasm, the concentration of K+ is around 120mM. A concentration 
gradient for K+ ions exist across the inner mitochondrial membrane, whereby the 
concentration of K+ in the mitochondrial matrix is approximately 30% the 
concentration in the cytoplasm, around 80mM (Nicholls and Ferguson, 2013). This 
gradient exists due to the mitochondria having a pH gradient of -0.5 because 3x the 
amount of H+ is pumped out of the matrix than what comes in (Garlid, 1996). K+ flow 
down its concentration gradient into the matrix can increase mitochondrial volume as 
water would follow the ions, causing the matrix to swell and possibly rupture (Costa et 
al., 2006). A system must therefore be in place to counterbalance this swelling upon 
opening of mitochondrial K+ channels (Garlid, 1996; Garlid and Paucek, 2003). The 
main exchanger responsible for K+ removal from the matrix is the H+/K+ exchanger, an 
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electroneutral exchanger which extrudes 1 K+ ion in exchange for 1 H+ ion. Activation of 
the H+/K+ exchanger is crucial to maintaining the ionic balance of the matrix. However, 
the activity of the exchangers, transporters and channels of the IMM are interlinked, 
and a change in the activity of one is likely to affect the activity of others. Increased 
activity of the H+/K+ exchanger, may increase the H+ concentration in the matrix 
stimulating H+ extrusion mechanisms, for example the leucine zipper- EF hand-
containing transmembrane 1 protein, LETM1 (Jiang, Zhao and Clapham, 2009). Influx of 
K+ into the matrix may lead to alkalinisation that results from increased proton 
pumping to compensate for increased K+ entry through mitochondrial K+ channels 
(Costa et al., 2006).  
1.11.2 Mitochondrial K+ channels 
K+ channels exist in both the IMM and OMM and can be active under both 
physiological and pathophysiological conditions (Bednarczyk et al., 2013). Eight 
mitochondrial K+ channels have so far been described, however their functions remain 
poorly understood. The mitochondrial K+ channels are the ATP-regulated channel 
(Smith, Nehrke and Brookes, 2017), calcium-regulated channels of large, intermediate 
and small conductance (Krabbendam et al., 2018), voltage-regulated Kv1.3  (Szabo and 
Zoratti, 2014) and Kv7.4 channels (Testai et al., 2015), two-pore-domain TASK-3 
channel (Szabo and Zoratti, 2014) and the SLO2 channel (Wojtovich et al., 2011). It is 
thought the primary role of these ion channels is to maintain the MMP (Garlid and 
Paucek, 2003). However, there are suggestions that these channels regulate 
respiration, mitochondrial volume and ROS production (Laskowski et al., 2016) and 
may even act as biological sensors of gasotransmitters (Walewska, Szewczyk and 
Koprowski, 2018).  
1.11.2.2 Mitochondrial Kv1.3 
The role of mitochondrial Kv1.3 channels in physiological conditions has not been 
explored in detail, despite plasma membrane (PM) Kv1.3 channels being implicated in 
energy homeostasis and body weight regulation (Xu et al., 2003; Tucker, Overton and 
Fadool, 2008). Under physiological conditions, the channel is expected to allow inward 
flux of K+ into the matrix, as long as a gradient exists for its entry (Bernardi, 1999). 
Along with other K+ channels, it is thought that mitochondrial Kv1.3 could regulate 
38 
 
MMP, matrix volume and ROS production (Laskowski et al., 2016). However, the 
channel has been implicated in the apoptosis of lymphocytes and cancer cell lines 
(Szabo et al., 2005; Szabó et al., 2008; Leanza et al., 2017; Venturini et al., 2017; 
Mattarei et al., 2018). Mitochondrial Kv1.3 channels can interact with the apoptotic 
protein Bax to induce apoptosis (Szabó et al., 2008). Bax independent mechanisms of 
apoptosis can also occur, whereby inhibiton of mitochondrial Kv1.3 channels causes 
MMP hyperpolarisation, and an increase in ROS, which activates the MPTP causing 
depolarisation and a fatal release of cytochrome c (Szabo and Zoratti, 2014). 
Therefore, the channel may be cytoprotective in tumour cells where mitochondrial 
Kv1.3 controls apoptosis, via a reactive oxygen species mediated pathway (Gulbins et 
al., 2010; Malinska, Mirandola and Kunz, 2010; Leanza et al., 2012; L Leanza et al., 
2013).When mitochondrial Kv1.3 inhibitors were used at lower concentrations, 
apoptosis did not occur in pancreatic ductal adenocarcinoma cells (PDACs), and 
proliferation was slightly stimulated (Peruzzo et al., 2017). However, the opposite 
effect was seen in a colon cancer cell line, COLO357 cells, where proliferation was 
reduced (Peruzzo et al., 2017). This suggests a cell specific effect of mitochondrial 
Kv1.3 on proliferation.  As inhibition of K+ flow through mitochondrial Kv1.3 can result 
in apoptosis and in some circumstances reduced proliferation, mitochondrial K+ flow 
likely plays an important role in cellular homeostasis and survival. Studies investigating 
the role of Kv1.3 in OXPHOS are limited. In 2014, no role was found for Kv1.3 in 
spontaneous cellular respiration of mouse skeletal muscle cells, as inhibition of these 
cells with PAP-1, Psora-4 and MgTx did not change the O2 uptake of these cells 
(Hamilton et al., 2014). However, MgTx would not inhibit mitochondrial Kv1.3 
channels, as only PAP-1 and Psora 4 are membrane permeable, albeit not 
mitochondrially targeted. This study also did not interrogate the contributions of 
glycolysis and OXPHOS to spontaneous cellular respiration. Therefore, we cannot 
exclude a role for mitochondrial Kv1.3 channels in respiration.   
1.11.3 Mitochondrial K+ Flow and Respiration 
K+ influx through other mitochondrial K+ channels can affect respiration. K+ influx into 
the mitochondria stimulates respiration without uncoupling the ETS from OXPHOS  
(Bajgar et al., 2001; Kowaltowski et al., 2001; Garlid et al., 2003). The mitoKATP channel 
increases K+ influx into the mitochondria causing a depolarisation of the MMP, which is 
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counterbalanced by an increased respiration rate, and more H+ pumping into the IMS 
(Manon et al., 1995). This did not lead to matrix alkalinisation because Pi/H+ and H+/ K+ 
exchangers brought more H+ into the matrix. In this study Manon et al.  found that 
although matrix pH did not change, the rate of the H+ proton cycle did. There are other 
reports of K+ influx into the mitochondria stimulating respiration. Mitochondrial KATP 
channel openers have been found to increase respiration (Malinska, Mirandola and 
Kunz, 2010). Diazoxide and pinacidil, KATP openers,  also increase the rate of O2 
consumption in a K+ flow dependent manner (Kopustinskiene, Pollesello and Saris, 
2004; Kopustinskiene et al., 2010). K+ influx into the matrix through other K+ channels 
can also stimulate respiration. Heinen et al. observed that activation of BKCa channels 
changed mitochondrial bioenergetics, increased respiration and stimulated superoxide 
production due to K+ influx into the matrix (Heinen et al., 2007). However, the MMP 
was maintained due to activation of the K+/H+ exchanger. High concentrations of 
channel openers caused MMP depolarisation via K+ flow into the matrix through BKCa 
channels (Heinen et al., 2007). In additon, energetic performance is improved by 
specific activation of K+ fluxes through KCa channels in heart mitochondria (Aon et al., 
2010). The control of respiration may result from a structural and functional coupling 
of BKCa channels to respiratory complexes of the ETS (Bednarczyk et al., 2013).  
1.11.4 Mitochondrial K+ Flow and Cytoprotection 
In addition to the cytoprotective roles of mitochondrial Kv1.3 channels previously 
mentioned (1.11.2.2), mitochondrial K+ influx through other channels, like KATP and 
BKCa, may also be cytoprotective, supporting a physiological role for K+ entry into the 
mitochondrial matrix (Kang et al., 2007; Sakamoto et al., 2008; Malinska, Mirandola 
and Kunz, 2010). K+ influx into the matrix causes partial depolarisation of the IMM 
which reduces the driving force for Ca2+ influx and therefore prevents triggering of the 
MPTP (Kang et al., 2007; Sakamoto et al., 2008). Activation of the BKCa channels has 
also been found to reduce ROS, regulate mitochondrial volume and improve 
mitochondrial respiratory control (Kang et al., 2007). In addition, K+ influx into the 
matrix through SKCa prevents mitochondrial dysfunction (Dolga et al., 2013). However, 
the cytoprotective roles of K+ influx into the matrix are not definitive. Sassi et al., found 
that mitochondrial IKCa had no effect on cell proliferation or cell death (Sassi et al., 
2010). There are contrasting reports of whether K+ influx into the matrix alters the 
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MMP (Manon et al., 1995; Heinen et al., 2007; Kang et al., 2007). The effect on MMP is 
likely to depend on the expression of mitochondrial K+ channels and thus the size of 
the resulting influx of K+ into the matrix (Heinen et al., 2007).  
1.12 Metabolism and Proliferation 
1.12.1 Role of Kv1.3 in Metabolism 
The metabolic role for mitochondrial Kv1.3 channels in physiological situations remains 
poorly defined. However, Kv1.3 channels in general, have been linked to metabolic 
homeostasis, but these effects cannot be attributed to Kv1.3 channels at any particular 
location in the cell. For example, Kv1.3 channels have been implicated in regulating 
body weight and energy homeostasis in mice, as Kv1.3 KO animals had a higher 
metabolic rate, as measured by indirect calorimetry, and lower body weight to their 
WT counterparts (Xu et al., 2003). Genetic abolition of Kv1.3 channels in mice also 
sensitised adipose tissue and skeletal muscle to insulin, and increased expression of 
GLUT4 at the plasma membrane (Xu et al., 2004). Pharmacological inhibition of PM 
Kv1.3 channel with ShK-186 counteracted the negative effects of an obesity promoting 
diet in mice by reducing weight gain, adiposity, fatty liver, blood levels of cholesterol, 
glucose, insulin and leptin and enhanced peripheral insulin sensitivity, leading the 
researchers to conclude Kv1.3 blockade could be a potential therapy for insulin 
resistance and obesity (Upadhyay et al., 2013). In addition, genetic identification of 
Kv1.3 channels in human samples found a variant in the promoter region of the Kv1.3 
gene that was associated with impaired glucose tolerance and insulin sensitivity 
(Tschritter et al., 2006). KO Kv1.3 in melanocortin null receptor 4 mice reduced weight 
and adiposity due to increased locomotor activity and energy expenditure (Tucker, 
Overton and Fadool, 2008). In 2013, Tucker et al. went on to declare Kv1.3 channels 
were ‘metabolic sensors’ in mitral cells, after finding that they were a substrate for 
phosphorylation by insulin (Tucker et al., 2013). In the same study the authors showed 
that the Kv1.3 channels themselves were sensitive to metabolically active D-glucose 
which increased Kv1.3 current amplitude in HEK293 cells (Tucker et al., 2013). These 
results indicate that Kv1.3 may sense energy status to activate sensory neurons 
governing smell or sight. It also indicates that Kv1.3 channels in other areas of the body 
may also sense energy status. Co-localisation of Kv1.3 channels and GLUT4 has been 
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found in the PM OF mouse olfactory bulbs (Kovach et al., 2016), suggesting this 
association, or association of Kv1.3 and other GLUT transporters, may occur in other 
cell types. 
However, in other studies no observation was made of Kv1.3 affecting weight gain and 
adiposity as long term treatments of rats with the plasma membrane Kv1.3 inhibitor 
Vm24 had no effect on body weight, adiposity and serum glucose levels, but did 
reduce serum insulin concentration and increase GLUT4 mobilisation to the PM 
(Jaimes-Hoy et al., 2017).  In addition, in another study Kv1.3 channels in human and 
mouse tissues were found to be insensitive to insulin (Straub et al., 2011). In addition, 
there are contradictory studies describing inhibition as opposed to activation of mitral 
cell Kv1.3 channels due to insulin dependent tyrosine phosphorylation (Fadool et al., 
1997, 2000; Fadool and Levitan, 1998; Marks and Fadool, 2007). Therefore, the effects 
of Kv1.3 on metabolism are likely to be tissue specific, and no study to date has 
explored the specific role of mitochondrial Kv1.3 channels in metabolism.  
Kv1.3 channels have also been linked to mitochondrial structure and expression. Kv1.3 
channels were found to increase mitochondrial biogenesis in T lymphocytes 
(DeCoursey et al., 1984). Deletion of Kv1.3 channels was found to alter mitochondrial 
morphology, resulting in smaller mitochondria, in mice olfactory bulbs (Kovach et al., 
2016). In addition, blockade of Kv1.3 channels with a targeted mitochondrial inhibitor 
caused mitochondrial swelling in cancer cells (Mattarei et al., 2018).  
1.12.2 Proliferation linked to metabolism 
Cellular proliferation has a high energy demand as ATP is required for processes like 
signal transduction, as well as DNA, RNA and protein synthesis (Lodish H, Berk A, 
Zipursky SL, Matsudaira P, Baltimore D, 2000; Vander Heiden, Cantley and Thompson, 
2009; Oronsky et al., 2014; Pontes, Sevostyanova and Groisman, 2015). Cancer cells 
are characterised by a highly proliferative and migratory phenotype and upregulate 
certain bioenergetic metabolic pathways. Increased glucose uptake , glycolysis and 
lactate production in the presence of adequate cellular O2 levels, is well described  in 
cancer biology and is known as aerobic glycolysis, or the Warburg Effect (Warburg, 
1925; Kroemer and Poussegur, 2008). There are suggestions that the increase in 
glycolysis is to maximise the synthesis of macromolecules needed for growth and 
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proliferation (Vander Heiden, Cantley and Thompson, 2009). However, highly 
proliferating cells may also retain, and in some circumstances also upregulate, their 
capacity for OXPHOS (Jose, Bellance and Rossignol, 2011; Ho et al., 2012; Robinson et 
al., 2012; Gentric, Mieulet and Mechta-Grigoriou, 2017; Liberti and Locasale, 2016)) 
.The metabolic flexibility demonstrated by highly proliferating cells may help them 
adapt to a changing nutrient environment (Ho et al., 2012; Robinson et al., 2012; Lu et 
al., 2015). This may explain why inhibition of glycolysis is unable to slow the 
proliferation of cancer cells, as they can switch to OXPHOS to meet energy demand 
(Robinson et al., 2012).  
High ROS production is also a characteristic of rapidly proliferating cells (Trachootham 
et al., 2008) and could be a consequence of electron leak from increased OXPHOS  
(Griffiths and Rutter, 2009; Vinnakota, Dash and Beard, 2011; Doonan et al., 2014). An 
increased MMP is also common amongst cells with high energy demands 
(Summerhayes et al., 1982; Fantin et al., 2002; Heerdt, Houston and Augenlicht, 2005; 
Houston, Augenlicht and Heerdt, 2011; Forrest, 2015; Martinez-Reyes et al., 2016). The 
increased electrical gradient increases the driving force for proton re-entry into the 
matrix, via the ATPsynthase. In addition, the larger the MMP the more resistant cells 
are to apoptosis (Zamzami et al., 1996). However, a hyperpolarised IMM may not 
always translate to increased OXPHOS, as in pulmonary artery hypertension where 
SMCs switch to a proliferative state, the SMCs exhibit IMM hyperpolarisation, but have 
reduced respiration and increased glycolysis (Dromparis and Michelakis, 2013). The 
factors leading to the differences in MMP between highly proliferating 
pathophysiological cancer cells and their physiological counterparts remains unclear 
(Kalyanaraman et al., 2017). One theory is that in cancer cells, aerobic glycolysis causes 
IMM hyperpolarisation, due to reverse proton pumping of the ATP synthase (Forrest, 
2015). In addition, MMP is linked to the availability of substrates that enter the 
mitochondria for oxidation, thus an increase in glycolysis can increase MMP (Poulsen 
et al., 2008; Olsen et al., 2009). In addition, ATP from glycolysis can also maintain MMP 
and prevent apoptotic cell death in activated macrophages (Garedew, Henderson and 
Moncada, 2010). 
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1.12.3 Proliferation and metabolism of VSMCs 
Mitochondria are highly expressed in VSMCs, providing energy for contraction 
(Kuznetsov et al., 2009). Mitochondrial metabolism in VSMCs is now recognised as 
having a key role in cell growth and proliferation (Salabei and Hill, 2013). There is 
evidence to suggest that control of mitochondrial metabolism may regulate 
pathological proliferation of VSMCs, as mitochondrial dysfunction is a key determining 
VSMC phenotype (Chiong et al., 2014). Healthy VSMCs display high rates of glucose 
metabolism and lactate production under normal and well oxygenated conditions 
(Butler and Siegman, 1985), resulting in around 90% of the flux through glycolysis 
resulting in lactate production. It is thought in healthy VSMCs, only 30% of ATP 
produced is from mitochondrial processes (Paul, 1983). Despite this, damage to VSMC 
mitochondrial DNA and VSMC mitochondrial dysfunction is thought to occur in 
atherosclerosis (Yu and Bennett, 2014). In a similar way to the Warburg effect in 
cancer cells, VSMCs may rewire their metabolic pathways; reducing mitochondrial 
metabolism, but increasing fatty acid oxidation and glycolysis, to provide biosynthetic 
molecules to support proliferation, such as NADPH, nucleotides, phospholipids, sugars 
and amino acids (Vander Heiden, Cantley and Thompson, 2009; Moncada, Higgs and 
Colombo, 2012; Salabei and Hill, 2013). However, there is also evidence that VSMCs 
can increase mitochondrial activity when proliferating (Moncada, Higgs and Colombo, 
2012). When ATP is in high demand, mitochondrial pyruvate dehydrogenase activity is 
increased, which increases the delivery of glycolytic substrates to the mitochondria 
(Sharma et al., 2005). In support of increased mitochondrial activity in proliferating 
VSMCs, in response to growth stimulation by PDGF, VSMCs have increased glycolysis 
and OXPHOS (Perez et al., 2010).  
There is a link between mitochondrial morphology and respiratory states, with high O2 
consumption and mitochondrial respiration occurring in elongated mitochondria that 
have undergone fusion (Parra et al., 2008, 2011; Kuzmicic et al., 2011), whilst oxidative 
capacity is reduced in fragmented mitochondria  (Chen et al., 2003). Fusion and fission 
may indeed regulate proliferation and differentiation (Mitra, 2013). When VSMC are 
proliferating, their mitochondria are dynamic and fragmented (Bonnet et al., 2006; 
Marsboom et al., 2012; Susan et al., 2012; Salabei and Hill, 2013), suggesting that 
glycolytic metabolism may be dominant over mitochondrial respiration (Marsboom et 
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al., 2012). However, Salabei and Hill, found that glycolytic metabolism decreased when 
VSMCs underwent phenotypic switching (Salabei and Hill, 2013). Although this seems 
contradictory, if glycolysis was still a dominant bioenergetic pathway, the 
mitochondria may still exhibit fragmentation. Fatty acid oxidation may increase in 
proliferating VSMCs to increase production of ATP as oxidation of one lipid molecule 
generates more ATP than oxidation of one carbohydrate molecule, thus providing 
more energy for proliferation (Salabei and Hill, 2013). 
Although the contribution of OXPHOS to proliferating VSMCs is not conclusive across 
all studies, an increased level of ROS among proliferating VSMCs suggests it is an active 
bioenergetic process in these cells (Mercer et al., 2012). Alterations in ROS are 
commonly seen in atherosclerosis, which further damage the vascular environment 
(Mercer et al., 2012). ROS can lead to lipid peroxidation, and damage to mitochondrial 
DNA which could lead to mitochondrial dysfunction which may lead to further 
deterioration of metabolic pathways (Ballinger, 2005; Nissanka and Moraes, 2018). 
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1.13 Aims and Objectives  
1.13.1 Aims 
VSMCs exhibit Kv1.3 upregulation and activation during the phenotypic switch that 
results in pathological proliferation, migration and de-differentiation in many 
vasculopathies associated with CVD. Multiple mechanisms which govern Kv1.3-induced 
VSMC proliferation have been proposed but the mechanisms remain unclear. Finding 
the mechanism that drives Kv1.3-induced proliferation of VSMCs is of clinical 
importance as new therapies are needed to improve outcomes for those with CVD. 
This thesis will explore whether mitochondrial Kv1.3 regulates cellular energy 
production, and thus links Kv1.3 to the proliferative state of the cell through 
adaptation of mitochondrial OXPHOS. By targeting therapies, such as Kv1.3 inhibitors, 
to cellular organelles where the channels may have a key role, such as the 
mitochondria, pharmacological treatments may become more effective and specific 
with fewer side effects.  
1.13.2 Objectives 
• Determine the bioenergetic and structural effects on the mitochondria of 
overexpressing Kv1.3 channels in HEK293 cells and identify intracellular 
localisation of Kv1.3 channels (Chapter Three). 
 
• Determine the role of mitochondrial Kv1.3 in the respiratory phenotype 
regulated by Kv1.3 in HEK293 cells (Chapter Four). 
 
• Define the mechanism/s through which mitochondrial Kv1.3 regulate and link 
cellular oxidative metabolism and proliferation (Chapter Five). 
 
• Determine ion-conduction independent effects of Kv1.3 channel on oxidative 
metabolism using Kv1.3 mutant channels (Chapter Six). 
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Chapter Two 
 
 
Methods and Materials 
 
 
2.1 Cell Culture 
Sterile plasticware was purchased from Corning (Corning Ltd, Flintshire, UK) or Star 
Labs (Star Labs, Surrey, UK). All reagents were obtained from Gibco (Life Technologies, 
Paisley, UK) or Sigma (Sigma Aldrich, Dorset, UK) unless otherwise stated. 
2.1.1 WT HEK293 cells 
Wild-type (WT) HEK293 cells were obtained from ECACC, Public Health England, Porton 
Down, UK. Culture medium contained: DMEM, 10% (v/v) fetal bovine serum (BioSera, 
East Sussex, UK), 1% (v/v) Antibiotic/ Antimycotic, 1% (v/v) Non-Essential Amino Acids, 
0.1% (v/v) Gentamicin (50mg/ml). All cells were grown in 75cm2 flasks and sub-
cultured each week once 70-90% confluence was reached. Culture medium was 
removed from the flask, and the cells washed with 10ml of Dulbecco’s phosphate 
buffered saline (DPBS). Cells were then incubated with 2ml of 0.05% TrypleE Express 
for 2-3 minutes (37oC; 95% air, 5% CO2). The side of the flasks were then gently tapped 
to ensure full cell detachment. 10ml of complete growth media was added to 
neutralise the trypsin, and the resulting cell suspension was placed in a 50ml falcon 
tube. This was then centrifuged for 6 minutes at 600g (rcf) in an Eppendorf Centrifuge 
5424 (Eppendorf UK Ltd, Stevenage, UK). The supernatant was removed, and the cells 
were resuspended in 1ml of culture media. Live cells were then counted using 0.4% 
Trypan Blue to stain for dead/dying cells and a Bio-Rad automated TC10 cell counter 
(Bio-Rad Laboratories, California, USA). Various dilutions of cells were used, normally 
1:10, 1:20, 1:40 and 1:80 (cells: medium), with 20ml being the final flask volume 
(75cm3 flasks). The flasks were then placed into a humidified incubator to grow (37oC; 
95% air, 5% CO2). If a low dilution of cells had been plated, and confluency was to be 
expected the following week, then after 4 days a media change would occur. 
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2.1.2 HEK293/Kv1.3 cells 
HEK293 cells engineered to overexpress the mouse Kv1.3 channel were a gift from José 
Ramón López López and colleagues, University of Valladolid, Spain. Stable transfection 
was carried out by Dr Jason Scragg, University of Leeds, UK. Culture medium was the 
same as WT HEK293 cells but with the addition of 0.4mg/ml Geneticin Sulphate G418 
(Santa Cruz Biotechnology) dissolved in 200µl 1M NaOH. Cells were used between 
passages 3 and 18 and sub-cultured using the same method as WT HEK293 cells. 
2.1.3 HEK293/Kv1.3-P118 cells 
These are HEK293 cells engineered to express human Kv1.3 channels tagged with 
mCherry fluorescent protein (P118). The DNA encoding this protein was again a gift 
from José Ramón López López, as above. Culture medium and culturing method were 
the same as HEK293/Kv1.3 cells. 
2.1.4 HEK293/Kv1.3 mutant cells (P89, P93 and P121) 
HEK293 cells were engineered to express mutated human Kv1.3 channels tagged with 
either mCherry (P121) or GFP (P89, P93). The DNA encoding these proteins were gifts 
from José Ramón López López, as above. Culture medium and culturing method were 
the same as HEK293/Kv1.3 cells. 
2.1.5 HEK293/Kv1.5 cells 
HEK293 cells were engineered to overexpress the human Kv1.5 (KCNA5) channel. 
Human Kv1.5 cDNA was amplified from a human foetal brain cDNA library (Clontech, 
Wooburn Green, Buckinghamshire, UK) using PCR, and transfected into HEK293 
cells, as previously described (Al-Owais et al., 2017). Stable transfection was carried 
out by Dr M. Al-Owais, University of Leeds, UK. Culture medium was the same as WT 
HEK293 cells but with the addition of 4.5µg/ml blasticidin. Cells were used between 
passages 3 and 18 and cultured using the same method as WT HEK293 cells. 
2.1.6 Human Saphenous Vein Smooth Muscle Cells (HSVSMCs) 
These cells were obtained from saphenous vein (SV) of patients undergoing coronary 
artery bypass graft surgery at Leeds General Infirmary, with consent and ethical 
approval. Patient demographics are shown in Table 2.1. Culture medium contained: 
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DMEM, 10% (v/v) fetal bovine serum (BioSera, East Sussex, UK), 1% (v/v) glutamine 
(200mM,), 1% (v/v) penicillin/streptomycin ((5,000 U/mL)). Cells were used between 
passages 3 and 6. Cells were isolated using the well-established protocol of Dr Karen 
Porter, University of Leeds, UK (Porter et al., 2002). Briefly, segments of SV were taken 
from patients and chopped into small fragments (1mm3). These explants were placed 
in 2ml of Roswell Park Memorial Institute medium supplemented with 10% FCS, in a 
25cm3 culture flask. The cells were left for 4-5 weeks in a humidified incubator (37oC; 
95% air, 5% CO2) so that the cells could migrate out of the explants and become 
confluent. Passage of the cells into normal T75cm3 culture flasks then ensued. Cells 
were cultured in the same way as HEK293 cells. However, due to their slower rate of 
growth, the flasks were seeded with higher concentrations of cells i.e. ratios of 1:10 
and 1:20 (cells: medium), with 20ml being the final flask volume. Media was changed 
twice weekly. 
 
 
 
 
Patient ID Gender Age at surgery (yrs) Diabetes (Y/N) 
1318 M 47 N 
1321 M 44 N 
1322 F 67 N 
1330 M 47 N 
1335 M 56 N 
1336 M 66 N 
1337 M 74 N 
1339 M 61 N 
1340 M 64 N 
1341 M 72 N 
1344 M 67 N 
1349 M 69 N 
1353 M 74 Y 
1354 M 72 Y 
1356 Unknown Unknown Unknown 
1358 M 61 N 
1359 M 61 Y 
Table 2.1 Patient demographics for human SV cells. Data for gender, age at surgery 
and diabetic status is shown for all patients apart from SV1356. M = male, F = female, 
yrs = years, Y = yes, N = no. 
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2.2 Generation of the HEK293/Kv1.3 mutant clones  
All reagents were obtained from Sigma (Sigma Aldrich, Dorset, UK) unless otherwise 
stated. 
2.2.1 Generation of Luria-Bertani (LB) agar plates 
LB agar was prepared by adding kanamycin (30 µg/ml final concentration) into 
autoclaved 3.5% LB agar. 20ml of agar solution was poured into each 60 x 15mm petri 
dish and then left to set for 40 minutes. They were then turned over for a further 40 
minutes to allow excess moisture to drip off the agar. Each plate then had its edge 
sealed with paraffin paper and was stacked into columns whilst remaining upside 
down. These columns were then covered with foil and left in the fridge overnight. The 
following morning the foil and parafilm were removed and the plates placed in a pre-
warmed oven at 37 ᵒC for 1 hour. 
2.2.2 DNA retrieval  
Filter paper carrying 2µg bacteria containing the DNA constructs for mutated Kv1.3 
channels were placed in 200µl distilled water to retrieve around 10ng/µl DNA. This was 
stored at -20ᵒC. The DNA encoded four types of K+ channel: 
Kv1.3-P118: Wild type human Kv1.3 channels with mCherry fluorescent tag. mCherry 
excitation (nm)/ emission (nm) wavelengths were 587/610. 
Kv1.3-P121: Human Kv1.3 channels with intact pore regions, and intact voltage 
sensors, but with defective phosphorylation due to a point mutation from tyrosine to 
alanine at position 447 on the C-terminus of the channel. These channels were also 
tagged with fluorescent mCherry. 
Kv1.3-P89: Mouse Kv1.3 channels, with mutated pores, intact voltage sensors and 
intact C-terminals, tagged with EGFP (enhanced green fluorescent protein). EGFP 
excitation (nm)/ emission (nm) wavelengths were 488/507. 
Kv1.3-P93: Mouse Kv1.3 channels with mutated pores and mutated voltage sensors, 
tagged with EGFP.  
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2.2.3 Generation of Kv1.3 mutant plasmids 
Generation of Kv1.3 mutant plasmids was carried out by José Ramón López López et 
al., University of Valladolid, Spain. Data in sections 2.2.3.1 and 2.2.3.2, Tables 2.2 and 
2.3, and Figures 2.1 and 2.2, was sourced from the López López group. 
2.2.3.1 Plasmid generation   
Information on the plasmids used for each of the mutant channels is summarised in 
Table 2.2, and the plasmid maps are shown in Figure 2.1. KCNA3 cDNA was cloned into 
the MCS region of both pEGFP-N3 and pmCherry-N1 (Figures 2.1A and 2.1B, 
respectively). The primer pairs used are shown in the final column of Table 2.2. This 
generated C-terminal EGFP (Kv1.3-P89 and Kv1.3-P93) and mCherry (Kv1.3-P121 and 
Kv1.3-p118) fusion proteins (Figures 2.1C and 2.1D, respectively), which were 
sequence verified. 
 
 
 
 
 
 
Mutant 
Kv1.3 
Channel 
Original 
Plasmid 
Type of 
Kv1.3 
(KCNA3) 
cDNA  
Fusion 
Protein 
Plasmid 
Primer Sequence (5' to 3')  
(forward and reverse) 
Kv1.3-
P89 and 
Kv1.3-
P93 
pEGFP-N3 mKv1.3  pEGFP-N3-
mKv1.3 
5'-ATCGAATTCAGACATGACCGTGGTG-3' 
5'-CAGAATTCTGGACATCAGTGAATATCTTCTTGA-3' 
Kv1.3-
P121 
and 
Kv1.3-
P118 
(WT) 
pmCherry-
N1 
hKv1.3 pmCherry-
N1-hKv1.3 
5’-AATGAATTCCCGACATGACCGTGGTGCC-3’ 
5'- ATTGGATCCACATCGGTGAATATCTTTTTGATG -3' 
Table 2.2 Plasmids for mutant Kv1.3 channels. Table showing the plasmids used for each 
mutant Kv1.3 cell type, the type of Kv1.3 channel (mKv1.3 = mouse Kv1.3 (Source 
Bioscience), hKv1.3 = human Kv1.3 (MagNA Pure Systems, Roche)), the fusion plasmid 
generated, and the primer sequence used for their generation. All plasmids were sourced 
from Clontech.  
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2.2.3.2 Kv1.3 channel mutations 
QuikChange II Site Directed Mutagenesis Kits (Stratagene) were used for mutagenesis of the 
Kv1.3 channel. Mutagenesis was carried out according to manufacturer’s instructions. The 
mutant primer pairs which were used are shown in Table 2.3. All DNA constructs were 
sequence-verified to confirm the integrity of the mutation.  
2.2.3.2.1 Kv1.3-P89 channels 
The mKv1.3-EGFP fusion protein was mutated to produce a non-conducting Kv1.3 point-
mutant with intact gating properties and voltage sensitivity, generated by a single point 
mutation from tryptophan (W) at position 389 to phenylalanine (F) in the S5-S6 linker (Figure 
2.2A). These channels were identical to the Kv1.3WF (W389F) population described by Cidad et 
al., (2012). 
A. B. 
C. D. 
Figure 2.1 Plasmid maps for mutant Kv1.3 channels. A. Original pEGP-N3 plasmid, note the 
MCS region between the CMV promoter and the EGFP. B. pEGP-N3 plasmid with the insertion of 
mKv1.3 (KCNA3) at the MCS region (pEGP-N3-mKv1.3). C. Original pmCherry-N1 plasmid, note the 
MCS region between the CMV promoter and the mCherry. D. pmCherry-N1 plasmid with the 
insertion of hKv1.3 (KCNA3) at the MCS region (pmCherry-N1-hKv1.3). 
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2.2.3.2.2 Kv1.3-P93 channels 
The mKv1.3-EGFP fusion protein was mutated to produce a non-conducting, voltage-
insensitive Kv1.3 mutant generated by the same W389F point mutant as above, but with an 
additional triple mutation in the S4 region. These three additional point mutations were; 
arginine (R) at position 320 to asparagine (N), leucine (L) at position 321 to alanine (A) and 
arginine (R) at position 326 to isoleucine (I) (Figure 2.2B).  These channels were identical to the 
Kv1.3WF3X (R320N/L321A/R326I) population described by Cidad et al., (2012). This triple 
mutation shifts the channel activation to potentials below -170 mV. This means that the 
channel stays inactive at physiological voltages and functions as an inward rectifier (Miller & 
Aldrich, 1996).  
2.2.3.2.3 Kv1.3-P121 channels 
The hKv1.3-mCherry fusion protein was mutated to produce a phosphorylation defective Kv1.3 
mutant with intact voltage sensing and gating properties, generated by a single point mutant 
from tyrosine (Y) at position 447 to alanine (A) (Figure 2.2C). These channels were identical to 
the Kv1.3-Y447A population described in Jimenez Perez et al., 2016.  
 
 
 
 
 
Mutant 
Kv1.3 
Channel 
Mutation Primer Sequence (5' to 3')  
(forward and reverse) 
Kv1.3-P89 W389F 
 
5'-TTTAACAGTATCCCGGATGCCTTCTTCTGGGCAGTAGTAA-3' 
5'-TTACTACTGCCCAGAAGAAGGCATCCGGGATACTGTTAAA-3' 
Kv1.3-P93 
 
W389F 
 
 
 
R320N 
 
 
 
L321A 
 
 
 
R326I 
 
5'-TTTAACAGTATCCCGGATGCCTTCTTCTGGGCAGTAGTAA-3' 
5'-TTACTACTGCCCAGAAGAAGGCATCCGGGATACTGTTAAA-3 
 
 
5'-TGGCCATTCTGAGAGTCATCAACGCAGTAAGGGTTTTCCGCATCTT-3' 
5'-AAGATGCGGAAAACCCTTACTGCGTTGATGACTCTCAGGATGGCCAG-3' 
 
 
5'-CCTGAGAGTCATCCGCGCAGTAAGGGTTTTCCGC -3' 
5'-GCGGAAAACCCTTACTGCGCGGATGACTCTCAGG -3' 
 
 
5'-CGCCTAGTAAGGGTTTTCATCATCTTCAAGCTCTCCCG-3' 
5'-CGGGAGAGCTTGAAGATGATGAAAACCCTTACTAGGCG -3’ 
Kv1.3-P121 Y447A 5’-AATGAATTCCCGACATGACCGTGGTGCC-3’ 
5'- ATTGGATCCACATCGGTGAATATCTTTTTGATG -3' 
Table 2.3 Primer pairs that were used for site directed mutagenesis of the Kv1.3 channel. 
Table shows the mutant channel, the name of the mutation, and the primer sequence used 
for its generation.The base pairs from the mutated residues are highlighted in bold. 
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Figure 2.2 Schematic showing the location of the mutations in the Kv1.3 channels. A. 
Single point mutation (W389F) in S5-S6 linker of the Kv1.3-P89 channel. B. Single point 
mutation (W389F) in S5-S6 linker plus three additional point mutations (R320N, L321A 
and R326I) in the S4 voltage sensor region of the Kv1.3-P93 channel. C. Single point 
mutation (Y447A) in the C-terminus of the Kv1.3-P121 channel.  
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2.2.4 DNA amplification 
DNA constructs were thawed at room temperature and 50µl aliquots of competent E. 
coli cells (Invitrogen) were thawed on ice for a few minutes. 4µl of each DNA construct 
was added to an aliquot of E. coli cells, flicked gently to mix contents and then placed 
on ice for 30 minutes. Heat shock was given by placing the mix in a 42°C water bath for 
30 seconds before being returned to the ice for 5 minutes. 950µl of SOC media 
(Invitrogen) was added and the aliquots were placed in a shaker at 37ᵒC and 250rpm 
for 1 hour. Three cell solutions were made up from each stock, with dilutions being 
made with SOC media. The final solutions were a 100% cell stock, a 1:4 and a 1:20 
dilution. A cell spreader was sterilised with 100% ethanol and flamed with a Bunsen 
burner, before being used to spread 200µl of each cell solution onto the pre-warmed 
agar plates. The lids were then placed on the plates and they were put in the oven 
overnight. Next morning the plates were covered with parafilm and placed in the 
fridge until use. 
Two single colonies from each construct were selected from agar plates. Each colony 
was dropped into LB broth containing 30µg/ml kanamycin. These universals were 
placed in the shaker overnight at 37ᵒC and 300rpm. Next morning a cloudy LB broth 
signified successful amplification of the bacterial colony. Glycerol stocks were made by 
combining 650µl of 80% glycerol with 650µl each culture broth in small tubes. The 
tubes were inverted 4-6 times to mix the contents and then stored in the -80ᵒC 
freezer. 
2.2.5 Harvesting of DNA – Mini Prep 
For this procedure, a QIAprep Spin Miniprep Kit (Qiagen, Hilden, Germany) was used 
and the manufacturer’s protocol was followed. The LB broth from each culture was 
split into two microtubes, each containing 1.5ml. The two microtubes were labelled A 
and B for each clone (1 and 2) of each cell Kv1.3 channel type (P118, P121, P89 and 
P93). The tubes were spun down at 7,000g for 3 minutes and the resulting supernatant 
was poured off. 250µl of P1 buffer was added to every microtube A. The pellet was 
resuspended by vigorous pipetting before the 250µl cell suspension was used to 
resuspend the pellet in microtube B. For every Kv1.3 channel type, there was now only 
two microtubes containing E. coli bacterial pellets for clone 1 and clone 2. 250µl of P2 
buffer was added to each of the 8 microtubes. Each microtube was inverted 4-6 times 
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and left for no longer than 5 minutes before the addition of 350µl neutralisation 
buffer. Microtubes were again inverted 4-6 times to mix and then centrifuged for 10 
minutes and 18,000g (Eppendorf Centrifuge 5424). The supernatant was then poured 
into spin columns and centrifuged for another 1 minute at 18,000g. The liquid in the 
collection tubes was discarded, each column was reassembled and 500µl PB buffer was 
added. This was centrifuged for another minute at 18,000g, the flow through was 
discarded and the columns were reassembled. 750µl PE buffer was added to the 
columns which were centrifuged at the same settings for another minute and then the 
flow through discarded. The columns were then placed in clean microtubes. 50µl 
elution buffer (EB) was applied directly to the membranes in the columns and left to 
stand for 1 minute before being centrifuged for a final minute at 18,000g. The resulting 
elution solutions contained the desired plasmid DNA which were then stored at -20ᵒC.  
2.2.6 Restriction analysis of DNA sequences  
Restriction enzymes were used to check that the sequence of interest has been 
incorporated into the harvested bacterial plasmids. The restriction enzyme EcoR1 cuts 
the 5-prime end of the sequence and the restriction enzyme BamH1 cuts at the 3-
prime end. The sequence is around 1500bp (base pairs) with the whole plasmid 
consisting of around 6200bp (6.2Kbp) (Figure 2.1). 
For each sample, a restriction control was performed, which consisted of 15µl de-
ionised water added to 5µl DNA. For the restriction digestion, a reaction mix was made 
up with 20µl of 10x Reaction Buffer 3, 20µl of 10x BSA and 100µl de-ionised water. 5µl 
of each sample of DNA was mixed with 14µl reaction mix and 1µl BamH1. Tubes were 
flicked gently and collected by pulse centrifugation. All tubes were then placed into a 
dry bath for 2 hours at 37°C. Then the samples were flicked gently and pulsed for 
another few seconds. They were placed on ice for 5 minutes before being stored back 
in the freezer at -20ᵒC. 
2.2.7 Gel electrophoresis 
Gels were prepared by adding 3µl ethidium bromide into 100 mL TAE (Tris-acetate-
EDTA) buffer containing 0.4% agarose (ThermoFisher Scientific). The DNA samples 
were prepared by adding 1µl of 0.25% bromophenol blue loading dye into 5µl of either 
the cut DNA (treated with restriction enzymes) or uncut DNA (control). 1kb DNA ladder 
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(New England Biosciences, UK) was used. 5µl of sample was loaded onto each well of 
the gel and the gel electrophoresis was performed at 80V for 90 minutes. Gel was 
imaged on a Bio-Rad gel image cabinet (Bio-Rad Laboratories, Hertfordshire, UK). From 
this, the clones which had the largest bands were selected for the maxi prep as they 
contained the most DNA.  
2.2.8 Harvesting of DNA – Maxi Prep 
For this procedure, a QIAGEN Plasmid Maxi Kit (Qiagen, Hilden, Germany) was used. 
Four 250ml conical flasks were prepared the day before the maxi prep. 2g LB broth 
was added to each of the flasks and mixed with 100ml de-ionised water. This was 
swirled vigorously to dissolve any lumps, lidded and taped before being sent for 
autoclaving.  
On the day of the experiment, 5ml LB broth was placed in four 25ml universals and 3µl 
kanamycin (50µg/ml) was added to each. The shaker was turned on to 37ᵒC and 
300rpm. A Bunsen burner was set up and used to sterilise an ethanol-soaked heat loop 
3 times. The glycerol stocks of the selected clone from each Kv1.3 channel type were 
retrieved from the -80°C freezer. The heat loop was sterilised again and used to scoop 
the first sample of glycerol into the LB broth, before this was repeated for the 
remaining samples. This procedure was carried out quickly to minimise the glycerol 
from thawing. The LB broth/DNA mixture was then put in the shaker for 8 hours until it 
was sufficiently cloudy. 
60µl kanamycin (50µg/ml) was added to the 100ml LB broth in the pre-prepared 
conical flasks. After 8 hours in the shaker, the universals containing the LB broth/DNA 
mixture were each tipped into one of the flasks. The flasks were covered with foil and 
placed back in the shaker overnight. 
Early the next morning, the P3 maxi prep buffer was placed in the fridge to chill. The 
centrifuge (Eppendorf Centrifuge 5424 R) was turned on, set to 4ᵒC and left to cool 
down for 20 minutes. 
The conical flasks were removed from the shaker. Each flask was divided into two 50ml 
falcon tubes, which were centrifuged for 25 minutes at 4000rpm. The supernatants 
were then discarded, and the pellets placed on ice. 10ml P1 buffer was used to 
resuspend the pellets (NB this was 10ml P1 in total per Kv1.3 channel clone – one 
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pellet was resuspended first, then this suspension was transferred to the other pellet 
to resuspend). After the manual resuspension, the four remaining falcon tubes were 
given a short pulse on a vortex mixer (Stuart, Cole-Palmer, Staffordshire, UK) to break 
up any remaining clumps of cloned bacteria. 2ml of P2 buffer was added to each tube 
and left for 5 minutes maximum at room temperature. Filter caps were put onto four 
filter cartridges, which were then placed into clean falcon tubes. Before the 5-minute 
P2 incubation was over, 10ml P3 was added to each bacterial mix, and the tubes were 
inverted 6 times. The bacterial lysates were then added to the barrels of the filter 
cartridges and left for 10 minutes at room temperature. The caps were removed, and a 
plunger was inserted into the cartridge. This was pushed down, and the filtered lysate 
was collected at the bottom of the falcon tube. The lysate was spun in the 4ᵒC 
centrifuge (Eppendorf Centrifuge 5424 R) at 4,000rpm for 90 minutes. During the last 
15 minutes of the spin, a Qiagen-tip 500 column (Qiagen, Fisher Scientific) was 
equilibrated with 10ml QBT buffer (Qiagen, Fisher Scientific) and allowed to drain. The 
supernatant from the centrifuged lysate was poured into the column and allowed to 
flow through. The column was washed twice with 30ml QC buffer (Qiagen, Fisher 
Scientific). The DNA was then eluted with 5ml elution buffer per Kv1.3 channel clone. 
The eluate was caught in a fresh plastic centrifuge tube, to which 7ml RT isopropanol 
(Sigma Aldrich) was added. This was spun at 4ᵒC for 30 minutes at 4,000rpm 
(Eppendorf Centrifuge 5424 R). The supernatant was poured off and 5ml of 70% 
ethanol (Sigma Aldrich) was added. This was spun again at 4ᵒC and 4,000rpm for 45 
minutes (Eppendorf Centrifuge 5424 R). The supernatant was removed and then pellet 
was left to air dry for 5 minutes. Any remaining liquid was removed using tissue and 
cotton buds. 1ml TE (Tris EDTA) buffer (pH 8, Sigma Aldrich) was then added to 
dissolve the DNA. To assess the purity of the DNA, a NanoDrop spectrophotometer 
(NanoDrop 2000 UV-Vis Spectrophotometer, ThermoFisher Scientific) was used (range 
2-15,000 ng/µl). DNA samples were then stored at -20°C. All constructs were verified 
by DNA sequence analysis before transfection by Sanger sequencing (Genewiz, 
Bishop’s Stortford, Hertfordshire, UK). 
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2.2.9. Cell transfection  
Transfection reagents (Cell Line Nucleofector Kit V) and equipment (Nucleofector™) 
are obtained Lonza (Lonza, Castleford, UK). Transfection mixture was made by 
combining 328µl of Nucleofector Solution with 72µl supplement. Pelleted WT HEK293 
cells (106 cells per sample) were resuspended in 100µl of transfection mixture. 2.5µg 
(as calculated using the NanoDrop Microvolume Spectrophotometer, ThermoFisher 
Scientific, Loughborough, UK) of each DNA sample was added to the cell solutions. The 
cell/DNA solutions were then transferred into transfection cuvettes, which were then 
placed in turn into a Nucleofector™ Device (Lonza, Castleford, UK). Programme Q-01 
was applied to each cuvette. 500µl media was then added to each cuvette, and the 
transfected cell solutions were transferred to 75cm2 flasks. These cells were left for 
two days to recover, before the selection antibiotic was added (G418, 1mg/ml). The 
cells were left to grow to confluency, when they were lifted and used to seed flasks at 
very low dilutions (1:80, 1:160, 1:320). These flasks were left for 2 weeks for the 
colonies of surviving cells to grow to appropriate size. Media was replaced regularly to 
maintain cell viability. Colonies were identified by holding the flask up to light, and 
then highlighted by tracing their perimeter with a marker pen on the bottom of the 
flask. When colonies had grown to an appropriate size, media was removed from the 
T75cm2 flasks and the cells washed with DPBS. The roof of the flask was broken into 
and peeled away to enable access to the cell colonies. Sterile cloning cylinders were 
coated with high vacuum seal grease and then pressed down firmly for 10 seconds 
around each of the selected colonies. Five colonies from each Kv1.3 channel clone 
were selected and 200µl 0.05% TrypleE Express was added to the inside of the cloning 
cylinders. This was left for 2 minutes before 200µl complete media was added to 
neutralise the TrypleE. This solution was mixed thoroughly before each suspension 
from the cylinders were removed and placed into separate T25cm2 flasks. 5ml media 
containing 1mg/ml G418 media was added to each flask. These were then left to reach 
confluency, when they could undergo experimental testing for Kv1.3 channel 
expression and phenotype. 
 
 
59 
 
2.3 Proliferation Assays 
All reagents were obtained from Gibco (Life Technologies, Paisley, UK) unless 
otherwise stated. 
Cells were grown in 75cm2 flasks and selected at 70-90% confluence. The cell pellets 
that were obtained by detachment and centrifugation as described above were 
resuspended in complete media. An aliquot of that was used to obtain the live cell 
numbers using trypan blue. Cells were seeded in a 24 well plate at a density of 2x104 
cells (HEK293 cells) or 1x104 cells (HSVMSCs) per well. Cells were plated in complete 
media and left to adhere to the wells for a minimum of 6 hours (HEK293 cells) or 
overnight (HSVSMCs). Then the complete media was replaced by no serum media.  
Cells were incubated in serum free media overnight (HEK293 cells) or for 2.5 days 
(HSVSMCs). This allowed the cells to become dormant, and thus created a 
synchronised growth state when complete media was re-added, in addition to the 
required drug being investigated (Table 2.4), on Day 0 of the assay. Drugs were added 
on Day 0 and left for the entire length of the proliferation assay. Day 0 was when the 
initial cell counts for the assay were carried out. Depending on the assay, additional 
counting occurred on days 0, 1, 2 and 3, or just day 3 (HEK293 cells), or on days 0, 2, 4 
and 7, or just day 4 (HSVSMCs). For HSVSMCs, proliferation assays were originally 7 
days in length to determine optimum assay length (which was then found to be 4 days 
of proliferation). Counts were carried out as explained using Bio-Rad TC10 automated 
cell counter (Bio-Rad Laboratories, California, USA) (HEK293 cells) or using a manual 
haemocytometer (HSVSMCs). For each condition, cells were counted in triplicate and 
the mean (±SEM) was generated. Please note, detachment of HSVSMCs using TrypleE 
express needed a longer incubation time that HEK293 cells, with 4-5 minutes used to 
detach cells from T75cm2 flasks and 5-6 minutes in the 24-well plate wells. 
Proliferation assays for HEK293/Kv1.5 cells were carried out by Dr M. Al-Owais, 
University of Leeds. 
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2.4 High Resolution Respirometry 
2.4.1 O2k Oxygraph and DatLab software 
All equipment sourced from Oroboros Instruments, Innsbruck, Austria unless 
otherwise stated. Before each experiment, a standard air calibration was carried out in 
the respirometer (Gnaiger, 2016). 
The O2k Oxygraph contains two chambers in which cell suspensions are placed and 
their oxygen (O2) consumption measured. Each chamber is maintained in a copper 
block that maintains the temperature at 37°C. The chamber itself is a 16mm Duran 
glass cylinder which holds a volume of 2ml. Each chamber is attached to a Clark type 
polarographic O2 sensor. The electrode measures the partial pressure of dissolved O2 
in an aqueous solution. It consists of a gold cathode, a silver anode and a potassium 
chloride electrolyte reservoir separated from the chamber sample by a 25µm FEP film 
membrane. The chambers are sealed with a stopper that contains a central capillary 
which enables chemicals to be titrated into the chambers. A 15x6mm electromagnetic 
stirrer bar sits in the bottom of the chamber to ensure maximum mixing of the 
aqueous sample suspension and to ensure a stable signal of the polarographic O2 
Drug Source Mode of Action Concentration 
PAP-1 Product P6124, 
Sigma Aldrich 
Inhibits all cellular Kv1.3 
channels 
0.1nM-30nM 
ShK-Dap22 Product 3220, 
Tocris Bioscience 
Inhibits plasma membrane 
Kv1.3 channels 
1pM-200pM 
PAPTP Gifted by Dr Robin 
Bon, Leeds 
University 
Inhibits mitochondrial Kv1.3 
channels 
3nM-100nM 
MitoQ Gifted by Professor 
Mike Murphy, 
University of 
Cambridge 
Scavenges mitochondrial ROS 5µM 
Table 2.4 Drugs added on Day 0 of proliferation assays. From left to right, columns show 
the name of the drug, it’s source, its mode of action and the working concentration used. 
ROS = reactive oxygen species.  
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sensor (constant stir speed of 750rpm). The decline in chamber O2 concentration every 
2s is recorded by DatLab software (DatLab Software. Oroboros Instruments, Innsbruck, 
Austria) that translates the respirometer data to a computer. At the O2 sensor, a 
polarisation voltage of 0.8V allows an amperometric signal to be converted to a 
voltage signal, which is recorded and used for data acquisition and analysis. All 
measurements are expressed as O2 consumption, pmol per million cells per second 
(pmol *s*Mill). To remove the aqueous samples from the chambers, an ISS integrated 
suction pump (120V) was used. ISS plastic tubing connected the waste solution to a 2-
litre waste bottle containing Virkon disinfectant (LanXess, Newbury, UK).  
2.4.2 Chemicals and medium 
All mitochondrial ETS inhibitors were purchased from Sigma (Sigma Aldrich, Missouri, 
USA), unless otherwise stated. Inhibitors were added to the chambers via the capillary 
in each chamber stopper. Hamilton micro syringes (either 10mm3 or 25mm3, Oroboros 
Instruments, Innsbruck, Austria) were used to treat cell samples with the compounds 
listed in Table 2.5. All of the compounds were made up in advance using well 
established protocols (Gnaiger, 2014) and stored at -20°C. All compounds were kept on 
ice during experiments. 
Respirometry medium was HEK293 cell culture medium without the addition of FBS. 
Media as follows: DMEM (31885), 1% (v/v) Antibiotic/ Antimycotic ((100x) 15240- 062), 
1% (v/v) Non-Essential Amino Acids ((100x) 11140-035), 0.1% (v/v) Gentamicin ((50 
mg/mL)15750060). 
2.4.3 Cell preparation 
T75cm2 flasks, at 70-80% confluence, were selected and cells counted (as in Section 
2.1.2). Cell pellet was resuspended in 0% FBS media in a 50ml falcon tube. Enough 
media was added to ensure cell suspension had a concentration of 1 x 106 cells/cm3. 
The cell suspension was then added to the respirometer chambers (or pre-treated with 
PAPTP, see Table 2.5). 
2.4.4 Whole-cell respirometry protocol 
To analyse whole cell respiration, the techniques used were based on the protocols 
created by Professor E. Gnaiger (Oroboros Instruments, Innsbruck, Austria). Cells were 
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placed into each chamber (37oC) of the OROBOROS Oxygraph-O2k respirometer. After 
closure of the chambers and once routine respiration stabilised mitochondrial activity 
was assessed using four drugs; oligomycin, FCCP, rotenone and antimycin A. Addition 
of 1µl oligomycin was added into each chamber to block the ATP synthase and destroy 
the link between the ETS and ATP production. This reduced the mitochondrial O2 flow, 
as far less protons could cross the IMM through the ATP synthase, and subsequently 
less were able to combine with O2 to form H2O. The only protons which were able to 
cross the IMM are those which leak across. This reduced O2 flow and allowed any 
changes in O2 flow as result of drugs to be localised to the function of the ETS. Next, 
FCCP was titrated in steps of 1µl until maximal uncoupling of the ETS was observed. As 
a protonophore, FCCP disrupts the H+ proton gradient which is created by the ETS, by 
permeabilising the IMM. This leads to H+ protons flooding into the mitochondrial 
matrix. At complex IV, O2 is combined with 4 protons, but due to oligomycin inhibiting 
the ATP synthase there is feedback inhibition of OXPHOS. As the concentration of FCCP 
increases, this feedback inhibition is relieved and O2 consumption increases until it 
reaches a maximum level i.e. the ETS is maximally uncoupled. 5µl of rotenone and then 
5µl antimycin A were added after maximum uncoupling by FCCP had been achieved. 
This was to disable the ETS and block all OXPHOS, enabling non-mitochondrial O2 to be 
calculated.  
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Drug Product details Function Concentration 
Oligomycin 75351, Sigma-Aldrich ATP synthase inhibitor 2µg/ml 
FCCP C2920, Sigma-
Aldrich 
Protonophore 
(permeabilises the IMM) 
Uncouples respiration 
Titrations of 
0.5µM 
Rotenone R8875, Sigma-
Aldrich 
Complex I inhibitor 2.5µM 
Antimycin A A8674, Sigma-
Aldrich 
Complex III inhibitor 0.5µM 
TMPD A4034, Sigma-
Aldrich 
Artificial substrate for 
reducing cytochrome C 
2mM 
Ascorbate 
T3134, Sigma-Aldrich 
Maintains TMPD in its 
reduced state 
0.5mM 
Sodium Azide 
S2002, Sigma-Aldrich 
Inhibits all mitochondrial 
respiration 
20mM 
PAP-1 P6124, Sigma-
Aldrich 
Inhibits all cellular Kv1.3 
channels 
100-300nM 
ShK-Dap22 3220, Tocris 
Bioscience 
Inhibits plasma membrane 
Kv1.3 channels 
500nM 
PAPTP Gifted by Dr Robin 
Bon, Leeds 
University 
Inhibits mitochondrial 
Kv1.3 channels 
100nM (30 
minute pre-
treatment) 
Table 2.5 Compounds and inhibitors used in respiratory experiments. Data shown, from left 
column to right; name of drug, product code, mode of action and working concentration. 
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2.4.5 Assessing Kv1.3 effect on respiration 
After closure of the O2k chambers, and establishment of a stable level of routine 
respiration, the Kv1.3 inhibitors PAP-1 and ShK-Dap22 could be added directly to the 
chambers prior to oligomycin treatment (see Table 2.5 for details). ShK-Dap22 
respirometry was carried out by Dr J. Boyle, University of Leeds.  For targeted 
inhibition of mitochondrial Kv1.3 channels, cells were pre-treated with the 
mitochondrial Kv1.3 inhibitor PAPTP (see Table 2.5 and Section 2.11 for details). This 
inhibitor was added to the cell suspension prior to it being added to the O2k chambers. 
Pre-treatment was for 30 minutes in a humidified incubator (37oC; 95% air, 5% CO2).  
2.4.6 Assessing activity of the malate/aspartate shuttle 
DM-2OG stimulates the malate/aspartate shuttle (Scaduto, 1994) whilst PhS inhibits it 
(Stamenkovic et al., 2015). The malate/aspartate shuttle is a protein complex in the 
IMM that transports NADH into the matrix (Naish, Syndercombe Court and Revest, 
2009). WT HEK293 cells were treated with 2mM DM-2OG to see if respiration 
increased compared to untreated WT HEK293 cells. HEK293/Kv1.3 cells were treated 
with 5mM PhS to see if respiration decreased compared to untreated HEK293/Kv1.3 
cells. WT HEK293 and HEK293/Kv1.3 cells were cultured as in Section 2.1. 24 hours 
prior to the experiment, media was replaced for 20ml fresh media containing either 
2mM DM-2OG (WT HEK293 cells) or 5mM PhS (HEK293/Kv1.3 cells). Cells were 
returned to a humidified incubator (37°C; 95% air; 5% CO2) for 24 hours. Normal 
respiratory protocol was then followed (Section 2.4.4). 
 
2.4.7 Assessing contribution of glycolysis to respiration 
2-Deoxy-D-Glucose inhibits glycolysis by competitively inhibiting the production of 
glucose 6 phosphate from glucose by hexokinase (Zhong et al., 2009). HEK293/Kv1.3 
and WT HEK293 cells were treated with 5mM 2DDG prior to respirometry to confirm 
that the increased OXPHOS in HEK293/Kv1.3 cells was not largely due to increased 
glycolysis. Cells were cultured according to methods section 2.1. 24 hours prior to the 
respirometry experiment, culture media was removed and replaced with 20ml fresh 
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media with the addition of 5mM 2DDG. Cells were returned to a humidified incubator 
(37°C; 95% air; 5% CO2) for 24 hours. Normal respiratory protocol was then followed 
(Section 2.4.4). 
 
2.4.8 Complex IV activity 
At the end of the whole-cell respirometry protocol, detailed in 2.4.4, after addition of 
rotenone and antimycin A, the activity of complex IV could be investigated. Ascorbate 
(ascorbate sodium salt) and TMPD (N, N, N', N'-Tetramethyl-p-phenylenediamine 
dihydrochloride) were added to the chambers of the O2k Oxygraph (details in Table 
2.5). TMPD acts as an artificial substrate for reducing complex IV, by donating 
electrons, and it is kept in the appropriate reduced state by ascorbate. 20mM sodium 
azide (details in Table 2.5) was then added to inhibit all mitochondrial respiration and 
act as control to correct for background O2 consumption that can occur due to 
oxidation of TMPD (Kuznetsov and Gnaiger, 2018). This assay can be used as a 
surrogate measure for mitochondrial content in the cells (Larsen et al., 2012).  
2.4.9 Data analysis 
Data was analysed using DatLab 6 software (Oroboros Instruments, Innsbruck, Austria), 
whereby the magnitude of O2 consumption was measured from the respirometer trace 
at different time points across the experiment. Figure 2.3 shows an example 
respirometry trace and how it was analysed. Measurements were taken routinely at 
four points; when O2 consumption initially plateaued after closure of the chambers 
(routine respiration), after the application of oligomycin (leak respiration), at the peak 
uncoupled state from FCCP titration (ETS respiration) and finally once OXPHOS had 
been inhibited with rotenone and antimycin A (residual O2 consumption, ROX). For 
complex IV activity experiments, measurements were also taken at the peak O2 
consumption after addition of ascorbate and TMPD.  
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2.5 Immunocytochemistry 
All reagents were obtained from Gibco (Life Technologies, Paisley, UK) or Sigma (Sigma 
Aldrich, Dorset, UK) unless otherwise stated. 
2.5.1 Cell preparation 
Sterile coverslips were placed into each well of a 6-well plate, washed with 1ml poly-L-
lysine, and left to dry. T75cm2 flasks were selected at 70-90% cell confluence. The cells 
were lifted, plated at appropriate dilutions with 10% FBS media, and left to grow to 30-
40% confluence. 
2.5.2 Detection of Kv1.3 channels 
2.5.2.1 Mutant Kv1.3 cells and HEK293/Kv1.3-P118 cells 
Kv1.3 channels in mutant Kv1.3 cells (HEK293/Kv1.3-P89, P93 and P121), and in 
HEK293/Kv1.3-P118 cells were detected by their fluorescent tags (Section 2.2.2) using 
a Zeiss LSM800 Upright confocal microscope. Images were processed using Zen Lite 
Figure 2.3 Analysis of O2k Oxygraph respiratory trace. Red line is the O2 consumption by 
the cells (pmol O2 per million cells per second) measured on the right Y axis. Blue line is the 
O2 concentration in the chamber (nmol/ml), measured on the left Y axis. Black arrows show 
the different stages of the protocol. Briefly, chamber is closed (1), oligomycin added (2), 
FCCP titrated (3,4 and 5), rotenone added (6), antimycin A added (7), chamber was re-
oxygenated (8), ascorbate added (9) and TMPD added (10). Black horizontal lines show 
where measurements were taken during post-experiment trace analysis, where A is routine 
respiration, B is leak respiration, C is maximum ETS capacity, D is ROX and E is maximum 
complex IV capacity.  
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(Zeiss, Cambridge, UK) and Image J software (Java-based image processing program 
developed at the National Institutes of Health by Wayne Rasband, NIH, UK). 
2.5.2.2 WT HEK293 and HEK293/Kv1.3 cells 
Once the cells had reached the optimum confluence they were fixed with 4% 
paraformaldehyde containing DPBS at RT for 20 minutes. The cells were washed 3 
times with 1ml DPBS and incubated for 20 minutes at RT in DPBS containing 0.05% 
Triton X100 and 10% NGS. The cells were washed again with DPBS (with 1% NGS), 
before the coverslips were inverted onto a parafilm covered glass plate containing the 
primary antibody (diluted in 1% NGS, see Table 2.6 for a list of antibodies). This was 
then placed into a humidified box and left overnight in the fridge (4°C). Next morning 
the coverslip washed with 1ml DPBS (1% NGS) for 3x5 minutes. An appropriate dilution 
of the secondary antibody was made up in DPBS (1% NGS, see Table 2.7 for a list of 
antibodies), and applied to cells for 1hr (RT, in the dark). Cells were then washed with 
DPBS (1% NGS) for 3x5 minutes. The coverslips were mounted with 5-10µl of 
VECTASHIELD HardSet Antifade Mounting Medium with DAPI (VECTOR Laboratories 
Ltd, Peterborough, UK) on a glass microscope slide and left to dry (RT, in the dark). 
Images were then taken on either a Zeiss LSM510, LSM700 inverted or an LSM880 
Upright confocal microscope and images processed and analysed as above (2.5.2.1). 
2.5.2.3 HSVSMCs 
Method was the same as above in 2.5.2.2 but imaged only on a Zeiss LSM510 inverted 
confocal microscope and processed and analysed as above (2.5.2.1) 
 
2.5.3 Detection of the mitochondrial network 
All cells were prepared on coverslips as mentioned in the above protocol (Section 
2.5.1). 3D analysis of the mitochondrial network in WT HEK293 and HEK293/Kv1.3 cells 
was carried out on an LSM800 Upright Confocal Microscope using z-stack composites 
of twenty 1μm slices through the cell. 
 
2.5.3.1 MitoTracker 
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Before fixation occurred, cells were incubated for 30 minutes (37oC; 95% air, 5% CO2) 
with MitoTracker reagents (see Table 2.6 for concentrations used and detection 
wavelengths). After treatment with MitoTracker, normal immunocytochemistry 
protocol resumed (as in section 2.5.2.1).  
2.5.3.2 Anti-Cox IV labelling 
The protocol outlined in section 2.5.2.1 was followed. The primary antibody used was 
targeted to mitochondrial complex IV protein and the secondary antibody was Alexa 
Fluor 488 or Alexa 555 (see Table 2.6 for details). Alexa Fluor 488 used with mCherry 
tagged Kv1.3 cells (HEK293/Kv1.3-P118 and HEK293/Kv1.3-P121) and Alexa Fluor 555 
used with GFP tagged Kv1.3 cells (HEK293/Kv1.3-P89 and HEK293/Kv1.3-P93). 
Determination of Kv1.3 channel co-localised within the mitochondrial network was 
carried out using a co-localisation analysis application in Image J.  
2.5.4 Detection of cellular ROS 
All cells were prepared on coverslips as mentioned previously (Section 2.5.2.1). Before 
fixation, cells were treated with 5µM CellROX Deep Red (ThermoFisher Scientific, 
Loughborough, UK) with or without 100µM menadione pre-treatment. Menadione 
(ThermoFisher) is an oxidative stress inducer and was used as a positive control 
(Tongul and Tarhan, 2014). To treat cells with menadione, it was added directly to 
culture wells and incubated for 1 hour (37oC; 95% air, 5% CO2). To treat cells with 
CellROX, the reagent was added directly to the culture well and the cells incubated for 
30 minutes (37oC; 95% air, 5% CO2). Normal immunocytochemistry protocols then 
resumed as the cells were prepared for imaging (Section 2.5.2.1) 
For each cell type i.e. WT HEK293 or HEK293/Kv1.3, three images were analysed during 
each experimental repeat (n=3 for the total experimental repeats). For each image, the 
mean fluorescent intensity (MFI) of 10 regions of cells was recorded using the line scan 
function in Image J.  
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Primary Antibodies Dilution Secondary Antibodies Excitation 
nm/Emission 
nm 
Dilution 
Anti-Kv1.3 
Clone L23/27, 
mouse monoclonal. 
(NeuroMab, 
Antibodies 
Incorporated, Davis, 
UK) 
1:500 Invitrogen Alexa Fluor 
488  
Donkey anti-Mouse IgG 
(H+L) 
(ThermoFisher) 
490/525 1:2000 
Anti-COX IV  
Mouse monoclonal.  
(Abcam, Cambridge, 
UK) 
1:500 Alexa Fluor 488 (as 
above) 
or 
Alexa Fluor 555 Donkey 
anti-mouse IgG (H+L).  
(ThermoFisher) 
 
490/525       
 
 
553/568 
1:2000 
        
 
1:2000                   
  Other Fluorescent 
Reagents 
  
  Diamidino-2-
phenylindole (DAPI) 
VECTASHIELD HardSet 
Antifade Mounting 
Medium with DAPI. 
(VECTOR Laboratories) 
360/460 1.5µg/ml 
  MitoTracker Red 
CMXRos  
(ThermoFisher) 
 
579/599 100nM  
(HEK293 cells) 
250nM  
(HSVSMCs) 
  Cell ROX Deep Red, 
(ThermoFisher) 
640/665 5µM Table 2.6 Reagents used in immunocytochemistry experiments. Dilutions of primary antibodies 
(anti-Kv1.3 and anti-COX IV) and their associated secondary antibodies (Alexa Fluor 488 and 555) 
are listed, as well as their appropriate excitation and emission wavelengths (nm). Concentrations 
and excitation/emission wavelengths (nm) are given for the nuclear dye DAPI, the mitochondrial 
network dye MitoTracker, and the cell ROS dye Cell ROX Deep Red. 
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2.6 Electrophysiology 
All reagents were obtained from Gibco (Life Technologies, Paisley, UK) or Sigma (Sigma 
Aldrich, Dorset, UK) unless otherwise stated.  
2.6.1 Solutions 
Extracellular Solution: 141mM NaCl2, 10mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid), 4.7mM KCl2, 1.2mM MgCl2, 1.8mM CaCl2 (Fluka 
Analytical, Romania), 10mM glucose (D+ glucose ACS reagent anhydrous (Acros 
Organics, ThermoFisher Scientific). pH 7.4 with NaOH. 
Intracellular Solution: 10mM EGTA (ethylene glycol-bis (2-aminoethylether)-N, N, N’, 
N’-tetraacetic acid), 10mM HEPES, 125mM KCl, MgCl2 4mM, MgATP 5mM. pH 7.2 with 
KOH. 
2.6.2 Cell preparation 
For electrophysiology, cells were plated onto sterile glass coverslips (22x22mm) and 
placed in a 6 well plate. 1-2ml media was added to each well and the cells were plated 
at a low enough dilution to ensure single cells would be present 3 days later. The cells 
were left overnight to attach to the coverslips, before the complete media was 
replaced for media free of any antibiotics the next morning. The cells were left for a 
further 1-2 days in antibiotic free media, to improve the integrity of the cell 
membranes (incubated at 37°C; 95% air, 5% CO2). On the day of the experiment, 
coverslips were transferred into 35mm petri dishes containing 1ml antibiotic free 
media.  The coverslips were cut into fragments using a diamond cutter so one 
fragment at a time could be transferred into the recording chamber.  
2.6.3 Electrophysiology rig set-up 
On the day of the experiment, extracellular and intracellular solutions were pre-
warmed to RT before using. A recording chamber was mounted over a CK40 light 
microscope (Olympus, London, UK). The recording chamber was continuously perfused 
with extracellular medium. This solution was placed into one of four reservoirs 
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connected to a 4-way Hamilton tap (Hamilton GB Ltd) by plastic Tygon tubing (0.83mm 
internal diameter, Merck, UK). To ensure continuous flow of solution, a suction tube 
connected to a vacuum pump (JUN-AIR, Redditch, UK) removed extracellular solution 
from the recording chamber. Borosilicate glass capillary tubes (0.86mm internal 
diameter, Harvard Apparatus, Cambridge, UK) were pulled on a micropipette puller 
(PP-83; Narishige, London, UK) to produce pipettes with a resistance of 3-7 MΩs when 
placed in the recording chamber. The pipettes were filled with intracellular solution 
ensuring no air bubbles formed. The pipette was then attached securely onto the 
electrode holder, ensuring that the silver/silver chloride recording electrode was both 
connected to the head stage and in contact with the intracellular solution. A 
silver/silver chloride ground electrode was placed in the recording chamber. The 
position of the head stage was controlled by a micromanipulator (Patch Star (PS-
700BC), Scientifica, East Sussex, UK) which allowed for very precise movements of the 
pipette. The electrode holder had an air outlet that was attached to more Tygon 
tubing. This allowed manual suction to be delivered to the membrane, causing it to 
rupture and therefore create the whole-cell configuration. To minimise electrical noise, 
all apparatuses were contained inside a Faraday cage. A common earth point was used 
for grounding individual electrical items. Patch clamp experiments were recorded on 
an Axopatch 200B amplifier (ALA Scientific Instruments, NY, USA), before being stored 
and digitized using a Digidata 1322A (Axon, Molecular Devices, CA, USA) and pClamp 
10 (Molecular Devices), respectively. 
2.6.4 Protocols 
IV relationships were measured by stepping from a holding potential of −80 mV to 
voltages between −60 and +60 mV in 10 mV increments for 300ms. Kv1.3 current 
screening was measured using a single pulse protocol stepping from −80 to +40 mV for 
200ms.  
2.6.4.1 Inhibition of Kv1.3 channels 
Electrophysiology solutions and equipment were set up as described in Section 2.6. In 
addition, additional extracellular solutions were made up containing different 
concentrations of the Kv1.3 inhibitors PAP-1 (200nM and 1µM) and ShK-Dap22 (20pM 
and 80pM). Once whole cell recordings had stabilised, extracellular solution was 
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changed for one containing either PAP-1 or ShK-Dap22. Whole cell currents were 
recorded over a time course of 12 minutes. For time course experiments, cells were 
held at -80mV and then repeatedly depolarised to +60mV (100ms, 0.2 Hz). Currents 
recorded and analysed as previously described (Section 2.6). Experiments were carried 
out by Dr M. Al-Owais, University of Leeds. 
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2.7 Western Blotting   
All reagents and materials purchased from Bio-Rad (Bio-Rad Laboratories, Inc, CA USA) 
unless otherwise stated. Western Blotting was carried out by Dr T. Hettiarachchi, 
University of Leeds. 
2.7.1 Buffers 
Cell sample buffer (stored at RT): 125mM tris(hydroxymethyl) aminomethane (Tris) 
HCl, pH 6.8, 2% (w/v) sodium dodecyl sulphate (SDS) , 20% (w/v) glycerol, 20μg/µl 
bromophenol blue and 10% β-mercaptoethanol.  
Running Buffer (made up fresh on day of experiment): 10x Tris/Glycine/SDS running 
buffer (1610772). 25mM Tris, 192mM glycine, 0.1% SDS, pH 8.3 following dilution to 1x 
with water. 
Transfer Buffer (made up fresh on day of experiment): 10x Tris/Glycine transfer buffer 
(1610734). 25mM Tris, 192mM glycine, pH 8.3 following dilution to 1x with water. 
2.7.2 Cell culture, lysis and protein extraction 
Cells grown to 90% confluence were washed with ice cold DPBS. The flask was placed 
on ice and cells were lysed by addition of 800μl M-per TM mammalian protein 
extraction reagent (Perbio Science, Tattenhall, Cheshire, UK) containing Complete Mini 
protease inhibitors (Roche Diagnostics UK Ltd, Lewes, East Sussex, UK). A cell scraper 
was used to aid removal of cells from the bottom of the flask. The protein lysate was 
collected and centrifuged at 15,000g for 3 minutes and the supernatant was used 
immediately (stored on ice) or stored in the freezer (-80°C) until use.  
2.7.3 BCA protein assay 
Protein levels of the cell lysates were then determined using a bicinchoninic acid (BCA) 
assay kit according to manufacturer’s instructions (Pierce, Illinois, USA). Total protein 
content is displayed as a colour change from green to purple in the protein samples. 
The purple coloured complex strongly absorbs light at 562nm. Protein standards were 
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defrosted (from storage at -20 degrees) at RT, and if samples were frozen, they were 
defrosted on ice. 10µl of each protein standard, and 2.5µl of each cell lysate sample, 
was pipetted into a well of a sterile 96 well plate. A working reagent solution was 
made up using a 1:40 ratio of Reagent B to Reagent A. 200µl of working reagent was 
then added to each well containing standard or sample. The plate was placed into a 
humidified incubator for 30 minutes at 37°C. The plate was then analysed using a pre-
configured BCA assay setting, which detected purple fluorescence using a green light 
filter (excitation/emission 525nm/580–640nm). The data was analysed with GraphPad 
Prism. The protein content of samples was determined using the linear fitting of 
standards. 25-50 µg of samples were used for SDS-polyacrylamide gel electrophoresis 
(PAGE). Samples were mixed with loading buffer to make the total loading volume to 
40µl. 
2.7.4 SDS-PAGE 
Gels were 12.5%, 0.75mm thick polyacrylamide-SDS gels (Bio-Rad) and were run on 
vertical mini gel (11cm x 11cm) apparatus (Mini Protean III electrophoresis cell, Bio-
Rad, Hemel Hempstead, UK). The gel cassette sandwich was inserted into the 
electrode assembly and then running buffer was poured over the gel. The gel comb 
was removed and either the cell samples or molecular weight marker was pipetted 
slowly into each of the wells to avoid overflow. For the molecular weight marker, 7µl 
of Precision Protein Plus Dual Colour Standard was added to either side of the samples. 
Gels were separated at 36mA for around 1 hour, or until the markers of interest had 
reached the right position. 
2.7.5 Electrophoretic transfer 
The proteins were transferred onto 0.45µm polyvinyl difluoride membranes (PVDF) 
(Millipore Corporation, Massachusetts, USA). Before the transfer could take place, the 
membrane, 2x sponges and 2x mini trans blot filter paper (Bio-Rad, Hemel Hempstead, 
UK) were soaked in methanol (Fisher Scientific, Rockford, USA) and then in transfer 
buffer. Blotting cassettes were assembled as follows: anode, sponge, filter paper, 
membrane, gel, filter paper, sponge, cathode. Blotting cassettes were then inserted 
into a Mini Trans-Blot electrophoretic transfer cell (Bio-Rad, Hemel Hempstead, UK). 
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An ice block was placed on the back of the transfer cell, before transfer buffer was 
poured over the cassette to cover it. The transfer was then run at 30V overnight.  
 
 
2.7.6 Immunodetection 
Then the cassettes were disassembled, and the membranes were blocked with 5% fat 
free milk powder in PBS-Tween (0.05%) for 1 hour. Membranes were immunostained 
with antibodies raised against the Kv1.3 channel, complex IV mitochondrial protein, 
the beta subunit of ATP synthase and -actin (Table 2.7). All antibodies were diluted in 
5% fat free milk in Tris buffered saline (TBS) tween and incubated at RT for 3 hours. 
Blots were then washed for 30 minutes in TBS tween and incubated with a HRP 
secondary antibody (Table 2.7) diluted in 5% fat free milk (TBS tween) for one hour. 
Membranes were washed again for 30 minutes in TBS tween, before they were left to 
dry slightly. This was to enable annotation with a LI-COR WesternSure pen (LI-COR 
Biosciences, Nebraska, USA). The pen was used primarily to highlight the standard 
ladder bands. A 1:1 mixture of LI-COR Western Sure ECL luminol enhancer solution 
with LI-COR Western Sure ECL stable peroxide was made up and used to wash the 
membranes for 5 minutes. The membranes were imaged immediately on a C-Digit Blot 
Scanner (LI-COR Biosciences) for 12 minutes, at a high resolution. Densitometry was 
carried out using Image J analysis software. 
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Primary Antibodies Dilution Secondary Antibody Dilution 
Anti-Kv1.3 clone 
L23/27 mouse 
monoclonal primary 
antibody (NeuroMab, 
NIH) 
 
Anti COX IV 
[Abcam33985] mouse 
monoclonal primary 
antibody 
(Abcam, Cambridge) 
 
Anti β-Actin Clone AC-
15 mouse monoclonal 
primary antibody 
(Sigma Aldrich) 
1:500 
 
 
 
 
 
1:500 
 
 
 
 
 
1:600 
HRP goat anti mouse IgG H+L 
secondary antibody (LI-COR 
Biosciences UK Ltd, Cambridge, UK) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1:20,000 
Anti ATPB 
[Abcam65378] rabbit 
polyclonal antibody 
(Abcam, Cambridge) 
1:500 
 
 
 
 
HRP goat anti rabbit IgG H+L 
secondary antibody (LI-COR 
Biosciences UK Ltd, Cambridge, UK) 
 
Table 2.7 Antibodies used in western blot experiments. From left to right columns; name 
of the primary antibody, primary antibody dilution ratio, the corresponding secondary 
antibody and finally the secondary antibody dilution ratio. 
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2.8 Cairn Photometry 
All reagents were obtained from Gibco (Life Technologies, Paisley, UK) or Sigma (Sigma 
Aldrich, Dorset, UK) unless otherwise stated. 
2.8.1 Perfusion medias 
Perfusion media was made up in advance and pre-warmed to RT before experiment. 
Perfusate was the same extracellular solution as that used for electrophysiology 
(Section 2.6.1) and made up in 1L double distilled (dd) H2O. 
Perfusion solution with mitochondrial inhibitors: extracellular solution with the 
addition of 20µM FCCP (carbonyl cyanide - p - (trifluoromethoxy)phenylhydrazone) and 
2.5µM oligomycin. 
Wash solution: ddH2O 
2.8.2 Cell culture  
Cells needed for cairn photometry were plated onto sterile glass coverslips (22x22mm) 
within a 6 well plate. The coverslips had been pre-coated with sterile filtered poly-l-
lysine to improve their adherence to the coverslip during perfusion. 2ml media was 
added to each well and the cells were plated at appropriate number to ensure 90% 
confluency on the day of experiment. 
2.8.3 TMRM treatment 
On the day of experiment, cells were washed with DPBS and then treated with 20nM 
Tetramethylrhodamine, methyl ester (TMRM) in media for 30 minutes (at 37°C; 95% 
air, 5% CO2). After incubation, TMRM media was removed, cells were washed with 
DPBS and then left in HBSS (Hank’s balanced salt solution with calcium and 
magnesium) whilst wrapped in foil until needed for the experiment. The coverslips 
were cut into fragments using a diamond cutter so one fragment at a time could be 
transferred into the recording chamber. 
2.8.4 Cairn photometry rig set up 
The recording chamber sat above an inverted epi-fluorescence microscope and was 
continuously perfused with solution. The perfusion system relied on gravity to pull the 
solutions down from the holding tubes into the perfusion bath. The holding tubes were 
78 
 
three 50ml disposable syringes that were connected by Tygon tubing (2.5mm outside 
diameter, 0.83mm inside diameter; Merck, UK) to a 6-way tap (Hamilton GB Ltd., UK). 
From this tap, more tubing delivered the perfusate to the cells in the perfusion bath 
via a metal inflow tube. Perfusate was removed from the bath via a metal suction 
tube, connected to tubing that was connected to a peristaltic pump (Gilson, Minipulse 
3, Anachem, UK) that disposed of the waste. Recordings were taken using a Cairn 
Research ME-SE Photometry system (Cairn Research, Cambridge, UK). The TMRM was 
excited by a Xeon Arc lamp with a monochromator to select the excitation wavelength 
of 548nm. Upon excitation of TMRM, light was emitted at 574nm. This was then 
converted from photon energy into electrical energy via a photomultiplier before the 
Cairn Optoscan analysed the data. The data acquisition engine 1.6.1 Software was used 
to visualise the traces. 
2.8.5 TMRM detection 
A fragment of coverslip containing TMRM treated cells was placed into the recording 
chamber. Cells were brought into focus until TMRM staining could be seen by eye 
down the eyepiece of the microscope. In the three holding tubes there was one 
containing normal perfusion media, one with perfusion media plus mitochondrial 
inhibitors (section 2.8.1), and finally one with just ddH2O. The cells were primarily 
perfused with the original perfusate (containing no mitochondrial inhibitors). When 
the recordings were started, the trace was run for about 200 seconds to record a 
baseline measurement. The normal perfusion media was then switched to the one 
containing 20µM FCCP and 2.5µM oligomycin. The FCCP depolarised cells and caused a 
reduction in the TMRM fluorescence, whilst the oligomycin prevented the ETS running 
backwards and counteracting the effects of the FCCP. The recording was left until the 
signal had reached a plateau. The recording trace was stopped, and the perfusion 
media was then replaced for H2O to wash the system out. Three traces were taken 
from each coverslip of cells, and three coverslips over different days and cell passages 
were used to compile mean values for the TMRM signal in WT HEK293 and 
HEK239/Kv1.3 cells. The trace was analysed using Graphing (an in-house plug-in 
application) and GraphPad Prism. The initial TMRM signal was recorded, as was the fall 
in the TMRM fluorescence with application of FCCP and Oligomycin.  
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2.9 Citrate Synthase Assay   
Products were purchased from Sigma Aldrich (Sigma Aldrich, Missouri, USA), unless 
otherwise stated.  
2.9.1 Stocks prepared monthly 
Acetyl-CoA (10mM): 12.14mg Acetyl-CoA + 1.5ml ddH2O. Aliquoted out into 300µl vials 
and stored at -20°C. Kept on ice during experiment.  
Tris HCl buffer (1M, pH 8.1): 2.422g Tris + 20ml ddH2O. Corrected pH with HCl acid. 
Stored in fridge at 4°C for one month.  
Tris HCl buffer (0.1M, pH 7.0): 2ml 1M Tris HCl buffer + 15ml ddH2O. Corrected pH to 7 
with HCl. Added 3ml ddH2O. Stored in fridge at 4°C for one month.  
2.9.2 Stocks prepared on day of experiment 
1mM DTNB: 2mg 5,5′-Dithiobis (2-nitrobenzoic acid) (DNTB) + 5ml 1M Tris HCL buffer 
8.1.  
10mM oxaloacetate: 6.6 mg diethyl oxaloacetate sodium salt (OAA) + 4.5ml ddH20 + 
0.5ml 1M Tris HCL buffer Ph 8.1.  
Citrate synthase (CS) standard: 2µl undiluted CS (8.9mg/ml, 370 units/mg) + 998µl 
(1:500) 0.1M Tris HCL pH 7 buffer, to give 6.586 U/ml. Kept on ice.  
Buffer Solution: 900µl PBS, 25µl Acetyl CoA and 100µl DTNB (0.25mM Acetyl CoA and 
0.1mM DTNB). This amount of solution was enough to fill five wells of a 96 well plate. 
For more wells, the amount of components needed to be multiplied accordingly. 
2.9.3 Cell lysis and protein extraction 
Cells were grown in T75cm2 flasks and selected when 70-90% confluent. The cells were 
lifted and pelleted as previously described (Section 2.1). The pellet was washed once 
using DPBS and 125µl of Cell LyticM (Mammalian Cell Lysis Reagent C2978, Sigma 
Aldrich, Dorset, UK) was used to resuspend the cells. The cell solution was placed into 
a 1.5ml microtube and slotted into a MACSmix Tube Rotator (Miltenyi Biotec, Surrey, 
UK) for 15 minutes. After this, the cell solution was placed into an Eppendorf 
Centrifuge 5424 (Eppendorf UK Ltd, Stevenage, UK) at 15,000g for 15 minutes. 100µl of 
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the supernatant was removed and this became the cell lysate sample. This sample was 
then used for both the BCA assay and the proceeding CS assay. 
2.9.4 BCA assay 
BCA assay was carried out according to the manufacturer’s instructions (Pierce, Illinois, 
USA) and as previously described (Section 2.7.3).  
2.9.5 CS assay principle 
CS is the primary enzyme in the Krebs cycle and is used as an exclusive marker for the 
mitochondrial matrix (Eigentler et al., 2015). Therefore, CS can be used to measure the 
size of the mitochondrial network in cells. The enzyme catalyses the reaction of Acetyl-
CoA with oxaloacetate to produce citrate. During citrate synthesis, DTNB is converted 
to Thio-bis-[2-nitrobenzoic acid]) cysteine (TNB) which can be detected at 412nm. The 
amount of TNB correlates to the amount of citrate produced and thus how much CS 
enzyme was present in the mitochondrial matrix. The equation below summarises this 
reaction:  
oxaloacetate + Acetyl-CoA + H2O → citrate + CoA-SH + H+ CoA-SH + DTNB →   TNB + CoA-S-S-TNB 
(↑ Absorbance at 412nm) 
2.9.6 CS assay 
2.9.6.1 Equipment set up 
CS activity was measured spectrophotometrically at 412nm with a Varioskan Flash 
microplate reader (Thermo Fisher Scientific Varioskan® Flash, Waltham, MA) using an 
established method (Eigentler et al., 2015).The Varioskan Flash reader first underwent 
a pre-programmed wash protocol using ddH2O. Then the system was loaded and 
primed with oxaloacetate 5ml stock in a 7ml bijoux tube.  
2.9.6.2 Protocol 
Cell samples were measured in triplicate in a sterile 96 well, clear plastic plate (3599, 
Costar, Corning Inc., Corning, NY). 200µl buffer solution and 1µl of cell sample was 
added to each experimental well. Two negative controls (200µl buffer) and two 
positive controls (200µl buffer + 1µl CS standard) were added to each plate.  
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The 96 well plate was then inserted into the machine, and the experiment was started. 
The recording period lasted for 10 minutes and measurements of the CS fluorescence 
were taken every 30 seconds. Once recording stopped, the raw data files were 
exported into a Microsoft Excel file (Microsoft Corporation, Redmond, Washington, 
USA). The protein content (µg/ml) that was assessed by the BCA assay at the beginning 
of the experiment, was used in the above step to normalise the values. Data given as a 
measure of international units (IU) per mg protein (IU/mg). 
2.10 Flow Cytometry 
All reagents were obtained from Gibco (Life Technologies, Paisley, UK) or Sigma (Sigma 
Aldrich, Dorset, UK) unless otherwise stated. 
Before the experiments, CCCP (carbonyl cyanide m-chlorophenyl hydrazine) was left to 
equilibrate to room temperature (protected from light), whilst cell culture media, 
0.05% TrypleE Express, DPBS and Hank’s balanced salt solution (HBSS) were warmed to 
37°C.  
2.10.1 Cell preparation 
Cells in T75cm2 flasks were selected when they had reached 70-90% confluence. Cells 
were detached and pelleted as before (Section 2.1.1). The supernatant was disposed 
of, and the cell pellet resuspended in 1ml HBSS. A sample was taken and counted as 
before (Section 2.1.1) using an automated TC10 cell counter (Bio-Rad Laboratories, 
Hertfordshire, UK). Enough HBSS was then added to the cell suspension to give a 
concentration of approximately 1x106 cells/ml. The cell suspension was then divided, 
with 1ml placed into 1.5ml microtubes, ready to be treated with fluorescent reagents 
(Table 2.8). Before staining the cells with fluorescent reagents (reagents and detection 
wavelengths described in Table 2.8), cells could be pre-treated with 100nM PAPTP for 
30 minutes in a humidified incubator (37°C; 95% air; 5% CO2). In all protocols, one 
microtube was left unstained to serve as a negative control.  
2.10.2 Protocols 
2.10.2.1 Mitochondrial membrane potential  
Three microtubes containing 1x106 cells in suspension were treated with 20nM TMRM. 
One microtube was additionally treated with 50µM CCCP (Sigma Aldrich). Another 
microtube was additionally treated with 0.5µM rotenone (Sigma Aldrich) and 2.5µM 
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antimycin A (Sigma Aldrich). All three microtubes were then incubated for 30 minutes 
in a humidified incubator (37°C; 95% air; 5% CO2).  
2.10.2.2 Mitochondrial Ca2+  
Three microtubes were treated with 1µM Rhod-2 AM (0.02% pluronic acid) for 30 
minutes at (37°C; 95% air, 5% CO2). The cells were then left to de-esterify for 30 
minutes before imaging (RT, in the dark). During the de-esterification period, one 
microtube was treated with 50µM CCCP, and one was treated with 0.5µM rotenone 
and 2.5µM antimycin A.  
2.10.2.3 NADH autofluorescence 
A large proportion of NADH autoﬂuorescence is due to mitochondrial NADH because 
NAD is non-ﬂuorescent and the level of cytosolic NADH is normally low (Buckler and 
Turner, 2013). Mitochondrial NADH can be oxidised to NAD by uncoupling 
mitochondrial respiration, while NAD can be reduced to NADH by inhibiting the 
electron transport system (Buckler and Turner, 2013). Uncouplers like CCCP and 
electron transport inhibitors like rotenone and antimycin A can be used to deﬁne a 
range for the mitochondrial NADH signal between conditions of maximal oxidation and 
reduction. Three microtubes containing 1x106 cells/ml were prepared as above. Before 
imaging, one microtube of cell suspension was treated with 50µM CCCP, and one 
microtube treated with a combination of 0.5µM rotenone and 2.5µM antimycin A (30 
minutes in a humidified incubator (37°C; 95% air; 5% CO2)).  
 
2.10.3 Data recording and analysis 
The samples were pelleted by centrifugation for 3 minutes at 600g in an Eppendorf 
Centrifuge 5424 (Eppendorf UK Ltd). The supernatants were then removed, and the 
cell pellet was washed twice with HBSS. The cells were resuspended in a final volume 
of 500µl HBSS. The samples were then analysed on a flow cytometer, with the 
appropriate excitation wavelength and emission filters (Table 2.8). Gates were applied 
using the unstained control, and the debris and duplicate cells were excluded. 
Standard compensation was applied using the CCCP-treated sample. The flow 
cytometer used was a BD LSRFortessa™ cell analyser (BD Biosciences, Franklin Lakes, 
NJ, USA) and the software used for data collection and analysis was the associated 
BD FACSDiva software (BD Biosciences, Franklin Lakes, NJ, USA). 
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2.11 Kv1.3 inhibitors 
2.11.1 PAP-1: 5-(4-Phenoxybutoxy) psoralen. Product P6124, Sigma Aldrich (Sigma 
Aldrich, Dorset, UK). Soluble in DMSO. Stored at -20°C in the dark to prevent photo-
oxidation. 
2.11.2 ShK-Dap22: Cat. No. 3220. Tocris Bioscience (Bio-Techne, Abingdon, UK). 
Soluble in H2O up to 1mg/ml. Stored at -20°C in the dark to prevent photo-oxidation. 
2.11.3 PAPTP: Kindly gifted by Dr Robin Bon, LICAMM, Leeds University. A positively 
charged TPP moiety was attached to a PAP-1 derivative, as described by (Leanza et al., 
2017). Soluble in DMSO. Stored at -20°C in the dark to prevent photo-oxidation. 
2.11.3.1 Synthesis of PAPTP  
The mitochondriotropic compound PAPTP was synthetized as shown in Figure 2.4. For 
full details, see STAR Methods in Leanza et al., 2017. 
 
 
 
 
 
 
 
Fluorescent Reagent Function Concentration Detection 
Wavelength 
RHOD-2AM Cellular Ca2+ 
detection 
20nM 548/574 nm 
TMRM MMP detection 1µM 552/581 nm 
NADH Autofluorescence* NADH detection N/A 350-360/470 nm 
Table 2.8. Fluorescent reagents used in flow cytometry experiments. From left to right 
columns, data shown is the name of the reagent, the function, the working concentration 
and its detection wavelength. * NADH autofluorescence is a property of the cell not a 
reagent.   
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2.12 Data Analysis and Statistics 
Data was input into GraphPad Prism (Version 6.03, GraphPad Software Inc, La Jolla, CA, 
USA), where unpaired Student’s T-Tests and/or one-way ANOVA Tests (followed by 
Dunnet’s or Tukey’s post hoc test, as appropriate) were used to analyse the data. 
Statistical significance was determined when p<0.05. ROUT analysis was used to 
remove outliers. 
 
 
 
 
  
Figure 2.4 Synthesis of PAPTP. Image adapted from Leanza et al., 2017. (1) Bergapten. (2) 4-
Hydroxy-7H-furo[3,2-g] benzopiran-7-one. (3) 4-(4-clorobutoxy)-7H-furo [3, 2, g] benzopyran-7-
one. (4) 4-(4-iodobutoxy)-7H-furo[3,2-g] benzopyran-7-one. (5) 4-(4-(4-(3-chloropropyl) 
phenoxy) butoxy)-7H-furo[3,2-g] benzopyran-7-one. (6) 4-(4-(4-(3-iodopropyl) phenoxy) 
butoxy)-7H-furo[3,2-g] benzopyran-7-one. (7) (3-(4-(4((7-oxo-7H-furo[3,2-g] benzopyran-4-yl) 
oxy) butoxy) phenyl) propyl) triphenyl phosphonium iodide (PAPTP). 
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Chapter Three 
 
Kv1.3 expressing HEK293 cells have an increased rate of proliferation 
and respiration. 
 
3.1 Introduction 
The Kv1.3 channel increases cellular proliferation through a number of mechanisms, 
including ion conducting effects on plasma membrane potential (Blackiston, 
McLaughlin and Levin, 2009), Ca2+ influx (Cheong et al., 2011) and cell volume 
regulation (Herrmann et al., 2012). Non-conducting properties of the channel (Cidad et 
al., 2012) and potential effects on cell signalling pathways (Lee et al., 2014) have also 
been implicated in proliferation. These mechanisms may not be mutually exclusive in 
driving cell proliferation.  
The Kv1.3 channel is localized to the inner mitochondrial membrane (IMM) of T 
lymphocytes (Szabo et al., 2005), hippocampal neurons (Bednarczyk et al., 2010), 
astrocytes (Cheng, Debska-Vielhaber and Siemen, 2010) and in cells isolated from a 
number of cancers (Mattarei et al., 2018). In cancer, mitochondrial Kv1.3 may regulate 
apoptosis. Inhibiting Kv1.3 activates a reactive oxygen species (ROS)-mediated 
signalling cascade resulting in Bax/Bak independent cell death (Leanza et al., 2012). 
However, the role of mitochondrial Kv1.3 in non-pathophysiological states is less well 
defined.  
Kv1.3 overexpressing HEK293 cells are a robust model for investigating the effects of 
Kv1.3 on cellular physiology (Peers et al., 2005; Scragg et al., 2008; Cidad et al., 2010, 
2012; Duckles et al., 2015; Jimenez-Perez et al., 2016). Cellular proliferation has a high 
energy demand, requiring ATP for processes ranging from signal transduction to DNA, 
RNA and protein synthesis (Vander Heiden, Cantley and Thompson, 2009; Oronsky et 
al., 2014; Pontes, Sevostyanova and Groisman, 2015). The distinct energy 
requirements of cellular proliferation (Lodish et al., 2000) coupled with the known 
mitochondrial localization of Kv1.3 (Szabo et al., 2005) may mean that this ion channel 
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links cellular energy metabolism to proliferation. Preliminary data generated in our 
laboratory indicates that Kv1.3 overexpressing HEK293 cells have increased O2 
consumption and respiratory capacity compared with wild type (WT) HEK293 cells.  
VSMC proliferation occurs in vasculopathies like atherogenesis and restenosis (Cheong 
et al., 2011). The vessel remodelling by proliferation of VSMCs is modulated by Kv1.3 
(Cidad et al., 2012). Proliferating VSMCs have altered metabolism compared to 
quiescent cells (Perez et al., 2010) yet the mechanisms which control this are unclear. 
It is also unknown whether Kv1.3 channels exist in VSMC mitochondria. 
 
3.2 Aims and Objectives 
 
The aim of this Chapter was to investigate the effect of Kv1.3 on cellular proliferation, 
energetics and respiration. A key set of objectives were designed to interrogate this 
aim: 
 
1) To determine the robustness of the HEK293 Kv1.3 overexpressing cell line as a 
model of functional Kv1.3 channels.  
 
2) To study the effects of Kv1.3 overexpression in HEK293 cells on proliferation. 
 
3) To assess the effects of Kv1.3 on cellular respiration and energetics, identify the 
specificity of these effects compared to the related Kv1.5 channel, and to investigate 
whether Kv1.3 localises to the mitochondrial network in HEK293 cells. 
 
4) To investigate the potential relevance to human physiology by identifying cellular 
location of Kv1.3 in human saphenous vein smooth muscle cells (HSVSMCs). 
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3.3 Results 
3.3.1 Confirmation of the HEK293/Kv1.3 cell line as a stably transfected 
overexpression system of functional Kv1.3 channels. 
Immunocytochemistry and immunoblotting were used to confirm that the 
HEK293/Kv1.3 cells were overexpressing the Kv1.3 channel (Figure 3.1). Using an anti-
Kv1.3 antibody, and a fluorescent secondary antibody, increased Kv1.3 was detected in 
the HEK293/Kv1.3 cells compared with WT HEK293 cells (Figure 3.1A and 3.1B). The 
channels are dispersed throughout the HEK293/Kv1.3 cells, indicating Kv1.3 channels 
are expressed within intracellular locations. As a secondary confirmation western 
blotting identified a low level of Kv1.3 protein expression in WT HEK293 cells, which 
was significantly higher in the HEK293/Kv1.3 cells (Figure 3.1C and 3.1D). Kv1.3 protein 
corresponds to a band of approximately 68-75 kDa. Non-specific staining by Alexa 
Fluor 488 in WT HEK293 and HEK293/Kv1.3 cells was assessed in cells without anti-
Kv1.3 primary antibody incubation (Figure 3.2). The image in Figure 3.1A is not 
representative of the amount of Kv1.3 protein, as detected by wester blot, in WT 
HEK293 cells (Figure 3.1C and D). 
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Figure 3.1 Increased Kv1.3 channel and protein expression in HEK293/Kv1.3 cell line. A and 
B. Representative images of  WT HEK293 (A) and HEK293/mKv1.3 cells (B) treated with Anti-
Kv1.3 Clone L23/27, mouse monoclonal primary antibody and Alexa Fluor 488 Donkey anti-
Mouse IgG (H+L) secondary antibody. Scale bars represent 10 µM. C. Representative western 
blots for 67-75kDa Kv1.3 protein, Kv1.3 (top panel), β-Actin control (bottom panel). D. 
Western blot densitometry data quantifying Kv1.3 protein in WT HEK293 and HEK293/Kv1.3 
cells. Data analysed using a Student’s t-test. ** p<0.01. WT HEK293 Kv1.3 protein expressed 
as 100 percent. Data expressed as mean ± SEM (n=5). WT = WT HEK293 cells, Kv1.3 = 
HEK293/Kv1.3 cells. Data in C and D was generated by Dr T. Hettiarachchi, University of 
Leeds. 
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A. B. 
Figure 3.2 Alexa Fluor 488 provides a specific secondary antibody in HEK293/Kv1.3 
and WT HEK293 cells. WT HEK293 (A) and HEK293/Kv1.3 (B) cells stained with Alexa 
Fluor 488 Donkey anti-Mouse IgG (H+L) secondary antibody (green). Cell nuclei stained 
with diamidino-2-phenylindole (DAPI) (blue). Scale bars (red lines) represent 20µM.  
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The functional properties of Kv1.3 channels were investigated using whole cell patch 
clamp electrophysiology (Figure 3.3). Cells were held at a holding potential of -80mV 
and periodically depolarised in 10mV steps from -60mV to +60mV to record the K+ 
current leaving the cells. This current was significantly greater in HEK293/Kv1.3 cells 
(Figure 3.3A) compared with WT HEK293 cells (Figure 3.3B). The IV relationship is 
shown in Figure 3.3C. At any voltage on the X axis, HEK293/Kv1.3 cells have a much 
higher K+ ion current than WT HEK293 cells. In Figure 3.3D, the K+ ion currents at 
+40mV in WT HEK293 cells and HEK2933/Kv1.3 cells are shown. In Figure 3.3D, the 
Kv1.3 channels in the HEK293/Kv1.3 cells were tagged with fluorescent mCherry 
marker protein and denoted HEK293/Kv1.3-P118 in the figure. These cells also elicited 
a much greater K+ current than WT HEK293 cells when depolarized from -80mV to 
+40mV (Figure 3.3D). The mCherry marker protein does not affect Kv1.3 channel 
biophysics (Jimenez-Perez et al., 2016). 
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Figure 3.3 HEK293/Kv1.3 cells have a larger potassium ion current than WT HEK293 cells. 
A and B. Example potassium ion currents in HEK293/Kv1.3 (A) and WT HEK293 cells (B), as 
determined by whole cell patch clamp electrophysiology. C. IV current traces of both 
HEK293/Kv1.3 cells (black dots) and WT HEK293 cells (black squares). Currents evoked by 
step-depolarisations from -60 to +60mV. Data expressed as mean ± SEM (n=7 for 
HEK293/Kv1.3, n=6 for WT HEK293 cells). Data analysed using two way ANOVA * p<0.05, 
** p<0.01, *** p<0.001, **** p<0.0001. D. Size of potassium currents (pA) in 
HEK293/Kv1.3-P118 (grey bar) and WT HEK293 cells (black bar) evoked by a single step 
depolarization from −80 to +40 mV. Data analysed using Student’s t-test **** p<0.0001. 
Data expressed as mean ± SEM (n=6 for each cell type). Data in A, B and C was generated 
by Dr M. Al-Owais, University of Leeds. 
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3.3.2 HEK293/Kv1.3 cells have increased proliferation and respiration compared to 
WT HEK293 cells. 
The rate of cell proliferation was interrogated in HEK293/Kv1.3 and WT HEK293 cells. 
HEK293/Kv1.3 cells exhibited an increased rate of proliferation compared to WT 
HEK293 cells (Figure 3.4A and B). Figure 3.4B shows HEK293/Kv1.3 cell proliferation 
normalised to the Day 0 cell count to account for variability between average Day 0 
counts in the two cell lines. 
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Figure 3.4 HEK293/Kv1.3 cells have an increased proliferation rate compared to WT 
HEK293 cells. A. HEK293/Kv1.3 cells (grey bars) proliferate more quickly than WT HEK293 
cells (black bars).  B. Data from graph (A) was normalised to Day 0 and expressed as percent 
increase from Day 0. Again, WT HEK293 data was shown in black bars and the 
HEK293/Kv1.3 data was in the grey bars. WT HEK293 data shown by black bars, 
HEK293/Kv1.3 data shown by grey bars. Data expressed as the mean ± SEM (n=3). For each 
day, data was analysed using Student’s t-test * p<0.05. 
93 
 
High Resolution Respirometry was used to assess the effect of Kv1.3 overexpression on 
mitochondrial function in HEK293 cells. A whole cell coupling control protocol was 
used, using a previously described method (Gnaiger, 2014). Coupling control protocols 
in whole cells use membrane-permeable inhibitors of OXPHOS, like oligomycin and 
antimycin A, and uncouplers like FCCP to interrogate cellular respiration (Gnaiger, 
2014).  
In Figure 3.5, there are representative respirometry traces for HEK293/Kv1.3 (Figure 
3.5A) and WT HEK293 cells (Figure 3.5B). The points at which measurements of O2 
consumption were taken are highlighted; R, L, ETS and ROX. R represents ‘Routine 
Respiration’ which is the basal level of respiration reached once the chamber is closed. 
L represents ‘Leak Respiration’ and represents the depressed O2 flow that exists after 
inhibition of ATP-synthase by oligomycin. Leak refers to the movement of H+ protons 
down the electrochemical proton gradient from the IMS across the IMM and into the 
matrix. ETS represents the O2 flow at ‘maximum capacity of electron transport system’ 
which is measured after maximum uncoupling by a protonophore like FCCP. ROX is 
Residual Oxygen Consumption and represents ‘non-mitochondrial O2 consumption’ 
after complete inhibition of mitochondrial respiration. The black arrows show the time 
points at which the uncoupler FCCP was added. Note that in WT HEK293 cells it took 
more titrations of FCCP to reach maximal ETS uncoupling than in HEK293/Kv1.3 cells. 
In Figure 3.5A and B, the higher the red trace line on the Y axis, the greater the O2 
consumption by the cells per second. The lower the blue trace line on the Y axis, the 
lower the concentration of O2 in the chambers. In A, after closure of the chamber, the 
O2 consumption by the cells (red line) is higher on the Y axis at R, L, ETS and ROX than 
in B, suggesting that HEK293/Kv1.3 cells have increased respiration than WT HEK293 
cells. The mean results from all coupling control protocols in WT HEK293 and 
HEK293/Kv1.3 cells are shown in Figure 3.5C. HEK293/Kv1.3 cells had significantly 
higher respiration than WT HEK293 cells. The routine level of O2 consumption was 
higher in HEK293/Kv1.3 cells, indicating higher basal respiration. HEK293/Kv1.3 cells 
had higher leak respiration, indicating more H+ proton movement into the matrix when 
ATP-synthase was inhibited. The maximum capacity of the ETS was also larger in 
HEK293/Kv1.3 cells.  
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Due to the nature of the coupling control protocol (Gnaiger, 2014), interrogation of the 
maximum capacity of the ETS requires repeated titrations of FCCP until no further 
increase in O2 consumption is recorded in response to the protonophore. Interestingly, 
WT HEK293 cells required more titrations of FCCP before they were maximally 
uncoupled (Figure 5A and 5B). This meant that ultimately WT HEK293 cells were 
treated with higher concentrations of FCCP. The reasons for this remain unclear but a 
greater response to FCCP in HEK23/Kv1.3 cells suggests that there is a greater 
electrochemical gradient for H+ across the inner mitochondrial membrane than in WT 
HEK293 cells. This suggests that the treatment with FCCP caused rapid diffusion of H+ 
into the matrix leading to more H+ being able to bind to O2 at complex IV. This would 
lead to a much greater O2 consumption in HEK293/Kv1.3 cells. To get the same amount 
of H+ binding to O2 in WT HEK293 cells, much more protonophore is required. 
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Figure 3.5 HEK293/Kv1.3 cells have increased OXPHOS compared to WT HEK293 cells. Example 
respirometry traces from HEK293/Kv1.3 cells (A) and WT HEK293 cells (B). Each trace is generated 
from a single enclosed chamber containing 2 million cells. Red line represents O2 consumption 
throughout the respiratory protocol (pmol/(s*mill)). Blue line represents O2 concentration in the 
chamber (nmol/ml). Black horizontal lines show the points at which O2 consumption was measured (R 
= Routine Respiration, L = Leak Respiration, ETS = Electron Transport System Maximum Respiration, 
ROX = Residual Oxygen Consumption. L was measured after addition of 2µg/ml oligomycin, ETS after 
titrations of 0.5µM FCCP and ROX after addition of 2.5µM rotenone and 0.5µM antimycin A. Black 
arrows show the points at which FCCP was added to the chamber. C. Results from respirometry 
experiments in HEK293/Kv1.3 (black bars) and WT HEK293 cells (grey bars). For each cell type, O2 
consumption has been measured at points denoted by R, L, ETS and ROX in (A) and (B). Data 
expressed as the mean ± SEM (n = 38, HEK293/Kv1.3 cells and n=27, WT HEK293 cells). At each point 
in the experiment (R, L, ETS and ROX), data from each cell type was analysed using a Student’s t-test 
** p<0.01, *** p<0.001 and **** p<0.0001.   
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In Figure 3.5 it is important to note that non-mitochondrial O2 consumption, as 
identified by ROX, was higher in HEK293/Kv1.3 cells. Therefore, baseline data was 
corrected for ROX (Figure 3.6). Figure 3.6A shows the Routine (basal) Respiration of 
WT HEK293 cells and HEK293/Kv1.3, where HEK293/Kv1.3 cells have a significantly 
higher Routine O2 consumption than WT HEK293 cells. There are no differences in Leak 
Respiration between the two cell types (Figure 3.6B). The measurement of Routine and 
Leak Respiration can be used to assess the ATP turnover in cells (Figure 3.6C) by finding 
the difference between the two figures. HEK293/Kv1.3 cells have a higher ATP 
turnover than WT HEK293 cells and O2 consumption is also significantly higher in 
HEK293/Kv1.3 cells at the FCCP-induced, maximum uncoupled state (Figure 3.6D). By 
finding the difference between this maximum respiration measurement and the 
Routine Respiration, the spare respiratory capacity (SRC) can be calculated. 
HEK293/Kv1.3 cells have a larger SRC than WT HEK293 cells (Figure 3.6E). As 
mentioned previously, as well as these increases in mitochondrial OXPHOS, the non-
mitochondrial O2 consumption (the ROX) is significantly much larger in HEK293/Kv1.3 
cells (Figure 3.6F). 
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Figure 3.6. Residual oxygen consumption-corrected respiration in WT HEK293 and 
HEK293/Kv1.3 cells. In all graphs (A-F) HEK293/Kv1.3 (Kv1.3) cell data is shown in the black 
bars, WT HEK293 (WTHEK) cell data is shown in the grey bars. A. Routine (basal) Respiration 
rate of HEK293/Kv1.3 cells and WT HEK293 cells B. Leak Respiration of HEK293/Kv1.3 cells 
and WT HEK293 cells. C. ATP turnover in HEK293/Kv1.3 cells and WT HEK293 cells. ATP 
turnover calculated by finding the difference between routine respiration (A) and leak 
respiration (B). D. Maximum Uncoupled Respiration in HEK293/Kv1.3 cells and WT HEK293 
cells. E. Spare respiratory capacity (SRC) in HEK293/Kv1.3 and WT HEK293 cells. SRC is 
calculated by finding the difference between Maximum Uncoupled Respiration (D) and 
Routine (basal) Respiration (A). F. Residual Oxygen Consumption (ROX) in HEK293/Kv1.3 and 
WT HEK293 cells. Data was analysed using a Student’s t-test * p<0.05 **p<0.01 **** 
p<0.0001. Data expressed as the mean ± SEM (n = 27 for WT HEK293 cells and n=38 for 
HEK293/Kv1.3 cells) 
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3.3.3 Overexpression of Kv1.5 in HEK293 cells decreases mitochondrial respiration. 
In contrast to Kv1.3, overexpression of Kv1.5 in WT HEK293 cells reduces cellular 
proliferation (Cidad et al., 2015). This was confirmed in our lab by Dr M. Al-Owais, who 
carried out proliferation assays with HEK293/Kv1.5 cells. HEK293/Kv1.5 cells 
proliferated significantly less than HEK293/Kv1.3 and WT HEK293 cells over 3 days 
(Figure 3.7). To investigate whether a K+ channel which reduces proliferation in 
HEK293 cells also reduces respiration, HEK293/Kv1.5 cells were examined using High 
Resolution Respirometry (Figure 3.8) as described previously. HEK293/Kv1.5 cells had 
lower Routine (basal) and Leak Respiration then either WT HEK293 or HEK293/Kv1.3 
cells, independent of correction for ROX (Figure 3.8A and B). However, there was no 
significant difference in the maximum respiration rate between HEK293/Kv1.5 and WT 
HEK293 cells. There is also no difference in ROX between HEK293/Kv1.5 and WT 
HEK293. There are however significant differences between maximum and residual O2 
consumption in HEK293/Kv1.3 and HEK293/Kv1.5.  These data suggest that the 
opposing effects on proliferation by Kv1.3 and Kv1.5 channel overexpression is 
mirrored by effects on mitochondrial respiration. 
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Figure 3.7 HEK293/Kv1.5 cells have decreased proliferation compared to WT HEK293 cells. A. 
HEK293/Kv1.3 (n=12, black circles), WT HEK293 (n=15, white circles) and HEK293/Kv1.5 (n=12, 
white squares) cell counts at days 0, 1, 2 and 3. Data expressed as the mean ± SEM. B. Mean cell 
counts  (± SEM) at day 3 for HEK293/Kv1.3 cells (n =12, black bars), WT HEK293 cells (n = 15, 
white bar) and HEK293/Kv1.5 cells (n=12, dotted bar). Student’s t-test confirmed HEK293/Kv1.3 
cell proliferation was significantly increased, and HEK293/Kv1.5 cell proliferation was 
significantly decreased compared to WT HEK293 cells. * p<0.05. Experiments and statistical 
analysis carried out by Dr M. Al-Owais, Leeds University. 
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Figure 3.8 HEK293/Kv1.5 cells have reduced OXPHOS compared to WT HEK293 and 
HEK293/Kv1.3 cells. A. Comparison of respiration in WT HEK293 (black bars), HEK293/Kv1.3 
(light grey bars) and HEK293/Kv1.5 (dark grey bars) cells. Oxygen consumption (O2 
consumption per million cells per second (pmol(s*Mill))) was measured at four points; 
routine=Routine/Basal Respiration, leak=Leak Respiration, ETS=maximum uncoupled 
respiration and ROX=non-mitochondrial oxygen consumption. B. Data from (A) corrected for 
ROX. In A and B, data expressed as mean ± SEM (WT HEK293, n=8, HEK293/Kv1.3, n=10, 
HEK293/Kv1.5, n=5). Data was analysed using one-way ANOVA * p<0.05, ** p<0.01, *** 
p<0.001 and **** p<0.0001. 
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3.3.4 Kv1.3 channels co-localise with the mitochondrial network in HEK293/Kv1.3 
cells. 
Immunocytochemistry was employed to investigate the cellular localization of Kv1.3 
channels in WT HEK293 and HEK293/Kv1.3 cells. Cells were stained to identify Kv1.3 
channels (anti-Kv1.3 antibody with a green fluorescence secondary reporter), and 
mitochondria (MitoTracker CMXRos, red fluorescence) and imaged using confocal 
microscopy (Figure 3.9). HEK293 cells do not exhibit autofluorescence within the 
Mitotracker detection wavelengths (Figure 3.10). Co-localisation of the channel with 
mitochondria was determined by the extent of yellow/orange fluorescence resulting 
from the overlap from Kv1.3 and mitochondrial staining. As expected HEK293/Kv1.3 
cells were observed to have greater staining for the Kv1.3 channel (Figure 3.9A vs D). 
Surprisingly, HEK293/Kv1.3 cells exhibited greater staining for mitochondria (Figure 
3.9B vs E). In both WT HEK293 and HEK293/Kv1.3 cells, the Kv1.3 channels were 
observed to co-localize with mitochondria (Figure 3.9C and F).   
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A. B. C. 
D. E. F. 
Figure 3.9 Mitochondrial and Kv1.3 co-localisation in HEK293/Kv1.3 cells. A, B and C = 
HEK293/Kv1.3 cells. Left panel (A) shows Kv1.3 channels stained with Anti-Kv1.3 
monoclonal primary antibody Alexa Fluor 488 secondary antibody (green fluorescence). 
Centre panel (B) shows mitochondria stained with MitoTracker Red CMXRos (red). Right 
panel (C) is composite image of previous two images, indicating Kv1.3 localisation to the 
mitochondria (yellow/orange). Scale bars are 10µM. D, E and F = WT HEK293 cells. Left 
panel (D) shows cells stained with Anti-Kv1.3 monoclonal primary antibody Alexa Fluor 488 
secondary antibody. Centre panel (E) shows mitochondria stained with MitoTracker Red 
CMXRos (red). Right panel (F) is composite image of previous two images. Scale bars are 
10µM. 
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A second immunocytochemistry method was used to investigate Kv1.3 and 
mitochondrial co-localisation in HEK293/Kv1.3 cells (Figure 3.11). In Figure 3.11 the 
HEK293/Kv1.3 cells expressed mCherry-tagged Kv1.3 channels and were referred to as 
HEK293/Kv1.3-P118 cells. WT HEK293 cells did not contain the marker protein and so 
were used as a control for background fluorescence at mCherry detection 
wavelengths. No antibodies against the Kv1.3 channel were used in Figure 3.11, only 
the mCherry fluorescence (red) was used to detect Kv1.3 channels in HEK293/Kv1.3-
P118 cells. The mitochondrial network was stained using an anti-COX IV antibody 
against cytochrome c oxidase (complex IV) of the mitochondrial respiratory chain. An 
Alexa 488 secondary antibody was used to highlight COX IV staining (green 
fluorescence). Co-localisation was determined by the crossover between the red 
(mCherry) and green (COX IV) fluorescence producing yellow/orange fluorescence if 
co-localisation existed. Images A-H show immunostained HEK293/Kv1.3-P118 cells and 
images I-P show WT HEK293 cells. The presence of yellow/orange fluorescence in (D) 
backed up the findings in Figure 3.9C, that Kv1.3 channels can co-localise with 
A. B. 
Figure 3.10 MitoTracker controls in WT HEK293 and HEK293/Kv1.3 cells. MitoTracker 
controls in WT HEK293 (A) and HEK293/Kv1.3 cells (B). Cells were stained with diamidino-
2-phenylindole (DAPI) (blue) for nuclei detection. Excitation/emission wavelengths were 
360nm/460nm. Cells also excited at the MitoTracker detection wavelengths of 
579nm/599nm (excitation/emission) to test for any red autofluorescence in these cells. 
Scale bars represent 20 µm.  
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mitochondria in HEK293 cells. HEK293/Kv1.3 cells do not exhibit autofluorescence 
within the COX IV detection wavelengths (Figure 3.11F). WT HEK293 cells do not 
display autofluorescence within both mCherry detection wavelengths (Figure 3.11K 
and O) or within COX IV detection wavelengths.  
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Figure 3.11 Mitochondrial and Kv1.3 co-localisation in HEK293/Kv1.3-P118 cells. A – H) 
Kv1.3 channel and mitochondrial co-localisation in HEK293/Kv1.3-P118 cells. A. DAPI 
staining of cell nuclei (blue). B. Immunostaining of cytochrome C oxidase to visualise the 
mitochondria (green). C. Red fluorescence of mCherry tagged Kv1.3 channels. D. Composite 
image of DAPI nuclear stain (blue), cytochrome C oxidase immunostain (green) and 
mCherry-tagged Kv1.3 cells (red).  E. DAPI staining of cell nuclei (blue). F. Control for non-
specific binding by the Alexa Fluor secondary antibody. Staining was performed as in (B) but 
without anti-COXIV antibody. G. Red fluorescence of mCherry tagged Kv1.3 channels. H. 
Composite image of E, F and G. I - P) Immunostaining of WT HEK293 cells for Kv1.3 channel 
and mitochondrial co-localisation. I. DAPI staining of cell nuclei (blue). J. Immunostaining of 
cytochrome C oxidase to visualise the mitochondria (green). K. Control for background red 
fluorescence. L. Composite image of DAPI nuclear stain (blue), cytochrome C oxidase 
immunostain (green) and background fluorescence (red).  M. DAPI staining of cell nuclei 
(blue). N. Control for non-specific binding by the Alexa Fluor secondary antibody. Staining 
was performed as in (J) but without anti-COXIV antibody. O. Control for background red 
fluorescence. P. Composite image of M, N and O. All scale bars are 10µm. 
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3.3.5 Kv1.3 channels co-localise with the mitochondrial network in Primary Human 
Saphenous Vein Smooth Muscle Cells. 
To examine whether the Kv1.3 channel mitochondrial localisation identified in HEK293 
cells translate to primary human cells, the cellular localization of Kv1.3 channels was 
investigated in primary human saphenous vein smooth muscle cells (HSVSMCs). 
HSVSMCs were isolated from patients undergoing surgery at Leeds General Infirmary. 
Kv1.3 channels visualised using an anti-Kv1.3 antibody and Alex Flour secondary 
detection antibody (green fluorescence) and mitochondria were stained using 
Mitotracker Red CMXRos (red fluorescence) (Figure 3.12A and B, respectively). Co-
localisation of Kv1.3 with the mitochondrial network is identified by yellow/orange 
fluorescence in the composite image (Figure 3.12C). Kv1.3 and mitochondrial staining 
was performed on HSVSMCs isolated from three other independent patients (Figure 
3.12D, E and F). Kv1.3 channels were identified as present in the mitochondria of the 
HSVSMCs. 
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Figure 3.12 Kv1.3 channels co-localise with mitochondria in primary human vascular smooth muscle cells.  Data shows cells isolated from four independent 
patients. Top row shows immunostained cells from one patient. Bottom row shows cells from three patients. A. Kv1.3 channels detected by anti-Kv1.3 clone 
L23/27 NEUROMAB mouse monoclonal primary antibody with Alexa Fluor 488 secondary antibody (green). B. Mitochondrial network stained with MitoTracker 
Red CMXRos. C. Composite images of A and B, with yellow/orange fluorescence indicating Kv1.3 channel co-localisation with the mitochondria. D, E and F show 
composite images, as in (C), generated by staining cells with the anti-Kv1.3 antibody in (A) and MitoTracker Red CMXRos in (B). Yellow/orange fluorescence 
indicates Kv1.3 channel co-localisation with the mitochondria. Scale bars represent 10µm. 
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3.3.6 HEK293 and HEK293/Kv1.3 cells have comparable amounts of mitochondria. 
To determine whether Kv1.3 expression alters mitochondrial content, a citrate 
synthase (CS) activity assay was performed in WT HEK293 and HEK293/Kv1.3 cells. CS 
is an enzyme present in the mitochondrial matrix which catalyses the condensation of 
Acetyl-CoA and oxaloacetate to produce citric acid. The hydrolysis of Acetyl-CoA in this 
reaction, produces a CoA molecule attached to a thiol group. This thiol group reacts 
with DTNB to produce TNB, which fluoresces and can be measured 
spectrophotometrically. Thus, the amount of CS directly relates to the amount of TNB 
fluorescence measured during this assay. The CS activity assay is a proxy measure for 
mitochondrial content (Eigentler et al., 2015), but it is better than other measures, 
such as measuring mitochondrial DNA. Mitochondrial DNA is not a good biomarker for 
mitochondrial content in skeletal muscle cells (Larsen et al., 2012) and suffers from 
multiple mitochondrial genome copy errors which lead to false results (Malik and 
Czajka, 2013). There was no difference in the activity of CS in WT HEK293 and 
HEK293/Kv1.3 cells (Figure 3.15A), indicating no significant difference in the 
mitochondrial content of these cells. 
A second assessment of mitochondrial content in WT HEK293 and HEK293/Kv1.3 cells 
was performed. High resolution respirometry was utilised to assess complex IV activity, 
another common biomarker for mitochondrial content (Larsen et al., 2012). Cells were 
acutely treated with ascorbate and TMPD and cellular respiration measured. TMPD 
artificially reduces complex IV by acting as an electron donor, whilst ascorbate 
maintains TMPD in its reducing state. There was no significant difference in the 
complex IV respiration in WT HEK293 and HEK293/Kv1.3 cell (Figure 3.14B). As with 
the citrate synthase assay these data indicate that mitochondrial content in these cells 
is not altered by Kv1.3 expression.  
Next, the protein expression of key mitochondrial respiratory chain components was 
examined in HEK293/Kv1.3 cells (Figure 3.13C, D and E). The protein expression of 
mitochondrial ATP synthase, as determined by the expression of the ATP beta subunit, 
was not different in HEK293/Kv1.3 cells compared to WT HEK293 cells (Figure 3.13C).  
Complex IV protein expression was also examined. Interestingly, a significant increase 
in complex IV in HEK293/Kv1.3 cells was identified (Figure 3.13D). However, on closer 
examination the band corresponding to complex IV on the blot for HEK293/Kv1.3 cells 
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suggests that there may be more of the protein complex in the transgenic cells (Figure 
3.13E). This phenomenon is not seen in the bands for the β-actin control or ATP 
synthase. As complex IV represents a multiprotein complex this finding may suggest 
that assembly of the complex is altered in the presence of increased mitochondrial 
Kv1.3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13 Kv1.3 expression does not alter mitochondrial content in HEK293 cells. A. 
Citrate synthase activity assay in WT HEK293 (black) and HEK293/Kv1.3 (grey) cells. Data 
expressed as the mean fluorescent intensity of TNB ± SEM (n=3). B. Results from complex IV 
respiratory assay in HEK293/Kv1.3 (black) and WT HEK293 (grey) cells. Data expressed as the 
mean oxygen consumption (pmol/(s*Mill)) ± SEM (n=5). C. Mean densitometry from 
mitochondrial ATP synthase protein western blotting in WT HEK293 (black) and 
HEK293/Kv1.3 (grey) cells. Data expressed as percent of WT HEK293 protein ± SEM (n=3). D. 
Mean densitometry from complex IV western blotting in WT HEK23 (black) and HEK293/Kv1.3 
(grey) cells. Data is expressed as a percentage of WT HEK293 protein ± SEM (n=5). E. Example 
blots showing ATP synthase beta subunit protein (top row), COX IV protein (middle row), and 
beta actin protein loading control (bottom row), in WT HEK293 (left column) and 
HEK293/Kv1.3 (right column) cells. For A-D, data was analysed by Student’s t-tests, * p<0.05. 
Data in C, D and E was generated by Dr T. Hettiarachchi, University of Leeds. 
 
* 
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A 3-dimensional (3D) imaging immunocytochemistry approach was used to investigate 
the mitochondrial content of HEK293/Kv1.3 cells (Figure 3.14). Cells were stained with 
Mitotracker (red) and imaged using 3D confocal microscopy. Images provide a complex 
interpretation of the mitochondrial cellular network. The degree of mitochondrial 
staining was similar in both WT HEK293 and HEK293/Kv1.3 cells. 3D imaging was also 
used to examine HEK293/Kv1.3 cells immunostained for mitochondrial complex IV 
(Figure 3.15 A-D). The gross structure of the mitochondrial network was unchanged by 
Kv1.3 expression (Figure 3.15D vs H). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. 
B. 
Figure 3.14 Kv1.3 expression does not alter mitochondrial networks in HEK293 cells. 
Mitochondrial networks in WT HEK293 and HEK293/Kv1.3 cells. 3D images of WT HEK293 
cells (A) and HEK293/Kv1.3 cells (B) pre-treated with 100nM MitoTracker Red CMXRos. Cell 
nuclei are stained with diamidino-2-phenylindole (DAPI) (blue). Images are z-stack 
composites of twenty 1μm slices through the cell. These are representative images of three 
biological replicates. Scale bars represent 50µm.  
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Figure 3.15 Kv1.3 expression does not alter mitochondrial complex IV protein content or affect the structure of the mitochondrial network in HEK293 cells. 
Comparison of mitochondrial networks in HEK293/Kv1.3 cells (top row) and WT HEK293 (bottom row). A and E. Three-dimensional image of cell mitochondrial 
network stained for complex IV (green). Cell nuclei are stained with diamidino-2-phenylindole (blue). B and F. Cell mitochondrial network stained for complex IV 
(green). C and G. Mitochondrial network staining for complex IV (green) with cell nuclei staining by diamidino-2-phenylindole (DAPI) (blue). D and H. Magnified 
images of complex IV and nuclear co-stained images highlighting the mitochondrial network. All scale bars represent 20µm. 
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3.4 Discussion 
 
This chapter characterised the HEK293/Kv1.3 cell line and identified a distinct 
proliferative and mitochondrial respiration phenotype resulting from Kv1.3 expression 
in HEK293 cells. 
The stable expression of ion channels in HEK293 cells as an experimental model is well 
established (Elies, Dallas, et al., 2014; Elies, Scragg, et al., 2014; Al-Owais et al., 2015; 
Duckles et al., 2015). The HEK293 cell line is commonly used due to their high 
proliferation rate, and their propensity for transfection (discussed in Stepanenko and 
Dmitrenko, 2015). The HEK293/Kv1.3 model has been used successfully to investigate 
the mechanisms of Kv1.3 induced proliferation, where overexpression of WT Kv1.3 and 
mutant Kv1.3 channels have led to the discovery of ion-conduction independent roles 
for Kv1.3 in proliferation (Cidad et al., 2012; Jimenez-Perez et al., 2016). 
HEK293/Kv1.3 cells were found to express functional Kv1.3 channels.  WT HEK293 cells 
were also found to express low levels of Kv1.3 protein. Kv1.3 channels have previously 
been observed in HEK293 cells (Jiang et al., 2002). However, expression was to a 
sufficiently low level in comparison with HEK293/Kv1.3 cells that they were considered 
a suitable control. In addition, electrophysiology experiments confirmed that there 
were significantly increased potassium currents in HEK293/Kv1.3 cells and that the 
contribution of the endogenous Kv1.3 channels to the observed currents in HEK293 
cells is negligible. This view is widely held, and researchers generally view the 
endogenous ion channel currents as insignificant when compared to the currents 
generated with channel overexpression in HEK293 cells (Varghese et al., 2006). 
Therefore the HEK293 cells were considered a reliable stable transfection and 
overexpression system for Kv1.3 (Thomas and Smart, 2005). 
HEK293/Kv1.3 cells displayed significantly higher levels of proliferation than WT 
HEK293 cells (Figure 3.4). This finding supports data from Cidad et al., who also saw 
this effect in HEK293 cells overexpressing the Kv1.3 channel (Cidad et al., 2012; 
Jimenez-Perez et al., 2016). The Kv1.3 channel has been a focus of research into 
proliferative disorders of vascular cells since 2010 (Cidad et al., 2010, 2012; Cheong et 
al., 2011; Jimenez-Perez et al., 2016). A study investigating the expression profile of 87 
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ion channels in various vascular beds found that Kv1.3 was upregulated during the 
phenotypic switch of VSMCs from a contractile state to a proliferative one (Cidad et al., 
2010). This study found that sensitivity to 5µM correolide, a non-selective potassium 
channel blocker, indicated that a larger proportion of the overall K+ current in 
proliferative VSMCs was attributable to Kv1 channels. Kv1.3 upregulation was 
confirmed by a 6-fold increase in sensitivity to the selective Kv1.3 blockers PAP-1 and 
Margatoxin, (MgTx) and increased Kv1.3 immunoreactivity in both an in vitro 
preparation and in vivo injured VSMCs. In addition, inhibition of Kv1.3 by 
pharmacological blockade with PAP-1 and molecular mutation reduced VSMC 
proliferation and migration.  
In this chapter HEK293/Kv1.3 cells were analysed in a high-resolution respirometer. 
Kv1.3 overexpressing cells displayed significantly higher O2 consumption and ATP 
turnover rates than WT HEK293 cells. To the best of the authors’ knowledge, no link 
has previously been described between Kv1.3 channels and oxidative phosphorylation. 
However, in 2014 Hamilton et al., found that there was no role for Kv1.3 in oxidative 
phosphorylation in mouse skeletal muscle cells (Hamilton et al., 2014). Interestingly, in 
rat olfactory bulbs, which contain high levels of Kv1.3 channels in the neurons, there is 
a respiratory control ratio which indicated mitochondrial activity was twice as high as 
neighbouring cells of the hypothalamus (Benani et al., 2009).  
In contrast, there have been several studies linking Kv1.3 to metabolic disorders. Kv1.3 
has been implicated in the regulation of both body weight and energy homeostasis (Xu 
et al., 2003). Xu et al., found that knockout Kv1.3 mice had a higher metabolic rate and 
displayed significantly lower body weight than those with the Kv1.3 gene. In 2004, the 
same group identified a role for Kv1.3 in modulation of peripheral insulin sensitivity, as 
both pharmacological inhibition and gene knockout of Kv1.3 upregulated GLUT4 at the 
plasma membrane (Xu et al., 2004). Tucker and colleagues found that the genetic 
ablation of Kv1.3 in melanocortin 4 receptor-null mice led to reduced body mass and 
adiposity in these animals compared to WT animals, partly due to increased energy 
expenditure and metabolism (Tucker, Overton and Fadool, 2008). Kv1.3 
pharmacological blockade suggests utility as a potential therapeutic for obesity and 
insulin resistance (Upadhyay et al., 2013).  
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These findings appear to run contrary to the observations of this chapter describing 
which increased O2 consumption in cells overexpressing the Kv1.3 channel, suggesting 
an increased metabolic rate. Despite this contradiction, it is plausible that the low body 
weight of the knockout/Kv1.3 inhibited animals could have been due in part to a lower 
level of cell growth and proliferation in these animals, a possibility that was not 
addressed in these studies. It could also suggest that Kv1.3 has specific effects on 
adipocyte hyperplasia in obesity. Finally, if Kv1.3 plays a physiological role in 
mitochondrial metabolism, channel KO or inhibition may lead to upregulation of other 
metabolic pathways to compensate (Obermeyer et al., 2013; Hardie et al., 2017).  
In addition, more recent studies have also identified opposing metabolic effects of 
Kv1.3 to those put forward by both Xu et al. and Tucker et al., (referenced above), 
including no observation of a role for Kv1.3 in weight gain and adiposity in rats (Jaimes-
Hoy et al., 2017) and no effect on insulin sensitivity of mice or in insulin insensitive 
human tissues (Straub et al., 2011).  
The results highlighted in this chapter pose additional key questions, including whether 
the incidence of an increased respiratory rate is directly related to the Kv1.3 channel, 
and drives the increased proliferative rate, or vice versa in which the increased 
proliferative rate is the initiator of increased energy metabolism. The possibility 
remains that the two process are carefully co-ordinated to facilitate effective cell 
growth. It is interesting to note that when Kv1.5 channels were transfected into the 
HEK293 cells, there was reduction in cellular respiration and proliferation in direct 
contrast to HEK293/Kv1.3 cells. Although not a well-established mitochondrial ion 
channel, there is some evidence which suggests that Kv1.5 channels are found in the 
inner mitochondrial membrane (Leanza et al., 2014). It may be that the ratio of Kv1.3 
to Kv1.5 channels determines the phenotypic state of vascular smooth muscle cells 
(Cidad et al., 2010; Jimenez-Perez et al., 2016).  
Kv1.3 channels have been found on the inner mitochondrial membrane of various cell 
types (Szabo et al., 2005; Bednarczyk et al., 2010; Cheng, Debska-Vielhaber and 
Siemen, 2010; Mattarei et al., 2018). This chapter used immunocytochemistry to 
identify localisation of Kv1.3 channels to the mitochondrial network of HEK293 cells 
and HSVSMCs.  
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Voltage gated potassium channels have been previously linked to mitogenesis in T 
lymphocytes (DeCoursey et al., 1984). However, the increased rate of cellular 
respiration in Kv1.3 overexpressing cells appeared to be dependent on increased rates 
of substrate oxidation as opposed to increased mitochondrial content. Kv1.3 channel 
overexpression in HEK293 cells did not affect the size or structure of the mitochondrial 
network as determined by CS activity assay, complex IV respiratory activity, 
assessment of mitochondrial protein concentrations and mitochondrial network 
imaging. However, the protein band corresponding to mitochondrial complex IV in 
western blotting displayed retarded progress on the gel which may correspond to an 
increased mass of the protein complex. This may represent an effect of Kv1.3 
overexpression on the formation or synthesis of the multiprotein complex. 
Nevertheless, the activity of complex IV was unaffected by Kv1.3 overexpression and 
therefore the potential protein modification does not appear to have a direct 
functional effect on the respiratory role of complex IV under the tested experimental 
conditions. In Figure 3.9 E it appears that WT HEK293 cells have decreased 
mitochondrial networks in comparison to Figure 3.9 B. However, this seems to be an 
anomaly, as in Figure 3.14 there is no obvious difference in the mitochondrial networks 
in WT HEK293 and HEK293/Kv1.3 cells. The difference in the level of immunostaining in 
Figure 3.9 could arise from either impaired staining of the mitochondria by 
MitoTracker CMXRos, or impaired imaging on the microscope. For example, it appears 
that in HEK293/Kv1.3 cells there is flooding of Mitotracker into the cell nuclei (Figure 
3.9 B). This suggests an incorrect concentration of the fluorescent agent in this sample 
of HEK293/Kv1.3cells. Co-localisation analysis of mitochondria and Kv1.3 channels can 
be found in Chapter 6, Figure 6.3. 
Genetic deletion of Kv1.3 channels in mice gives rise to animals with altered 
mitochondrial morphology (Kovach et al., 2016). These animals had smaller 
mitochondria with a more circular shape than wild type mice. Although no quantitative 
measure of cristae was carried out, the researchers observed that these structures 
were more longitudinally arranged in wild type animals. In addition, a recent study 
testing mitochondrially targeted Kv1.3 inhibitors on cancer cells found that these 
compounds caused mitochondrial swelling (Mattarei et al., 2018). It is well established 
that mitochondrial potassium cycling is tightly regulated in order to protect the 
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mitochondria from damaging changes in cell volume that can affect bioenergetics 
(Garlid, 1996; Garlid and Paucek, 2003). An integral part of mitochondrial matrix 
volume homeostasis is the K+/H+ antiporter (Garlid and Paucek, 2003). In this study, no 
differences were observed in the structure of mitochondria in cells overexpressing 
Kv1.3. However, more advanced methods, such as electron microscopy of the 
mitochondrial ultrastructure, should be considered for further analyses. A more 
advanced imaging method may also be able to determine whether Kv1.3 
overexpression effects complex IV expression or protein size. For example, the cristae 
may become more folded, as high metabolic rates have been found to cause structural 
changes of the IMM and matrix (Lehninger, 1982), generating a greater surface area to 
express higher amounts of complex IV. However, no change in complex IV activity was 
observed in the HEK293/Kv1.3 cells investigated as part of this study. However, it may 
be that no difference in mitochondrial structure was due to tight regulation of 
mitochondrial volume homeostasis, which causes swift extrusion of the excess influx of 
K+ into the matrix through Kv1.3 channels (Garlid and Paucek, 2003).   
In summary, this chapter set out to characterise and investigate the proliferative and 
cellular energy phenotype of Kv1.3 overexpression in HEK293 cells. Increased rates of 
proliferation and respiration could not be attributed to differences in mitochondrial 
number or general structure. In addition, Kv1.3 was found to reside in the 
mitochondria of both HEK293/Kv1.3 cells and HSVSMCs.  
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Chapter Four 
 
Mitochondrial Kv1.3 channels regulate proliferation and respiration in 
HEK293 cells. 
 
 
 
4.1 Introduction 
 
The ion channel Kv1.3 has previously been shown to have a regulatory role in cellular 
proliferation in multiple cell types including HEK293 and vascular smooth muscle cells 
(Cidad et al., 2010, 2012; Cheong et al., 2011; Jimenez-Perez et al., 2016). Kv1.3 
channels can be found on the plasma membrane of cells, but have also been identified 
in intracellular locations, including the IMM (Szabo et al., 2005; Bednarczyk et al., 
2010; Cheng, Debska-Vielhaber and Siemen, 2010; Mattarei et al., 2018). Szabo and 
colleagues proposed that that mitochondrial and plasma membrane Kv1.3 channels 
may have distinct effects on cell function, in that plasma membrane channels regulate 
the membrane potential, proliferation and maturation of T lymphocytes, whilst IMM 
channels regulate apoptosis (Szabo et al., 2005; Szabó et al., 2008). Using the unique 
properties of several pharmacological Kv1.3 channel inhibitors, the distinct function of 
Kv1.3 channels localised to either intracellular or extracellular-facing plasma 
membrane locations can be probed (Leanza et al., 2012). The sea anemone toxin ShK 
and its analogues are highly potent and specific inhibitors of plasma membrane Kv1.3 
(Kalman et al., 1998; Norton, Pennington and Wulff, 2004; Rashid et al., 2013; 
Upadhyay et al., 2013). These toxins cannot enter the cell but bind to the outer 
vestibule of the Kv1.3 channel in the plasma membrane, blocking the external 
entrance to the channel’s pore. In contrast, 5-(4-phenoxybutoxy) psoralen (PAP-1), a 
member of the psoralen family of plant derived Kv1.3 inhibitors, can diffuse across the 
plasma membrane. PAP-1  can, therefore, inhibit intracellular Kv1.3 channels, and 
functions by binding to residues that become accessible when the Kv1.3 channel is in 
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its c-type inactivated state (Schmitz et al., 2005). Once bound, PAP-1 causes a 
conformational change in the protein structure which prevents the channel from 
returning to its active state, inhibiting K+ flow through the channel. PAP-1 non-
specifically inhibits intracellular Kv1.3 channels, including those located at the cis-
Golgi, nucleus and the mitochondria (Rasmusson et al., 1998) (Hoshi and Armstrong, 
2013). However, PAP-1 derivates can be bound to triphenyl phosphonium (TPP) 
lipophilic cation to-target the inhibitor to the mitochondria forming PAPTP (Leanza et 
al., 2017). The PAPTP conjugate is positively charged and  is attracted to the negatively 
charged mitochondrial membrane (Leanza et al., 2012, 2017; Mattarei et al., 2018).  
 
The role of Kv1.3 in physiological mitochondrial function has thus far received little 
attention (Khanna et al., 2001). In Chapter Three, Kv1.3 overexpressing HEK293 cells 
were shown to have increased rates of both cellular proliferation and mitochondrial 
respiration. In addition, Kv1.3 was confirmed to localise to the mitochondrial network 
in both HEK293 and HSVSMCs. The development of pharmacological tools, such as Shk, 
PAP-1 and PAP-1-TPP (PAPTP) facilitate the investigation of the extracellular, 
intracellular and mitochondrial-specific roles of Kv1.3 channels, respectively.  
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4.2 Aims and Objectives 
 
This chapter aimed to investigate and characterise the distinct role of plasma 
membrane and mitochondrial Kv1.3 channels in cellular proliferation and 
mitochondrial respiration. To achieve this aim a key set of objectives were designed: 
 
1) To investigate the effect of intracellular Kv1.3 inhibition using PAP-1 on the cellular 
proliferation of HEK293 and HSVSMCs. 
 
2) To determine the effect of plasma membrane Kv1.3 channel inhibition using Shk on 
cellular proliferation. 
 
3) To use Shk, PAP-1 and PAPTP to characterise the effect of plasma membrane, 
intracellular and mitochondrial-specific Kv1.3 channel inhibition, respectively, on 
cellular respiration in HEK293 cells. 
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4.3 Results 
 
4.3.1 Inhibition of intracellular Kv1.3 channels with PAP-1 reduces proliferation of 
HEK293/Kv1.3 cells at low concentrations. 
 
PAP-1 is a plasma membrane-permeable and highly specific inhibitor of the Kv1.3 
channel (Schmitz et al., 2005). In Chapter Three HEK293/Kv1.3 cells were observed to 
have an increased rate of proliferation compared to WT HEK293 cells. Therefore, the 
effect of PAP-1 Kv1.3 channel inhibition on the proliferation of WT HEK293 cells (Figure 
4.1) and HEK293/Kv1.3 (Figure 4.2). PAP-1, in the concentration range 0.1nM to 30nM, 
had no effect on the proliferation of WT HEK293 cells (Figure 4.1A). In HEK293/Kv1.3 
cells there was a trend for a reduction in proliferation with concentrations of PAP-1 
between 0.3nM and 3nM (Figure 4.2A). Day 3 count for cells treated with 1nM PAP-1 
was 54% of the mean count for untreated control cells. However, this reduction was 
not significant by ANOVA, likely due to a high degree of variation in the controls. The 
WT HEK293 and HEK293/Kv1.3 cells were counted using an automated cell counter, 
and Trypan Blue was used to assess cell viability. PAP-1 had no effect on WT HEK293 or 
HEK293/Kv1.3 cell viability assessed using a cell count of detached cells in the 
proliferation assay media (Figures 4.1B and 4.2B, respectively) or Trypan Blue staining 
of HEK293/Kv1.3 cells (Figure 4.2C). This confirms the trend for decreased proliferation 
with lower PAP-1 concentrations was not due to cell death.  
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Figure 4.1 Proliferation of WT HEK293 cells is unaffected by PAP-1. A. Dose response 
curve of the effect of PAP-1 (0.1nM – 30nM) on WT HEK293 cell proliferation after 3 days 
of growth. Data is expressed as the raw cell counts. Wells were counted in triplicate, and 
the averages from each repeat collected and displayed on the graphs with the SEM. One-
way ANOVA was carried out and the results were not significant p>0.05. Day 0, Day 3 
Control, 10nM and 30nM counts (n=5), 0.1nM-3nM (n=3). B. Dead cell counts for WT 
HEK293 cells treated with PAP-1 (0.1nM-1µM). ROUT analysis performed, and an outlier 
removed. Control, 10nM and 30nM counts (n=5), 0.1nM-3nM (n=1) and 0.1µM-1 µM 
(n=4). 
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Figure 4.2 Proliferation of HEK293/Kv1.3 cells trends towards a reduction at low nanomolar concentrations of PAP-1. A. Dose response curve showing the 
effect of PAP-1 (0.1nM-30nM) on HEK293/Kv1.3 cell proliferation after 3 days of growth. Day 0, Day 3 Control, 10nM and 30nM counts (n=5), 0.1nM-3nM 
(n=3). Data is expressed as the raw cell counts. Wells were counted in triplicate, and the averages from each repeat collected and displayed on the graphs with 
the SEM. One-way ANOVA was carried out and the results were not significant p>0.05. B. Dead cell counts for HEK293/Kv1.3 cells treated with PAP-1 (0.1nM-
1µM). ROUT analysis performed, and an outlier removed. Control and 10nM (n=5), 0.1nM, 0.3nM, 30nM and 1µM (n=3), 1nM and 3nM (n=2) and 0.1µM and 
0.3µM (n=1). C. Viability of HEK293/Kv1.3 cells treated with PAP-1 (0.1nM-1µM). Viability expressed as a percentage of alive cells. Control, 10nM and 30nM 
(n=4), 0.1nM-3nM (n=3), 0.1µM-1 µM (n=1). Data expressed as mean ± SEM and was analysed (0.1nM-30nM PAP-1) using one-way ANOVA. Results were not 
significant p>0.05.   
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To ensure that PAP-1 inhibited Kv1.3 channels, whole cell patch clamp 
electrophysiology was carried out on HEK293/Kv1.3 cells (Figure 4.3). PAP-1 reduced 
the K+ ion current in HEK293/Kv1.3 cells (Figure 4.3), however, a high concentration of 
the drug (1µM) was required to inhibit the whole cell K+ current. This concentration is 
in excess of the low nanomolar concentrations observed to inhibit proliferation. This is 
a surprising result and is not what is echoed in the literature, whereby the plasma 
membrane K+ ion currents are strongly inhibited by 0.1µM PAP-1 (Perez-Garcia, Cidad 
and Lopez-Lopez, 2018). 
 
 
 
 
 
 
 
 
 
  
Figure 4.3 PAP-1 inhibits the potassium ion current in HEK293/Kv1.3 cells. A. Percentage 
decrease in Kv1.3 current amplitude with 1µM PAP-1 (n=5). B. Whole cell voltage clamp 
trace showing inhibition of Kv1.3 current by PAP-1 (0.2µM-1 µM). C. Time course 
experiment of a single HEK293/Kv1.3 cell, with percentage decrease in Kv1.3 current 
amplitude with PAP-1 (0.2µM-1µM) plotted against time and peak current amplitude 
normalized to cell size. D. Example time-course control of a HEK293/Kv1.3 cell being held at 
-80mV for 8 minutes. Experiments were carried out by Dr M. Al-Owais, University of Leeds. 
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4.3.2 PAP-1 can reduce proliferation of HSVSMCs. 
In Chapter Three (Figures 3.9, 3.11 and 3.12), Kv1.3 channels were observed 
intracellularly and within the mitochondrial network of HEK293 and HSVSMCs. To 
assess whether the presence of these channels could affect proliferation in a clinically 
and physiologically relevant model, PAP-1 was applied to HSVSMCs during a 
proliferation assay (Figure 4.4). HSVSMCs proliferate at a slower rate than HEK293 cells 
with a high degree of inter-patient variability (Figure 4.4A and B). Therefore, a 7 day 
proliferation assay was adopted. Cell counts were made on days 0, 2, 4 and 7. The 
results of this assay on HSVSMCs isolated from three patients is shown in Figure 4.4B. 
Based on this data day 4 was assessed as a suitable time point to use for subsequent 
proliferation assays in HSVSMCs (Figure 4.4C). Low nanomolar concentrations of PAP-1 
trended towards inhibiting the proliferation of the HSVSMCs, assessed at day 4 of 
proliferation (Figure 4.4C). One-way ANOVA did not find that PAP-1 significantly 
decreased proliferation compared to Day 4 control, possibly due to the high variability 
in control counts. However, Day 3 counts of cells treated with 3-30nM PAP-1 were 
significantly lower than those treated with 1µM PAP-1. Cells were counted manually 
using Trypan Blue staining for cell death. PAP-1 did not increase Trypan Blue staining 
(Figure 4.4C), therefore effects on proliferation are unlikely to be due to cytotoxic 
effects on HSVSMCs. 
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Figure 4.4 PAP-1 inhibits HSVSM cell proliferation. A. The proliferation of HSVSM cells 
from three patients; SV1321, SV1322 and SV1318. Wells were counted in triplicate on days 
0, 2, 4 and 7. Data expressed as the mean percent increase from day 0 ± SEM. B. Mean 
proliferation data from (A). One-way ANOVA was used for statistical analysis, *** p<0.001, 
**** p<0.0001. C. The effect of PAP-1 (0.1nM-1µM) on HSVSM cell proliferation after 4 
days. Wells were counted in triplicate for each experimental repeat. Day 0, Day 4 control, 
10nM and 30nM (n=13; SV1330, SV1335, SV1336, SV1337, SV1339, SV1340, SV1341, 
SV1344, SV1349, SV1354, SV1356, SV1358 and SV1359), 0.1nM-3nM (n=5; SV1349, 
SV1354, SV1356, SV1358 and SV1359) and 0.1μM-1μM (n=8; SV1330, SV1335, SV1336, 
SV1337, SV1339, SV1340, SV1341 and SV1344). Data expressed as mean raw cell count (± 
SEM). Data analysed using ROUT analysis to remove outliers and one-way ANOVA with 
Tukey’s post hoc test, * p<0.05, *** p<0.001, **** p<0.0001. D. Dead cell counts for 
HSVSM cells with PAP-1 treatment (0.1nM-1µM) after 4 days. Control (n=7), 0.1nM-3nM 
(n=1), 10nM and 30nM (n=5), 0.1µM and 0.3µM (n=2) and 1µM (n=6). 
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4.3.3 PAP-1 decreases mitochondrial respiration in HEK293 cells. 
The Routine Respiration of HEK293/Kv1.3 cells was analysed using the O2k Oxygraph. 
This respiration rate is designated Routine 1. PAP-1 was added to the respirometry 
chambers and the respiration rate measured. This respiration rate is designated 
Routine 2. PAP-1 decreased the O2 consumption of HEK293/Kv1.3 cells (Figure 4.5).  
The addition of the OXPHOS and electron transport chain inhibitors oligomycin (ATP 
synthase inhibitor) and FCCP (OXPHOS uncoupler) had very little effect on the 
respiratory function of the cells after treatment with PAP-1. Addition of rotenone 
(complex I inhibitor) and antimycin A (complex III inhibitor) caused an initial, rapid 
decrease in O2 consumption, which led O2 consumption to fall well below zero, as 
indicated by the dotted downward line on the trace in Figure 4.5. However, the cells 
recovered very quickly and their O2 consumption always stabilised above zero. The 
resultant residual O2 consumption (ROX) was due to non-mitochondrial sources. The 
decrease in O2 consumption below zero with rotenone and antimycin A occurred in all 
HEK293 cells tested in the respirometer, and ROX was always measured once O2 
stabilised above zero. The decrease in O2 consumption below zero may have been due 
to the larger volume of rotenone and antimycin being added to chambers (5µl) 
compared to oligomycin and FCCP (1µl), which momentarily disrupted the O2 
consumption measurements. 
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Strikingly, the severe increase in cellular O2 consumption with FCCP (Figure 4.6A) was 
inhibited in PAP-1 treated cells (Figure 4.6B and C) suggesting the inhibitory effect of 
PAP-1 is due to inhibition of the ETS. PAP-1 decreases routine respiration by 60% in 
HEK293/Kv1.3 cells when respiration is uncorrected for ROX (Figure 4.6B), and by 90% 
when respiration is corrected for ROX (Figure 4.6C). Moreover PAP-1 significantly 
decreased ATP turnover (Figure 4.7) and spare respiratory capacity in HEK293/Kv1.3 
cells (Figure 4.8).  
 
 
Figure 4.5 PAP-1 can reduce oxygen consumption of HEK293/Kv1.3 cells. An example 
trace showing the O2 consumption (pmol per million cells per second, pmol/(s*Mill)) in 
HEK293/Kv1.3 cells treated with PAP-1 (final concentration 200nM). Orange arrows 
represent the points at which PAP-1 was added to the chamber. Black arrows represent the 
points at which measurements were taken; R1=Routine Respiration, R2=Routine Respiration 
after PAP-1 treatment, L=Leak Respiration, E=ETS (electron transport system) uncoupling 
and ROX=residual O2 consumption.  
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Figure 4.6 PAP-1 reduces oxidative phosphorylation in HEK293/Kv1.3 cells. A. Oxygen (O2) 
consumption (pmol per second per million cells, pmol/(s*Mill)) in total HEK293/Kv1.3 cells 
(n=38). O2 consumption was measured at four points; Routine 1=Routine Respiration, 
Leak=Leak Respiration, ETS=electron transport system uncoupling and ROX=residual O2 
consumption. Data expressed as the mean O2 consumption ± SEM. Data analysed using 
one-way ANOVA with Tukeys multiple comparison test, **** p<0.0001. B. O2 consumption 
(pmol per second per million cells, pmol/(s*Mill)) in total HEK293/Kv1.3 cells treated with 
100-300nM PAP-1 (n=6). Black arrow represents PAP-1 addition to the chamber. O2 
consumption measured at five points; Routine 1=Routine Respiration before PAP-1 
addition, Routine 2=Routine Respiration after PAP-1 addition, Leak, ETS and ROX as in (A). 
Data expressed as the mean O2 consumption ± SEM. Data analysed using one-way ANOVA 
with Tukeys multiple comparison test, ** p<0.01, *** p<0.001. There were no significant 
differences between Routine 2, Leak, ETS and ROX. C. Data in (B) corrected for residual O2 
consumption (ROX). Data analysed using one-way ANOVA with Tukey’s multiple 
comparison test, *** p<0.001, **** p<0.0001. 
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Figure 4.7 Effect of PAP-1 on ATP Turnover Rate of HEK293/Kv1.3 cells. ATP turnover rate 
in total HEK293/Kv1.3 cells (n=38) and in HEK293/Kv1.3 cells (n=6) treated with PAP-1 (100-
300nM). ATP turnover is the difference between Routine and Leak Respiration. Data 
expressed as mean O2 consumption (pmol/(s*Mill)) ± SEM. Data analysed using Student’s t-
test, **** p<0.0001.  
 
Figure 4.8 Effect of PAP-1 on Spare Respiratory Capacity of HEK293/Kv1.3 cells. Spare 
Respiratory Capacity (SRC) in total HEK293/Kv1.3 cells (n=38) and in HEK293/Kv1.3 cells 
treated with PAP-1 (n=6) (100nM-300nM). SRC is the difference between Routine 
Respiration and maximum uncoupling of the electron transport system. Data expressed as 
mean O2 consumption (pmol/(s*Mill)) ± SEM. Data analysed using Student’s t-test, **** 
p<0.0001. 
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 4.3.4 WT HEK293 respiration was decreased by PAP-1 
WT HEK293 cell respiration was also affected by acute administration of PAP-1 (100-
200nM). An example experiment trace is shown in Figure 4.9. 100nM PAP-1 caused an 
initial rapid reduction in WT HEK293 O2 consumption, which then plateaued, and then 
reduces again following addition of another 100nM PAP-1. As was the case in 
HEK293/Kv1.3 cells, addition of oligomycin (before Leak Respiration (L) was measured) 
and FCCP (before ETS Respiration (ETS) was measured) had little effect on the 
respiration of WT HEK293 cells which had been treated with PAP-1. Again, addition of 
rotenone and antimycin A (before ROX was measured) caused a severe reduction in O2 
consumption below zero, as shown by the downward dotted trace line (between ETS 
and ROX measurements), which rapidly recovered and stabilised above zero.  
 
  
Figure 4.9 PAP-1 can reduce oxygen consumption of WT HEK293 cells. An example trace 
showing the O2 consumption (pmol per million cells per second, pmol/(s*Mill)) in WT 
HEK293 cells treated with PAP-1 (final concentration 200nM). Orange arrows represent 
the points at which PAP-1 was added to the chamber. Black arrows represent the points at 
which measurements were taken; R1=Routine Respiration, R2=Routine Respiration after 
PAP-1 treatment, L=Leak Respiration, E=ETS (electron transport system) uncoupling and 
ROX=residual O2 consumption.  
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Figure 4.10 shows all the respirometry data for PAP-1 treated WT HEK293 cells. The 
concentrations of PAP-1 used on WT HEK293 cells were between 100-200nM. Once 
again, the severe increase in cellular O2 consumption with FCCP (Figure 4.10A) was 
inhibited in PAP-1 treated cells (Figure 4.10B and C), supporting the idea that the 
inhibitory effect of PAP-1 is due to inhibition of the ETS. PAP-1 decreases Routine 
Respiration by 78% in WT HEK293 cells when respiration is uncorrected for ROX (Figure 
4.10B), and by 85% when respiration is corrected for ROX (Figure 4.10C). Due to the 
variation in PAP-1 concentrations on WT HEK293 cells (100-200nM), and the variation 
between the concentrations used on HEK293/Kv1.3 cells(100nM-300nM), no direct 
comparisons can be made between the effect of PAP-1 on the two cells types. All that 
can be concluded is that inhibition of Kv1.3 channels with PAP-1 is able to reduce 
respiration in HEK293 cells. In addition, PAP-1 was able to reduce ATP turnover (Figure 
4.11) and SRC (Figure 4.12) in WT HEK293 cells. However, due to the severity of the 
response to PAP-1 in HEK293 cell respiration, and the lack of a HEK293/Kv1.3 cell-
specific effect, these results raise the possibility that PAP-1 has off target effects on 
respiration, rather than due to targeted inhibition of mitochondrial Kv1.3 channels. 
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Figure 4.10 PAP-1 can reduce Routine Respiration in WT HEK293 cells. A. Oxygen (O2) 
consumption (pmol per million cells per second, pmol/(s*Mill)) in total WT HEK293 cells 
(n=27). O2 consumption was measured at four points; Routine1=Routine Respiration, 
Leak=Leak Respiration, ETS=electron transport system uncoupling and ROX=residual O2 
consumption. Data expressed as the mean O2 consumption ± SEM. Data analysed using 
one-way ANOVA with Tukeys multiple comparison test, ** p<0.01, **** p<0.0001. B. O2 
consumption (pmol/(s*Mill) in total WT HEK293 cells treated with 100-200nM PAP-1 
(n=3). Black arrow represents PAP-1 addition to the chamber. O2 flow measured at five 
points; Routine1=Routine Respiration before PAP-1 addition, Routine2=Routine 
Respiration after PAP-1 addition, Leak, ETS and ROX as in (A). Data expressed as the mean 
O2 consumption ± SEM. Data analysed using one-way ANOVA with Tukeys multiple 
comparison test, *** p<0.001. There were no significant differences between Routine 2, 
Leak, ETS and ROX. C. Data for (B) corrected for ROX. Data analysed using one-way ANOVA 
with Tukeys multiple comparison test, *** p<0.001.  
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Figure 4.12 PAP-1 reduces spare respiratory capacity of WT HEK293 cells. Spare 
Respiratory Capacity (SRC) in control WT HEK293 cells (left column, n=27) and PAP-1 
treated WT HEK293 cells (right column, n=3). SRC is the difference between maximum ETS 
capacity and Routine Respiration. Data was analysed using Student’s t-tests, *** p<0.001. 
 
Figure 4.11 PAP-1 reduces ATP turnover of WT HEK293 cells. ATP turnover in control WT 
HEK293 cells (left column, n=27) and in PAP-1 treated WT HEK293 cells (right column, n=3). 
ATP turnover is the difference between Routine Respiration and Leak Respiration. Data 
analysed by Student’s t-test and was significant, *** p>0.001.  
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4.3.5 ShK-Dap22 inhibits plasma membrane potassium currents but does not 
decrease proliferation in HEK293/Kv1.3 cells. 
ShK-Dap22 is an analogue of  the potent inhibitor of Kv1.3 channels, ShK, derived from 
the sea anemone Stichodactyla Helianthus (Rashid et al., 2013). It cannot permeate 
the cell’s plasma membrane, and therefore cannot bind to intracellular Kv1.3 channels. 
The EC50 of ShK-Dap22 is 23pM for inhibition of Kv1.3 currents. A dose-response assay 
was used to assess the effect of ShK-Dap22 (1-200pM) on the proliferation of WT 
HEK293 (Figure 4.13A) and HEK293/Kv1.3 cells (Figure 4.14A). ShK-Dap22 did not affect 
the proliferation of WT HEK293 (Figure 4.13A) or HEK293/Kv1.3 cells (Figure 4.14A). 
ShK-Dap22 did not induce cell death in WT HEK293 cells, as assessed by counting 
detached cells in the culture media of the wells in the proliferation assay (Figure 4.13B) 
and by Trypan Blue viability of cells (Figure 4.13C). ShK-Dap22 did have a cytotoxic 
effect on HEK293/Kv1.3 cells, as on one occasion there was an increase in the floating 
cells in the media of the well of the proliferation assay with 50pM ShK-Dap22 (Figure 
4.14B). As this was not sustained and/or increased with further increases in ShK-Dap22 
concentration, it is likely that the effect on cell death was not associated with the 
concentration of the toxin. In addition, Trypan Blue staining of HEK293/Kv1.3 cells did 
not detect any cytotoxic effects of ShK-Dap22 (Figure 4.14C). This is supported by the 
fact that across all five repeats of the ShK-Dap22 dose response assay, there was no 
consistent and significant decrease in the cell counts with 50pM ShK-Dap22 (Figure 
4.14A). 
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Figure 4.13 ShK-Dap22 does not affect the proliferation of  WT HEK293 cells. A. Dose response curve of WT HEK293 cells treated with ShK-Dap22 (1pM-
200pM) (n=3). Black bar = Day 0 counts, grey bars = Day 3 counts. Data is expressed as the mean raw cell counts ± SEM, wells were counted in triplicate. B. 
Viability counts for WT HEK293 cells treated with ShK-Dap22 (n=1). Detached cells in the media were stained with Trypan Blue and counted using a manual 
haemocytometer. C. Percentage of viable WT HEK293 cells during counting, calculated on the automated cell counter by trypan blue staining (n=1). 
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Figure 4.14 ShK-Dap22 does not affect the proliferation of HEK293/Kv1.3 cells. A. Dose response curve of HEK293/Kv1.3 cells treated with ShK-Dap22 (1pM-
200pM) (n=5). Black bar = Day 0 counts, grey bars = Day 3 counts. Data is expressed as the mean raw cell counts ± SEM, wells were counted in triplicate. B. 
Viability counts for HEK293/Kv1.3 cells treated with ShK-Dap22, as assessed by counting dead cells floating in the media of the wells (n=1).  C. Percentage of 
viable HEK293/Kv1.3 cells during counting, calculated on the automated cell counter by Trypan Blue staining (n=5 for control, 50pM and 100pM, n=3 for 1pM, 
150pM and 200pM. Data expressed as the mean percentage viability ± SEM. Data was analysed using a one-way ANOVA Test (p>0.05).   
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Electrophysiology was used to confirm that ShK-Dap22 inhibited the plasma 
membrane Kv1.3 channels in HEK293/Kv1.3 cells (Figure 4.15). ShK-Dap22 (80pM) 
reduced the potassium currents in HEK293/Kv1.3 cells (Figure 4.15).  
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4.15 ShK-Dap22 inhibits the potassium ion current in HEK293/Kv1.3 cells. A. 
Percentage decrease in Kv1.3 mean current amplitude with 80pM ShK-Dap22 (n=5 ± SEM). 
B. Whole cell voltage clamp trace showing inhibition of Kv1.3 current by ShK-Dap22 (20pM-
80pM). C. Time course experiment of a single HEK293/Kv1.3 cell, with percentage decrease 
in Kv1.3 current amplitude with ShK-Dap22 (20pM and 80pM) plotted against time and 
peak current normalised to cell size. D. Example time-course control of a HEK293/Kv1.3 cell 
being held at -80mV for 8 minutes. Experiments were carried out by Dr M. Al-Owais, 
University of Leeds 
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4.3.6 ShK-Dap22 has no effect on the respiration of HEK293/Kv1.3 cells. 
HEK293/Kv1.3 cells were treated with 500pM ShK-Dap22 in an OROBOROS Oxygraph-
2K High Resolution Respirometer (Figure 4.16). 500pM was the final concentration 
tested as ShK-Dap22 was titrated periodically throughout the experiment in steps of 
50pM. The concentration was increased to determine a concentration-dependent 
response in the respiration rate. No response to 500pM ShK-Dap22 was observed in 
HEK293/Kv1.3 cells across Routine, Leak, ETS or ROX Respiration stages (routine, leak, 
ETS or ROX). 
  
Figure 4.16 ShK-Dap22 has no effect on the respiration of HEK293/Kv1.3 cells. Respiration 
(O2 consumption, pmol per million cells per second (pmol/s*Mill)) of HEK293/Kv1.3 cells 
treated with 500pM ShK-Dap22 (white bars). Black bars = untreated control data. Data is 
expressed as the mean O2 consumption at Routine, Leak, ETS and ROX Respiration ± SEM 
(n=3). Data was analysed using Student’s t-tests for Routine, Leak, ETS and ROX. No 
significant difference was observed between drug treated and control cells (p>0.05). 
Experiments were carried out by Dr J. Boyle. 
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4.3.7 A mitochondrially targeted Kv1.3 channel inhibitor decreases HEK293/Kv1.3 cell 
proliferation. 
Next, the role of mitochondrial Kv1.3 channels as regulators of cellular proliferation 
was investigated. A mitochondrially targeted, PAP-1 derivative, PAPTP was synthesised 
by Dr Robin Bon at Leeds University, following the protocol provided by Leanza et al., 
(2017) (see Methods Section 4.11) 
A dose-response assay was set up to assess the effect of PAPTP (3nM-100nM) on 
HEK293/Kv1.3 cell proliferation (Figure 4.17). PAPTP did not affect proliferation in WT 
HEK293 cells (Figure 4.17A) and had no significant effects on cell viability as 
determined by Trypan Blue staining (Figure 4.17B). 100nM PAPTP had a tendency to 
reduce HEK293/Kv1.3 cell proliferation (Figure 4.17C) although this was not significant 
by ANOVA. The decrease in proliferation was not due to cytotoxic effects of 100nM 
PAPTP on HEK293/Kv1.3 cells (Figure 4.17D), again determined by a Trypan Blue 
viability assay. The total reduction in proliferation by 100nM PAPTP was calculated as 
28.98% of control proliferation (Figure 4.18A), and this was significant when analysed 
with Student’s t-test. In addition, the effect of 100nM PAPTP on HEK293/Kv1.3 cells 
may have been underestimated, as the potency of PAPTP reduced with experimental 
repeat (Figure 4.18B). 
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  Figure 4.17 PAPTP tends to reduce proliferation in HEK293/Kv1.3 cells at 100nM. A. Dose 
response proliferation assay of WT HEK293 cells treated with PAPTP (3nM-100nM). Black 
bar = Day 0 counts, grey bars = Day 3 counts, (n = 3).  Statistical analysis was carried out 
using a one-way ANOVA (p>0.05). Wells were counted in triplicate. Raw cell counts 
expressed on graph as mean ± SEM. B. Percentage viability of WT HEK293 cells, as assessed 
by trypan blue staining in the automated TC10 cell counter (n=3). Data expressed as the 
mean percentage viability ± SEM. Statistical analysis was carried out using one-way ANOVA 
(p>0.05). C. Dose response proliferation assay of HEK293/Kv1.3 cells treated with PAPTP 
(3nM-100nM). Black bar = Day 0 counts, grey bars = Day 3 counts, (n = 4).  Statistical 
analysis was carried out using a one-way ANOVA (p>0.05). Wells were counted in triplicate. 
Cell counts expressed on graph as mean ± SEM. D. Percentage viability of HEK293/Kv1.3 
cells, as assessed by trypan blue staining in the automated TC10 cell counter (n=4). Data 
expressed as the mean percentage viability ± SEM. Statistical analysis was carried out using 
one-way ANOVA (p>0.05).  
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Figure 4.18 100nM PAPTP can reduce HEK293/Kv1.3 proliferation despite losing potency. 
A. 100nM PAPTP decreased the proliferation of HEK293/Kv1.3 cells (n=4). Data is from 
Figure 4.17c displayed as mean percentage change from Day 3 control proliferation ± SEM.  
Student’s t-tests were used for analysis (** p<0.01). B. PAPTP lost its potency across the 
experimental repeats (1-4). Black bars = HEK293/Kv1.3 control day 3 counts. Grey bars = 
HEK293/Kv1.3 PAPTP treated (100nM) day 3 counts. 
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4.3.8 100nM PAPTP can reduce respiration in HEK293/Kv1.3 cells. 
The effect of mitochondrially targeted Kv1.3 channel inhibition on respiration rate 
using 100nM PAPTP was examined in WT HEK293 and HEK293/Kv1.3 cells (Figure 
4.19). In HEK293/Kv1.3 cells 100nM PAPTP reduced Routine Respiration, increased 
Leak Respiration and reduced ETS Respiration (Figure 4.19A). In WT HEK293 cells, 
100nM PAPTP did not affect Routine or ETS Respiration rates but did increase the rate 
of Leak Respiration (Figure 4.19B).  
In these experiments, cells were incubated for 30 minutes (37°C; 95% air, 5% CO2) in 
serum free cell suspension prior to respirometry, to facilitate PAPTP intracellular 
accumulation and mitochondrial targeting to Kv1.3 channels. This pre-treatment phase 
may have reduced the respiration rate of the cells (compared to Figure 3.5, Chapter 
Three). This reduction in respiration is apparent for example in Figure 4.19, where 
there is little difference between the Routine Respiration O2 consumption in 
HEK293/Kv1.3 and WT HEK293 cells. The reduction in O2 consumption during this pre-
treatment phase was disproportionate between HEK293/Kv1.3 and WT HEK293 cells 
and may have reduced the response to 100nM PAPTP in HEK293/Kv1.3. cells. 
 
 
 
  
Figure 4.19 The effect of 100nM PAPTP on HEK293/Kv1.3 respiration. A. The effect of 
100nM PAPTP on Routine, Leak and ETS Respiration in HEK293/Kv1.3 cells (n=5). Data is 
corrected for residual O2 consumption (ROX). B. The effect of 100nM PAPTP on Routine, 
Leak and ETS Respiration in WT HEK293 cells (n=4). Data is corrected for ROX and displayed 
as the mean ± SEM. Data was analysed using Student’s t-tests on routine, leak and ETS 
respiration, * p<0.05. 
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PAPTP (100nM) reduced ATP turnover rate in HEK293/Kv1.3 cells by 45.6%, compared 
to a 22.1% in WT HEK293 cells (Figure 4.20). Therefore, PAPTP was twice as efficient at 
reducing ATP turnover in HEK293/Kv1.3 cells. This was likely to do with the fact that 
100nM PAPTP significantly reduced Routine Respiration in HEK293/Kv1.3 cells but not 
in WT HEK293 cells (Figure 4.19). In addition, 100nM PAPTP reduced SRC in 
HEK293/Kv1.3 cells (Figure 4.21A), likely due to the reductions seen in Routine 
Respiration and ETS Respiration (Figure 4.19), but not in WT HEK293 cells (Figure 
4.21B). 
 
 
  
Figure 4.20 100nM PAPTP reduced ATP turnover in both HEK293/Kv1.3 cells and WT 
HEK293 cells. ATP turnover was calculated by finding the difference between Routine 
Respiration and Leak Respiration (Figure 4.19). A. PAPTP reduced HEK293/Kv1.3 cell ATP 
turnover by 45.55% (n=6). B. PAPTP reduced WT HEK293 cell ATP turnover by 22.07% 
(n=4).  Data corrected for residual O2 consumption and expressed as a percentage of 
control ± SEM. Data analysis carried out by Student’s t-tests (** p<0.01, *** p<0.001).  
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Figure 4.21 100nM PAPTP reduced spare respiratory capacity in HEK293/Kv1.3 cells. 
Spare Respiratory Capacity (SRC) was calculated by finding the difference between ETS 
Respiration and Routine Respiration (Figure 4.19). A. PAPTP reduced HEK293/Kv1.3 cell SRC 
by 8% (n=6). B. PAPTP had no significant effect on WT HEK293 cell SRC (n=4). Data 
corrected for residual O2 consumption and expressed as a percentage of control ± SEM. 
Data analysis carried out by Student’s t-tests (* p<0.05).  
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4.4 Discussion 
 
This chapter confirms that the Kv1.3 inhibitor PAP-1 reduces cellular proliferation in 
HEK293 cells, as observed in other cells including VSMCs (Cidad et al., 2010, 2012; 
Cheong et al., 2011; Jimenez-Perez et al., 2016). Although PAP-1 did not affect 
proliferation of WT HEK293 cells, the inhibitor in the low nanomolar range reduced 
proliferation of HEK293/Kv1.3 cells. Interestingly, the effect of PAP-1 on HEK293/Kv1.3 
cell proliferation decreased as the concentrations of the inhibitor increased from 3nM. 
However, micromolar concentrations of PAP-1 were required to inhibit the membrane 
K+ currents of HEK293/Kv1.3 cells in electrophysiology experiments. These findings 
may suggest that K+ flux through the Kv1.3 channel in the plasma membrane is not the 
primary inducer of cell proliferation. This is in agreement with recent work by Cidad et 
al., in which they identify ion flux independent mechanisms of proliferation stimulated 
by Kv1.3 channels in HEK293 cells (Cidad et al., 2012; Jimenez-Perez et al., 2016). 
Another possibility is that at low concentrations, PAP-1 (0.3nM and 1nM) may pass 
through the plasma membrane and inhibit Kv1.3 channels at intracellular locations 
without complete inhibition of plasma membrane Kv1.3 channels. Previous work has 
shown that Kv1.3 channels at the nucleus could also be key moderators of cellular 
proliferation, by regulating the gene expression of transcription factors including CREB 
and c-Fos (Jang et al., 2015). Nuclear Kv1.3 channels may also regulate ribosome 
biogenesis, essential for protein synthesis that is essential for cellular proliferation 
(Jang et al., 2015). In addition, Kv1.3 in the cis-Golgi membrane may control it’s 
function of organising and distributing cell proteins in rat astrocytes, thus potentially 
playing a role in cell proliferation (Zhu, Yan and Thornhill, 2014). However, this thesis 
identifies a role for mitochondrial Kv1.3 channels in the regulation of cellular 
proliferation. 
Strangely, the effect of PAP-1 on cellular proliferation reduced at concentrations above 
low nanomolar in HEK293/Kv1.3 and HSVSMCs. Higher concentrations of PAP-1 may 
induce counter-regulatory mechanisms which reduce the anti-proliferative effects of 
the inhibitor. Cell volume is a known regulator of the cell cycle and can be modulated 
by K+ ions (Deutsch and Lee, 1988). Interestingly, there exists a bell shaped relationship 
between cell volume and proliferation/progression of cell cycle (Perez-Garcia, Cidad 
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and Lopez-Lopez, 2018). When K+ efflux is inhibited i.e. by Kv1.3 channel inhibition, cell 
volume may increase as a higher intracellular concentration of K+ ions generates a 
chemiosmotic gradient driving water influx (Dubois and Rouzaire-Dubois, 2004). 
Therefore, at concentrations of PAP-1 above 3nM, the blockade of Kv1.3 channels may 
alter the water balance of the cell. A high cell volume may either reduce the PAP-1 
inhibitory effect on proliferation or may stimulate the cell to proliferate. Interestingly, 
much higher concentrations of PAP-1 (100-300nM) was needed to reduce respiration 
in both WT HEK293 and HEK293/Kv1.3 cells. As found in Chapter Three, WT HEK293 
cells do express Kv1.3 channels, and evidence suggested mitochondrial co-localisation 
in these cells as well as HEK293/Kv1.3 cells. PAP-1 inhibition of respiration in HEK293 
cells suggests that the Kv1.3 channel regulates physiological respiration in these cells. 
The fact that PAP-1 had no effect on WT HEK293 cell proliferation, but can inhibit 
respiration, suggests that proliferation and respiration may be independently 
regulated by Kv1.3 channels. In addition, the fact that low nanomolar concentrations 
of PAP-1 inhibited HEK293/Kv1.3 proliferation, but high nanomolar concentrations 
were needed to supress HEK293/Kv1.3 respiration, may also indicate independent 
effects of Kv1.3 on these processes. However, inhibition of Kv1.3 by PAP-1 in 
HEK293/Kv1.3 and WT HEK293 cells reduced routine respiration, maximal uncoupled 
ETS respiration, ATP turnover and spare respiratory capacity, which would almost 
definitely reduce the energy available for proliferation in these cells. The severity of 
the inhibition of respiration by PAP-1 in WT HEK293 and HEK293/Kv1.3 cells may 
suggest that PAP-1 is having off target effects on respiration, not due to inhibition of 
Kv1.3 or mitochondrial Kv1.3 channels. These results are concerning and must be 
further investigated due to the large body of research that uses PAP-1 for treatment of 
various conditions (Wulff et el., 2009). Whether these effects on proliferation and 
respiration were specifically a result of mitochondrial Kv1.3 inhibition was then 
investigated. Initially, plasma membrane Kv1.3 channels were inhibited using ShK-
Dap22, an analogue of ShK isolated from the sea anemone Stichodactyla helianthus. In 
1995, Pennington and colleagues first isolated and synthesised a biologically active 
form of ShK toxin, that was capable of blocking K+ channels in vitro (Pennington et al., 
1995). However, at sub-nanomolar concentrations this toxin also blocked Kv1.1, 1.4 
and 1.6. Three years later they published their work on enhancing the specificity of the 
drug (Kalman et al., 1998). They used mutant cycle analysis and site directed 
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mutagenesis to gain more information on how the ShK toxin bound to its K+ channel 
target. In doing so, they identified a critical Lys 22 that was important for binding, and 
replaced it with a positively charged, non-natural amino acid, diamino propionic acid 
(ShK-Dap22) which increased the toxins specificity for Kv1.3 channels.  
Although ShK-Dap22 displayed extremely potent effects on the whole cell K+ currents 
of HEK293/Kv1.3 cells, it did not reduce proliferation of the cells, suggesting that 
intracellular but not extracellular Kv1.3 channels contribute to the proliferative 
phenotype. ShK analogues have  previously been observed to reduce cellular 
proliferation in lymphocytes and other immune cells (Hu et al., 2013; Chang et al., 
2015). However, in immune cells the membrane potential (regulated by Kv channels) is 
the main determinant of proliferation stimulation via modulation of Ca2+ influx, which 
is crucial to activation of immune cells (Perez-Garcia, Cidad and Lopez-Lopez, 2018). 
Interestingly, Margatoxin (MgTx), another membrane impermeable Kv1.3 channel 
inhibitor, was found to inhibit smooth muscle migration and proliferation in human 
and mouse smooth muscle cells (Cheong et al., 2011). MgTx reduced the migration of 
HSVSMCs by 40%, therefore targeting both intracellular and plasma membrane Kv1.3 
channels may further inhibit proliferation in VSMCs. Cheong and colleagues suggested 
the reduction in proliferation and migration by Kv1.3 channel inhibition was primarily 
driven by a reduction in Ca2+ entry. However this work may be confounded by the 
reported inhibitory action of MgTx on other Kv channels (Bartok et al., 2014), such as 
Kv1.2, whose inhibition has been found to reduce proliferation of rat mesenchymal 
stem cells (Deng et al., 2007). ShK-Dap22 also did not affect cellular respiration in 
either WT HEK293 or HEK293/Kv1.3 cells, suggesting that plasma membrane Kv1.3 
channels are unlikely to be involved in the altered metabolic phenotype in 
HEK293/Kv1.3 cells. Therefore, depolarisation of the plasma membrane by PAP-1 is 
unlikely to have altered cation entry, specifically Ca2+ entry into the cell, causing or 
contributing to the reduction in respiration by the inhibitor. More specifically, these 
results suggest that intracellular Kv1.3 channels are likely to have a role in the 
regulation of respiration, particularly OXPHOS. It is of note that upregulation of Kv1.3 
expression would lead to increased plasma membrane, mitochondrial, cis-Golgi and 
nuclear levels of the channel and therefore may alter multiple signalling pathways that 
could contribute to the increased proliferation. Elucidating the Kv1.3-mediated 
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signalling pathways with the greatest effect on proliferation would have significant 
benefit for the development of targeted, highly specific and safe future treatments for 
Kv1.3-induced proliferative disorders of vascular smooth muscle cells.  
A mitochondrially-targeted Kv1.3 inhibitor, PAPTP, was then used to investigate the 
role of mitochondrial Kv1.3 in cellular proliferation and respiration. PAPTP had 
differential effects on WT HEK293 cells and HEK293/Kv1.3 cell proliferation. In WT 
HEK293 cells, PAPTP had no effect on proliferation whereas in HEK293/Kv1.3 cells 
there was a trend for PAPTP to decrease proliferation. PAPTP at 100nM did not reduce 
cell viability or exhibit cytotoxic effects in HEK293/Kv1.3 or WT HEK293 cells, but this 
concentration did significantly reduce proliferation when normalised to the final Day 3 
control count in HEK293/Kv1.3 cells. This suggests that mitochondrial Kv1.3 plays a role 
in the proliferation in HEK293 cells. However, this is in contrast to other prominent 
work in the field. For example, Cidad et al., found that the shuttling of Kv1.3 channels 
to the plasma membrane was necessary to induce proliferation in HEK293 cells (Cidad 
et al., 2012). In addition, Leanza and colleagues propose that mitochondrial Kv1.3 
regulates apoptosis in cancer cells (Leanza et al., 2012, 2017; Luigi Leanza et al., 2013; 
Venturini et al., 2017; Mattarei et al., 2018). However, in these studies, concentrations 
of Kv1.3 and mitochondrial Kv1.3 inhibitors were far higher (between 1-20µM) than 
the concentrations used in this study (3-100nM), which may have accounted for the 
difference in cytotoxicity. In HEK293/Kv1.3 cells PAPTP significantly reduced Routine 
Respiration and Maximal Uncoupled Respiration in response to FCCP, and significantly 
increased Leak Respiration. In WT HEK293 cells, 100nM PAPTP significantly increased 
Leak Respiration. An ability to increase IMM leak would suggest that 100nM PAPTP 
increases the proton motive force across the IMM. This could either be due to an 
increase in the electrical gradient across the inner mitochondrial membrane i.e. the 
mitochondrial membrane potential or due to an increase in the chemical gradient for 
proton entry, mitochondrial pH (Brand and Nicholls, 2011). In terms of the 
mitochondrial membrane potential, a hyperpolarisation of the IMM would increase 
the proton motive which would attract more H+ into the matrix, increasing the leak. 
This suggests that under normal circumstances, without pharmacological inhibition, 
mitochondrial Kv1.3 channels cause a depolarisation of the MMP. This would make 
sense in terms of ion flow dynamics, as an influx of K+, through Kv1.3 channels, and 
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into the matrix would make the matrix less negative (depolarisation) and therefore 
reduce the MMP. This situation would dispel the current thinking that mitochondrial 
Kv1.3 channels are not open under normal circumstances and at physiological 
mitochondrial membrane potentials. This is because any ion flow across the IMM 
would dissipate the energy generated by oxidative phosphorylation and the ETS. 
Disruption of the electrochemical gradient across the IMM should uncouple OXPHOS 
from ATP synthesis. However, this is not the case, as we saw in Chapter Three, as 
HEK293/Kv1.3 cells have significantly increased respiration across all stages, apart from 
Leak Respiration. If PAPTP increases Leak Respiration, then overexpression of Kv1.3 
channels should reduce leak, but interestingly this was not the case. The effect of 
Kv1.3 on the MMP will be explored in the following chapter.  
The changes in respiration led to a reduction in ATP turnover in both WT HEK293 and 
HEK293/Kv1.3 cells, which would mean less ATP is available for cell proliferation. 
PAPTP had a larger effect on respiration of HEK293/Kv1.3 cells than WT HE2K93 cells, 
reducing the ATP turnover by 45% vs 22% (respectively) and the SRC by 8% vs 0% 
(respectively). Both ATP turnover and SRC are commonly used measures to assess 
mitochondrial dysfunction in cells (Brand and Nicholls, 2011). These measures require 
the inhibition of the ATP synthase using oligomycin, but it is important to note that 
using the inhibition of the ATP synthase to calculate ATP turnover is only an 
estimation, and is likely to underestimate actual ATP synthesis rate by up to 10% 
(Affourtit and Brand, 2009). In Chapter Three, HEK293/Kv1.3 cells were shown to have 
a larger SRC than WT HEK293 cells. In this chapter inhibiting the mitochondrial Kv1.3 
channels reduced the SRC. SRC by definition is the ability of electron transport to 
increase in response to a demand for energy. Thus, if the HEK293/Kv1.3 cells are more 
rapidly proliferating, they would have a greater demand for ATP, and so a larger SRC 
would be of benefit. This data suggests that increased Kv1.3 expression gives 
HEK293/Kv1.3 cells a greater SRC than WT HEK293 cells, which operate closer to their 
bioenergetic capacity, which may limit their ability to respond to increases in energy 
demand, as seen in proliferation. The larger reduction in ATP turnover and SRC in 
HEK293/Kv1.3 cells treated with PAPTP may account for why 100nM PAPTP was able 
to significantly reduce proliferation in HEK293/Kv1.3 cells, but not in WT HEK293 cells. 
However, these results still suggest that mitochondrial Kv1.3 channels are involved in 
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maintaining respiration in these HEK293 cells. This is a novel finding that indicates 
respiration in non-cancerous cells may be regulated by Kv1.3 under physiological 
conditions. However, the effect of PAPTP on cellular respiration was blunted in 
comparison with PAP-1. This could suggest that PAP-1 has off target effects within the 
cell, inhibiting OXPHOS. Regardless,  it is clear that mitochondrial Kv1.3 channels 
regulate more than just apoptosis in cells (Mattarei et al., 2018). 
It would appear counterintuitive that K+ flow into the matrix could lead to increased 
respiration, as the integrity of the ETS depends on the IMM being impermeable to 
ions. Any cation flow into the matrix could potentially dissipate the proton motive 
force and uncouple respiration. However, there are numerous instances where K+ flow 
into the matrix does not cause uncoupling of respiration (Bajgar et al., 2001; 
Kowaltowski et al., 2001; Garlid et al., 2003). In these studies, K+ influx through the 
channels correlated to a 1-2mV change in the MMP and a very small stimulation of 
around 5ng atom O/min-1 mg-1 on respiration, clearly abrogating the notion that K+ 
influx through mitochondrial K+ channels can uncouple the functioning of the ETS. 
However, these results may have been due to the fact that there could have been a 
relatively low amount of the K+ channels in the IMM. In scenarios where there would 
exist an upregulation of certain K+ channels i.e. an increase in Kv1.3 channels in 
proliferating HSVSMCs or artificially enhanced levels in our HEK293/Kv1.3 cells, 
mitochondrial K+ influx may have greater effects. Obviously, this might result in more 
of a depolarisation of the IMM and a lowering of the MMP, but it has been found that 
mitochondria may be able to compensate for situations like this and increase 
respiratory activity. For example, stimulation of OXPHOS occurs in response to K+ influx 
in yeast mitochondria, and ATP synthesis increases (Manon et al., 1995). Although the 
work in this study was focusing on the mitoKATP channel, it is a good indication that 
such K+ ion flow into the matrix can work efficiently in a physiological situation and not 
just in a pathological one. 
If Kv1.3 channels are affecting mitochondrial respiration, there is a possibility that they 
are also affecting ROS levels in HEK293 cells. Leanza and colleagues found that PAPTP 
treatment raised levels of ROS in cancer cells which led to apoptosis (Leanza et al., 
2012, 2017; L Leanza et al., 2013; Peruzzo et al., 2017; Mattarei et al., 2018). As 
mentioned previously, ROS can be both a benefit or burden to cells; depending on the 
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level and length of exposure. One explanation for the differing results in the Leanza 
studies (above) and this work may be the levels of ROS generated. In the cancer cells 
treated with mitochondrial Kv1.3 inhibitors, the ROS levels exceed threshold levels and 
induce apoptosis. As a high level of ROS generation is a hallmark of rapidly proliferating 
cells (Trachootham et al., 2008), due to their high rate of respiration, it is possible that 
HE293/Kv1.3 cells also have increased levels of ROS to WT HEK293 cells, but reduced 
levels compared to cancer cells. Therefore, PAPTP treatment of HEK293/Kv1.3 cells 
may push ROS levels up to a point where they become detrimental to cells and reduce 
proliferation levels. This would explain the variation in results with 100nM PAPTP 
treatment in HEK293/Kv1.3 cells and WT HEK293 cells. At this stage, this is just 
hypothetical and would need to be tested further to make any conclusions. However, 
there is likely a key window of ROS levels, specific for each cell type, in which the ROS 
has beneficial cell signalling effects (Linley et al., 2012; Peers et al., 2015). Any ROS 
level lying outside of this window may be detrimental and/or have different signalling 
effect i.e. increased proliferation rather than decreased proliferation. ROS are able to 
regulate ion channels to control proliferation  and ROS can both increase or decrease 
cell proliferation (Scragg et al., 2008; Elies, Scragg, et al., 2014; Duckles et al., 2015). An 
increase in ROS with increasing levels of PAP-1 in HEK293/Kv1.3 and HSVSM cells may 
be one explanation for the increasing proliferation with higher concentrations of the 
Kv1.3 inhibitor, as displayed by the bell-shaped proliferation curve. The discrepancy 
between the low concentrations of PAP-1 needed to reduced proliferation in 
HEK293/Kv1.3 cells, and the higher nanomolar concentrations needed to reduce 
respiration may also be explained by ROS. The high doses of PAP-1 used in the 
respiratory experiments may promote ROS generation in the cell (Luigi Leanza et al., 
2013), which may surpass a threshold level and act as cell signalling molecules to 
regulate respiration (Holzerova and Prokisch, 2015). For example, increased ROS by 
PAP-1 treatment could have inhibited proteins and enzyme complexes of the electron 
transport chain (Murphy, 2009). In the following chapter, ROS levels in HEK293/Kv1.3 
and WT HEK293 cells have been explored. 
It is important to note that there are some caveats to using a mitochondrially targeted 
ion channel inhibitor, such as PAPTP, in this work. The first is that it is difficult to prove 
whether or not the compound actually targets the mitochondrial channel of interest, in 
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this case mitochondrial Kv1.3. Electrophysiology of isolated mitoplasts would be 
required (Leanza et al., 2017) and fluorescent tagging of the TPP moiety may help to 
visualise the location of this compound in the mitochondrial networks. 
Electrophysiology experiments would also need to test whether 100nM PAPTP blocks 
any plasma membrane Kv channels. There is also evidence to suggest that TPP is toxic 
to cells when it accumulates in the mitochondria (Murphy et al., 2009) (Trnka, Elkalaf 
and Anděl, 2015). This toxicity presents as disruption of the inner mitochondrial 
integrity, respiration and ATP synthesis. This makes it hard to ascertain if the effect on 
respiration and proliferation seen in this study is due to the inhibition of mitochondrial 
Kv1.3 channels, or down to the TPP molecule the inhibitor is attached to. However, 
evidence exists which supports the former scenario. Murphy et al., state that 
concentrations of TPP compounds which lie in the range of 0.1-1µM, which was the 
case for our experiments, avoid toxicity. Many published studies are using PAPTP at 
the same concentrations as in this study and do not report negative consequences of 
the compound (Checchetto et al., 2018; Mattarei et al., 2018). In addition, when 
100nM PAPTP was tested on the respiration of both WT HEK293 and HEK293/Kv1.3 
cells, there was a differential response between the cell types, with HEK293/Kv1.3 cell 
respiration being significantly affected by the compound. If the effects we saw were 
solely due to the TPP moiety, then the effects on both WT HEK293 and HEK293/Kv1.3 
cells would be expected to be the same. However, to improve this study, our results 
would need to be repeated using control cells treated with 100nM decylTPP only. 
Finally, optimal targeting of PAP-1 to the mitochondria would involve conjugating PAP-
1 to TPP using the smallest possible linker molecule to minimise any chance of 
disruption to the mitochondrial membrane (Trnka, Elkalaf and Anděl, 2015). 
To summarise, these findings suggest that mitochondrial Kv1.3 channels contribute to 
normal respiratory function in HEK293 cells. In situations where there are high 
numbers of these channels, as in the HEK293/Kv1.3 cell line, mitochondrial Kv1.3 
channels contribute to increased respiration and proliferation. What remains uncertain 
is how K+ influx into the matrix, through Kv1.3 channels, alters the levels of oxidative 
phosphorylation and proliferation.  
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 Chapter Five 
 
Probing the mechanisms through which mitochondrial Kv1.3 regulates 
respiration and proliferation. 
 
5.1 Introduction 
In Chapter Four of this thesis, it was suggested that mitochondrial Kv1.3 channels 
regulate proliferation and respiration of HEK293/Kv1.3 cells. By targeting Kv1.3 
inhibitors to the mitochondria, it may be possible to specifically control cellular energy 
metabolism and limit proliferation, whilst minimising unwanted effects relating to 
channel inhibition at other cellular sites. However, the mechanism through which 
Kv1.3 links mitochondrial function to proliferation is unknown.  
Research conducted  in cancer cell lines, suggests that mitochondrial Kv1.3 has a role 
in apoptosis (Leanza et al., 2017; Mattarei et al., 2018). It has been proposed that on 
inhibition of mitochondrial Kv1.3, the inner mitochondrial membrane (IMM) is 
hyperpolarised as K+ cations are prevented from entering the matrix. This leads to an 
increase in cellular reactive oxygen species (ROS), which surpasses a threshold level 
and triggers the apoptotic cascade by activating the mitochondrial permeability 
transition pore (MPTP). The mitochondria experience an influx of solutes into the 
matrix, which causes water to follow. The mitochondria swell, and their 
transmembrane potential is lost. This leads to a loss of cytochrome c and production of 
further ROS, triggering apoptosis. In contrast, the work described in Chapters Three 
and Four of this thesis demonstrate that the inhibition of Kv1.3 in HEK293/Kv1.3 cells 
did not cause cell death but rather reduced the rate of cellular proliferation. Cancer 
cells display an altered metabolic phenotype, characterised by  high rates of ROS (Liou 
and Storz, 2010). This difference may account for the discrepancies in observed 
phenotypes. In addition, the higher concentrations of mitochondrial Kv1.3 inhibitors 
used by Leanza and colleagues (10-20µM), compared to the concentrations used in 
this study (100nM), may have accounted for the abnormally high levels of ROS in these 
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studies that led to apoptosis of cancer cells (Leanza et al., 2017; Mattarei et al., 2018). 
Nevertheless, this does not preclude a role for ROS in the anti-proliferative effect of 
Kv1.3 inhibition in HEK293/Kv1.3 cells.  
As mentioned previously, the level of ROS is critical in determining the effect seen in 
the cells. Hypothetically, there could be alternative mechanisms, involving ROS, for 
why mitochondrial Kv1.3 inhibitors reduce proliferation. As in the work by Leanza and 
colleagues (referenced above), PAPTP may raise ROS to a level where proliferation is 
inhibited (Yang et al., 2012; Moloney and Cotter, 2017), but to a level not high enough 
to induce apoptosis (as seen in (Leanza et al., 2017)). However, cell ROS have also been 
found to be pro-proliferative in various cell types, such as microglia, colon cancer cells 
and B cells (Wheeler and DeFranco, 2012; Bordt and Polster, 2014; Juhasz et al., 2017). 
Therefore, PAPTP may reduce ROS via a reduction in OXPHOS (Koopman et al., 2010; 
Shadel and Horvath, 2015), and therefore a pro-proliferative ROS stimulus on 
proliferation may be switched off. Since expression of Kv1.3 in HEK293 cells increased 
the cellular respiration rate, this thesis will ask whether enhanced respiration in these 
cells leads to greater ROS production and whether this ROS production contributes to 
the enhanced proliferative phenotype of HEK293/Kv1.3 cells.  
Another potential mechanism of action underlying the effect of Kv1.3 on mitochondrial 
respiration is the influx of K+ ions into the mitochondrial matrix through the 
mitochondrial Kv1.3 channels, which may affect the MMP. Changes to the ionic 
balance of the mitochondrial matrix may then have reciprocal effects for OXPHOS 
(Garlid and Paucek, 2003; Garlid et al., 2003). In addition, any changes to the 
concentration of one ion in the matrix may have subsequent effects on the 
concentration of other ions. Mitochondrial Ca2+ has been observed to stimulate 
OXPHOS (Griffiths and Rutter, 2009; Vinnakota, Dash and Beard, 2011; Doonan et al., 
2014). Therefore, the effect of Kv1.3 expression in HEK293 cells on both the MMP and 
mitochondrial Ca2+ levels are explored in this chapter. 
Kv1.3 can regulate peripheral glucose homeostasis in mouse adipose and skeletal 
muscle cells, by modulating the expression of GLUT transporters in response to insulin 
(Xu et al., 2004). Therefore, an increased Kv1.3 expression in HEK293/Kv1.3 cells may 
alter glucose metabolism. Altered glycolysis would impact the amount of Acetyl-CoA 
entering the TCA cycle, which could either stimulate or inhibit the ETS via alterations to 
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NADH and FADH2. Altered glucose metabolism occurs in cancer, whereby many 
tumour cells increase glycolysis despite adequate O2 for OXPHOS, in a phenomenon 
known as the Warburg effect (Kroemer and Pouyssegur, 2008). This is thought to be a 
beneficial adaptation to support the biosynthesis of macromolecules for proliferation 
(Kroemer and Pouyssegur, 2008). In other cells, an increase/decrease in one 
bioenergetic pathway leads to a compensatory decrease/increase in another pathway, 
highlighting the flexibility of bioenergetic regulation (Jose, Bellance and Rossignol, 
2011; Goetzman and Prochownik, 2018). However, in some proliferating cells, such as 
retinoblastoma cells, both glycolysis and OXPHOS are increased (Takebayashi et al., 
2015). With this in mind, we decided to investigate glycolysis in HEK293/Kv1.3 cells to 
see if it was increased or decreased to WT HEK293 cells. 
This chapter will focus on probing these potential mechanisms to elucidate how 
mitochondrial Kv1.3 channels drive the oxidative and proliferative phenotype in 
HEK293 cells previously defined in Chapters Three and Four of this thesis. 
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5.2 Aims and Objectives 
The aim of this chapter was to explore the mechanism/s through which mitochondrial 
Kv1.3 regulate and link cellular oxidative metabolism and proliferation. To achieve this 
aim a key set of objectives were designed: 
 
1) To assess the cellular energy status and glycolytic function of HEK293/Kv1.3 cells. 
 
2) To investigate the effect of Kv1.3 expression on the MMP in HEK293/Kv1.3 cells. 
 
3) To examine mitochondrial Ca2+ status of HEK293/Kv1.3 cells. 
 
4) To define the production of ROS in HEK293/Kv1.3 cells, and using the mitochondrial-
targeted antioxidant MitoQ, establish the effect of decreased ROS availability on 
cellular proliferation (Kelso et al., 2001; Smith, Hartley and Murphy, 2011).  
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5.3 Results 
 
5.3.1 Kv1.3 increases cellular NADH in HEK293 cells. 
Chapters Three and Four identified that HEK293/Kv1.3 cells have an increased rate of 
OXPHOS. NADH is the principal electron carrier during OXPHOS and is generated 
during glycolysis, pyruvate conversion into Acetyl-CoA and in the TCA Cycle. NADH 
displays auto-fluorescence with a wavelength of 470nm following excitation, and an 
emission wavelength of 350-360nm. This auto-fluorescence is an indicator of 
mitochondrial redox status, OXPHOS activity and ATP production (Bonuccelli et al., 
2017). A large proportion of NADH autoﬂuorescence is due to mitochondrial NADH 
because NAD is non-ﬂuorescent and the level of cytosolic NADH is normally low 
(Buckler and Turner, 2013). NADH autofluorescence was measured in WT HEK293 and 
HEK293/Kv1.3 cells. NADH concentrations were greater in HEK293/Kv1.3 compared 
with HEK293 cells (black bars, Figure 5.1A). NADH auto-fluorescence was also 
measured with the addition of 20µM CCCP to maximally oxidise the NAD+/NADH pool, 
and measured with the addition of both 0.5µM rotenone plus 2.5µM antimycin A to 
maximally reduce the NAD+/NADH pool (Figure 5.1A). NADH concentrations were 
significantly higher in HEK293/Kv1.3 cells compared with HEK293 cells following 
treatment with CCCP or rotenone and antimycin A. The difference in fluorescence 
between the maximally oxidised and maximally reduced NAD+/NADH pools (NADH 
range) estimates the total mitochondrial NADH and NAD+ (Buckler and Turner, 2013). 
HEK293/Kv1.3 cells also had an increased mitochondrial NADH autofluorescence range 
compared to WT HEK293 cells (Figure 5.1B). HEK293/Kv1.3 cells were then treated 
with 100nM PAPTP to see if mitochondrial Kv1.3 inhibition could reduce the NADH 
autofluorescence. 100nM PAPTP had no effect on NADH autofluorescence in 
HEK293/Kv1.3 cells (Figure 5.1C). 
 
. 
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Figure 5.1 HEK293/Kv1.3 cells have increased NADH autofluorescence to WT HEK293 
cells. A. NADH autofluorescence baseline (black bars), NADH autofluorescence with 20µM 
CCCP (light grey bars) and NADH autofluorescence with 0.5µM rotenone and 2.5µM 
antimycin A (dark grey bars) in WT HEK293 cells (left columns) and HEK293/Kv1.3 cells 
(right columns). Data is expressed as the mean fluorescent intensity (MFI) ± SEM (WT 
HEK293 cells, n=5, HEK293/Kv1.3 cells, n=6). Data analysed by Student’s t-tests, * p<0.05, 
** p<0.01, *** p<0.001. B. NADH range in WT HEK293 cells (black bar) and HEK293/Kv1.3 
cells (grey bar). NADH range is the difference between NADH autofluorescence with CCCP 
and NADH autofluorescence with rotenone and antimycin a (as in A). Data expressed as the 
MFI ± SEM (WT HEK293 cells, n=5, HEK293/Kv1.3 cells, n=6). Data analysed using Student’s 
t-tests, * p<0.05. C. NADH autofluorescence in control HEK293/Kv1.3 cells (grey bar) and 
100nM PAPTP treated HEK293/Kv1.3 cells (white bar). Data is the NADH range, as in (B), 
expressed as the MFI ± SEM (n=3). Data was analysed using Student’s t-tests, p>0.05. 
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5.3.2 Manipulation of the malate/aspartate shuttle with Dimethyl-2-Oxoglutarate 
and Phenylsuccinate did not affect respiration in HEK293 cells. 
In Figure 5.2, WT HEK293 cells were treated with Dimethyl-2-Oxoglutarate (DM-2OG) 
to stimulate the malate/aspartate shuttle. In Figure 5.2, 2mM DM-2OG had no effect 
on the O2 consumption of WT HEK293 cells at Routine, Leak and Maximum Uncoupled 
Respiration. DM-2OG also did not affect residual O2 consumption (ROX). In Figure 5.3, 
HEK293/Kv1.3 cells were treated with 5mM Phenylsuccinate (PhS) to inhibit the 
malate/aspartate shuttle. 5mM PhS had no effect on the O2 consumption of 
HEK293/Kv1.3 cells at Routine, Leak and Maximum Uncoupled Respiration. DM-2OG 
also did not affect ROX. This suggests that the increase in HEK293 cell respiration is not 
due to the mitochondrial Kv1.3 channel having an effect on the malate/aspartate 
shuttle.   
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Figure 5.2 Dimethyl-2-Oxoglutarate has no effect on WT HEK293 cell respiration. A. 
Respiration of WT HEK293 control cells (black bars) and WT HEK293 cells treated with 2mM 
Dimethyl-2-Oxoglutarate (DM-2OG) (grey bars). Data expressed as mean O2 consumption 
(pmol) per million cells per second (pmol/(s*Mill)) ± SEM (n=3). Data was analysed using 
Student’s t-tests between control and drug treated cells, p>0.05.  
 
Figure 5.3 Phenylsuccinate has no effect on HEK293/Kv1.3 cell respiration. A. Respiration 
of HEK293/Kv1.3 control cells (black bars) and HEK293/Kv1.3 cells treated with 5mM 
Phenylsuccinate (PhS) (grey bars). Data expressed as mean O2 consumption (pmol) per 
million cells per second (pmol/(s*Mill)) ± SEM (n=7). Data was analysed using Student’s t-
tests between control and drug treated cells, p>0.05.  
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5.3.3 HEK293/Kv1.3 cells have an increased O2 consumption compared to WT HEK293 
cells when glycolysis is knocked down by 2-Deoxy-D-Glucose. 
HEK293/Kv1.3 cells had increased concentrations of NADH. NADH can be generated 
through several cellular metabolic processes including glycolysis and the TCA cycle. To 
investigate the source of increased intracellular NADH in HEK293/Kv1.3 cells and its 
contribution to the increased OXPHOS rate and energy production In HEK293/Kv1.3 
cells, these cells were treated for 24 hours with the glucose analogue and competitive 
inhibitor of glycolysis 2-Deoxy-D-Glucose (2DDG) (5mM) before being analysed by 
respirometry.  
24-hour pre-treatment of cells with 5mM 2DDG demonstrated that competitive 
inhibition of glycolysis significantly decreased both Leak Respiration and ROX in 
HEK293/Kv1.3 cells but not WT HEK293 cells (Figure 5.4A). There was no significant 
effect on Routine (baseline) or ETS Respiration (Figure 5.4A). To examine 
mitochondrial-specific effects the data was corrected for ROX (Figure 5.4B). 
HEK293/Kv1.3 cells treated with 2DDG still had a significantly reduced Leak 
Respiration, but interestingly their Routine Respiration was significantly increased 
(Figure 5.4B). This would suggest that competitive inhibition of glycolysis in 
HEK293/Kv1.3 cells reduces non-mitochondrial O2 consumption (ROX), which is 
compensated for by a reciprocal increase in routine OXPHOS. This phenomenon was 
not observed in WT HEK293 cells (Figure 5.4B), and although not statistically 
significant, there was a trend for 2DDG to reduce the O2 consumption at each stage of 
respiration in WT HEK293 cells (Routine, Leak and ETS).  
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Figure 5.4 5mM 2-Deoxy-D-Glucose reduced the residual oxygen consumption and leak 
oxygen consumption in HEK293/Kv1.3 cells. A. Effect of 5mM 2-Deoxy-D-Glucose 
(2DDG) on HEK293/Kv1.3 and WT HEK293 cell respiration. Black solid bars = control 
HEK293/Kv1.3 cells (n=4), black dotted bars = 2DDG treated HEK293/Kv1.3 cells (n=4). 
Grey solid bars = control WT HEK293 cell respiration (n=3), grey dotted bars = 2DDG 
treated WT HEK293 cells (n=3). Respiration was measured at four stages; Routine, Leak, 
ETS and ROX. Data expressed as the mean oxygen (O2) consumption per million cells per 
second (pmol/(s*Mill)) ± SEM. Data analysed using one-way ANOVA and Tukey’s multiple 
comparison post hoc test within each stage of respiration, * p<0.05, ** p<0.01, *** 
p<0.001, **** p<0.0001. B. Data in (A) corrected for residual O2 consumption (ROX). 
Data expressed as the mean O2 consumption per million cells per second (pmol/(s*Mill)) 
± SEM. Data analysed using one-way ANOVA and Tukey’s multiple comparison post hoc 
test within each stage of respiration, * p<0.05, ** p<0.01, *** p<0.001. 
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5.3.4 HEK293/Kv1.3 cells have a hyperpolarised mitochondrial membrane potential 
compared with WT HEK293 cells. 
Next, the MMP of HEK293/Kv1.3 and WT HEK293 cells was investigated using the Cairn 
Photometry system (Figures 5.5A and 5.5B). Tetramethylrhodamine, methyl ester 
(TMRM) is a cell-permeant dye that accumulates in active mitochondria with intact 
membrane potentials. TMRM is attracted to the negative charge of the mitochondrial 
membrane, accumulating more readily when the hyperpolarisation of mitochondria is 
greater. Figure 5.5A shows that TMRM accumulation is greater in HEK293/Kv1.3 cells. 
This suggests a more hyperpolarised membrane potential in HEK293/Kv1.3 cells. To 
confirm this, the uncoupler FCCP was applied to the cells to dissipate the MMP. The 
difference in the TMRM signal after FCCP addition gives an accurate indication of 
mitochondrial TMRM accumulation, since mitochondrial TMRM is released as the 
MMP is dissipated. In HEK293/Kv1.3 cells, there was a trend towards a greater 
decrease in mean fluorescent intensity (MFI) with FCCP, indicating a potentially greater 
hyperpolarised MMP than in WT HEK293 cells, however this failed to reach significance 
(Figure 5.5B).  
Flow cytometry was then utilised as an independent means of verifying the effect of 
Kv1.3 on HEK293 MMP (Figure 5.5C and 5.5D). Cells were stained with TMRM only, and 
then some were treated with FCCP (Figure 5.5C). The results in Figure 5.5D display the 
difference in the MFI between the two conditions. The difference in TMRM 
fluorescence with and without FCCP treatment was significantly larger in 
HEK293/Kv1.3 cells (Figure 5.5D), confirming that these cells had a higher MMP.   
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Figure 5.5 HEK293/Kv1.3 cells have greater hyperpolarisation of the mitochondrial 
membrane potential than WT HEK293. (A-B) Data from Cairn Photometry experiments. A. 
Mean fluorescence intensity (MFI) of cells treated with 20nM TMRM (WT HEK293 cells 
shown in left column, HEK293/Kv1.3 cells in right column). Data expressed as the voltage-
corrected raw MFI ± SEM  (n=9 for both WT HEK293 and HEK293/Kv1.3 cells). Student’s t-
tests confirmed HEK293/Kv1.3 cells had a significantly higher initial TMRM fluorescence 
than WT HEK293 cells (* p<0.05). B. Mitochondrial membrane potential (MMP) of WT 
HEK293 (left column) and HEK293/Kv1.3 (right column) cells. MMP is the difference 
between initial TMRM fluorescence and the TMRM fluorescence when cells were treated 
with 20µM FCCP, and 2µg/ml Oligomycin (n=9 for both WT HEK293 and HEK293/Kv1.3 
cells). Data displayed as MFI ± SEM. Student’s t-test was used to analyse the data (p>0.05). 
(C-D) Data from Flow Cytometry experiments. C. TMRM initial fluorescence (20nM) and 
CCCP effect (20µM) on TMRM fluorescence in WT HEK293 cells (n=7) and HEK293/Kv1.3 
cells (n=9). Left two data columns represent WT HEK293 cell data, and right two columns 
represent HEK293/Kv1.3 cell data. Data expressed as MFI of TMRM fluorescence ± SEM. 
Data analysed by one-way ANOVA with Tukey’s multiple comparisons post hoc test *** 
p<0.001, **** p<0.0001. D. Mitochondrial membrane potential (MMP) of WT HEK293 cells 
(Black bar, n=7) and HEK293/Kv1.3 cells (Grey bar, n=9). Data expressed as the difference in 
TMRM (20nM) MFI and the TMRM MFI when cells were treated with FCCP (20µM) ± SEM. 
Student’s t-test confirmed the difference was significant (*** p<0.001).  
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To investigate the role of mitochondrial Kv1.3 channels in the MMP phenotype, the 
mitochondrially targeted Kv1.3 channel inhibitor PAPTP was applied to cells WT 
HEK293 and HEK293/Kv1.3 cells. Flow cytometry was again used to assess MFI of 
TMRM and TMRM + FCCP treated cells, but with the addition of additional treatments; 
TMRM + PAPTP and TMRM + FCCP + PAPTP (Figures 5.6A and 5.6B). PAPTP was added 
during TMRM incubation in both HEK293/Kv1.3 and WT HEK293 cells. PAPTP did not 
affect the MMP (Figures 5.6C and 5.6D), suggesting that the increased MMP observed 
in HEK293/Kv1.3 cells is not directly dependent on mitochondrial Kv1.3 channels. 
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Figure 5.6 100nM PAPTP has no significant effect on the mitochondrial membrane 
potential of HEK293 cells. A-D) All data gathered by flow cytometry. A. TMRM (20nM) 
fluorescence and TMRM fluorescence with CCCP (20µM) in WT HEK293 control cells (black 
bars) and PAPTP treated (100nM) WT HEK293 cells (white bars). Data expressed as mean 
fluorescent intensity (MFI) of TMRM fluorescence ± SEM (n=3). Data was analysed using 
one-way ANOVA and Tukey’s pot hoc test, p>0.05. B. TMRM (20nM) fluorescence and 
TMRM fluorescence with CCCP (20µM) in HEK293/Kv1.3 control cells (grey bars) and PAPTP 
treated (100nM) HEK293/Kv1.3 cells (white bars). Data expressed as MFI of TMRM 
fluorescence ± SEM (n=4). Data was analysed using one-way ANOVA and Tukey’s post hoc 
test, **** p<0.0001. C. MMP in WT HEK293 control cells (black bar) and PAPTP (100nM) 
treated WT HEK293 cells (white bar). MMP is the difference between TMRM (20nM) MFI 
and TMRM MFI with CCCP (20µM). Data expressed as MFI of TMRM fluorescence ± SEM 
(n=3).  Data was analysed using Student’s t-tests, p>0.05. D. MMP in HEK293/Kv1.3 control 
cells (grey bar) and PAPTP (100nM) treated WT HEK293 cells (white bars). Data expressed 
as MFI of TMRM fluorescence ± SEM (n=3). Data was analysed using Student’s t-tests, 
p>0.05.  
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5.3.5 Mitochondrial Ca2+ is not increased by Kv1.3 expression HEK293 cells. 
WT HEK293 and HEK293/Kv1.3 cells were screened for differences in their cellular and 
mitochondrial Ca2+ levels using flow cytometry. Cells were stained with the fluorescent 
Ca2+ indicator Rhod-2 AM.  Cellular and mitochondrial Ca2+ levels were tested across 
two conditions; baseline Rhod-2 AM fluorescence and Rhod-2 AM fluorescence with 
20µM CCCP. There was no significant difference in cellular Ca2+ concentrations 
between HEK293/Kv1.3 and WT HEK293 cells in either condition (Figure 5.7A).The 
mitochondrial Ca2+ range can be estimated by examining the difference in Rhod-2 AM 
fluorescence between baseline and CCCP treatment (Figure 5.7B). The mean 
mitochondrial range in HEK293/Kv1.3 cells was larger than in WT HEK293 cells, 
however this result was not significant (Figure 5.7B).  
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Figure 5.7 Mitochondrial calcium is not significantly different in HEK293/Kv1.3 cells 
compared to WT HEK293 cells. A. Data expressed as mean fluorescence intensity (MFI ± 
SEM) of Rhod-2 AM fluorescence. The two left data columns represent WT HEK293 cell data 
(n=5), while the right two columns represent HEK293/Kv1.3 cell data (n=5). In both WT 
HEK293 and HEK293/Kv1.3 cells, the black bars represent baseline Rhod-2 AM fluorescence, 
and the grey bars represent Rhod-2 AM fluorescence with the addition of 20µM FCCP. Data 
analysed using one-way ANOVA and Tukey’s multiple comparison post hoc test, ** p<0.01. 
B. Mitochondrial calcium in WT HEK293 cells (n=5) and HEK293/Kv1.3 cells (n=5). Data was 
calculated by finding the difference between the baseline and the FCCP results (in A) for 
each repeat of the experiment. Results are displayed as the MFI ± SEM. Student’s t-test 
confirmed there was no difference in mitochondrial calcium range in HEK293/Kv1.3 cells 
and WT HEK293 cells, p>0.05. 
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5.3.6 HEK293/Kv1.3 cells have a greater concentration of cellular reactive oxygen 
species than WT HEK293 cells. 
Mitochondria are one of the main sites of cellular reactive oxygen species (ROS) 
production through the action of ETS leak. As HEK293/Kv1.3 cells have increased basal 
respiration and increased Maximum ETS Respiration (Chapter Three) compared to WT 
HEK293 cells, it was hypothesised that this may result in an increased level of ROS in 
these cells. WT HEK293 and HEK293/Kv1.3 cells from equal passages were stained 
using the cell permanent dye CellROX Deep Red reagent which exhibits fluorescence 
upon oxidation by ROS. HEK293/Kv1.3 cells had significantly greater levels of ROS than 
WT HEK293 cells (Figure 5.8). Representative images of cell ROS in HEK293/Kv1.3 and 
WT HEK293 cells are shown in Figure 5.9.  
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Figure 5.8 HEK293/Kv1.3 cells have a higher level of reactive oxygen species than WT 
HEK293 cells. A. Reactive oxygen species (ROS) in WT HEK293 cells (black bar) and 
HEK293/Kv1.3 cells (grey bar). Cells were stained with 5µM CellROX deep red reagent. Data 
expressed as the mean fluorescent intensity (MFI) of CellROX ± SEM (n=3). Data was 
analysed using Student’s t-test, *** p<0.001.   
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Figure 5.9 Representative images showing HEK293/Kv1.3 cells have a higher level of 
reactive oxygen species (ROS) than WT HEK293 cells. A. Reactive oxygen species (ROS) 
(red) in WT HEK293 cells stained with 5µM CellROX deep red reagent and diamidino-2-
phenylindole (DAPI) to highlight cell nuclei (blue). B. Control for non-specific binding by 
the CellROX reagent. Staining was performed as in (A) but without CellROX. C. ROS (red) in 
HEK293/Kv1.3 cells stained with 5µM CellROX deep red reagent and DAPI to highlight cell 
nuclei (blue). D. Control for non-specific binding by the CellROX reagent in HEK293/Kv1.3 
cells. Staining was performed as in (C) but without CellROX. All scale bars represent 20µm.  
 
A. B. 
C. D. 
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The compound menadione generates cellular ROS through redox cycling. WT HEK293 
and HEK293/Kv1.3 cells were treated with 100μM menadione. ROS production in 
response to menadione was greater in HEK293/Kv1.3 cells than WT HEK293 cells 
(Figure 5.10). Together, with the respirometry data this data suggests that the 
increased mitochondrial respiration in HEK293/Kv1.3 cells leads to greater 
concentration of cellular ROS. Although commonly associated with negative cellular 
consequences, ROS are important chemical messengers which have been found to 
enhance cellular proliferation. Therefore, the increased ROS in HEK293/Kv1.3 cells may 
contribute to the proliferative phenotype induced by Kv1.3 expression. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 5.10 HEK293/Kv1.3 cells have a greater increase in cell reactive oxygen species 
(ROS) in response to 100µM menadione than WT HEK293 cells. From left to right, first two 
columns represent WT HEK293 cell data, last two columns represent HEK293/Kv1.3 cell 
data. Data expressed as mean fluorescence intensity (± SEM) of 5µM CellROX deep red 
reagent (patterned bars) and without (solid bars) pre-treatment of 100µM menadione 
(n=3). Data was analysed using one-way ANOVA and Tukey’s post hoc multiple comparison 
test, ** p<0.01, **** p<0.001.  
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5.3.7 The ROS scavenger MitoQ, may reduce proliferation of HEK293 cells. 
To determine whether ROS in HEK293/Kv1.3 cells was contributing to the proliferative 
phenotype of these cells, a ROS scavenger, MitoQ, was applied to the cells in a 
proliferation assay (Figures 5.11 and 5.12). In both HEK293/Kv1.3 cells and WT 
HEK9293 cells, in individual experiments there was occasions when, MitoQ was able to 
reduce cellular proliferation (Figure 5.11A and 5.11B). In WT HEK293 cells, there was a 
less consistent and distinct effect of MitoQ on the proliferation of these cells (Figure 
5.12A and 5.12B). Although not significant, perhaps due to the variation in the cell 
counts, the reduction in proliferation by MitoQ in HEK293/Kv1.3 cells translated to a 
mean Day 3 count over 30% lower than untreated control counts (Figure 5.11B). In WT 
HEK293 cells, the mean Day 3 count was around 20% lower than untreated control 
counts (Figure 5.12B). The effect of MitoQ on cell viability was not significant in either 
cell type, but more repeats, would be needed to confirm that this ROS scavenger was 
not effecting cell viability at all, as the MitoQ treated cells had slightly lower viability in 
both HEK293/Kv1.3 and WT HEK293 cells. 
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Figure 5.11 MitoQ had no effect on proliferation of HEK293/Kv1.3 cells. A. Proliferation of HEK293 cells treated with 5µM MitoQ (n=3). Cell counts on Day 0 
(black bars), Day 3 (light grey bars) and on Day 3 when treated with MitoQ (dark grey bars). Wells were counted in triplicate and expressed as the raw cell 
count mean ± SEM. Student’s t-tests were used to analyse Day 3 control counts with Day 3 MitoQ counts, * p<0.05, *** p<0.001. B. Mean day 3 data from the 
experiments in (A) ± SEM (n=3). Data was analysed using Student’s t-tests, p>0.05. C. Viability counts for HEK293/Kv1.3 control (left data point) and 5µM MitoQ 
treated HEK293/Kv1.3 cells (right data point). Data expressed as percent viability of cells counted on Day 3, using trypan blue. Data analysed using Student’s t-
tests and MitoQ had no significant effect on cell viability, p>0.05.  
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Figure 5.12 MitoQ had no effect on WT HEK293 proliferation. A. Proliferation of WT HEK293 cells treated with 5µM MitoQ (n=3). Cell counts on Day 0 (black 
bars), Day 3 (light grey bars) and on Day 3 when treated with MitoQ (dark grey bars). Wells were counted in triplicate and expressed as the raw cell count mean 
± SEM. Student’s t-tests were used to analyse Day 3 control counts with Day 3 MitoQ counts, *** p<0.001. B. Mean data from the experiments in (A) ± SEM 
(n=3). Data was analysed using Student’s t-tests, p>0.05. C. Viability counts for WT HEK293 control (left data point) and 5µM MitoQ treated WT HEK293 cells 
(right data point). Data expressed as the percent viability of cells counted on Day 3, using trypan blue. Data analysed using Student’s t-tests and MitoQ had no 
significant effect on cell viability, p>0.05.  
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5.4 Discussion 
 
This chapter aimed to examine the potential mechanisms through which Kv1.3 
channels induce an increased oxidative and proliferative phenotype, with a focus on 
several processes including cellular NADH production and glycolysis, MMP, 
mitochondrial Ca2+ and ROS production and signalling.    
HEK293/Kv1.3 cells were shown to have increased concentrations of cellular NAD(P)H 
compared to WT HEK293 cells, consistent with data from Chapter Three which showed 
a greater ATP turnover rate in HEK293/Kv1.3 cells. This may indicate a link between 
the energy generated in HEK293/Kv1.3 cells and their rate of proliferation. The 
mechanisms through which Kv1.3 may be altering cellular NADH were therefore 
explored. Whether shuttling of NADH into the mitochondria was influenced by Kv1.3 
was investigated through inhibition and stimulation of the malate/aspartate shuttle 
using phenylsuccinate (PhS) and dimethyl-2-oxoglutarate (DM-2OG), respectively. In 
HEK293/Kv1.3 cells, if OXPHOS were being fuelled by greater transportation of NADH 
into the matrix via the malate/aspartate shuttle, then inhibition by PhS should reduce 
OXPHOS. Conversely, stimulating the malate/aspartate shuttle with DM-2OG in WT 
HEK293 cells should increase the levels of OXPHOS. Treatment of WT HEK293 cells with 
DM-2OG, and inhibition of the activity of the malate/aspartate shuttle using PhS in 
HEK293/Kv1.3 cells, did not affect respiration. Alternatively, increased cellular NADH 
concentrations may be generated by increased TCA cycle activity in the mitochondrial 
matrix. Citrate synthase activity is a measure of matrix volume and its activity regulates 
the rate of the TCA cycle (Halestrap, 1989; Garlid, 1996). However, in Chapter Three, 
there was no difference in citrate synthase activity between HEK293/Kv1.3 and WT 
HEK293 cells, suggesting the increased NADH is not due to increased activity of the 
TCA cycle via citrate synthase. 
Therefore, the increased NADH in HEK293/Kv1.3 cells may result from upstream of the 
TCA cycle, perhaps by enhanced glycolysis. Increased glucose uptake, glycolysis and 
lactate production in the presence of adequate cellular O2 levels, is well described  in 
cancer biology and is known as aerobic glycolysis, or the Warburg Effect (Warburg, 
1925). Both aerobic glycolysis and OXPHOS can be upregulated in cells (Liberti and 
Locasale, 2016) and highly proliferating cells retain their capacity for OXPHOS (Jose, 
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Bellance and Rossignol, 2011; Ho et al., 2012; Robinson et al., 2012; Gentric, Mieulet 
and Mechta-Grigoriou, 2017). When glycolysis in HEK293/Kv1.3 cells and WT HEK293 
cells was inhibited using 2-Deoxy-D-Glucose (2DDG) only the respiration of 
HEK293/Kv1.3 cells was affected. This would suggest that glycolysis is of greater 
importance for cellular energy balance in the HEK293/Kv1.3 cells. Interestingly, 2DDG 
was observed to increase routine respiration in HEK293/Kv1.3 cells. This could suggest 
that HEK293/Kv1.3 cells can upregulate O2 consumption via OXPHOS in times of ‘stress’ 
i.e. knockdown of glycolysis. This plasticity in energy metabolism has been described as  
a key hallmark of rapidly proliferating cancer cells (Robinson et al., 2012). In addition, 
inhibition of glycolysis in H460 tumour cells led to activation of pro-survival 
oncoproteins like Akt (Zhong et al., 2009), which regulate energy metabolism and may 
be responsible for the rise in routine respiration (Robey and Hay, 2009). 
To directly interrogate the effect of the mitochondrial Kv1.3 channels on the cellular 
NADH concentrations, the effect of mitochondrial-specific Kv1.3 channel inhibitor, 
PAPTP, was tested on NADH concentration in HEK293/Kv1.3 cells. PAPTP did not affect 
cellular NADH concentrations (Figure 5.1C). Intriguingly, this may suggest that non-
mitochondrial Kv1.3 channels influence cellular NADH, especially as glycolysis is a 
cytosolic process. However, PAPTP inhibits ion conductance through the mitochondrial 
Kv1.3 channel, and Kv1.3 channels have been found to have cell signalling functions 
independent to their ion conducting properties (Cidad et al., 2012; Jimenez-Perez et 
al., 2016). Therefore, these results cannot preclude non-conducting roles of the 
channel that may affect cellular NADH concentrations.  
An important caveat to this work is that the NAD(P)H autofluorescence protocol, does 
not separate the proportion of NAD(P)H autofluorescence attributable to NADH and 
NADPH. To quantify the levels of NADH and NADPH in these cells, NADPH fluorescent 
lifetime imaging microscopy (FLIM) may be an applicable method for future work 
(Blacker and Duchen, 2016). Nevertheless, an increase in NAD(P)H autofluorescence 
would still require an initial increase in NADH. 
This thesis may highlight a link between glycolysis and the MMP in HEK293/Kv1.3 cells. 
2DDG treatment significantly reduced leak respiration in HEK293/Kv1.3 cells (Figure 
5.4). Therefore, MMP may be becoming more depolarised in a setting of impaired 
glycolysis. This suggests that glycolysis could regulate the MMP in HEK293/Kv1.3 cells. 
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NADH molecules are negatively charged, and a greater concentration of NADH, 
originating from glycolysis, may lead to MMP hyperpolarisation. In support of this, 
glycolysis has been found to regulate MMP oscillations (Olsen et al., 2009). Olsen et al., 
suggested that glycolysis is coupled to MMP through ATP. ATP generated by glycolysis 
can be hydrolysed by the ATP-synthase, which hyperpolarises the MMP. They 
previously concluded that the ADP/ATP antiporter is an essential part of this process, 
as it determines the level of ATP reaching the ATP-synthase (Poulsen et al., 2008). 
Beltran et al., found that in response to inhibition of respiration, Jurkat cells displayed 
MMP hyperpolarisation due to the hydrolysis of glycolytic ATP (Beltrán et al., 2000).  
Aerobic glycolysis also caused IMM hyperpolarisation in cancer cells, due to reverse 
proton pumping of the ATP synthase (Forrest, 2015). In this chapter HEK293/Kv1.3 
cells were found to have a larger MMP compared to WT HEK293 cells. However, 
inhibition of mitochondrial Kv1.3 channels with PAPTP did not decrease the MMP, 
suggesting the mechanism for this effect is independent of ion conductance through 
the mitochondrial Kv1.3 channels, and may be via a glycolysis-mediated mechanism.  
Indeed, a hyperpolarised MMP upon opening of the mitochondrial Kv1.3 channel is the 
opposite of what would be expected. Opening of the Kv1.3 channels would likely result 
in an influx of K+ ions into the matrix, depolarising the MMP. Nevertheless, the 
identification of a greater hyperpolarisation in HEK293/Kv1.3 cells is consistent with 
other findings of this study. HEK293/Kv1.3 cells have an oxidative and highly 
proliferative phenotype. Greater hyperpolarisation of the MMP is advantageous for, 
and in evidence in highly proliferating cells (Heerdt, Houston and Augenlicht, 2005; 
Houston, Augenlicht and Heerdt, 2011; Forrest, 2015; Martinez-Reyes et al., 2016). A 
more negative MMP increases the proton motive force that drives protons through the 
ATP-synthase during OXPHOS, which would ultimately increase the amount of ATP 
generated. In addition to providing the energy for proliferation, a more hyperpolarised 
MMP may protect the cell from apoptosis. A depolarisation of MMP, via influx of Ca2+ 
though the MCU, triggers the opening of the MPTP (Luigi Leanza et al., 2013). 
Therefore, a more hyperpolarised MMP inhibits the activation of the apoptotic 
cascade. 
HEK293/Kv1.3 cells were observed to have increased levels of cellular ROS compared 
to WT HEK293, using the MMP independent dye CellROX. Mitochondria are considered 
178 
 
the primary source of ROS in the cell, so any enhancement of the mitochondrial ETS 
could potentially alter the level of these molecules (Murphy, 2009). These findings are 
consistent with the enhanced respiratory phenotype of HEK293/Kv1.3 cells. Increased 
ROS may result from the increased OXPHOS (Holzerova and Prokisch, 2015), 
specifically at Complexes 1 (Koopman et al., 2010) and Complexes 3 (Raha et al., 2000). 
The increased oxidation of NADH at complex 1, combined with the overall increase in 
ETS activity, would lead to electrons combining with ambient O2 to produce 
superoxide. Moreover, ROS levels in HEK293/Kv1.3 cells increased significantly more 
than in WT HEK293 cells in response to treatment with the oxidant menadione (Figure 
5.10). Menadione is metabolised in the mitochondria by Complex 1 (Criddle et al., 
2006). The ability of Complex 1 to reduce menadione depends on the ability of NADH 
to donate electrons. The resulting semiquinone can combine with O2 and enter a redox 
pathway where it is regenerated as menadione, whilst concomitantly releasing ROS. As 
ROS is generated, levels of NADH decline. Therefore, increased levels of NADH in 
HEK293/Kv1.3 cells would increase the capacity for ROS production by menadione 
metabolism. Although, it is also possible that WT HEK293 cells could more readily 
adapt to oxidative insult by menadione treatment. HEK293/Kv1.3 cells have higher 
basal levels of ROS and so may have a lower pool of available ROS scavenger 
molecules.  
Interestingly ROS may underlie the observed decrease in ROX specific to HEK293/Kv1.3 
cells treated with 2DDG, since ROX is related to ROS (Hutter et al., 2002). Glycolysis 
can stimulate ROS in cells, and these ROS can in turn further stimulate glycolysis 
(Liemburg-Apers et al., 2015), the latter being a process that can occur in highly 
proliferating cells (Brand, 1997). Glycolysis not only contributes to energy and redox 
balance of the cell, but recent developments link this pathway to cellular proliferation. 
Glycolysis synthesises the macromolecular building blocks necessary for cells to grow 
i.e. NADH and carbon from Acetyl-CoA (Vander Heiden, Cantley and Thompson, 2009), 
and NADPH via the pentose phosphate pathway (PPP) (Riganti et al., 2012; Du et al., 
2013). 
In addition, the decreased ROX in response to 2DDG (Figure 5.4a) may also suggest 
that non-mitochondrial O2 consumption is fuelled by glycolysis in HEK293/Kv1.3 cells. 
This would suggest that in HEK293/Kv1.3 cells, a higher level of glycolysis may 
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contribute to the greater ROX, despite not being an O2 consuming process. An increase 
in OXPHOS supported glycolysis is described by the Warburg effect and is a 
phenomenon that is seen in many cancer cells (Vander Heiden, Cantley and Thompson, 
2009; Liberti and Locasale, 2016; Gentric, Mieulet and Mechta-Grigoriou, 2017). In 
order for glycolysis to continue at a high rate, NADH must be continuously re-oxidised 
(Herst et al., 2004). The main method of NADH regeneration is by lactate 
dehydrogenase, which catalyses the reduction of pyruvate by NADH to form lactate 
and NAD+ (Augoff, Hryniewicz-Jankowska and Tabola, 2015). However, lactate 
dehydrogenase can also be a source of NADH, facilitating the oxidation of lactate to 
pyruvate and the subsequent reduction of NAD+ to NADH (Kim et al., 2017). Lactate 
dehydrogenase could therefore be involved in the increased NADH in HEK293/Kv1.3 
cells. The activity of lactate dehydrogenase has been linked to metabolism (Brooks, 
2018) and its activity has been found to be necessary for vascular smooth muscle cell 
proliferation and migration (Kim et al., 2017). Thus, investigation of lactate 
dehydrogenase activity in HEK293/Kv1.3 cells would be necessary to identify any links 
to the high NADH in these cells and their proliferative phenotype.  
Another redox reaction which regenerates NAD+ occurs in the plasma membrane, 
where, in a similar way to that in the IMM, electrons are transported across the 
membrane to bind with O2 (Goldenberg, Crane and Morre, 1979). Both plasma 
membrane and mitochondrial electron transport compete for NADH, as it is their 
source of electrons (Herst et al., 2004). This plasma membrane O2 consumption may 
be responsible for O2 dependent cell growth when mitochondrial ETS activity is 
reduced (Shen et al., 2003). In 2004, inhibitors of glycolysis and glucose inhibited cell 
surface O2 consumption in HL60 tumour cells (Herst et al., 2004). Non-mitochondrial O2 
consumption is essential to recycle NADH to maintain glycolysis and may explain why 
2DDG treatment reduced ROX in HEK293/Kv1.3 cells. These results suggest that Kv1.3 
may be involved in the regulation of plasma membrane O2 consumption.  
Under inhibitory glycolytic conditions (2DDG), OXPHOS was still greater in 
HEK293/Kv1.3 cells compared with WT HEK293 cells (Figure 5.4). The increased ATP 
that likely results from this greater OXPHOS may also fuel cell proliferation (Ho et al., 
2012). In addition, increased ATP might also increase proliferation via a reduction in 
AMP activated protein kinase (AMPK) (Motoshima et al., 2006), since high levels of ATP 
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decrease the AMP/ATP ratio, deactivating AMPK signalling, leading to a stimulation of 
the cell cycle.   
Plasma membrane O2 consumption, and the associated activity of plasma membrane 
NADPH oxidases, are sources of ROS (Shen et al., 2003). However, there are numerous 
other sites of extra-mitochondrial ROS production in cells, such as the endoplasmic 
reticulum, peroxisomes and the cytosol, that may have contributed to the higher basal 
ROS detected in HEK293/Kv1.3 cells (Brown and Borutaite, 2012). Oxidase enzymes, 
such as diamine oxidase, D-amino acid oxidase, nitric oxide synthases and lipoxygenase 
are enzymes involved in nutrient metabolism and may be sites of ROS 
generation(Brown and Borutaite, 2012) (Holzerova and Prokisch, 2015). Their links to 
substrate metabolism are interesting and would require further investigation to 
determine if they are involved in the altered metabolic and proliferative phenotype of 
HEK293/Kv1.3 cells.  
There was a trend for MitoQ to decrease HEK293/Kv1.3 cell proliferation (Figure 5.11), 
and so ROS may directly stimulate proliferation in these cells. ROS have been found to 
stimulate proliferation in various cell types; microglia (Bordt and Polster, 2014), 
immune cells (Wheeler and DeFranco, 2012), colon (Juhasz et al., 2017) and other 
cancers (Sullivan et al., 2015; Moloney and Cotter, 2017). ROS have also been known 
to regulate ion channel function (Scragg et al., 2008; Elies, Dallas, et al., 2014; Elies, 
Scragg, et al., 2014; Al-Owais et al., 2015; Duckles et al., 2015; Peers et al., 2015). In 
Figure 5.11 the results suggest that the increased ROS production may contribute to 
the proliferative phenotype of these HEK293/Kv1.3 cells, as the mean proliferation for 
MitoQ treated cells was 68% that of untreated controls. 
Further work needs to be done to establish whether K+ influx through mitochondrial 
Kv1.3 is large enough to significantly alter the MMP without any non-mitochondrial 
factors such as glycolysis. Alterations in the ionic balance of the matrix may affect the 
MMP, so it would need to be established whether the mitochondrial ultrastructure is 
altered in HEK293/Kv1.3 cells. Mitochondrial volume has been implicated in cellular 
bioenergetics (Halestrap, 1989), and alterations to the ionic balance are likely to have 
some effect on the water content of the matrix. A more advanced investigation into 
the ultrastructure and volume of the matrix is necessary compared to the basic 
investigation into mitochondrial structure in Chapter Three. Pharmacological inhibition 
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of the different exchangers involved in the mitochondrial K+ cycle, for example the 
LETM1, H+/K+ and H+/Pi exchangers would need to be tested on the MMP and on the 
respiration and proliferation of HEK293/Kv1.3 cells. To improve these investigations, 
they could also be tested in isolated mitochondria. Finally, regarding glycolysis it would 
also be interesting to explore the effect of glycolysis inhibition on the MMP of 
HEK293/Kv1.3 cells, and also an investigation into the reasons for the increased 
glycolysis is needed. Two key avenues could be explored: 
1) Do the Kv1.3 channels cause more glucose to enter the cell? There could be a 
physical interaction between the Kv1.3 channel and GLUT transporters whereby 
activation of the channel could also activate GLUT proteins. GLUT channels have PDZ 
domains (Bunn, Jensen and Reed, 1999), which may interact with Kv1.3 and lead to 
altered function. Or perhaps there exists a cell signalling pathway/s whereby the 
metabolic milieu is sensed by the Kv1.3 channels and this information is relayed to the 
nucleus which upregulates glucose influx (Tucker et al., 2013). Identification of GLUT 
transporters and/or their activity in HEK293/Kv1.3 compared to WT HEK293 cells 
would be necessary. 
2) Do the Kv1.3 channels cause there to be an increase in the expression of enzymes in 
glycolysis which may lead to an increased rate of glycolysis (Lee et al., 2018). Again, 
perhaps a cell signalling pathway exists between mitochondrial Kv1.3 channels and the 
nucleus which increases these enzymes. Measurement of enzymes such as hexokinase, 
phosphofructokinase and pyruvate kinase would be needed to determine if any are 
significantly upregulated compared to WT HEK293 cells 
This chapter explored the mechanisms in which mitochondrial Kv1.3 may contribute to 
enhanced respiration and proliferation. HEK293/Kv1.3 cells have increased NADH 
levels, likely due to increased rates of glycolysis. Interestingly, the increased cellular 
NADH may be independent of the ion-conducting role of mitochondrial Kv1.3 channels. 
Moreover HEK293/Kv1.3 cells in which glycolysis is inhibited have higher levels of 
OXPHOS than WT HEK293 cells. HEK293/Kv1.3 cells have a more hyperpolarised MMP 
which may arise from the increased glycolysis or due to an imbalance in cation and 
anion composition of the mitochondrial matrix. Compellingly, HEK293/Kv1.3 cells have 
increased cellular ROS compared to WT HEK293 cells and this may directly contribute 
to the high proliferation rate of these cells.   
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How the overexpression of the Kv1.3 ion channel, specifically the mitochondrial Kv1.3 
channel, leads to the upregulation of metabolic pathways warrants further 
exploration. Mitochondrial Kv1.3 may act as a metabolic sensor to upregulate 
glycolysis and OXPHOS. Kv1.3 function as a K+ channel may not be essential for its role 
in stimulating proliferation. In the final results chapter, non-conducting Kv1.3 channel 
mutants will be tested to determine whether the channel has ion-conducting 
independent effects on respiration. 
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Chapter Six 
 
Kv1.3 channels have non-conducting properties which increase 
respiration and proliferation in HEK293 cells. 
 
6.1 Introduction 
 
In Chapter Five of this thesis, inhibition of mitochondrial Kv1.3 channels with PAPTP 
had no significant effect on redox metabolism (NADH autofluorescence) or MMP. 
Therefore Kv1.3-mediated K+ flow into the mitochondrial matrix may not be 
responsible for the increased NADH autofluorescence and hyperpolarised MMP in 
HEK293/Kv1.3 cells. This suggests that the Kv1.3 ion channel may have non-conducting 
properties which function to increase respiration and proliferation. 
In recent years, ion-conducting independent roles of ion channels have been 
established, in which channel proteins can act as cell signalling mediators. K+ channels 
can have permeation independent mechanisms involving voltage dependent 
conformational changes or protein-protein interactions which modulate proliferation 
(Urrego et al., 2014).  EAG and KCa channels can increase proliferation via ion 
independent signalling (Hegle, Marble and Wilson, 2006; Millership et al., 2011, 
respectively). Kv1.3 inhibition with MgTx and PAP-1 prevents proliferation and 
depolarises VSMCs, but depolarisation, with either inhibitors of other Kv channels or 
by increasing extracellular K+ concentration, does not prevent proliferation in HEK293 
cells (Cidad et al., 2010). In addition, activation of Kv1.3 channels and Kv1.5 channels 
both hyperpolarise the plasma membrane, but Kv1.3 channels increase proliferation 
whilst Kv1.5 channels reduce it (Cidad et al., 2012). These studies suggest the 
proliferation stimulating effect of Kv1.3 channels may not be caused by K+ flow 
through the channel. Eight phosphorylation residues, either threonine, serine or 
tyrosine, on the C-terminus of the Kv1.3 channel have been identified (Jimenez-Perez 
et al., 2016), and three of these residues are essential for the proliferation stimulating 
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effect of Kv1.3 channels, as their mutation to alanine abolished Kv1.3 induced 
proliferation (Jimenez-Perez et al., 2016). 
To investigate whether these residues also have an effect on mitochondrial respiration, 
we were kindly gifted three plasmids encoding the mutant Kv1.3 channels from López 
López et al. The first two mutants are described in their 2012 paper (Cidad et al., 
2012), where they were called Kv1.3WF and Kv1.3WF3X. From here on in, Kv1.3WF will 
be referred to as Kv1.3-P89, and Kv1.3WF3X as Kv1.3-P93. Kv1.3-P89 is a voltage 
sensitive but non-conducting Kv1.3 channel with intact gating properties. It is unable 
to conduct due to a single point mutation in the channel pore region (S5-S6). Kv1.3-P93 
is a voltage insensitive and non-conducting Kv1.3 channel. As well as having the same 
point mutation as Kv1.3-P89 channel in the pore region, it has three additional point 
mutations in the voltage sensor (S4). The final mutant that was used in this work was 
described in the 2016 López López et al. paper (Jimenez-Perez et al., 2016), where it 
was designated Kv1.3-Y447A. From here on in, this channel will be referred to as 
HEK293/Kv1.3-P121. Kv1.3-P121 is a phosphorylation defective Kv1.3 mutant, which is 
voltage sensitive and able to conduct K+ ions. It is phosphorylation defective due to an 
alanine substitution of a tyrosine residue at position 447 on its C-terminus which 
prevents ERK1/2 dependent phosphorylation (Jimenez-Perez et al., 2016).  
Kv1.3-P89, Kv1.3-P93 and Kv1.3-P121 mutants were expressed in HEK293 cells and 
used to show that Kv1.3 channels require an intact voltage sensor to increase 
proliferation (Cidad et al., 2012). It is thought that upon voltage sensing, the Kv1.3 
channel exhibits a conformational change which exposes key phosphorylation sites, 
and enables them to be phosphorylated as part of a signalling cascade that drives 
proliferation (Jimenez-Perez et al., 2016). This signalling cascade requires ERK, but the 
exact mechanism through which this signalling cascade increases proliferation is 
unknown. Interestingly, ERK is located in mitochondria (Wainstein and Seger, 2016) 
and may have roles in cell survival (Lee et al., 2004), proliferation and tumour cell 
phenotype (Galli et al., 2008; Lan et al., 2018), phosphorylation of transcription factors 
(Gough, Koetz and Levy, 2013) and mitochondrial gene expression (Fehrenbacher, Bar-
Sagi and Philips, 2009). There are also suggestions that ERK acts as a signalling 
molecule between the mitochondria and the nucleus (Galli et al., 2009) and as a kinase 
which directly phosphorylates respiratory complex proteins (Horbinski and Chu, 2005). 
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Thus, there may be signalling cascades in the mitochondria which function 
downstream of Kv1.3 activation which affect cell respiration and proliferation. The 
effect of mutant Kv1.3 channels on respiration is unknown, and in this chapter the link 
between the non-conducting properties of Kv1.3 channels, proliferation and 
respiration in HEK293 cells was investigated. 
 
6.2 Aims and Objectives 
The aim of this chapter was to explore whether the Kv1.3 channel-stimulated 
respiration in HEK293 cells is regulated by non-conducting mechanisms. To achieve this 
aim a key set of objectives were designed: 
 
1) To stably transfect HEK293 cells with the mutant Kv1.3 channels. The channels 
either had a functioning voltage sensor but a mutated pore (Kv1.3-P89), neither a 
functioning pore nor a functioning voltage sensor (Kv1.3-P93) or a functioning pore 
and voltage sensor, but non-functional phosphorylation sites (Kv1.3-P121). 
 
2) To confirm that non-conducting Kv1.3-P89 mutant channels, possessing a 
functioning voltage sensor and disrupted pore, could increase proliferation of HEK293 
cells. 
 
3) To investigate mitochondrial respiration in HEK293 cells transfected with the Kv1.3-
P89, Kv1.3-P121 and Kv1.3-P93 mutant Kv1.3 channels to elucidate whether the 
channel voltage sensor, pore or phosphorylation sites are key to Kv1.3-stimulated 
respiration. 
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6.3 Results 
 
6.3.1 The Kv1.3-P89, Kv1.3-P93 and Kv1.3-P121 mutant channels co-localise with 
mitochondria in HEK293 cells. 
In Chapter Three, Kv1.3 channels were found in the mitochondria of WT HEK293 
(Figure 3.9), HEK293/Kv1.3 (Figure 3.9 and 3.11) and HSVSM cells (Figure 3.12). 
Therefore, whether the mutant Kv1.3 channels also co-localized with mitochondria in 
HEK293/Kv1.3-P89, HEK293/Kv1.3-P93 and HEK293/Kv1.3-P121 cells was investigated. 
In Figure 6.1 staining for Kv1.3-P89 and Kv1.3-P93 is shown, where nuclei are stained 
blue, mitochondria red and mutant Kv1.3 in green. The yellow/orange fluorescence in 
panels D and L (Figure 6.1) highlights mitochondrial mutant Kv1.3 channels in 
HEK293/Kv1.3-P89 and HEK293/Kv1.3-P93 cells (respectively). In Figure 6.2 
HEK293/Kv1.3-P121 cells were stained for mitochondrial Kv1.3 localisation, where 
nuclei are stained blue, mitochondria green and mutant Kv1.3 in red. Co-localisation 
was shown as yellow/orange fluorescence in panel D (Figure 6.2). The mCherry red 
fluorescence of mutant Kv1.3 channels in panels C and G (Figure 6.2), is lower than the 
GFP staining of mutant Kv1.3 channels in panels C,G,K and O (Figure 6.1) which 
suggests a lower expression of mutant Kv1.3 channels in HEK293/Kv1.3-P121 cells than 
in HEK293/Kv1.3-P89 or HEK293/Kv1.3-P93 cells. To ensure the yellow/orange 
fluorescence was not an optical illusion/artefact of just closely situated (but not co-
localised) Kv1.3 channels and mitochondria, co-localisation analysis was carried out to 
determine exact pixel intensity correlation (Johannes Schindelin, no date). The results 
are shown in Figure 6.3, where the white dots reflect areas of the cell where there is 
perfect correlation between mitochondria and Kv1.3 channels. All cells exhibited some 
degree of mitochondrial Kv1.3 co-localisation (Figure 6.3. 
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Figure 6.1 Mitochondrial and Kv1.3 co-localisation in HEK293/Kv1.3-P89 and 
HEK293/Kv1.3-P93 cells. A – H) Mutant Kv1.3 channel and mitochondrial co-localisation in 
HEK293/Kv1.3-P89 cells. A. DAPI staining of HEK293/Kv1.3-P89 cell nuclei (blue). B. 
Immunostaining of cytochrome C oxidase in HEK293/Kv1.3-P89 cells to visualise the 
mitochondria (red). C. GFP tagged mutant Kv1.3 channels in HEK293/Kv1.3-P89 cells (green). 
D. Composite image of DAPI nuclear stain (blue), cytochrome C oxidase immunostain (red) 
and GFP-tagged mutant Kv1.3 cells (green). E. DAPI staining of HEK293/Kv1.3-P89 cell nuclei 
(blue). F, Control for non-specific binding by the Alexa Fluor secondary antibody. Staining was 
performed as in (B) but without anti-COX IV antibody. G. GFP tagged mutant Kv1.3 channels 
in HEK293/Kv1.3-P89 cells (green). H. Composite image of E, F and G. I - P) Mutant Kv1.3 
channel and mitochondrial co-localisation in HEK293/Kv1.3-P93 cells. I. DAPI staining of 
HEK293/Kv1.3-P93 cell nuclei (blue). J. Immunostaining of cytochrome C oxidase in 
HEK293/Kv1.3-P93 cells to visualise the mitochondria (red). K. GFP tagged mutant Kv1.3 
channels in HEK293/Kv1.3-P93 cells (green). L. Composite image of DAPI nuclear stain (blue), 
cytochrome C oxidase immunostain (red) and GFP-tagged mutant Kv1.3 cells (green). M. 
DAPI staining of HEK293/Kv1.3-P93 cell nuclei (blue). N. Control for non-specific binding by 
the Alexa Fluor secondary antibody. Staining was performed as in (J) but without anti-COXIV 
antibody. O. GFP tagged mutant Kv1.3 channels in HEK293/Kv1.3-P93 cells (green). P. 
Composite image of E, F and G. All scale bars are 10µm. 
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Figure 6.2 Mitochondrial and Kv1.3 co-localisation in HEK293/Kv1.3-P121 cells. A – D) 
Mutant Kv1.3 channel and mitochondrial co-localisation in HEK293/Kv1.3-P121 cells. A. 
DAPI staining of HEK293/Kv1.3-P121 cell nuclei (blue). B. Immunostaining of cytochrome C 
oxidase in HEK293/Kv1.3-P121 cells to visualise the mitochondria (green). C. mCherry 
tagged mutant Kv1.3 channels in HEK293/Kv1.3-P121 cells (red). D. Composite image of 
DAPI nuclear stain (blue), cytochrome C oxidase immunostain (green) and mCherry-tagged 
mutant Kv1.3 cells (red).  E. DAPI staining of HEK293/Kv1.3-P121 cell nuclei (blue). F. 
Control for non-specific binding by the Alexa Fluor secondary antibody. Staining was 
performed as in (B) but without anti-COXIV antibody. G. mCherry tagged mutant Kv1.3 
channels in HEK293/Kv1.3-P121 cells (red). H. Composite image of E, F and G. All scale bars 
are 10µm. 
 
E. F. G. H. 
A. B. C. D. 
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Figure 6.3 Mitochondrial Kv1.3 co-localisation analysis of HEK293/Kv1.3 and 
HEK293/Kv1.3 mutant cells. A. HEK293/Kv1.3-P118 cells. B. HEK293/Kv1.3-P121 cells. 
C. HEK293/Kv1.3-P89 cells. D. HEK293/Kv1.3-P93 cells. A - B. Immunostaining of 
cytochrome C oxidase in cells to visualise the mitochondria (green). Kv1.3 channels in 
these cells were tagged with mCherry (red). White dots indicate areas of co-localisation 
between mitochondria and Kv1.3 channels. C - D. Immunostaining of cytochrome C 
oxidase in cells to visualise the mitochondria (red). Kv1.3 channels in these cells were 
tagged with GFP (green). White dots indicate areas of co-localisation between 
mitochondria and Kv1.3 channels. Co-localisation analysis was carried out using the 
Coloc 2 plugin within Image J analysis software. Scale bars are 10µm. 
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6.3.2 HEK293/Kv1.3-P89, HEK293/Kv1.3-P93 and HEK293/Kv1.3-P121 had reduced K+ 
currents compared to HEK293/Kv1.3 cells. 
To determine if the mutations in the Kv1.3 channel functionally impair K+ currents in 
the transfected cells, whole cell patch clamp electrophysiology was carried out (Figure 
6.4). HEK293/Kv1.3 cells have larger K+ currents than WT HEK293 cells (Chapter Three, 
Figure 3.3). Figure 6.4 shows the IV curve of HEK293/Kv1.3 cells, when depolarised 
from -60mV to +60mV, compared to the Kv1.3-P121, Kv1.3-P89 and Kv1.3-P93 mutant 
HEK293 cells. HEK293/Kv1.3 cells had significantly greater K+ currents compared to 
HEK293/Kv1.3-P121, HEK293/Kv1.3-P89 and HEK293/Kv1.3-P93 cells (Figure 6.4). 
HEK293/Kv1.3-P121 cells displayed larger K+ currents compared to HEK293/Kv1.3-P89 
and HEK293/Kv1.3-P93 at +60mV. HEK293/Kv1.3-P121 cells have an intact voltage 
sensor and a functional pore region, and only have a mutation at a tyrosine residue at 
position 447. Therefore, these cells should illicit K+ currents which are no different to 
those in HEK293/Kv1.3 cells (Jimenez Perez et al., 2016), unless phosphorylation of the 
Y447 residue increases K+ conductance of these channels. The lower K+ currents in 
HEK293/Kv1.3-P121 cells compared to HEK293/Kv1.3 cells could also be due to lower 
Kv1.3-P121 channel expression in these cells, as suggested by their low mCherry red 
fluorescence (Figure 6.2), compared to the GFP green fluorescence of mutant channels 
in HEK293/Kv1.3-P89 and HEK293/Kv1.3-P93 cells (Figure 6.1). HEK293/Kv1.3-P89 cells 
have Kv1.3 channels with a non-functioning K+ conducting pore and HEK293/Kv1.3-P93 
cells have Kv1.3 channels with neither a functioning voltage sensor nor a K+ conducting 
pore. As expected, HEK293/Kv1.3-P89 and HEK293/Kv1.3-P93 cells displayed greatly 
reduced K+ currents upon depolarisation from -60mV to +60mV. 
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Figure 6.4 Potassium ion currents in Kv1.3 mutant cells. A. Current/voltage (IV) 
relationship for potassium ion currents between -60mV and +60mV in HEK293/Kv1.3 cells 
(n=7, blue circles), HEK293/Kv1.3-P121 cells (n=7, green squares), HEK293/Kv1.3-P89 cells 
(n=6, purple triangles) and HEK293/Kv1.3-P93 cells (n=6, red triangles). Data expressed as 
the mean current (pA) ± SEM at each voltage. At each voltage, one-way ANOVA with post 
hoc Tukey’s multiple comparison test was used to define significant differences between 
the potassium currents in each cell type. Green stars = mean current is significantly 
different to that in HEK293/Kv1.3-P121 cells. Purple stars = mean current is significantly 
different to that in HEK293/Kv1.3-P89 cells. Red stars = mean current is significantly 
different to that in HEK293/Kv1.3-P93 cells.  * p<0.05, ** p<0.01, *** p<0.001. **** 
p<0.0001. 
192 
 
6.3.3 HEK293/Kv1.3-P89 cells have increased proliferation compared to WT HEK293 
cells. 
HEK293/Kv1.3-P89 cells displayed increased proliferation compared to WT HEK293 
cells (Figure 6.5). This suggests that Kv1.3 channels which have an intact voltage 
sensor, without an ion conducting pore, can increase the proliferation of HEK293 cells. 
However, the proliferation of HEK293/Kv1.3-P89 cells was still significantly decreased 
compared with HEK293/Kv1.3 cells, perhaps indicating that ion flow through the Kv1.3 
channel can further increase proliferation. HEK293/Kv1.3-P121 cells did not have 
increased proliferation compared to WT HEK293 cells, despite having a functional 
Kv1.3 voltage sensor and ion pore (Figure 6.5). The point mutation of tyrosine 447 to 
alanine on the C-terminal of the Kv1.3-P121 channel prevents the increase in 
proliferation. This tyrosine is a phosphorylation site and so the Kv1.3-P121 channel is 
phosphorylation defective. In HEK293/Kv1.3-P93 cells, the lack of an ion conducting 
pore and a mutated voltage sensor on the Kv1.3 channel prevented Kv1.3-dependent 
proliferation of HEK293 cells (Figure 6.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5 HEK293/Kv1.3-P89 cells have increased proliferation compared to WT HEK293 
cells. Proliferation of WTHEK293, HEK293/Kv1.3, HEK293/Kv1.3-P121, HEK293/Kv1.3-P89 
and HEK293/Kv1.3-P93 cells (from left to right, respectively). Data expressed as percent 
increase from Day 0 to Day 3. Wells counted in triplicate and data expressed as the mean ± 
SEM (WT HEK293 cells, n=9, HEK293/Kv1.3 cells, n=4, HEK293/Kv1.3-P121 cells, n=7, 
HEK293/Kv1.3-P89 cells, n=9 and HEK293/Kv1.3-P93 cells, n=6).  Data was analysed using 
one-way ANOVA with Tukeys post hoc test., ** p<0.01, *** p<0.001, **** p<0.0001.  
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6.3.4 Disruption of the Kv1.3 channel pore in the Kv1.3-P89 mutation did not 
abrogate Kv1.3-stimulated respiration in HEK293 cells.  
Using the standard respirometry assay employed in previous chapters, the Routine, 
Leak, ETS and ROX Respiration of the mutant Kv1.3 cells was measured. In Chapter 
Three, we showed that HEK293/Kv1.3 cells have increased respiration compared to WT 
HEK293 cells (Figures 3.5 and 3.6). The Routine, Leak, ETS and ROX Respiration of 
HEK293/Kv1.3-P89 cells was not significantly different from that of HEK293/Kv1.3 cells 
(Figure 6.6A). It is worth noting however that the ETS Respiration (Maximum 
Uncoupled Respiration) in HEK293/Kv1.3-P89 cells trended towards being lower than 
that in HEK293/Kv1.3 cells. In addition, HEK293/Kv1.3-P89 cells displayed significantly 
increased Routine Respiration, as well as an increased level of residual O2 consumption 
(ROX) compared to WT HEK293 cells (Figure 6.6A). Although both the mean Leak 
Respiration and the mean Maximum Uncoupled Respiration trended higher in 
HEK293/Kv1.3-P89 cells compared to WT HEK293 cells, these were not statistically 
significant increases. When respiration was corrected for ROX, only Routine 
Respiration was significantly increased compared to WT HEK293 cells (6.6B) However, 
Routine, Leak and ETS Respiration were no different from that of HEK293/Kv1.3 cells. 
There were no differences in Leak Respiration between any of the cell types (6.5B). 
Since the Kv1.3-P89 mutation disrupts the channel pore, an increase in Routine 
Respiration in HEK293/Kv1.3-P89 cells indicates that K+ flow into the mitochondria is 
not necessary to increase the respiration of HEK293 cells. The presence of an intact 
voltage sensor may be needed to increase the respiration of HEK293 cells. The 
increased respiration rate is consistent with the increased proliferation rate in the 
HEK293/Kv1.3-P89 cells (Figure 6.5).  
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Figure 6.6 HEK293/Kv1.3-P89 cells have increased routine respiration compared to WT 
HEK293 cells. A. Respiration of WT HEK293 (black bars), HEK293/ Kv1.3 (light grey bars) and 
HEK293/Kv1.3-P89 (dark grey bars) cells. HEK293/Kv1.3 and WT HEK293 data is from total 
experiments (n=38 and n=27, respectively), HEK293/Kv1.3-P89 (n=9). Data is the mean O2 
consumption (O2 per cells per second, pmol/(s*Mill)) uncorrected for residual O2 
consumption (ROX). One-way ANOVA and Tukey’s post hoc test was used to analyse the 
data, * p<0.05, ** p<0.01 and *** p<0.001. Student’s t-test found HEK293/Kv1.3-P89 
routine and ROX respiration significantly higher than in WT HEK293 cells, # = p<0.05. B. 
Data in (A) corrected for ROX. One-way ANOVA and Tukey’s post hoc test was used to 
analyse the data, * p<0.05. Student’s t-test found HEK293/Kv1.3-P89 routine respiration 
significantly higher than in WT HEK293 cells, # = p<0.05. 
 
R
o
u
t
i n
e
L
e
a
k
E
T
S
R
O
X
 
0
5 0
1 0 0
1 5 0
2 0 0
H E K 2 9 3 / K v 1 . 3 - P 8 9  C e l l  R e s p i r a t i o n
O
2
 
f
l
o
w
 
p
e
r
 
c
e
l
l
s
 
p
m
o
l
/
(
s
*
M
i
l
l
)
W T  H E K 2 9 3
H E K 2 9 3 / K v 1 . 3
H E K 2 9 3 / K v 1 . 3 - P 8 9
* * *
* *
* *
* * *
#
#
A .
R
o
u
t
i n
e
 
L
e
a
k
 
E
T
S
 
0
5 0
1 0 0
1 5 0
2 0 0
H E K 2 9 3 / K v 1 . 3 - P 8 9  C e l l  R e s p i r a t i o n
O
2
 
f
l
o
w
 
p
e
r
 
c
e
l
l
s
 
p
m
o
l
/
(
s
*
M
i
l
l
)
*
#
*
W T  H E K 2 9 3
H E K 2 9 3 / K v 1 . 3
H E K 2 9 3 / K v 1 . 3 - P 8 9
B .
O
2
 c
o
n
su
m
p
ti
o
n
 p
er
 c
e
lls
 
(p
m
o
l/
 (
s*
M
ill
))
 
O
2
 c
o
n
su
m
p
ti
o
n
 p
er
 c
e
lls
 
(p
m
o
l/
 (
s*
M
ill
))
 
195 
 
6.3.5 Disruption of both the Kv1.3 voltage sensor and ion pore in HEK293/Kv1.3-P93 
cells reduces respiration compared to HEK293/Kv1.3 cells. 
HEK293/Kv1.3-P93 cells have both a non-functioning voltage sensor and non-
functioning ion conducting pore. The Routine, Leak, ETS and ROX Respiration was 
reduced in HEK293/Kv1.3-P93 cells compared to HEK293/Kv1.3 cells (Figure 6.7A). 
There was no difference between the respiration of HEK293/Kv1.3-P93 cells and WT 
HEK293 cells (Figure 6.7A). When respiration data was corrected for ROX (Figure 6.7B), 
there was once again no difference in Leak Respiration between any of the cell types. 
Despite not being statistically significant, the mean Routine and ETS respiration of 
HEK293/Kv1.3-93 trended towards being lower than that of HEK293/Kv1.3 cells (Figure 
6.7B). This suggests that the reduced respiration of HEK293/Kv1.3-P93 cells compared 
to HEK293/Kv1.3 cells is consistent with their reduced proliferation (Figure 6.5). In 
addition, the results in Figure 6.7 suggest that mitochondrial Kv1.3 channels also 
increase non-mitochondrial cellular respiration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
196 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7 Loss of the functioning ion channel pore and voltage sensor in Kv1.3 channels 
abrogates Kv1.3 induced respiration in HEK293 cells. A. Respiration of WT HEK293 (black 
bars), HEK293/Kv1.3 (light grey bars) and HEK293/Kv1.3-P93 (dark grey bars) cells. 
HEK293/Kv1.3 and WT HEK293 data is from total experiments (n=38 and n=27, 
respectively), HEK293/Kv1.3-P93 (n=9). Data is the mean O2 consumption (O2 per cells per 
second, pmol/(s*Mill)) uncorrected for residual O2 consumption (ROX). One-way ANOVA 
and Tukey’s post hoc test was used to analyse the data, * p<0.05, ** p<0.01, *** p<0.001 
and *** p<0.0001. B. Data in (A) corrected for ROX. One-way ANOVA and Tukey’s post hoc 
test was used to analyse the data, * p<0.05.  
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6.3.6 Mutation of tyrosine 447 to alanine in the Kv1.3-P121 mutant prevents Kv1.3 
induced respiration in HEK293 cells. 
HEK293/Kv1.3-P121 cells have a single point mutation of tyrosine to alanine at position 
447 on the C-terminal of the Kv1.3 channel. This tyrosine is a putative phosphorylation 
site, which is thought to involve the MAP kinase ERK (Jimenez-Perez et al., 2016), and 
so the Kv1.3-P121 channel is phosphorylation defective. The Routine, Leak, ETS and 
ROX Respiration in HEK293/Kv1.3-P121 cells was reduced compared to HEK293/Kv1.3 
cells (Figure 6.8A). Maximum Uncoupled Respiration (ETS) of HEK293/Kv1.3-P121 cells 
was decreased below that of WT HEK293 cells (Figure 6.8A). When data was corrected 
for ROX (Figure 6.8B), Leak Respiration was not significantly different between the 
three cell types. Both Routine and ETS Respiration were reduced in HEK293/Kv1.3-
P121 cells compared to HEK293/Kv1.3 cells (Figure 6.8B). These data suggest that the 
loss of the putative phosphorylation site on tyrosine 447 in Kv1.3-P121 channels 
reduces the Maximum Uncoupled Respiration in HEK293/Kv1.3-P121 cells. The 
reduced respiration of HEK293/Kv1.3-P121 cells is consistent with their reduced 
proliferation compared to HEK293/Kv1.3 cells (Figure 6.5). 
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Figure 6.8 Mutation of tyrosine 447 to alanine on the C terminus of the Kv1.3-P121 
channel abolishes Kv1.3 stimulated respiration in HEK293 cells. A. Respiration of WT 
HEK293 (black bars), HEK293/ Kv1.3 (light grey bars) and HEK293/Kv1.3-P121 (dark grey 
bars) cells. HEK293/Kv1.3 and WT HEK293 data is from total experiments (n=38 and n=27, 
respectively), HEK293/Kv1.3-P121 (n=6). Data is the mean O2 consumption (O2 per cells per 
second, pmol/(s*Mill)) uncorrected for residual O2 consumption (ROX). One-way ANOVA 
and Tukey’s post hoc test was used to analyse the data, ** p<0.01, *** p<0.001 and **** 
p<0.0001. Student’s t-test found HEK293/Kv1.3-P121 ETS respiration significantly lower 
than in WT HEK293 cells, # = p<0.05. B. Data in (A) corrected for ROX. One-way ANOVA and 
Tukey’s post hoc test was used to analyse the data, * p<0.05. Student’s t-test found 
HEK293/Kv1.3-P121 ETS respiration significantly lower than in WT HEK293 cells, # = p<0.05. 
 
 
 
 
199 
 
6.3.7 Disruption of the Kv1.3 channel pore in the Kv1.3-P89 mutation did not 
abrogate Kv1.3-stimulated residual oxygen consumption in HEK293 cells.  
On collection of the data from the standard respirometry assays, ROX Respiration in 
the mutant Kv1.3 HEK293 cells was analysed (Figure 6.9). In Chapter Three we showed 
that HEK293/Kv1.3 cells have increased ROX compared to WT HEK293 cells. As stated 
in Figure 6.6, HEK293/Kv1.3-P89 ROX Respiration was no different to HEK293/Kv1.3 
cells, while HEK293/Kv1.3-P93 (Figure 6.7) and HEK293/Kv1.3-P121 (Figure 6.8) was 
significantly lower. In Figure 6.9, HEK293/Kv1.3-P89 ROX Respiration trended towards 
being around twice that of HEK293/Kv1.3-P93 cells, and around three times that of 
HEK293/Kv1.3-P121 cells. This may indicate that a voltage dependent conformational 
change in the Kv1.3 channel exposes key phosphorylation residues on the C-terminus 
of the channel, which are essential for stimulating the non-mitochondrial respiration in 
HEK293 cells. Phosphorylation of tyrosine 447 is especially important in this signalling 
pathway as mutation to alanine in HEK293/Kv1.3-P121 cells abolished Kv1.3 stimulated 
ROX Respiration (Figure 6.9), despite having a functional voltage sensing and K+ 
conducting Kv1.3 channel. 
 
  
Figure 6.9 Comparison of Residual Oxygen Consumption in WT HEK293, HEK293/Kv1.3 
and HEK293/Kv1.3 mutant cells. Data obtained and collated from previous figures (Figures 
6.5, 6.6 and 6.7). Data expressed as the mean O2 consumption per million cells per second 
(pmol/(s*Mill)) ± SEM. One-way ANOVA and Tukey’s post hoc test was used to analyse the 
data, * p<0.05 and *** p<0.001. Student’s t-test found HEK293/Kv1.3-P89 ROX was 
significantly higher than in WT HEK293 cells, # = p<0.05. 
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6.3.8 Mutation of the Kv1.3 pore independent of the voltage sensor did not affect 
Kv1.3 channel-stimulated ATP turnover in HEK293/Kv1.3-P89  
From the respirometry data ATP turnover rate was calculated for WT, Kv1.3, Kv1.3-
P121, Kv1.3-P89 and Kv1.3-P93 HEK 293 cells (Figure 6.10). HEK293/Kv1.3-P89 cells 
had a significantly higher ATP turnover rate than WT HEK293 cells, with no significant 
difference between the ATP turnover rate of HEK293/Kv1.3 and HEK293/Kv1.3-P89 
cells (Figure 6.10). There was no difference between the ATP turnover in WT HEK293 
cells, HEK293/Kv1.3-P93 and HEK293/Kv1.3-P121 cells (Figure 6.10). These data 
suggest that the Kv1.3 channel voltage sensor, but not the ion pore, contribute to 
Kv1.3 channel-mediated ATP turnover. The data also suggests that in HEK293/Kv1.3-
P121 cells, the phosphorylation defective Kv1.3-P121 channel abolishes the Kv1.3 
induced increase in ATP turnover, indicating the tyrosine 447 residue as being essential 
for the increased ATP turnover in HEK293/Kv1.3 cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10 HEK293/Kv1.3-P89 cells have ATP turnover increased to WT HEK293 cells and 
no different to HEK293/Kv1.3 cells. ATP turnover rate in WT HEK293, HEK293/Kv1.3, 
HEK293/Kv1.3-P89, HEK293/Kv1.3-P93 and HEK293/Kv1.3-P121 cells (left to right columns). 
ATP turnover is the difference between routine respiration and leak respiration. Data 
expressed as the mean O2 consumption per cells (pmol/(s*mill)) ± SEM (WT HEK293, n=27, 
HEK293/Kv1.3, n=38, HEK293/Kv1.3-P89, n=9, HEK293/Kv1.3-P93, n=9, HEK293/Kv1.3-
P121, n=6). Data analysed using One-way ANOVA with Tukey’s post hoc test, * p<0.05. 
Student’s t-tests were used to analyse results, # p<0.05.  
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6.3.9 HEK293/Kv1.3-P121 cells had reduced spare respiratory capacity compared to 
WT HEK293 cells. 
The spare respiratory capacity (SRC) was calculated for WT, Kv1.3, Kv1.3-P121, Kv1.3-
P89 and Kv1.3-P93 HEK293 cells (Figure 6.11). Compared to WT HEK293 cells, none of 
the Kv1.3 mutant cell lines displayed an increased SRC (Figure 6.11), seen in 
HEK293/Kv1.3 cells. HEK293/Kv1.3-P121 cells had a significantly reduced SRC 
compared to WT HEK293 and HEK293/Kv1.3 cells (Figure 6.11), due to their 
significantly reduced ETS respiration (Figure 6.8). In contrast to previous data in this 
chapter, which showed both HEK293/Kv1.3 and HEK293/Kv1.3-P89 cells share a similar 
respiratory phenotype, with increased respiration compared to WT HEK293 cells, this 
was not the case for the SRC in these cells (Figure 6.11). The difference in SRC between 
HEK293/Kv1.3 and HEK293/Kv1.3-P89 cells could be due to the K+ flow through the 
channel in HEK293/Kv1.3 cells, whereby the inability of K+ flow through the Kv1.3 
channel in HEK293/Kv1.3-P89 cells, due to the pore mutation, may prevent the 
increase in SRC. However, Kv1.3-P121 channels have similar biophysics to Kv1.3 
channels, yet HEK293/Kv1.3-P121 cells had a reduced SRC compared to HEK293/Kv1.3 
cells, suggesting it is not the flow of K+ through the channel that contributes to the 
SRC. The data suggests that the presence of both the channel pore and the tyrosine 
447 phosphorylation site are needed in unison for the increased SRC seen in 
HEK293/Kv1.3 cells.  
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Figure 6.11 HEK293/Kv1.3-P121 cells have a reduced spare respiratory capacity compared 
to WT HEK293 and HEK293/Kv1.3 cells. Spare respiratory capacity in WT HEK293, 
HEK293/Kv1.3, HEK293/Kv1.3-P89, HEK293/Kv1.3-P93 and HEK293/Kv1.3-P121 cells (left to 
right columns). Spare respiratory capacity is the difference between routine respiration and 
maximum uncoupled respiration. Data expressed as the mean O2 consumption per million 
cells per second (pmol/(s*mill)) ± SEM (WT HEK293, n=27, HEK293/Kv1.3, n=38, 
HEK293/Kv1.3-P89, n=9, HEK293/Kv1.3-P93, n=9, HEK293/Kv1.3-P121, n=6). Data analysed 
using one way ANOVA with Tukeys post hoc test, * p<0.05. Student’s t-tests used to 
analyse results, # p<0.05. 
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6.4 Discussion 
 
In this chapter we show that mutant Kv1.3 channels co-localise to the mitochondria in 
HEK293/Kv1.3-P89, HEK293/Kv1.3-P93 and HEK293/Kv1.3-P121 cells. Mitochondrial 
Kv1.3 channels have not previously been described in HEK293 cells. We confirmed that 
HEK293/Kv1.3-P89 cells have increased proliferation compared to WT HEK293 cells, 
and, since the Kv1.3-P89 mutant has a defective channel pore, that this was 
independent of K+ flow through the channel. As the proliferation of HEK293/Kv1.3-
P121 cells was no different to WT HEK293 cells, despite having voltage sensitive Kv1.3 
channels with functional K+ conduction, we confirmed that the presence of tyrosine at 
position 447 on the C-terminus of the channel is necessary for the Kv1.3 induced 
increase in proliferation (in HEK293/Kv1.3-P121 cells the tyrosine at 447 is mutated to 
alanine). These findings are in support of those described by Cidad et al., (2012) and 
Jimenez-Perez et al., (2016). 
A link between Kv1.3 non-canonical functions and metabolism has not previously been 
explored. These results present a novel finding which shows that disruption of the 
Kv1.3 channel pore in HEK293/Kv1.3-P89 cells did not abrogate Kv1.3 stimulated 
respiration in HEK293 cells; however disruption of both the voltage sensor and the 
pore did impair Kv1.3 stimulated respiration (HEK293/Kv1.3-P93 cells). Therefore, the 
Kv1.3 voltage sensor must be key to increasing respiration in HEK293/Kv1.3 cells. In 
addition, it seems that the presence of tyrosine 447 on the C-terminal is also necessary 
to increase the respiration of HEK293 cells. Mutation of tyrosine 447 to alanine 
abolished the Kv1.3 stimulated respiration in HEK293/Kv1.3-P121 cells, despite the 
Kv1.3 channels in these cells having a functional voltage sensor and an intact pore. 
HEK293/Kv1.3-P121 cells also had significantly lower SRC than WT HEK293 cells, 
suggesting that under physiological conditions, tyrosine at position 447 in Kv1.3 
channels is essential for maintaining respiration in HEK293 cells. However, presence of 
tyrosine 447 must not be the only factor which contributes to SRC, as HEK293/Kv1.3-
P89 cells have a SRC no different to WT HEK293 cells, despite having intact tyrosine 
447 at the C-terminus. This suggests that in addition to tyrosine 447, K+ flow through 
the Kv1.3 channel may also contribute to the increased SRC seen in HEK293/Kv1.3 
cells. Also, our results indicate that increased non-mitochondrial respiration (ROX) in 
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HEK293/Kv1.3 cells may depend on the presence of a functional voltage sensor and 
tyrosine 447. HEK293/Kv1.3-P89 cells had ROX Respiration no different to 
HEK293/Kv1.3 cells, but this was abolished in cells with a mutated Kv1.3 channel 
voltage sensor (HEK293/Kv1.3-P93 cells) or had tyrosine 447 on their C-terminus 
substituted to alanine (HEK293/Kv1.3-P121 cells). This suggests that the Kv1.3 channel 
effects respiration at other locations in the cell, in addition to in the mitochondria, and 
this depends on the channel having a functional voltage sensor and tyrosine 447 at the 
C-terminus. Non-mitochondrial O2 consumption has been described at the cell surface 
(Herst et al., 2004, 2008; Herst and Berridge, 2006) due to trans-plasma membrane 
electron transport (t-PMET). T-PMET is ubiquitous to all cells (Principe et al., 2011) and 
is involved in NADH redox regulation (Herst et al., 2004). It functions to recycle NADH 
to NAD+, which is necessary to maintain glycolysis and proliferation in some highly 
proliferating cells, like leukemic cancer cells (Herst and Berridge, 2007). As in the 
mitochondrial ETS, O2 is the terminal electron acceptor in t-PMET, and so an increase 
in t-PMET would lead to increased O2 consumption at the membrane. NADPH oxidases 
are a class of enzymes which contribute to t-PMET, and are another source of O2 
consumption at the plasma membrane as they reduce O2 to superoxide (Principe et al., 
2011). In Chapter Five, HEK293/Kv1.3 cells were found to have higher NADH 
autofluorescence, and so t-PMET may be higher in these cells, possibly contributing to 
the higher level of ROX compared to WT HEK293 cells. It is possible that Kv1.3 channels 
may contribute to O2 consumption at the plasma membrane, by a yet unknown 
mechanism. This may involve a cell signalling cascade involving ERK, as mutation of 
tyrosine to alanine in HEK293/Kv1.3-P121 cells renders the channels phosphorylation 
defective at tyrosine 447 (Jimenez-Perez et al., 2016) and is sufficient to abolish the 
increased ROX. T-PMET has been found to have roles in cell signalling involving the 
phosphorylation and activation of other protein kinases, such as p70S6K. Interestingly, 
T-PMET dependent phosphorylation of p70S6K is needed for ribosomal protein 
synthesis which supports proliferation in skeletal muscle (Kelly et al., 2018), which 
suggests t-PMET may also support proliferation in other cells and by other cell 
signalling cascades. T-PMET cell signalling depends on generation of ROS from NADPH 
oxidases in the plasma membrane (Kelly et al., 2018). Therefore, a link between 
plasma membrane Kv1.3 channels, phosphorylation of tyrosine 447 on the C-terminus, 
ROS generation and proliferation may exist and warrants further exploration. 
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 The lack of a channel pore in HEK293/Kv1.3-P89 cells did not affect the ATP turnover 
rate, but mutation of the voltage sensor (HEK293/Kv1.3-P93) and tyrosine 447 on the 
C-terminus (HEK293/Kv1.3-P121) did reduce it. This suggests that the voltage sensor 
and tyrosine 447 in Kv1.3 channels are key to the maintenance of ATP turnover in 
HEK293 cells. For the first time we have shown that the non-conducting properties of 
Kv1.3 channels can affect cellular respiration. Not only do these non-canonical 
properties of the Kv1.3 channel increase OXPHOS of HEK293 cells, but they appear to 
also increase non-mitochondrial respiration. These Kv1.3 mediated changes to 
respiration result in an increase in ATP turnover which may then support cellular 
proliferation. In the quest for new therapeutics for proliferative disorders with a Kv1.3 
channel component, such as atherosclerosis, restenosis and hypertension, this 
research suggests potential new drug targets, including the channel voltage sensor and 
putative phosphorylation site, tyrosine 447. Specific targeting of signalling pathways 
which prominently increase proliferation means that selective treatments with 
minimal side effects can be developed. What remains to be confirmed is the signalling 
cascades and mechanisms which underly how the non-conducting properties of Kv1.3 
channels can mediate respiration and proliferation.  
Several of the observed effects of Kv1.3 on HEK293 respiration are dependent on both 
a functioning voltage sensor and presence of an intact tyrosine residue at position 447 
on the C-terminus of the Kv1.3 channel. Therefore, a signalling pathway may link the 
putative phosphorylation of tyrosine 447 to the respiration of HEK293 cells. Upon 
voltage sensing, it is thought the Kv1.3 channel undergoes a conformational change 
which exposes key residues on the C-terminal to various kinases (Jimenez-Perez et al., 
2016; Lopez-Lopez, Cidad and Perez-Garcia, 2018; Perez-Garcia, Cidad and Lopez-
Lopez, 2018). There are three key residues on the C-terminus of Kv1.3 channels which 
can abolish Kv1.3 stimulated proliferation when they are mutated (Jimenez Perez et 
al., 2016). Tyrosine 447, serine 459 and tyrosine 477 all abolish Kv1.3 induced 
proliferation when they are mutated to alanine, with tyrosine 447 having the most 
potent effects (Jimenez Perez et al., 2016). The mechanism by which these residues 
increase proliferation is not clear, however, at least for the case of tyrosine 447, it is 
thought to involve phosphorylation of the residue by ERK1/2 (extracellular signal 
related kinase). ERK1/2 is involved in Kv1.3 induced proliferation of VSMCS because 
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treatment of these cells with either blockers of the channel, or of the ERK1/2 signalling 
pathway inhibited VSMC proliferation in a non-additive fashion (Cidad et al., 2015). In 
VSMCs the exact ERK signalling cascades have not been confirmed. The results from 
this work and Jimenez Perez et al.’s work (2016) present the possibility that 
phosphorylation of tyrosine 447 on the mitochondrial Kv1.3 channel may increase 
respiration and proliferation of HEK293 cells via an ERK1/2 dependent pathway.  
Therefore, the possibility of mitochondria as key signalling organelles in Kv1.3 induced 
cell proliferation must be considered. Interestingly, many kinases like PKC, PKA, Akt 
and MAPKs have already been found to participate in mitochondrial signalling 
pathways (Antico Arciuch et al., 2009). ERK has also been observed to localise to the 
mitochondria (Wainstein and Seger, 2016), where it is found near the IMM, IMS and 
OMM. 
Our results would suggest that availability of tyrosine 447 on the Kv1.3 channel 
increases respiration. Kinases, such as ERK1/2 have been found to have a role in 
energy homeostasis. For example, ERK1/2 can increase lipolysis in adipocytes (Jeong et 
al., 2015), which would increase the substrates available for the TCA cycle and 
therefore increase the activity of the ETS. ERK1/2 has also been found to regulate the 
transition by which adipocytes change from energy-storing white cells to energy-
consuming brown cells, by increasing O2 consumption and uncoupling protein in the 
mitochondria (Zhang et al., 2016). HEK293/Kv1.3-P89 cells (poreless mutants with 
accessible tyrosine 447 on the C-terminus) had increased mitochondrial O2 
consumption and ROX compared to WT HEK293 cells. As mentioned previously, a 
source of non-mitochondrial O2 consumption is t-PMET at the cell surface. T-PMET is 
dependent on glycolysis (and the TCA cycle) to generate NADH, because for O2 to be 
reduced at the plasma membrane, electrons from NADH must be donated to a 
ubiquinone in the plasma membrane. In highly proliferating cancer cells, an increase in 
glucose entering the cell via GLUT1, and an increase in hexokinase activity (the enzyme 
that catalyses the first step of glycolysis, generating glucose-6-phosphate), increases 
the amount of t-PMET and O2 consumption. Therefore, the level of non-mitochondrial 
O2 consumption is very much dependent on the level of glycolysis. In HEK293/Kv1.3 
cells, results in Chapter Five indicated that they had increased glycolysis compared to 
WT HEK293 cells. If glycolysis increases non-mitochondrial O2 consumption at the 
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plasma membrane, then an increase in ROX in HEK293/Kv1.3-P89 cells suggests they 
too have an increase in glycolysis. Interestingly, ERK has been found to regulate 
glucose entry into proliferating cells via its activation of the transcription factor, c-myc, 
which increases GLUT1 at the plasma membrane (Papa, Choy and Bubici, 2019). An 
increase in glucose entering HEK293/Kv1.3 cells may lead to an increase in glycolysis, 
and thus generation of NADH. An increase in T-PMET would need to occur in order to 
minimise reductive stress (an increase in NADH), which would inhibit respiratory 
pathways if NAD+ was unavailable for reduction. An increase in t-PMET in 
HEK293/Kv1.3 cells may also contribute to the increased ROS seen in these cells 
(Chapter Five), as activity of NADPH oxidases in the plasma membrane generate 
superoxide. The levels of ROS in the mutant Kv1.3 cells would need to be determined 
in future work. 
Regardless of the extent to which non-mitochondrial respiration is mediated by Kv1.3 
channels, HEK293/Kv1.3-P89 cells still displayed increased mitochondrial respiration 
compared to WT HEK293 cells. Ion-conduction independent roles for the channels 
must exist and are likely to involve phosphorylation of tyrosine 447 on the C-terminus. 
Interestingly, there exists ROS dependent, ERK mediated mitochondrial-nuclear 
communication in Leydig cells (Galli et al., 2008). Galli et al., (2008) demonstrate that 
low levels of ROS can initiate oxidation and translocation of ERK to the nucleus, whilst 
high levels of ROS can inhibit activation of ERK. If ERK is ROS dependent, then the 
levels of ROS exhibited in HEK293/Kv1.3 and HEK293/Kv1.3-P89 cells may be optimum 
for ERK activation, leading to translocation of ERK to the nucleus and stimulation of 
proliferation. The level of ROS in a cell is also linked to its SRC. The SRC provides the 
mitochondria with extra capacity during times of oxidative stress and is therefore 
important for cell survival (Nicholls and Ferguson, 2013). The higher the basal ROS 
level in cells, the higher the SRC would be expected to be. A low SRC in 
phosphorylation defective HEK293/Kv1.3-P121 cells indicates these cells are less able 
to cope with oxidative stress than their WT Kv1.3 counterpart (Brand and Nicholls, 
2011). The high SRC in HEK293/Kv1.3 cells may be an adaptation to a higher level of 
ROS, generated in part by the increased mitochondrial (and perhaps non-
mitochondrial) respiration in these cells. The reduction in SRC in HEK293/Kv1.3-P121 
cells, compared to both WT HEK293 and HEK293/Kv1.3 cells, suggests that 
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phosphorylation of tyrosine 447 initiates a signalling cascade which is important for 
normal cellular respiration and the ability of the respiratory system to adapt to 
changes in the oxidative environment.   
It is important to note that non-conducting roles of the channel are not the only 
mechanism by which Kv1.3 channels increase proliferation. Proliferation is significantly 
different between the HEK293/Kv1.3 and HEK293/Kv1.3-P89 cells, but their respiration 
is the same. This confirms that there must be non-metabolic and/or K+ conduction 
dependent Kv1.3 mechanisms contributing to the proliferative phenotype of 
HEK293/Kv1.3 cells. For example, hyperpolarisation from K+ flow through plasma 
membrane K channels has previously been found to be necessary for proliferation of 
VSMCs (Neylon et al., 1999; Ivanov et al., 2006). As previously mentioned, multiple 
mechanisms have been proposed for Kv1.3 induced proliferation and they may not be 
mutually exclusive (Lopez-Lopez, Cidad and Perez-Garcia, 2018). These mechanisms 
involving K+ conductance, such as regulation of membrane potential, cell volume and 
intracellular Ca2+ concentration could also be contributing to the increased 
proliferation rate of HEK293/Kv1.3 cells (Lopez-Lopez, Cidad and Perez-Garcia, 2018).  
Currently we are only able to speculate, based on the literature, that ERK is involved in 
the proliferation and respiration of mutant Kv1.3 cells. Furthermore, we do not explore 
the contributions to proliferation and respiration of the other phosphorylation 
residues on the Kv1.3 C-terminus and potential associated signalling mechanisms. We 
are unable to confirm whether the increase in respiration driven by Kv1.3 is directly 
linked to the proliferative phenotype of the channel.  
To build on the data found in Chapter Five, it would be interesting to measure MMP, 
cell ROS, glycolysis and NADH levels in HEK293/Kv1.3-P89, H3K293/Kv1.3-P93 and 
HEK293/Kv1.3-P121 cells. This would enable us to identify whether key sites on the 
Kv1.3 channel were responsible for changing the unique phenotypes observed in these 
parameters via a cell signalling mechanism. Moreover, inhibition of respiration, whilst 
measuring proliferation would confirm if the increased respiration in HEK293/Kv1.3-
P89 cells does generate the energy required to drive the proliferative phenotype. 
Treatment of cells with the antioxidant MitoQ would allow us to determine if ROS 
contributed to the increased proliferation in HEK293/Kv1.3 cells. Treating the 
HEK293/Kv1.3 and Kv1.3-P121 cells with an inhibitor of the ERK signalling pathway and 
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monitoring proliferation and respiration would be important to investigate the 
potential Kv1.3/mitochondrial/nuclear signalling cascades. Finally, it will be important 
to identify other putative phosphorylation residues on the Kv1.3 channel which may 
affect respiration. 
In summary, Kv1.3 channels increase cellular respiration in a K+ conduction-
independent manner which requires an intact voltage sensor and the putative 
phosphorylation site at tyrosine 447 of the C-terminal region. The proliferation rate of 
HEK293/Kv1.3 mutant clones mirrors the respiration rate. This may suggest that cell 
signalling via the Kv1.3 channel stimulates respiration in the mitochondria, which 
provides the energy for proliferation. Non-conducting mutant channels also have 
increased ROX. Future identification of the non-conducting Kv1.3 mechanisms which 
drive changes in metabolism will be needed.  
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Chapter Seven 
 
General Discussion and Future Directions 
 
7.1 Summary 
Pathological proliferation of VSMCs occurs in vascular diseases like atherosclerosis, 
hypertension and restenosis (Owens, 1988; Lusis, 2000; Rzucidlo, Martin and Powell, 
2007). Atherosclerosis and hypertension lead to vascular remodelling which can result 
in myocardial infarction and stroke, two of the most common causes of death in the 
western world (World Health Organisation, 2018). The number of deaths from these 
conditions are expected to rise in coming years (Khavjou, Phelps and Leib, 2016; 
Wilkins et al., 2017). An additional concern is that the incidence of these morbidities in 
developing countries is rising (Gaziano et al., 2010). A better understanding of the 
mechanisms which drive pathological proliferation of VSMCs is of upmost importance 
to reduce the numbers of deaths from CVD. The phenotypic switch in VSMCs sees 
them change from contractile cells, to proliferative and secretory cells (Owens, Kumar 
and Wamhoff, 2004). The Kv1.3 channel has been implicated in this phenotypic switch, 
but the mechanism underlying how it contributes to proliferation is a subject of debate 
(Perez-Garcia, Cidad and Lopez-Lopez, 2018). Elucidating the mechanisms driving this 
proliferation will be key to the development of new therapies. Previously thought to 
only exist in the plasma membrane, the Kv1.3 channel has now been found at multiple 
intracellular positions, notably on membranes of the nucleus, the cis-Golgi and the 
mitochondria (Szabo et al., 2005; Zhu, Yan and Thornhill, 2014; Jang et al., 2015). The 
contribution of these intracellular Kv1.3 channels to VSMC proliferation has not been 
explored. However, a role for mitochondrial Kv1.3 channels in the apoptosis of cancer 
cells has been described (Szabó et al., 2008; Leanza et al., 2017; Venturini et al., 2017; 
Mattarei et al., 2018). Whether these channels regulate physiological mitochondrial 
functions was not known. This work aimed to explore the role of mitochondrial Kv1.3 
channels in HEK293 cell proliferation and respiration. The work was carried out in 
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stable ion channel overexpression HEK293 cell system (Scragg et al., 2008; Cidad et al., 
2010, 2012; Duckles et al., 2015; Jimenez-Perez et al., 2016). 
7.2 Principle Findings 
In Chapters Three and Four, the relationship between mitochondrial Kv1.3 channels, 
proliferation and respiration were assessed in HEK293/Kv1.3 cells. In line with previous 
reports (Cidad et al., 2012), overexpression of Kv1.3 channels in HEK293 cells increased 
their proliferation. For the first time, we reported that overexpression of Kv1.3 in 
HEK293 cells increased respiration, correlating to increased ATP turnover and SRC. 
Increased respiration in HEK293/Kv1.3 cells could not be attributed to differences in 
mitochondrial number or mitochondrial network structure, despite some suggestions 
that Kv1.3 may alter these parameters (DeCoursey et al., 1984; Kovach et al., 2016). 
Kv1.3 channels were detected in the mitochondria of HEK293 cells and HSVSM cells. 
While mitochondrial channels have been found in various cells types (Szabo et al., 
2005; Bednarczyk et al., 2010; Cheng, Debska-Vielhaber and Siemen, 2010; Leanza et 
al., 2017; Mattarei et al., 2018), this is the first report of their location in HSVSMCs. 
Targeted inhibition of these channels reduces proliferation and respiration in HEK293 
cells, which opens up the possibility that the channels may have a physiological role in 
increasing these processes in proliferating VSMCS, where Kv1.3 is upregulated (Cidad 
et al., 2010; Cheong et al., 2011).  
The mechanisms behind mitochondrial Kv1.3 induced respiration and proliferation in 
HEK293 cells were further elucidated. Chapter Five presented data suggesting 
increased cellular glycolysis and NADH, a more hyperpolarised MMP and an increase in 
ROS level in HEK293/Kv1.3 cells. Inhibition of mitochondrial Kv1.3 with 100nM PAPTP 
had no effect on overall MMP but was able to increase leak respiration in HEK293 cells, 
suggesting that it could hyperpolarise the MMP. This indicates that while K+ flow 
through mitochondrial Kv1.3 depolarises the MMP, it is not large enough to affect the 
overall MMP in HEK293 cells. This is in line with previous reports suggesting K+ flow 
into the mitochondria through IMM channels has little effect on the MMP 
(Kowaltowski et al., 2001; Heinen et al., 2007). We speculated that the increased 
glycolysis in HEK293/Kv1.3 cells could be the reason behind the hyperpolarisation of 
the MMP (Beltrán et al., 2000; Poulsen et al., 2008; Olsen et al., 2009; Forrest, 2015), 
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but further work is required to confirm this. A hyperpolarised MMP would increase the 
protonmotive force between the IMS and the matrix, and thus would increase ATP 
production at the ATP synthase (Nicholls and Ferguson, 2013). In addition, glycolysis 
may have additional functions in supporting the biosynthesis of molecules necessary 
for growth (Vander Heiden, Cantley and Thompson, 2009). Increased mitochondrial 
NADH may also result from the increased glycolysis (Herst and Berridge, 2006; Vander 
Heiden, Cantley and Thompson, 2009). As mitochondrial Kv1.3 had no effect on the 
NADH level in HEK293/Kv1.3 cells, the increase in NADH may have originated from 
non-mitochondrial metabolism (Herst and Berridge, 2006, 2007). Increased NADH 
delivery to complex one would result in more electrons being donated to the ETS, 
leading to increased proton pumping and ATP synthesis via the ATP-synthase (Nicholls 
and Ferguson, 2013). In addition, increased NADH would result in increased ROS 
formation caused by electron slip at the complexes (Nicholls and Ferguson, 2013). 
These ROS were found to have direct stimulatory effects on proliferation of 
HEK293/Kv1.3 cells. Thus, in the case of HEK293 cells, glycolysis and OXPHOS are both 
upregulated and may complement each other to maximise ATP production and 
support growth. 
The influence of non-conducting roles of Kv1.3 (Cidad et al., 2012; Jimenez-Perez et al., 
2016) on cellular respiration were further investigated in Chapter Six. It had previously 
been established that a functional voltage sensor and intact phosphorylation residues 
on the C-terminus of Kv1.3 channels were necessary to increase proliferation in 
HEK293 cells (Cidad et al., 2012; Jimenez-Perez et al., 2016). It is suggested that upon 
sensing of voltage, there is a conformational change in the Kv1.3 channel, which along 
with opening the channel pore can expose key residues to phosphorylation, which 
activates a signalling cascade regulating proliferation. Three residues, tyrosine 447, 
serine 459 and threonine 477 were involved in Kv1.3 induced proliferation(Jimenez-
Perez et al., 2016). Tyrosine 447 was identified as being part of a signalling pathway, 
involving phosphotyrosine activation and ERK1/2 activity (Jimenez Perez et al., 2016). 
ERK1/2 is involved in cell proliferation, most commonly by increasing the transcription 
of cell cycle machinery (Mebratu and Tesfaigzi, 2009). In Chapter Six, we used Kv1.3 
channel mutants to investigate their effects on respiration in HEK293 cells. It was 
found that to increase respiration, K+ conduction through Kv1.3 was unnecessary, as 
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non-conducting pore mutants which had a functioning voltage sensor and intact 
tyrosine 447 increased respiration in HEK293 cells to a similar extent as was observed 
in HEK293/Kv1.3 cells.  These results correlated with an increased rate of proliferation 
in these cells (Cidad et al., 2012; Jimenez-Perez et al., 2016). The increase in 
respiration in these pore mutants correlated to an increased ATP turnover rate and 
ROX. As glycolysis contributed significantly to both these parameters in HEK293/Kv1.3 
cells (Chapter Five), it suggests that glycolysis may also be increased in the pore 
mutants and future experiments will be required to confirm this. Glycolysis would 
increase NADH levels and t-PMET activity, leading to O2 consumption at the cell surface 
(Herst et al., 2004) which would contribute to ROX. In addition t-PMET is regulated by 
oxidases in the plasma membrane, such as NOX1, which would produce ROS, further 
increasing ROX (Kelly et al., 2018). An increase in glycolysis (and the associated NADH) 
and an increase in OXPHOS, would likely increase ROS in HEK293/Kv1.3-P89 cells 
(Nicholls and Ferguson, 2013) as was the case in HEK293/Kv1.3 cells with a similar 
respiratory profile. In support of this, the increased ROX in HEK293/Kv1.3-P89 cells 
suggests that ROS is higher in these cells, which may then contribute to their higher 
level of proliferation (as in HEK293/Kv1.3 cells). In addition, other sources of non-
mitochondrial O2 consumption may contribute to HEK293/Kv1.3 ROX, for example 
desaturase enzymes involved in lipid metabolism (Shanklin et al., 2009) or P450 types 
enzymes involved in the metabolism of various substances (Lynch and Price, 2007; 
Guengerich, Waterman and Egli, 2016).The conclusions from Chapter Six identified 
that the Kv1.3 channel can increase respiration via non-canonical cell signalling 
pathways, which rely on the presence of a functional voltage sensor and presence of 
tyrosine 447 on the C-terminus. Although the exact cell signalling pathways are 
unknown, availability of tyrosine 447 suggests that phosphotyrosine and ERK1/2 could 
be involved (Jimenez Perez et al., 2016). We have shown that the Kv1.3 channel has 
profound effects on cellular bioenergetics which may regulate Kv1.3 induced 
proliferation. Importantly, there are some key areas for future work which have arisen 
from this study. 
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7.3 Future Work 
Identification of non-conducting roles of mitochondrial Kv1.3 channels 
We show that mitochondrial Kv1.3 has a direct role in respiration and proliferation in 
HEK293 cells. In Chapter Six, we can only deduce that the mutated Kv1.3 channel, 
which retains its ability to sense voltage and expose tyrosine 447, increases 
respiration. Treatment of all three mutant Kv1.3 cell types used in Chapter Six with 
PAPTP, PAP-1 and SHK-Dap22 would be essential to dissect the contributions of the 
signalling by Kv1.3 channels at different cellular locations. Using these inhibitors, with 
the mutants, it would also be necessary to measure other parameters such as 
glycolysis and ROS to identify their origin.  
Identification of the Kv1.3 signalling pathways involved 
Based on previous work (Cidad et al., 2012; Jimenez-Perez et al., 2016) we can only 
hypothesise that ERK1/2 is involved in the signalling cascade from Kv1.3 tyrosine 447. 
Its mitochondrial localisation (Antico Arciuch et al., 2009), roles in mitochondrial-
nuclear signalling (Poderoso et al., 2008; Galli et al., 2009), potential to phosphorylate 
ETS complexes (Kowalczyk and Zablocka, 2008), role as an ATP sensor in the 
mitochondria (Monick et al., 2008) and ability to regulate glycolysis (Papa, Choy and 
Bubici, 2019) make it an attractive candidate as a signalling molecule involved in Kv1.3 
induced respiration and proliferation. Investigations could focus on knock-down of 
ERK1/2 and subsequent measurement of respiration (glycolysis and OXPHOS) and 
proliferation. As there are additional phosphorylation residues on the Kv1.3 C-terminal 
which have been found to contribute to the non-canonical regulation of proliferation 
(Jimenez Perez et al., 2016), it would also be necessary to investigate if any additional 
phosphorylation residues on the Kv1.3 channel that stimulate respiration and 
proliferation. 
Characterising increased glycolysis in HEK293/Kv1.3 cells 
Investigation into the ERK 1/2 signalling pathway may shed light onto how Kv1.3 
causes a coordinated increase in glycolysis, as many signalling pathways and kinases 
have been found to be involved in regulating glycolysis (Ward and Thompson, 2012). It 
would also be interesting to measure the enzymes which regulate glycolysis in WT 
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HEK293 vs HEK293/Kv1.3 vs HEK293/Kv1.3 mutants to assess if the Kv1.3 channel is 
involved in upregulating them. Increased glycolysis may provide energy for the 
enhanced OXPHOS by providing the TCA cycle with increased pyruvate. In terms of 
measuring the effects of glycolysis upregulation on HEK293 cells, it would be 
interesting to inhibit/stimulate glycolysis in HEK293 cells and measure MMP and NADH 
and ROS to determine if these parameters were affected by glycolysis. And finally, 
treating cells with PAPTP, PAP-1 and SHK-Dap22 before measuring glycolysis could help 
identify any effects of specific cellular populations of Kv1.3 channels on glycolysis. 
Measurement of t-PMET  
Increased ROX and glycolysis in HEK293/Kv1.3 cells suggests that t-PMET may also be 
increased in these cells to limit reduction stress and maintain glycolysis, which may 
contribute to the proliferation of these cells (Herst and Berridge, 2006, 2007; Kelly et 
al., 2018). Measurement of t-PMET would need to be carried out to confirm this as an 
alternative mechanism of ROS generation (Kelly et al., 2018). Methods could include 
measuring the disappearance of the electron donor NADPH, measuring ubiquinone 
reduction or measuring hydroquinone oxidation (Principe et al., 2011). In addition, 
monitoring the reduction of artificial electron acceptors like ferricyanide using 13C 
nuclear magnetic resonance spectroscopy would allow real-time measurement of t-
PMET using a non-invasive technique (Himmelreich and Kuchel, 1997). 
Determination of the physiological relevance of Kv1.3 in human primary models 
This work would first need to be extended into HSVSMCs. Initial results, showing PAP-1 
reduces HSVMC proliferation and Kv1.3 channels exist in the mitochondria of HSVSMCs 
(Chapter Three) suggests this work in HEK293 cells may be translatable to HSVSMCs. 
Identification of the effect of PAPTP on HSVSMC respiration and proliferation is 
essential, as is determining the contribution of ROS to proliferation in these cells. 
Inhibiting signalling molecules like phosphotyrosine and ERK1/2 would also be 
necessary to examine if the non-conducting roles of Kv1.3 channels translate in 
HSVSMCs. Finally, this work would need to move into in vivo knockout mouse models 
to further explore the mechanisms. Mouse models of hyperplasia could be used to 
elucidate clinical relevance and determine if mitochondrial Kv1.3 channel blockers are 
viable drug targets in whole organisms to reduce Kv1.3 induced proliferation.  
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Optimisation of mitochondrial Kv1.3 inhibitors 
The initial findings in this thesis support a role for mitochondrial Kv1.3 inhibitors such 
as PAPTP in reducing Kv1.3 induced proliferation and respiration. Further work is 
needed to optimise the dosage and specificity which allows for the optimum inhibition 
of respiration and proliferation without off target effects. There is likely a key window 
where the therapeutic potential of mitochondrial Kv1.3 inhibitors exceeds potential 
detrimental effects on respiration. In addition, the mitochondrial content of cells varies 
among individuals and tissue type and depends on a variety of factors, such as age and 
activity levels (Chistiakov et al., 2014; Marquez and Han, 2017). To minimise off target 
effects on mitochondrial function, mitochondrially targeted pro-drugs such as PAPOH 
could be a better alternative to TPP containing molecules which may lead to TPP build 
up in the mitochondria over time (Nicholls and Ferguson, 2013; Leanza et al., 2017). 
PAPTP and other mitochondrial Kv1.3 inhibitors have received attention as putative 
therapeutics in the cancer field (Leanza et al., 2017; Venturini et al., 2017; Checchetto 
et al., 2018; Mattarei et al., 2018) for their specificity to target pathological cells. This 
relies on drugs like PAPTP and PAPOH being attracted to the negatively charged 
mitochondrial matrix. This characteristic of these molecules is exploited since cancer 
cells, like HEK293/Kv1.3 cells, exhibit greater hyperpolarisation of the MMP than WT 
cells. Therefore, these molecules selectively accumulate in diseased cells (Leanza et al., 
2017).  
7.4 Conclusions 
Kv1.3 channels contribute to normal mitochondrial function in HEK293 cells. The Kv1.3 
channel may also increase glycolysis to fuel enhanced OXPHOS. Thus, there are two 
fundamental differences in the metabolism of WT HEK293 cells and HEK293/Kv1.3 
cells; HEK293/Kv1.3 cells have both increased glycolysis and increased OXPHOS. In 
addition, HEK293/Kv1.3 cells have increased levels of ROS which may drive 
proliferation. Enhanced cellular respiration driven by Kv1.3 is independent of K+ flow 
through the Kv1.3 channel. However, a functioning voltage sensor and putative 
phosphorylation site, tyrosine 447, are essential for Kv1.3 driven respiration. Further 
investigation into the non-canonical mechanisms which lead to Kv1.3 induced 
respiration and proliferation are needed. However, targeting potential therapies to 
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subcellular organelles may be a novel way to increase the specificity and thus reduce 
side effects in treatment of Kv1.3 induced proliferative disorders. 
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